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Chapter 1
General introduction
HISTORY OF CANCER
The e a r lie s t  descrip tions of p a tie n ts  w ith  cancer w ere found  in  p ieces of w riting  
by H ippocrates, th e  G reek  p hysic ian  w ho lived  25 cen tu rie s  ago. H e described 
p a tie n ts  w ith  lu m p s on th e  skin, nose an d  b re a s ts . In sp ire d  by th e  sh ap es of 
th e se  lu m p s h e  spoke abou t k a rk in o s  (crab) or karc inom a.
H ippo cra tes w as v ery  re lu c ta n t  in  tre a t in g  cancer: “W hen th e  lum p is  no t 
septic, one shou ld  ju s t  leave i t  a t  th a t”, h e  said. A w ise decision, becau se  cu ttin g  
i t  aw ay, a t  th a t  tim e th e  only possib le tre a tm e n t, w as a v ery  risk y  a n d  p a in fu l 
p rocedure.
The causes of d iseases w ere ex p la in ed  by h u m o u ra lism . T h is th eo ry  he ld  
th a t  w hen  a p e rson  is  h e a lth y  th e  four b asic  su b stan ces of th e  h u m a n  body; 
blood, yellow bile, b lack  b ile an d  ph legm  a re  supposed  to be in  balance. “C ancer 
o rig in a ted  by local accum ulation  of th e  b lack  b ile” ra ise d  th e  physic ian  G alenos 
in  th e  second cen tu ry  A.D. The tre a tm e n t  of cancer re m a in e d  sim ila r u n til  the  
19th cen tury ; d iets, laxatives, a n d  ph lebotom y (bloodletting).
S ince th e  19th c e n tu ry  th e  th eo rie s  abou t h e a lth  an d  d iseases chang ed  
rad ica lly  a fte r th e  discovery of o rgans, t is su e s  a n d  cells of th e  h u m a n  body. W ith 
th e  use  of new found a n a e s th e tic s  a n d  in s ig h ts  in  hygiene, th e  p o ssib ilities  for 
su rg ica l in te rv e n tio n s  an d  la te r  ra d io th e ra p y  an d  ch em o th erap y  chang ed  th e  
chances for in c rea sed  su rv iv a l strongly. C ancer is  u p p erm o st a d isease  of m odern  
tim es. In  th e  N e th e rla n d s  cancer is now adays th e  m ost f re q u e n t cause  of d e a th 1.
SOME NUMBERS
C ancer is  a  collective te rm  for m ore th a n  h u n d re d  d ifferen t d iseases. Al these  
d ifferen t types of cancer h av e  one sh a re d  ch arac te ris tic : ab n o rm a l uncon tro lled  
g row th  of cells, loss of fun ction  an d  d issem in a tio n 2. In  2005 a t  le a s t 81.000 new
cases w ere d iagnosed  w ith  cancer in  th e  N e th e rlan d s , 42.000 w ere m en, 39.000 
w ere w om en. The to ta l p revalence  of cancer in  th e  N e th e rla n d s  w as e s tim a te d  
a ro u n d  400.000 p a tie n ts , 2.5% of th e  popu lation . B re a s t cancer is  th e  m ost 
com m on type  of cancer followed by sk in  cancer, colon cancer an d  p ro s ta te  cancer. 
C om pared  to 2004 th e  n u m b er of new cases rose, m ain ly  because of g row th  an d  
aging of th e  popu la tion . The changes of su rv iv a l depen d  on th e  type  a n d  s tage  of 
cancer. A pprox im ately  h a lf  of a ll p a tie n ts  w ho a re  d iagnosed  w ith  cancer receive 
oncological tre a tm e n t  w ith  th e  in te n t  to cure. The chances of su rv iv a l have  
in c rea sed  slowly b u t stead y  in  th e  la s t  decenn ia3.
FATIGUE IN CANCER SURVIVORS 
Research at the Expert Centre for Chronic Fatigue
Now th a t  th e  p revalence  of cancer is  in c reas in g  a n d  m ore p a tie n ts  survive, m ore 
people h av e  to deal w ith  th e  consequences of cancer. F a tig u e  is th e  firs t 
m en tioned  consequence by th e  D u tch  C ancer Society. N ot only for p a tie n ts  who 
a re  liv ing w ith  cancer4, b u t also as a  long te rm  consequence for cancer su rv ivors5.
The E x p ert C en tre  C hronic F a tigue , as a p a r t  of th e  R adboud  U n iversity  
N ijm egen M edical C entre , w as founded  in  1990. I t  s ta r te d  as a  co llaboration  of 
sc ien tis ts  from  d ifferen t d iscip lines to stu d y  incidence an d  orig in  of chronic 
fa tig ue  an d  chronic fa tig ue  syndrom e, an d  in  la te r  y ea rs  also th e  t re a tm e n t an d  
im p lem e n ta tio n  of tre a tm e n t  s tra teg ies . S ince th e n  i t  also focused on fa tig ue  in  
o th e r groups, for exam ple am ong em ployees6, C am bodia v e te ra n s 7, in  p a tie n ts  
w ith  n eu ro m u scu la r d iso rd ers8- 9, m u ltip le  sc lero sis10, an d  rh e u m a to id  a r th r i t i s 11.
In  1996 th e  E x p ert C en tre  s ta r te d  to stu d y  fa tig ue  in  cancer survivors. A 
review , b ased  on s tu d ies  be tw een  1980 an d  2001, show ed th a t  th e  p revalence  of 
fa tig ue  d u rin g  cancer t re a tm e n t  v a r ie d  b e tw een  25% an d  99% in  d ifferen t 
sam ples of cancer p a tie n ts  an d  m easu red  w ith  d ifferen t q u es tio n n a ires . In  
d isease-free cancer p a tie n ts  fa tig u e  re m a in e d  p ro b lem atic  in  abou t 20% to 
40% 12,13.
F a tig u e  w as s tu d ied  in  sev era l g roups of d isease-free cancer p a tie n ts , who 
fin ish ed  t re a tm e n t  a t  le a s t 6 m on th s before p a rtic ip a tio n . T hese s tu d ies  show ed
12
G eneral introduction.
th a t  severely  fa tig u ed  cancer su rv ivors experienced  n u m ero u s prob lem s and  
lim ita tio n s  in  sev era l a re a s  of life, such as  psychological w ell-being, fun ctional 
im p a irm en t in  daily  life, sleep d is tu rb an ces , physical activ ity , neuropsychological 
im p a irm en t, social function ing /social support, self-efficacy an d  causa l 
a t tr ib u t io n s 14. A lo n g itu d in a l study, th a t  followed fa tig u ed  in  b re a s t cancer 
surv ivors for two y ea rs  fo u n d  th a t,  w om en w ho only received  su rg ery  w ith o u t 
com plications w ere a t  low er r isk  for p e rs is te n t  fa tigue . P e rs is te n t  fa tig u e  w as 
u n re la te d  to type  of surgery , type  of a d ju v an t th e ra p y  an d  to tim e since 
t re a tm e n t  w as fin ish e d 15,
P h y sic ian s an d  o th e r care  p ro v iders now recognize th a t  fa tig u e  afte r 
successful cancer tre a tm e n t  is  a  serious problem . P a tie n t  o rg an iza tio n s an d  
in d iv id u a l cancer su rv ivors accom plished  a lo t to get th is  problem  
acknow ledged16. U n fo rtu n a te ly  m any  cancer surv ivors a re  to ld  th a t  severe 
fa tig ue  is  a  consequence of th e ir  fo rm er oncological t re a tm e n t  an d  th a t  th ey  “ju s t  
h ave  to live w ith  i t”. C o n tra ry  to th is  m essage, cancer su rv ivors shou ld  be 
in fo rm ed  abou t th e  t re a tm e n t  op tions for ongoing severe fa tig ue . An effective 
t re a tm e n t option  is in d iv id u a lly  ta ilo red  cognitive beh av io u r th e ra p y  (CBT) for 
post cancer fa tig ue .
Cognitive Behaviour Therapy for postcancer fatigue
For a p ro per u n d e rs ta n d in g  of chronic fa tig ue  following successful cancer 
t re a tm e n t a  m odel of p re c ip ita tin g  a n d  p e rp e tu a tin g  fac to rs  w as in troduced . The 
assu m p tio n  is th a t  th e  cancer i tse lf  an d  th e  t re a tm e n t  m igh t h av e  trig g e red  
fa tig ue , b u t a s  i t  w as d e m o n stra te d  th a t  d isease  an d  tre a tm e n t  ch a rac te r is tic s  
w ere u n re la te d  to th e  sev erity  of post-cancer fa tig u e 12- 17"21, i t  is  p lau sib le  th a t  
over tim e o th e r fac to rs cau sed  fa tig ue  to p e rs is t. To t re a t  chronic fa tig ue  in  
cancer surv ivors a  specific k in d  of CBT w as developed d irec ted  a t  th e  
p e rp e tu a tin g  fac tors. The t re a tm e n t  protocol encom passes six m odules th a t  
coincide w ith  th e  following p e rp e tu a tin g  factors: 1) Poor coping w ith  cancer an d  
cancer tre a tm e n t, 2) E xcessive fea r of d isease  rec u rren ce20’ 21, 3) D ysfunctional 
cognitions reg a rd in g  fa tig u e , such as som atic  a ttr ib u tio n s , non-acceptance of 
sym ptom s / im p a irm en ts , c a ta s tro p is in g 22 an d  n egativ e  self-efficacy, 4)
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D ysreg u la to ry  sleep-w ake cycle12- 19 21, 5) D y sreg u la to ry  ac tiv ities, such  as 
physica l m e n ta l a n d  social activ ities, 6) low social su p p o rt a n d  negative  
in te ra c tio n s23. A RCT show ed th a t  CBT w as a h igh ly  clin ically  an d  sign ifican tly  
effective t re a tm e n t  for long te rm  cancer surv ivors suffering  from  severe fatigue. 
This effect w as m a in ta in e d  a fte r abou t two y ea r follow-up period. CBT for 
postcancer fa tig u e  elic ited  a clin ically  re le v a n t red u c tio n  in  fa tig u e  an d  
fu n c tio n a l im p a irm e n ts  in  long te rm  cancer survivors. in  severely  fa tig u ed  cancer 
surv ivors w ho fin ish ed  cancer tre a tm e n t  abou t five y ea rs  e a r lie r  24 25.
A lthough severe fa tig u e  in  long te rm  cancer su rv ivors can  be tre a te d  
successfully  w ith  CBT i t  w ould  be m ore d es irab le  to p re v en t fa tig ue  in  cancer 
surv ivors by a n  in te rv e n tio n  in  an  e a r lie r  stage. Therefore, one of th e  a im s of th is  
re se a rc h  pro ject w as to ev a lu a te  w h e th e r an  in te rv e n tio n  d u rin g  t re a tm e n t of 
cancer w as effective in  m an ag in g  fa tig u e  an d  w h e th e r i t  could p re v en t p e rs is te n t 
fa tig ue  in  cancer survivors.
The course of fatigue in cancer patients
In  th e  l ite ra tu re  a few lo n g itu d in a l s tu d ies  on fa tig u e  in  cancer p a tie n ts  have 
been  rep o rted . For exam ple, fa tig u e  w as in v estig a ted  in  b re a s t cancer p a tie n ts  
w ho received  ch em o th e rap y 26 or ra d io th e ra p y 27. In  bo th  s tu d ies  w om en w ere 
a ssessed  before th ese  oncological tre a tm e n ts  an d  in  th e  y ea rs  th e re a f te r . In  th e  
stu d y  of N ieboer e t al. (2005) w om en w ere a ssessed  1, 2  an d  3  y ea rs  a fte r 
chem otherapy , an d  in  th e  stu d y  of G ein itz e t al. (2004) 2,5 y ea rs  afte r 
rad io th e rap y . I t  is g en era lly  a ssu m ed  th a t  th e  level of fa tig u e  in c rea se s  from  th e  
pre- to th e  p o s t- tre a tm e n t period, b u t bo th  s tu d ies  fo u n d  no t change in  fa tig u e . 
T his inconsistency  could be th e  re s u lt  of m ethodological flaw s, such as fa tig u e  no t 
being  a ssessed  freq u en tly  enough  to detec t f lu c tu a tio n s28. T he find ing  th a t  no 
change in  fa tig u e  w as fo u n d  could also be due to th e  re la tiv e ly  hom ogeneous 
c h a rac te r is tic s  of th e  sam ple, or th e  fac t th a t  m ost w om en w ere no t t re a tm e n t 
naïve a t  baseline.
Two o th e r s tu d ies  in v e s tig a te d  fa tig u e  in  a group of cancer p a tie n ts  tre a te d  
for v a rio u s m alignancies. In  th e  s tu d y  of G iven e t al., (2001) o lder cancer p a tie n ts  
w ere observed  a t 6-8, 12-16, 24-30, a n d  52 w eeks29. In  th e  stu d y  of S m ets  e t al.,
14
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(1998)30 fa tig u e  w as ex am in ed  in  d isease-free cancer p a tie n ts  9 m o n th s a fte r 
being  tre a te d  w ith  rad io th e rap y . B oth  s tu d ies  did  fin d  a n  effect of d isease 
ch arac te r is tic s  on fa tigue . F o r exam ple, lu n g  cancer p a tie n ts  h a d  th e  m ost 
fa tigue. I t  shou ld  be no ted  th a t  th e  b ase lin e  asse ssm en t took place in co n g ru en t 
w ith  th e  p h ases  of th e  oncological t re a tm e n ts . N one of th e se  lo n g itu d in a l s tud ies 
p rov ided  in s ig h t in  th e  course of fa tig u e  from  d iagnosis in to  th e  y ear a fte r cancer 
tre a tm e n t.
I t  is  gen era lly  assu m ed  th a t  fa tig u e  a rise s  d u rin g  active cancer tre a tm e n t, 
as a  consequence of th e  oncological tre a tm e n t, th e  d isease  itself, a n d  possib ly 
assoc ia ted  d istress .
M any  cancer p a tie n ts  experience fa tig u e  in  th e  period  d u rin g  active 
t re a tm e n t for cancer. P revalen ces of 90% or h ig h e r h av e  even been  re p o rte d 12’ 19. 
W hen cancer t re a tm e n t  is  f in ish ed  m ost cancer su rv ivors recover spon taneously  
from  th e  d irec t effects of th e  oncological tre a tm e n t. B ased  on th e  stu d y  of S ervaes 
e t al. (2007) i t  w as expected  th a t  a  re la tiv e ly  la rg e  group of cancer p a tie n ts  w ould 
be severely  fa tig u ed  sho rtly  a fte r  cancer tre a tm e n t, abou t 40 - 50%. I t  is a ssu m ed  
th a t  th e  occurrence of severe fa tig u e  d ecreases d u rin g  th e  f irs t  y ea r a fte r  cancer 
t re a tm e n t to abou t 30% - 40% an d  w ould  stab ilize  in  th e  y ea rs  th e re a f te r  to about 
25% 15. T hese assu m p tio n s  how ever w ere never been  confirm ed in  lo n g itu d in a l 
s tu d ies  w ith  a sse ssm en ts  before th e  s ta r t  of an y  oncological tre a tm e n ts .
The design  of th e  s tu d ies  described  in  th is  th e s is  w as as  follows: p a tie n ts  
w ho ju s t  received  th e  d iagnosis cancer w ere a ssessed  before th e  s ta r t  of cancer 
tre a tm e n t, sho rtly  a fte r cancer tre a tm e n t, an d  m on th ly  for a y ea r th e rea fte r . 
P a tie n ts  w ere ask ed  to p a r tic ip a te  in  a  RCT in  w hich  th ey  w ould  be ass ig n ed  to 
one of th re e  conditions: 1) CB T in te rv en tio n , 2) b rie f  n u rs in g  in te rv e n tio n  3) 
u su a l oncological care. W ith  th e  RCT w e could te s t  th e  sh o rt an d  long te rm  
effectiveness of th ese  two in te rv e n tio n s  in  red u c in g  fa tig ue  d u rin g  cu ra tiv e  
cancer tre a tm e n t. W ith  th is  design  also o th e r q uestions could be an sw ered  such 
as; a) Is  severe fa tig ue  a lread y  an  issu e  before th e  s ta r t  of cancer tre a tm e n t?  b) 
W hat is  th e  n a tu ra l  course of fa tig u e  in  th e  y ear a fte r  cancer t re a tm e n t  is 
fin ished?  c) C an  we id en tify  p red ic to rs  of p e rs is te n t  fa tig ue  a fte r successful
15
cancer tre a tm e n t?  These a n d  o th er re se a rc h  q uestions a re  o u tlin ed  in  th is  
d isse rta tio n .
OUTLINE OF THIS DISSERTATION
W hen th is  re se a rc h  pro ject s ta r te d  th e  l i te ra tu re  w as lack ing  solid evidence to 
w h a t ex ten t psychosocial in te rv e n tio n s  could be effective to red uce  fa tig u e  in  
p a tie n ts  w ho w ere actively  tre a te d  for cancer. T here  w ere som e rev iew s th a t  
inc luded  psychosocial in te rv e n tio n s  as  a  s tra te g y  to m anage  fa tig u e , b u t  th ese  
rev iew s w ere b ased  on in te rv e n tio n s  for cancer p a tie n ts  irre sp ec tiv e  of th e  p h ase  
of cancer tre a tm e n t. T h u s th e  rev iew s w ere b a sed  on s tu d ies  th a t  inc luded  
p a tie n ts  d u rin g  cancer tre a tm e n t, p a tie n ts  w ho fin ish ed  cancer tre a tm e n t, or 
both. The second ch ap ter  describes th e  sy s tem atic  rev iew  th a t  e v a lu a te d  if 
psychosocial in te rv e n tio n s  w ere effective in  red uc ing  fa tig u e  in  cancer p a tie n ts  
receiv ing  active t re a tm e n t  fo r cancer. A dditionally  i t  w as d e te rm in e d  w hich 
specific types of psychosocial in te rv e n tio n s  d u rin g  cancer t re a tm e n t  w ere th e  
m ost effective in  red uc ing  fa tig ue .
S tu d y in g  th e  l ite ra tu re  rev ea led  th a t  fa tig u e  in  cancer p a tie n ts  p rio r to 
t re a tm e n t w as seldom  in v estig a ted , a lth o u g h  th e re  w ere in d ica tio n s th a t  fa tig u e  
could a lread y  be p ro b lem atic  p a rtic u la r ly  a t th a t  stage. T herefore we 
in v es tig a ted  th e  occurrence of severely  fa tig u e d  a fte r being  d iagnosed  w ith  
v a rio u s types of m alignancies, b u t before in itia tio n  of any  m edical tre a tm e n t  for 
cancer. Secondly, i t  could be es tab lish ed  w hich  fac to rs  co n trib u te d  to severe 
fa tig ue  in  t re a tm e n t  naïve cancer p a tie n ts . The re s u lts  of th is  s tu d y  are  
p re se n te d  in  c h a p te r  th ree .
In  th e  fou rth  ch ap ter  two in te rv e n tio n s  for fa tig u e  d u rin g  cu ra tiv e  cancer 
t re a tm e n t  w ere  e v a lu a te d  a n d  com pared  to u su a l care  in  a  ran d o m ised  con tro lled  
tria l. The firs t  in te rv en tio n  w as a b rie f  n u rs in g  in te rv en tio n  (BNI), th e  la tte r  
cognitive beh av io u r th e ra p y  (CBT).
The B N I focused  only on physica l activ ity . In te rv en in g  on p hysica l ac tiv ity  
to red uce  fa tig u e  is  b a sed  on th e  assu m p tio n  th a t  a  lack  of p hysica l ac tiv ity  an d
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deconditioning d u rin g  cancer tre a tm e n t  can  w orsen  fatigue . W hen p a tie n ts  a re  
d iagnosed  w ith  cancer, th e ir  ac tiv ity  p a t te rn  chang es a n d  th ey  becom e physically  
less active, possib le lead in g  to deconditioning. I t  is  p re su m ed  th a t  th is  is  th e  
re s u lt  of a  n eg a tiv e  sp iral, because w h en  p a tie n ts  becom e physica lly  less  active 
th ey  becom e m ore easily  fa tigued , an d  w hen  p a tie n ts  experience fa tig u e  th ey  
re a c t by  becom ing physica lly  even less active. W ith  th e  B N I it  w as in te n d e d  to 
avoid or b re a k  th is  n egativ e  sp iral.
The CBT w as, in  add ition  to b re ak in g  th e  n egativ e  sp ira l of physica l 
activ ity , focused on o th e r e lem en ts  such as  chang ing  dysfunction al cognitions 
abou t fa tigue, chang ing  a d is to rte d  sleep-w ake rh y th m , an d  on coping w ith  the  
consequences of hav in g  cancer. In  th is  stu d y  i t  w as in v es tig a ted  if fa tig u e  sho rtly  
a fte r cancer t re a tm e n t could be red u ced  ea rly  or p re v en ted  w ith  th ese  
in te rv e n tio n s  given d u rin g  cancer tre a tm e n t.
I t  is  gen era lly  a ssu m ed  th a t  in c reas in g  p hysica l ac tiv ity  is  im p o rta n t in  
red uc ing  fa tig u e  d u rin g  cancer tre a tm e n t. H ow ever, th e  con trib u tio n  of physica l 
a c tiv ity  in  in te rv e n tio n s  w as p rev iously  no t estab lished . T herefore  we a im ed  to 
in v es tig a te  if  in c reas in g  p hysica l ac tiv ity  h a d  a m ed ia tin g  ro le on th e  red u c tio n  
in  fa tigue.
The in te rv e n tio n  stu d y  focused on a b ro ad  group of p a rtic ip a n ts . P a tie n ts  w ith  
v a rio u s m alignancies, receiv ing  t re a tm e n t w ith  cu ra tiv e  in te n t  p a r tic ip a ted , b u t 
also w ith  d ifferen t p re - tre a tm e n t levels of fa tig u e  an d  o th e r sym ptom s. T herefore 
it  w as expected  th a t  some g roups of p a tie n ts  w ould  benefit m ore from  an
in te rv en tio n  for fa tig u e  d u rin g  cancer t re a tm e n t  th a n  o thers . I n  c h a p te r  f i v e an
exp lo ra to ry  stu d y  is p re se n te d  th a t  id en tified  w hich  p a tie n ts  b en e fitted  th e  m ost 
from  th e  in te rv en tio n . As fa tig u e  w as a ssessed  every  m o n th  d u rin g  a y ea r a fte r 
th e  p o st-in te rv en tio n  asse ssm en t th e  long te rm  effects of th e  in te rv e n tio n s  in  the  
y ear p o s t-in te rv en tio n  could be in v e s tig a te d  too. The follow-up re s u lts  of the 
in te rv e n tio n s  a re  also p re se n te d  in  th is  chap ter.
In  ch ap ter six  we describe th e  n a tu ra l  course of fa tig u e  in  cancer su rv ivors in  a 
p rospective follow-up s tu d y  from  diagnosis in to  th e  y ear a fte r successful cancer
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tre a tm e n t. The firs t aim  of th is  s tu d y  w as to d e te rm in e  th e  occurrence of severe 
p e rs is te n t  fa tig ue  in  th e  y ea r a fte r successful cancer tre a tm e n t. E a rly  
iden tifica tio n  an d  t re a tm e n t of cancer p a tie n ts  a t  r isk  for p e rs is te n t  fa tig u e  could 
sh o rten  th e  period  of in v a lid a tin g  p e rs is te n t  fa tigue . T herefore  our second aim  
w as to explore w hich  p re - tre a tm e n t, p o s t- tre a tm e n t an d  can ce r-re la ted  fac tors 
p red ic ted  p e rs is te n t  fatigue.
O ur la s t  aim  w as to in v es tig a te  if  th e  know n fa tig ue  p e rp e tu a tin g  fac tors 
found  in  long te rm  cancer surv ivors (described above in  detail) also h av e  a 
p red ic tive  v a lu e  for p e rs is te n t  fa tig u e  in  th e  y ear a fte r cancer tre a tm e n t?  M ore 
specifically, can  th e  six fa tig u e  p e rp e tu a tin g  fac to rs a ssessed  sho rtly  a fte r  cancer 
t re a tm e n t p red ic t p e rs is te n t  fa tigue?  If th is  w ould  be th e  case, cancer surv ivors 
suffering  from  severe fa tig ue  m igh t a lread y  be tre a te d  w ith  CB T for postcancer 
fa tig ue  a t a n  e a r lie r  stage, sho rtly  a fte r  successful cancer tre a tm e n t.
In  th e  fin a l c h a p te r  se v e n , ou r re s u lts  a re  p u t in  a  b ro ad er d ay ligh t an d  
lea rn in g  p o in ts  a re  d iscussed.
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Chapter 2
Psychosocial interventions for reducing 
fatigue during cancer treatm ent in adults
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ABSTRACT
B ackground: F a tig u e  is  a  com m on sym ptom  in  cancer p a tie n ts  receiv ing  active 
tre a tm e n t. T here  a re  a l im ited  n u m b er of rev iew s ev a lu a tin g  in te rv e n tio n s  for 
fa tig u e  d u r in g  active tre a tm e n t, a n d  th ey  a re  re s tr ic te d  to p a tie n ts  w ith  
advan ced  cancer, or to p a tie n ts  d u rin g  rad io th e rap y . To d a te  th e re  is  no 
sy s tem atic  rev iew  on psychosocial in te rv e n tio n s  for fa tig ue  d u rin g  cancer 
tre a tm e n t.
O bjectives: To e v a lu a te  if  psychosocial in te rv e n tio n s  a re  effective in  
red uc ing  fa tig u e  in  cancer p a tie n ts  receiv ing  active t re a tm e n t  for cancer, an d  
w hich  types of psychosocial in te rv e n tio n s  a re  th e  m ost effective.
Search  m ethods: In  S ep tem ber 2008 we sea rch ed  th e  C ochrane C en tra l 
R eg iste r of C on tro lled  T ria ls  (CENTRAL) (The Cochrane Library), PUBM ED, 
M E D LIN E, EM BASE, CIN A H L an d  PsycIN FO , an d  checked th e  reference  lists.
Selection  c rite ria : R andom ised  con tro lled  t r ia ls  (RCTs) w ere  inc luded  w hich 
e v a lu a te d  psychosocial in te rv e n tio n s  in  ad u lt  cancer p a tie n ts  d u rin g  tre a tm e n t, 
w ith  fa tig ue  as a n  outcom e m easure .
D a ta  collection a n d  an alysis: T hree  rev iew  a u th o rs  in d ep en d en tly  ex trac ted  
d a ta  from  th e  selected  stud ies, an d  a ssessed  th e  m ethodological q u a lity  using  
sev era l q u a lity  ra t in g  scales a n d  ad d itio n a l c rite ria .
R esu lts: T w enty-seven  s tu d ies  m et th e  inc lusion  c r ite ria  w ith  a to ta l  of 3324 
p a r tic ip a n ts , an d  seven s tu d ies  rep o rted  sign ifican t effects of th e  psychosocial 
in te rv en tio n  on fatigue . In  th re e  s tu d ies  th e  effect w as m a in ta in e d  a t  follow-up. 
The q u a lity  of th e  s tu d ies  w as g en era lly  m odera te . E ffect sizes v a ried  betw een  
0.17 to 1.07. The effectiveness of in te rv e n tio n s  specific for fa tig u e  w as 
sign ifican tly  h ig h e r (80%) com pared  to in te rv e n tio n s  no t specific for fa tig ue  
(14%). In  five s tu d ies  th e  in te rv e n tio n s  w ere specifically focused  on fa tig u e , w ith  
four being  effective. The five in te rv e n tio n s  w ere brief, consisting  of th ree  
in d iv id u a l sessions, p rov ided  by (oncology) n u rses . In  genera l, d u rin g  th ese  
in te rv e n tio n s  p a r tic ip a n ts  w ere ed u ca ted  abou t fa tig ue , w ere ta u g h t in  self-care 
or coping techn iq ues, an d  le a rn e d  ac tiv ity  m an ag em en t. O f th e  rem a in in g  22 
s tu d ies  only th re e  w ere  effective in  red uc ing  fa tig ue , an d  th ese  in te rv e n tio n s  h a d  
a  m ore g en era l approach . T hese in te rv e n tio n s  w ere a im ed  a t  psychological 
d is tress , m ood an d  p hysica l sym ptom s, a n d  v a r ie d  strong ly  in  d u ra tio n  an d  
conten t.
A u th o rs ' conclusions: T here  is  lim ited  evidence th a t  psychosocial 
in te rv e n tio n s  d u rin g  cancer t re a tm e n t  a re  effective in  red u c in g  fa tig u e . A t 
p re sen t, psychosocial in te rv e n tio n s  specifically for fa tig u e  a re  a  p ro m ising  type of 
in te rv en tio n . H ow ever, th e re  is  no solid evidence for th e  effectiveness of 
in te rv e n tio n s  no t specific fo r fa tig u e . M ost asp ec ts  of th e  inc luded  s tu d ies  w ere 
heterogeneous, an d  th ere fo re  i t  could no t be es tab lish ed  w hich  o th e r types of 
in te rv en tio n s , or e lem en ts  w ere e sse n tia l in  red uc ing  fa tig ue .
PLAIN LANGUAGE SUMMARY
T here  is  l im ited  evidence th a t  psychosocial in te rv e n tio n s  a re  effective in  red ucing  
fa tig u e  d u rin g  active t re a tm e n t  in  cancer p a tie n ts . M ost p ro m ising  a re  
psychosocial in te rv e n tio n s  specifically designed  to t r e a t  fa tigue . In  general, 
du rin g  th e se  in te rv e n tio n s  p a tie n ts  w ere  e d u ca ted  abou t fa tig ue , w ere  ta u g h t in  
self-care or coping techn iq ues, an d  le a rn e d  to m anage  th e ir  activity. 
In te rv e n tio n s  th a t  d id  no t focus on fa tig u e  w ere ra re ly  effective in  red uc ing  
fa tig ue.
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BACKGROUND
In  rec en t y ea rs  th e  t re a tm e n t  of cancer h a s  changed, as m ore people a re  tre a te d  
an d  an  in c reas in g  n u m b er surv ive th e  d isease . T he p rim a ry  focus of t re a tm e n t 
for cancer is  surv ival, b u t  alongside th is  th e  m an ag em en t of sym ptom s an d  
q u a lity  of life of p a tie n ts  a re  also becom ing im p o rta n t. F a tig u e  is  one of the  
sym ptom s m ost com m only re p o rte d  by cancer p a tie n ts  a n d  is  g a in ing  m ore 
recognition  by oncologists. In  add ition  to th is  scientific know ledge abou t fa tig ue 
in  cancer p a tie n ts  is growing. F a tig u e  can  be described  in  te rm s of perceived  
energy, m e n ta l capac ity  a n d  psychological s ta tu s  a n d  is  th erefo re  a 
m u ltid im en sio n a l concep t1- 2. F a tig u e  is som etim es seen as a con tinuum , ran g in g  
from  tire d n e ss  to ex h a u s tio n 3.
C an cer-re la ted  fa tig u e  (CRF) is  a  te rm  th a t  is  freq u en tly  used. The N atio n a l 
C om prehensive C ancer N etw ork  (NCCN) defines CRF as a d istress ing , 
p e rs is te n t, sub jective sense of physical, em otional and /or cognitive tire d n e ss  or 
exhau stion , re la te d  to cancer or cancer t re a tm e n t  th a t  is  no t p ro p o rtio n a l to 
rec en t ac tiv ity  a n d  in te r fe re s  w ith  u su a l fu n c tion in g4. C ancer p a tie n ts  can 
experience fa tig u e  a t d ifferen t stages, fo r exam ple, d u rin g  cancer tre a tm e n t  or 
sho rtly  a fte r  f in ish in g  tre a tm e n t. D isease-free  cancer p a tie n ts  can  also 
experience fa tigue . The p revalence  of fa tig u e  d u rin g  cancer tre a tm e n t  ran g es  
from  25% to 99% depend ing  on th e  sam ple an d  on th e  type  of in s tru m e n t u se d  to 
m easu re  fa tig u e 5. A fter successful cancer tre a tm e n t, fa tig u e  can  still be a 
p rob lem  in  up to 38% of cancer su rv ivors a n d  can  p e rs is t  for m any  y e a rs6. I t  is 
im p o r ta n t  to no te  th a t  th e  te rm  CRF does no t m ake a d istinc tion  b etw een  fa tig u e  
d u rin g  cancer tre a tm e n t, an d  fa tig u e  a fte r  fin ish in g  tre a tm e n t, b u t covers the  
w hole period.
E ffo rts to m anage  fa tig u e  shou ld  firs t focus on iden tify ing  an d  tre a tin g  the 
com orbid ities th a t  m ay cause  it, for exam ple, an aem ia  or hypothyro id ism . 
H ow ever, often no specific cause  for fa tig ue  can  be id en tified  in  p a tie n ts  during  
cancer tre a tm e n t, o th e r th a n  th e  cancer or th e  t re a tm e n t  itse lf. In  th ese  
s itu a tio n s  th e  m an ag em en t of fa tig u e  u su a lly  involves m u ltip le  s tra teg ies . The
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s tra teg ie s  a re  o ften  d iv ided  in to  pharm aco log ical a n d  non-pharm acological 
in te rv en tio n s.
M in ton  (2008) rev iew ed  d ru g  th e ra p y  for th e  m an ag em en t of CRF an d  
concluded th a t  e ry th ro p o ie tin  a n d  darbopoetin , d ru gs th a t  im prove an aem ia , are  
effective in  m an ag in g  CRF in  p a tie n ts  w ho a re  anaem ic  as  a  re s u lt  of 
ch em o th erap y 7. H ow ever, c u rre n tly  concerns a re  ra ise d  abou t th e  safety  of these  
d ru gs as a  series of recen t, ran d o m ised  placebo-contro lled  clin ical t r ia ls  rep o rted  
adverse  effects inc lud ing  en h an ced  tu m o u r p ro g ression  a n d  in c rea sed  m o rta lity 8, 
9. M e th y lp h en id a te  w as also effective, b u t m ore re se a rc h  is  needed  to confirm  
th is . No d a ta  c u rre n tly  su p p o rts  th e  use  of p aro x e tin e  or p ro g esta tio n a l stero ids 
for t re a tm e n t  of C R F7. T his rev iew  inc luded  s tu d ies  th a t  re c ru ite d  p a r tic ip a n ts  a t  
any  po in t of th e  cancer t re a tm e n t  spectrum . A  C ochrane rev iew  is  also in  
p ro g ress  e v a lu a tin g  d ru gs for th e  tre a tm e n t  of fa tig ue  in  p a llia tiv e  care10.
T here  a re  a n  in c reas in g  n u m b er of s tu d ies  w ith  exercise as a  non- 
pharm aco log ical in te rv e n tio n  for cancer p a tie n ts . C u rre n t l ite ra tu re  suggests 
th a t  exercise is  likely  to be beneficial, b u t th e  la te s t  rev iew s draw  conflicting 
conclusions abou t th e  ro le of exercise on m an ag in g  fa tig u e11. Som e rev iew s 
concluded th a t  exercise h a d  a positive effect on fa tig u e12, 13 w hile  o th e rs  found  no 
effect of exercise on fa tig u e14-16. In  add ition  a C ochrane rev iew  in v estig a tin g  
exercise for fa tig ue  in  cancer p a tie n ts  is also now p u b lished17.
All rev iew s m en tioned  above w ere b ased  on s tu d ies  th a t  inc luded  cancer 
p a tie n ts  d u rin g  active tre a tm e n t  a n d  d isease-free survivors. In  th e  rev iew  of 
A hlberg  (2003) a d istinc tion  w as m ade betw een  s tu d ies  ev a lu a tin g  exercise 
du rin g  cancer t re a tm e n t a n d  a fte r tre a tm e n t, a n d  concluded th a t  in  a ll s tud ies 
th e  exercise g roups h a d  low er levels of fa tig u e3. C o n tra ry  to th is , th e  C ochrane 
rev iew  of M ark es (2006) concluded th a t  exercise h a d  no effect on fa tig u e  in  b re a s t 
cancer p a tie n ts  d u rin g  a d ju v an t th e ra p y 18.
In  rec en t y ea rs  m ore s tu d ies  h av e  e v a lu a te d  psychosocial in te rv e n tio n s  for 
th e  m an ag em en t of fa tigue . The aim  of a  psychosocial in te rv e n tio n  is  to influence 
or change cognitions, em otions, behav iour, th e  social en v iro n m en t or a 
com bination  of these , w ith  th e  u ltim a te  goal to decrease  fatigue.
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Som e rev iew s h av e  inc luded  psychosocial in te rv e n tio n s  as a  subgroup for 
m anag ing  fa tig ue  in  cancer p a tie n ts  an d  th e se  in te rv e n tio n s  h av e  been  reg a rd ed  
as some of th e  m ore p ro m ising  tre a tm e n ts , b u t fu r th e r  re se a rc h  w as 
recom m ended  19, 20. A  rec en t m e ta -an a ly s is  is  less  positive  an d  concluded th a t  
th e re  is lim ited  sup port for th e  clin ical use for psychological in te rv e n tio n s  for 
CRF14. H owever, th ese  rev iew s w ere b ased  on s tu d ies  th a t  in c lu d ed  p a tie n ts  
d u rin g  th e  w hole sp ec tru m  of cancer tre a tm e n t, as w ell as d isease-free  survivors.
T here  a re  only a lim ited  n u m b er of rev iew s th a t  e v a lu a te d  in te rv e n tio n s  for 
fa tig ue  in  p a tie n ts  w ho received  active tre a tm e n t. T hese rev iew s w ere re s tr ic te d  
to ce r ta in  p a tie n t  groups, for exam ple to p a tie n ts  w ith  advan ced  cancer21, 
m e ta s ta tic  b re a s t  cancer22, or to p a tie n ts  d u rin g  ra d io th e ra p y 23- 24.
To date , no sy s tem atic  rev iew  h a s  been  p u b lish ed  ev a lu a tin g  th e  
effectiveness of psychosocial in te rv e n tio n s  for fa tig u e  d u rin g  cancer tre a tm e n t, 
w hich  w as th e  goal of th is  review . In  th is  rev iew  w e id en tified  s tu d ies  th a t  te s te d  
th e  effectiveness of psychosocial in te rv e n tio n s  in  ran d o m ised  con tro lled  tr ia ls  
(RCT). F irs t  we described  w hich  psychosocial in te rv e n tio n s  w ere effective in  
red uc ing  fatigue , a n d  how strong  th e  effects w ere  by u sin g  effect sizes. Secondly, 
th e  q u a lity  of th e  s tu d ies  w as eva lua ted . F inally , th e  m ore p rom ising  
psychosocial in te rv e n tio n s  for red u c in g  fatigue d u rin g  cancer tre a tm e n t  are  
discussed.
OBJECTIVES
The p rim a ry  objective w as to ev a lu a te  if  psychosocial in te rv e n tio n s  a re  effective 
in  red uc ing  fatigue in  cancer p a tie n ts  receiv ing  active t re a tm e n t  for cancer. The 
secondary  objective w as to consider w hich specific types of psychosocial 
in te rv e n tio n s  d u rin g  cancer t re a tm e n t a re  th e  m ost effective in  red uc ing  fatigue.
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METHODS
Criteria for considering studies for this review
Types of intervention
O nly RCTs w ere in c lu d ed  in  th is  review . In  add ition , s tu d ies  w ith  sm all sam ple 
sizes (less th a n  te n  p a r tic ip a n ts )  w ere excluded, a s  th is  causes a lack  of pow er to 
d em o n stra te  th e  effect of a n  in te rv en tio n . T his m ean s th a t  w h en  no sign ifican t 
effect of a n  in te rv en tio n  is  found, th is  doesn 't necessarily  m ean  th a t  the 
in te rv en tio n  is  no t effective a t  all. F in d in g  no effect of th e  in te rv en tio n  can  be 
ex p la in ed  by th e  sm all sam ple size of th e  stud ies. T hus th e  re s u lts  of th ese  
s tu d ies  can  be m is in te rp re te d  easily.
Types of participants
A dult (those aged  16 y ea rs  an d  above) cancer p a tie n ts  of e ith e r sex, receiv ing 
active t re a tm e n t for cancer, w ith  cu ra tiv e  or p a llia tiv e  in ten tio n . T his review  
focused only on p a tie n ts  receiv ing  active cancer t re a tm e n t  an d  no t on p a tie n ts  
w ho fin ish ed  cancer tre a tm e n t. A lthough  som e cancer survivors, specifically 
b re a s t  cancer survivors, con tinu e  to receive horm one th e ra p y  for sev era l years, in  
th is  rev iew  th is  group of su rv ivors w as considered  as a  group w ho fin ish ed  the  
active period  of receiv ing  cancer tre a tm e n t.
Types of interventions
A b ro ad  ra n g e  of in te rv e n tio n s  w ere considered, such as psy cho th erapy , psycho­
educa tion  an d  also in te rv e n tio n s  con ta in ing  e lem en ts  such as; education , 
cognitive re s tru c tu r in g  an d  chang ing  coping s tra teg ies . In te rv e n tio n s  focusing on 
b eh av io u ra l chang es w ere included , for exam ple; b eh av io u ra l th e rap y , self-help 
or self-care. In  add ition  o th e r in te rv en tio n  types such as; su p p o rt groups, 
re lax a tio n , energy  conservation , or s tre s s  m an ag em en t, an d  in te rv e n tio n s  
com bining psychosocial e lem en ts  w ith  p hysica l ac tiv ity  w ere included . B oth 
in d iv id u a l a n d  group-focused in te rv e n tio n s  w ere included.
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The psychosocial in te rv e n tio n  needed  to fu lfil th e  following conditions:
• th e  in te rv e n tio n s  involved a sy s tem atic  tre a tm e n t  consisting  of a process 
be tw een  th e  p a tie n t  an d  th e  p e rson  giving th e  in te rv en tio n ;
• th e  in te rv e n tio n s  consis ted  of a t  le a s t two con tac ts b e tw een  th e  p a tie n t  an d  
th e  care  p ro v ider w ho gave th e  in te rv en tio n ;
• d u rin g  th e  in te rv e n tio n  a care  p ro v ider gave th e  p a tie n t  som e k in d  of 
p e rso n a l feedback  concerning th e  chang es th ey  w ere try in g  to achieve, for 
exam ple, in  th e  f irs t  session  a care  p ro v ider could advise  a p a tie n t  to change 
th e ir  coping beh av io u r a im ing  to red uce  fatigue , w h ils t d iscussing  th e  
p ro g ress  of th e  p a tie n t  a n d  giving feedback  on th e ir  beh av io u r in  la te r  
sessions.
Types of outcome measures
In  th e  inc luded  stud ies, fa tig u e  w as a t  le a s t one of th e  outcom e m easures. 
S tu d ies  w ere inc luded  w hen  fa tig u e  w as m easu red  w ith  a q u es tio n n a ire  
specifically designed  to ev a lu a te  fa tigue , or o th e r in s tru m e n ts  u se d  by a u th o rs  to 
ev a lu a te  fa tig ue . F o r exam ple, fa tig u e  w as m easu red  as p a r t  of a  q u a lity  of life 
in s tru m e n t, w ith  a v isu a l analogue scale (VAS), or a s  p a r t  of a sym ptom  lis t  and  
scored as ‘p re se n t’ or ‘a b se n t’.
Search methods for identification of studies
1) E lec tron ic  d a tab ases
We sea rch ed  th e  C ochrane C en tra l R eg iste r of C on tro lled  T ria ls  (CENTRAL) 
(The Cochrane L ibrary, S ep tem ber 2008), PU B M ED  (1950 to S ep tem b er 2008), 
M E D L IN E  (1966 to S ep tem ber 2008), EM BA SE (1980 to S ep tem ber 2008), 
CIN A HL (1982 to S ep tem ber 2008) an d  PsycIN FO  (1806 to S ep tem ber 2008).
We id en tified  s tu d ies  for th is  rev iew  usin g  sea rch  s tra teg ie s  b a sed  on the  
M E D L IN E  (via OVID) s tra te g y  se t ou t in  A ppendix  1, w hich  u se s a com bination  
of M eSH  an d  free tex t te rm s. M eSH  te rm s  w ere exploded. T erm s w ere searched  
in  th e  title , ab s tra c t, sum m ary , h ead in g  or keyw ords. We ap p lied  th e  C ochrane 
C ollaboration  filte r for th e  iden tifica tion  of RCTs, a s  p u b lish ed  in  th e  C ochrane
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H andbook for S y stem atic  R eview s of In te rv e n tio n s25. We a d ju s ted  th e  search  
s tra teg y  ap p ro p ria te ly  for each  d a ta b a se  searched.
2) R eference search
We checked th e  reference  lis ts  of re le v a n t a rtic le s  for ad d itio n a l stud ies, and  
app lied  back w ard  a n d  fo rw ard  sea rch ing  to th e  re le v a n t artic les.
3) Jo u rn a ls
W hen no d ig ita l a rtic le s  a re  availab le , we h a n d  sea rch ed  th e  jo u rn a ls .
4) C om m unications
We con tac ted  a u th o rs  of sev era l s tu d ies  to req u ire  ad d itio n a l in form ation .
5) O ngoing stud ies
We checked The A u stra lia n  New Z ea lan d  C lin ical T ria ls  R egistry , the  
C lin icalT rials.gov reg is try , th e  ISR C T reg is te r, U M IN  C lin ical T ria ls  R egistry , 
a n d  th e  D u tch  T ria l R eg iste r, for ongoing stud ies. We sea rch ed  each  re g is te r  for 
th e  keyw ords 'cancer' a n d  'fa tigue ', an d  se lected  s tu d ies  th a t  w ere cu rren tly  
rec ru itin g  p a r tic ip a n ts . T here  w as no lan g u ag e  re s tr ic tio n  on studies.
Data collection and analysis
Selection of trials
O ne rev iew  a u th o r  (MMG) screened  tit le s  an d  a b s tra c ts  a n d  e lim in a ted  those 
clearly  no t re le v a n t to th is  review . W hen th e  title  a n d  a b s tra c t d id  no t provide all 
th e  in fo rm atio n  concerning th e  c rite ria , fu ll p a p e r copies w ere re tr ie v e d  an d  
screened. A u th o rs  of s tu d ies  w ere con tac ted  w hen  ad d itio n a l in fo rm atio n  w as 
re q u ire d  to assess  if  th e  s tu d ies  m et th e  c r ite ria  for inclusion. T hree  review  
a u th o rs  (MMG, M G an d  GB) screened  th e  rem a in in g  s tu d ies  for th e ir  elig ib ility  
a n d  d iscussed  in  accordance w ith  th e  above defined  c rite ria , i f  th e  s tu d ies  w ere 
inc luded  or excluded. D isag reem en t abou t th e  selection  of a  t r ia l  w as reso lv ed  by 
consensus. The rev iew  a u th o rs  w ere a lread y  fam ilia r w ith  som e of th e  studies, 
an d  th e re fo re  th e  re le v a n t s tu d ies  w ere no t b lin d ed  for assessm en t.
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Quality assessment
T hree  rev iew  a u th o rs  (MMG, M G an d  GB) in d ep en d en tly  a ssessed  the 
m ethodological q u a lity  of th e  se lected  stud ies. The RCTs w ere e v a lu a te d  u sin g  a 
Q u ality  R a tin g  Scale. T h is scale co n ta in ed  a ll th e  c r ite r ia  of th e  O xford Q uality  
S cale26, th e  D elph i l is t27 an d  ad d itio n a l c r ite ria  l is te d  by V an  T u ld er (1997)28. 
The following asp ec ts  of th e  selected  s tu d ies  w ere scored to ev a lu a te  the  
m ethodological quality:
• ran d o m  assign m ent;
• lo sses to follow-up;
• b lin d  analysis;
• in te n tio n -to -tre a t analysis;
• p a r tic ip a n ts  adherence;
• adverse  effects of th e  in te rven tion ;
• elig ib ility  crite ria ;
• follow-up m easu rem en ts;
• pow er calculation;
• possib le differences betw een  th e  t re a tm e n t  group an d  th e  contro l group, and  
in  th e  tim in g  of th e  assessm en ts;
• concealed  allocation;
• con tam ination .
C oncealm ent of allocation  w as e v a lu a te d  u sin g  th e  c r ite ria  defined  in  The 
C ochrane H andbook25. W hen n o th in g  w as described  abou t concealm ent of 
a llocation  in  th e  stud ies, concealed allocation  w as e v a lu a te d  as ‘u n c lea r’. To 
in v es tig a te  th e  effectiveness of an  in te rv e n tio n  it  is  im p o rta n t to m inim ize 
con tam ina tion . C o n tam in a tio n  m ean s th a t  p a tie n ts  in  th e  contro l group get 
in fo rm ed  abou t th e  in te rv e n tio n  a n d  i ts  con ten t, a n d  su b seq u en tly  use th is  
in fo rm ation . W hen th is  h a p p e n s  th e  effect of th e  in te rv e n tio n  i tse lf  is  h a rd e r  to 
d em o n stra te . To m in im ize co n tam in a tio n  i t  is  adv isab le  to avoid con tac t be tw een  
p a tie n ts  in  th e  contro l condition, a n d  care  p ro v iders giving th e  in te rv en tio n , or 
o th e r s ta ff in fo rm ed  abou t th e  in te rv en tio n .
A dditio nal asp ec ts  w ere scored to ev a lu a te  th e  q u a lity  of th e  in te rv en tio n :
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• how m any  care  p ro v iders gave th e  in te rv en tio n ;
• if  care  p ro v iders w ere tra in ed ;
• if  care  p ro v iders w ere  supervised;
• if  an  in te rv e n tio n  protocol w as used;
• if  an  in te g r ity  check w as described.
In  m ost q u a lity  ra t in g  scales b lind ing  is  ev a lu a te d  on sev era l levels, such as 
b lind ing  of p a tie n ts  an d  care  p rov iders. These scales a re  o ften  u se d  to te s t  the  
q u a lity  of p lacebo-contro lled  m edication  stud ies. H ow ever, th e  n a tu re  of RCTs 
te s tin g  psychosocial in te rv e n tio n s  is  d ifferent. In  th ese  t r ia ls  i t  is  nea rly  
im possib le to b lin d  th e  p a tie n ts  to th e  in te rv e n tio n  th ey  w ere ass ig n ed  to. In  
add ition  i t  is  also im possib le  to b lin d  th e  care  p ro v iders to th e  in te rv en tio n  th ey  
a re  g iving to th e  p a tie n ts . T hus, b lind ing  of p a tie n ts  an d  care  p ro v iders w ere not 
scored in  th e  Q uality  R a tin g  Scale.
The th re e  rev iew  a u th o rs  m et to d iscuss a ll item s of th e  Q u ality  R ating  
Scale of th e  stud ies, a n d  to rea ch  a fin a l q u a lity  score by consensus. The to ta l 
score of th e  Q u ality  R a tin g  Scale v a r ie d  betw een  one an d  25 an d  w as d iv ided  in to  
th re e  categories. W hen th e  to ta l  score w as b e tw een  one a n d  nine, th e  q u a lity  w as 
ra te d  as poor, w h en  b etw een  te n  a n d  17 as m oderate , a n d  w h en  b etw een  18 and  
25 as good.
Data extraction
T hree  rev iew  a u th o rs  (MMG, M G an d  GB) in d ep en d en tly  e x tra c te d  d a ta  from  the 
selected  s tu d ies  using  d a ta  ex trac tio n  form s. The d a ta  ex trac tio n  form  w as 
designed  usin g  lis te d  c r ite ria  described  by V an T u ld er (1997)28, an d  a scale to 
ev a lu a te  RCTs developed by th e  E B R O -forum 29, a n d  w as ex p an d ed  w ith  
necessa ry  in fo rm atio n  on th e  psychosocial in te rv e n tio n s  to be eva lu a ted . A ny 
d isag reem en t w as reso lved  th ro u g h  consensus.
F rom  each  selected  stu d y  th e  following d a ta  w as ex trac ted :
P a tie n t  charac teris tics^
• D em ographic  c h a rac te r is tic s  such as  age an d  gender.
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• D isease  c h a rac te r is tic s  such as  type  of cancer, stage of cancer, types and  
d u ra tio n  of tre a tm e n t.
In te rv en tio n  characteris tics^
• D u ra tio n  of th e  in te rv en tio n , to ta l  n u m b er of sessions an d  d u ra tio n  of each 
session.
• The n a tu re  a n d  co n ten t of th e  psychosocial in te rv en tio n .
• The n u m b er of care  p ro v iders a n d  th e  profession.
• D u ra tio n  an d  n a tu re  of tra in in g  an d  superv ision  given to th e  care  prov iders.
• P a tie n t  com pliance an d  con tam ination .
In fo rm ation  on statistics^
• N u m b er of p a r tic ip a n ts  in  each  arm .
• D u ra tio n  of sh o rt- te rm  follow-up and , i f  availab le, long -term  follow-up.
• In s tru m e n ts  used, key  outcom es an d  descrip tion  of m issing  data .
Data synthesis and effect of psychosocial interventions
A n a rra tiv e  overview  of th e  inc luded  RCTs w as p rov ided  in  th is  review . We 
a ssessed  w hich  in te rv e n tio n s  d u rin g  cancer tre a tm e n t  w ere  effective in  red uc ing  
fa tigue , a n d  described  ex p lan a tio n s for th e  effectiveness w here  possib le. To 
d e te rm in e  th e  m ag n itu d e  of th e  effect, effect sizes w ere ca lcu la ted  of th e  s tu d ies  
th a t  w ere effective in  red uc ing  fatigue . The size of th e  effect is  ca lcu la ted  in  a 
s ta n d a rd ized  w ay, an d  th ere fo re  th e  effect sizes across th e  v a rio u s s tu d ies  can  be 
com pared . The effect sizes w ere  ca lcu la ted  by u sin g  th e  m ean s an d  s ta n d a rd  
dev ia tions of two g roups (ex perim en ta l group an d  contro l group) of th e  p o s t­
in te rv en tio n  or follow-up m easu rem en t, in  th e  following way:
Effect size = M  - M/apookd 
w h ere  apooled = V[(a i2+ a 22)/2 ]
As th e  ch a rac te r is tic s  of th e  inc luded  stud ies, th e  in s tru m e n ts , an d  the  
in te rv e n tio n s  w ere very  diverse, we concluded th a t  a  m e ta -an a ly s is  or a subgroup 
a n a ly sis  w as no t sensib le or ap p ro p ria te .
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RESULTS
Description of studies
Excluded studies
The sea rch  of th e  electron ic  d a ta b a se s  re tr ie v e d  2210 pub lica tions. A fter 
e lim in a tin g  th e  du p lica tes  1753 p u b lica tions w ere id en tified  for fu r th e r  
consideration . A fter screening  th e  t it le s  a n d  electron ic  av ailab le  a b s tra c ts  1668 
p u b lica tions w ere excluded. R easons for excluding p u b lica tions w ere the  
following:
• s tu d ies  w ere no in te rv en tio n  stud ies, for exam ple s tu d ies  w ere rev iew s, or 
com m ents;
• s tu d ies  e v a lu a te d  no psychosocial in te rv en tio n s , for exam ple m edical 
tre a tm e n ts , exercise, or m assage;
• s tu d ies  w ere no RCTs, for exam ple s tu d ies  d id  no t h av e  a contro l group, or 
p a r tic ip a n ts  w ere  no t random ised;
• s tu d ies  d id  no t focus on cancer p a tie n ts  or only a p a r t  of th e  sam ple w ere 
cancer p a tien ts ;
• s tu d ies  e v a lu a te d  in te rv e n tio n s  in  cancer p a tie n ts  a fte r fin ish in g  cancer 
tre a tm e n t;
• fa tig u e  w as no t a ssessed  as  an  outcom e m easure .
A fter th is  in it ia l  screening, th e  fu ll-tex t a rtic le s  w ere re tr ie v e d  of th e  rem ain in g  
85 p o te n tia l stud ies. F rom  th ese  fu ll-tex t a rtic le s  56 s tu d ies  w ere excluded 
leav ing  29 s tu d ies  to review . T hese 56 s tu d ies  w ere  excluded for th e  following 
reasons; 15 s tu d ies  w ere  excluded  becau se  th e  in te rv e n tio n s  w ere given to 
p a r tic ip a n ts  a fte r fin ish in g  cancer tre a tm e n t. O ne stu d y  w as excluded  because 
m ost p a r tic ip a n ts  did  no t receive cancer t re a tm e n t  d u rin g  th e  in te rv en tio n . Five 
s tu d ies  d id  no t describe if  p a r tic ip a n ts  received  cancer t re a tm e n t  d u rin g  the 
in te rv en tio n . O ne stu d y  focused on p a r tic ip a n ts  receiv ing  colorectal su rg e ry  and  
d id  no t only inc lude  cancer p a tie n ts , b u t also p a tie n ts  w ith  o th e r types of 
d iseases. Six s tu d ies  w ere no t RCTs. Two stu d ies  h a d  less th a n  te n  p a rtic ip a n ts  
in  each  condition. In  fou r s tu d ies  fa tig u e  w as no t m easu red  an d  th re e  s tu d ies  did
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no t describe se p a ra te  re s u lts  on fa tigue . N in e teen  s tu d ies  id en tified  d id  not 
inc lude  psychosocial in te rv en tio n s . In  two stu d ies  th e  in te rv en tio n  w as m ain ly  
focused on chang ing  exercise behav iour. In  th re e  s tu d ies  n u tr i t io n a l  beh av io u r 
w as th e  focus of th e  in te rv en tio n  an d  one focused on m edication . In  13 stud ies 
th e  in te rv e n tio n s  w ere no t psychosocial in te rv en tio n s  according to our defin ition  
described  in  'Types of in te rv en tio n '. The in te rv e n tio n s  d id  no t consist of a 
sy s tem atic  p rocess be tw een  th e  p a tie n t  an d  th e  perso n  giving th e  in te rv en tio n . 
The excluded  s tu d ies  a re  described  in  m ore d e ta il in  Table 1: C h a ra c te r is tic s  of 
excluded studies.
Ongoing studies
The sea rch  for ongoing s tu d ies  found  e igh t RCTs th a t  a re  c u rre n tly  rec ru itin g  
p a rtic ip a n ts . T hree  of th e se  s tu d ies  a re  e v a lu a tin g  d ifferen t types of yoga 
in te rv en tio n  (Cohen, 2007a; Cohen, 2007b; Oh, 2008b). P u rce ll (2008) is 
e v a lu a tin g  a group ed u ca tio n  an d  su p p o rt in te rv en tio n , an d  S av a rd  (2008) a self 
help  tre a tm e n t  for in som nia . Two stu d ies  a re  e v a lu a tin g  tw o in te rv en tio n s  
com pared  to u su a l  care. C ohen (2004a) is e v a lu a tin g  m in d fu lness re lax a tio n , an d  
m usic re lax a tio n . G oedendorp (2005) is  e v a lu a tin g  cognitive beh av io u r th e rap y  
an d  a n u rs in g  in te rv en tio n . Cohen (2006) is  also e v a lu a tin g  a cognitive behav iou r 
in te rv en tio n . The ongoing s tu d ies  a re  described  in  m ore d e ta il in  T able 2: 
C h ara c te r is tic  of ongoing stud ies.
Included studies
Two re m a rk s  shou ld  be m ade w ith  re g a rd s  to th e  29 inc luded  stud ies. In  the 
S an d g ren  (2003)30 s tu d y  th e  im m ed ia te  effects of th e  in te rv e n tio n  a re  described 
w h e reas  th e  dup lica te  stu d y  S an d g ren  (2007)31 in c ludes th e  follow-up. Goodwin
(2001)32 an d  i t 's  dup lica te  stu d y  B orde leau  (20 03)33 described  th e  effects of the  
sam e in te rv en tio n , b u t p re se n te d  re s u lts  on d ifferen t outcom e m easu res. 
T herefore th e se  29 p u b lica tions w ere  e v a lu a te d  as 27 se p a ra te  inc luded  studies.
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P a r tic ip a n ts
D isease  characteristics
A m ajo rity  of th e  stud ies, 13, focused on p a tie n ts  w ith  one type  of m alignancy, 
m ain ly  p a tie n ts  w ith  b re a s t  cancer. In  e leven s tu d ies  p a r tic ip a n ts  w ere  p a tie n ts  
w ith  b re a s t  cancer, how ever, w ith  d ifferen t s tag es  of cancer. T hree stud ies 
inc luded  b re a s t  cancer p a tie n ts  w ith  s tag es I- I I34-36. S an d g ren  (2003)30 an d  
M oadel (2007)37 inc luded  p a tie n ts  w ith  stages I-III, an d  G asto n -Jo h an sso n  
(2000)38 inc luded  p a tie n ts  w ith  stag es II-IV. Two stu d ies  focused on p a tie n ts  w ith  
o th e r types of cancer, such as  p ro s ta te  can ce r39, or m a lig n an t m elan o m a40. Six 
s tu d ies  inc luded  only m e ta s ta tic  cancer p a t ie n ts 32, 41-45. F ive of th ese  s tu d ies  
inc luded  p a tie n ts  w ith  m e ta s ta tic  b re a s t  can ce r32, 41, 43-45, an d  one; p a tie n ts  w ith  
m e ta s ta tic  re n a l  cell carc inom a42.
The rem a in in g  s tu d ies  inc luded  cancer p a tie n ts  w ith  m ore th a n  one 
diagnosis. Two stu d ies  focused on p a tie n ts  w ith  two types of cancer. The firs t 
s tu d y  inc luded  p a tie n ts  being  tre a te d  for p ro s ta te  or b lad d e r cance r46. The second 
stu d y  inc luded  p a tie n ts  receiv ing  t re a tm e n t  for g a s tric  or colon cancer47. R aw l 
(2002) inc luded  p a tie n ts  w ith  th re e  d ifferen t types of cancer: b re a s t, colorectal 
a n d  lu n g  cancer48. T en s tu d ies  focused on cancer p a tie n ts  in  g en era l an d  inc luded  
p a tie n ts  w ith  sev era l types of cancer, such as lym phom a's , b re a s t, lung, 
colorectal, p ro s ta te , gynaecologic, te s tic u la r  cancer, a n d  o th e r solid tu m o u rs49-57, 
how ever, one stu d y  excluded  p a tie n ts  w ith  abdom inal can ce r58.
One stu d y  explicitly  described  th a t  p a tie n ts  w ere  tre a te d  w ith  cu ra tive  
in te n t50, a n d  B row n (2006)51 focused on p a tie n ts  w ith  advan ced  cancer. E leven 
s tu d ies  inc luded  cancer p a tie n ts  w ith  v a rio u s  stag es  of cancer, w ith  or w ith o u t 
m e ta s ta s is46'49, 52'58.
Cancer trea tm en t
All 27 inc luded  s tu d ies  described  re s u lts  of in te rv e n tio n s  given to p a tie n ts  d u ring  
cancer tre a tm e n t. In  15 s tu d ies  a ll p a t ie n ts  w ere receiv ing  cancer t re a tm e n t
d u rin g  th e  in te rv en tio n  30, 34, 36, 38, 42, 46-51, 54, 55, 57, 58. In  te n  s tu d ies  m ost, b u t  no t
all, p a tie n ts  w ere receiv ing  active cancer tre a tm e n t  d u rin g  th e  in te rv e n tio n 32, 35,
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37, 39-41, 43 52, 53 56. The pe rcen tag e  of p a tie n ts  receiv ing  active t re a tm e n t  d u rin g  th e  
in te rv en tio n  v a r ie d  from  a t le a s t 44% 35 to 91% 53. E d e lm an  (1999), S av a rd  (2006) 
an d  Spiegel (1981) did no t describe how  m any  p a tie n ts  ac tu a lly  received  cancer 
t re a tm e n t d u rin g  th e  in te rv e n tio n 43-45. H owever, th ese  s tu d ies  focused on 
p a tie n ts  w ith  m e ta s ta tic  cancer, a n d  th erefo re  i t  is  expected  th a t  th e se  p a tie n ts  
w ould  h av e  received  t re a tm e n t  som etim e d u rin g  th e  in te rv en tio n .
In  m ost s tu d ies  th e  in te rv e n tio n s  w ere given to p a tie n ts  receiv ing
ch em o th erap y  only36, 47-49, 55, 57, or ra d io th e ra p y  only 46, 51, 54, 58. F our stud ies
inc luded  p a r tic ip a n ts  receiv ing  ch em o th erap y  or ra d io th e ra p y  34, 35, 50, or 
ch em o th erap y  or horm one th e ra p y 41. F ive s tu d ies  inc luded  p a r tic ip a n ts  w ith  
sev era l t re a tm e n t  reg im es. O ne stu d y  inc luded  p a r tic ip a n ts  w ho h a d  surgery , 
ra d io th e ra p y  or horm one th e ra p y 39. Five s tu d ies  inc luded  p a r tic ip a n ts  receiv ing 
chem otherapy , ra d io th e ra p y  or horm one th e ra p y  30, 32, 52, or ad d itio n a lly  su rgery  
or o th e r tre a tm e n t  37, 53. In  one s tu d y  som e p a r tic ip a n ts  received  chem otherapy , 
b u t i t  is  u n c lea r if  p a r tic ip a n ts  also received  o th e r types of t r e a tm e n t56. T hree 
s tu d ies  focused on o th e r t r e a tm e n ts 38, 40, 42. The f irs t  s tu d y  inc luded  p a tie n ts  
receiv ing  im m u n o th e rap y 40. The second stu d y  focused on p a tie n ts  receiv ing 
neph recto m y  an d  vaccine t r e a tm e n t42 an d  th e  th ird  stu d y  inc luded  p a tie n ts  
receiv ing  bone m arrow  tra n s p la n ta tio n 38.
O ther criteria  for inclusion
In  two stu d ies  th e  p a r tic ip a n t sam ple w as strik in g ly  d ifferen t th a n  th e  o ther 
stud ies. De W it (1997)53 inc luded  only p a r tic ip a n ts  w ith  cancer re la te d  pain , and  
S av a rd  (2006)44 focused on d ep ressed  m e ta s ta tic  b re a s t cancer p a tien ts .
Two stu d ies  described  inc lu sion  c r ite ria  for fa tigue . A rm es (2007)49 explicitly  
described  th a t  cancer p a tie n ts  w ith  sign ifican t fa tig u e  w ere included, a n d  G iven
(2002)55 inc luded  p a tie n ts  rep o rtin g  bo th  fa tig ue  a n d  p a in  a t  base line . As 
p a tie n ts  w ere inc luded  d u rin g  chem otherapy , i t  is  expected  th a t  th e  m ajo rity  of 
th e  p a tie n ts  w ould  experience sym ptom s a t tim e of accrual.
M ost s tu d ies  described  ad d itio n a l exclusion c rite ria . P a r tic ip a n ts  w ere 
excluded for sev era l reasons. Som e rea so n s  w ere cancer or t re a tm e n t  re la ted . 
T hree  s tu d ies  excluded  cancer p a tie n ts  w ith  p rev io u s40, 41 or o th e r can ce r39. Six
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stu d ies  excluded  p a tie n ts  w ho received  p rev ious cancer t re a tm e n t47, such  as 
ch em o th erap y 42, 57, ra d io th e ra p y 54, cytokine tre a tm e n t49, or im m u n o th e rap y 42. 
O ne stu d y  excluded  p a tie n ts  if  th e ir  t re a tm e n t p lan  in c lu d ed  stem  cell 
t ra n sp la n ta tio n , in te r leu k in s , in te rfe ro n s, or tu m o u r necrosis fac to r50.
O th e r ad d itio n a l c r ite ria  w ere  also described. M ost s tu d ies  excluded cancer 
p a tie n ts  w ith  o th e r com orbid ities30, 32, 39, 41-43, 47, 49, 50, 56, or c u r re n t  or a h is to ry  of 
p sy ch ia tric  illn esses  32, 34, 39, 40, 44, 47, 49, 51, 54, 56, 57. E ig h t s tu d ies  excluded  cancer 
p a tie n ts  involved in  in te rv e n tio n  s tu d ie s50, 51, or o th e r types of care  p ro g ram s44, 
such as  su p p o rt g ro u p s32, 39, a t te n d in g  yoga37 or m edical qigong56, or receiv ing 
p sy ch o th e rap y 49. Six s tu d ies  d id  no t describe ad d itio n a l c r i te r ia 35, 36, 45, 46, 52, 57.
In te rv en tio n s
S tu d ies  w ere only inc luded  in  th is  rev iew  if p a r tic ip a n ts  received  th e  in te rv en tio n  
d u rin g  cancer tre a tm e n t.
In  m ost s tu d ies  th e  in te rv en tio n  w as s ta r te d  d u rin g  cancer tre a tm e n t, 
a lth o u g h  it  often re m a in e d  u n c lea r a t  w h a t stage  of cancer tre a tm e n t the  
in te rv e n tio n s  ended. O f th e  s tu d ies  th a t  ev a lu a te d  sho rt in te rv e n tio n s  (four 
w eeks or less) i t  is  likely  th a t  p a r tic ip a n ts  con tinu ed  w ith  cancer t re a tm e n t a fte r 
th e  in te rv e n tio n 36, 42, 50, 51. W hen th e  d u ra tio n  of th e  in te rv en tio n  w as longer it 
re m a in e d  u n c lea r how m any  p a r tic ip a n ts  co n tin u ed  w ith  cancer t re a tm e n t  a fte r 
th e  in te rv en tio n . O nly  four s tu d ies  described  explicitly  a t w h a t stage of cancer 
t re a tm e n t  th e  in te rv e n tio n  ended. In  F a ith fu ll (2001) th e  in te rv e n tio n  s ta r te d  a t 
th e  beg inn ing  of cancer t re a tm e n t an d  en d ed  a t  th e  en d  of th e  t re a tm e n t46. In  
th re e  s tu d ies  th e  in te rv e n tio n  co n tin u ed  a fte r  p a r tic ip a n ts  f in ish ed  cancer 
t r e a tm e n t38, 47, 58.
F orm at
In  m ost s tu d ies  th e  in te rv en tio n  w as a d m in is te red  by n u rs e s 30, 36, 40, 46-50, 53, 55, 57.
In  th e  s tu d y  of O h (2008)56 a n  experienced  in s tru c to r  gave m edical qigong. In  the  
stu d y  of M oadel (2007)37 th e  yoga in s tru c to r  w as also a n  oncologist. In  the  
rem a in in g  s tu d ies  th e  in te rv en tio n  w as a d m in is te red  by social w o rk e rs34, 38, 
(p sy cho)therap is ts43, 58, psychologists44, or g ra d u a te  s tu d e n ts35, 52, 54. In  five
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stu d ies  th e  in te rv e n tio n  w as m u ltid isc ip lin a ry 32, 39, 41, 45, 51. In  seven s tu d ies  th e re  
w as one care  p ro v ider g iving th e  in te rv e n tio n 34, 37, 48, 49, 52, 56, 58. In  th re e  s tu d ies  it 
w as u n c lea r how  m any  care  p ro v id ers  gave th e  in te rv e n tio n 38, 40, 46, b u t i t  m ay 
h av e  been  only one. In  a ll o th e r s tu d ies  m ore th a n  one care  p ro v ider gave the  
in te rv en tio n .
In  ten  s tu d ies  th e  in te rv en tio n  w as given in  g ro u p s32, 34, 37, 39, 41, 43, 45, 51, 52, 56, 
in  th e  re m a in in g  s tu d ies  th e  in te rv e n tio n  w as given ind iv idually . The ind iv id u a l 
sessions w ere m ostly  face-to-face, b u t  seven w ere exceptions. In  th e  s tu d ies  of 
S an d g ren 30, 35 an d  B arsev ick  (2004)50 th e  p a r tic ip a n ts  received  only te lephone 
sessions. T hree  s tu d ies  com bined face-to-face con tac t a n d  te lepho ne calls in  th e  
in te rv e n tio n 36, 53, 55. In  one stu d y  p a r tic ip a n ts  received  in d iv id u a l w ritin g  
in s tru c tio n s , for sev era l occasions42. The in s tru c tio n s  s tim u la te d  p a r tic ip a n ts  to 
w rite  abou t th e ir  th o u g h ts , fee lings a n d  consequences on th e ir  lives. We decided 
to inc lude  th is  s tu d y  as change of cognitions an d  beh av io u r w ere th e  focus of the  
in te rv en tio n .
In  14 s tu d ies  ad d itio n a l in fo rm atio n  m a te r ia ls  w ere given to the  
p a r tic ip a n ts34, 36-38, 41, 43, 46, 47, 49, 51-54 56. In  e ig h t s tu d ies  p a r tic ip a n ts  received  
w ritte n  in fo rm atio n  36, 43, 46, 47, 49, 51, 53, 56. In  one s tu d y  p a r tic ip a n ts  received 
au d io ta p es37, an d  in  five s tu d ies  p a r tic ip a n ts  received  bo th  w ritte n  in fo rm ation  
a n d  a u d io ta p es34, 38, 52, 54 an d  ad d itio n a l v id eo tap es41.
D uration
The n u m b er of sessions w as described  in  22 stud ies, b u t th e re  w as a lo t of 
v a ria tio n . Am ong th ese  s tu d ies  th e  n u m b er of sessions v a r ie d  from  two to 12, 
w ith  a m ed ian  of six sessions. In  tw o stu d ies  th e  n u m b er of sessions w as no t fixed 
for p a r tic ip a n ts37, 56. In  th e  rem a in in g  th re e  s tu d ies  th e  in te rv en tio n  consis ted  of 
w eekly  90 m in u te  sessions, for th e  d u ra tio n  of a t  le a s t one year, b u t th e  ac tu a l 
n u m b er of sessions w as no t given. The n u m b er of sessions could be e s tim a te d  to 
be a ro u n d  5 032, 41, 45.
F o u r s tu d ies  fa iled  to describe th e  d u ra tio n  of each  session 38, 43, 47, 57. Among 
th e  rem a in in g  23 s tu d ies  th e  d u ra tio n  of th e  sessions v a r ie d  from  te n  m in u te s  to
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th re e  hou rs. The m ost com m on d u ra tio n  w as 30 m in u te s  for in d iv id u a l sessions 
an d  90 m in u te s  for group sessions.
The d u ra tio n  of th e  fu ll in te rv e n tio n  w as described  in  20 s tu d ies  or could be 
e stim a ted . The to ta l  d u ra tio n  of th e  in te rv e n tio n s  v a r ie d  from  two w eek s36 to 20 
w eeks43, 55, w ith  th re e  exceptions h av in g  a d u ra tio n  of a t  le a s t one y e a r32, 41, 45. 
F rom  six s tu d ies  th e  a c tu a l len g th  of th e  in te rv en tio n  w as no t clear, b u t 
depen ded  on th e  cancer t re a tm e n t  p a r tic ip a n ts  h a d  received. For exam ple the  
sessions took place on specific p o in ts  in  p a tie n ts ’ t re a tm e n t  reg im es38, 46, 47, 57, 
took p lace d u rin g  p a tie n ts ’ clinic v is its40, or depen ded  on th e  d u ra tio n  of the  
h o sp ita l ad m issio n 53. O ne s tu d y  did  no t describe th e  to ta l  len g th  of th e  
in te rv e n tio n 54.
C ontent
In  only five s tu d ies  th e  in te rv e n tio n  w as specifically focused on fa tig u e 36, 47, 49, 50,
57. All th e  o th e r in te rv e n tio n s  focused on o th e r aspects . E ig h t in te rv en tio n s  
a im ed  to in fluence d ep ression44, depression  an d  an x ie ty 39, or m ood s ta te s  in  
g en e ra l41-43, 45, 52, 54. Som e in te rv e n tio n s  focused on sym ptom s, such as p a in 53, or 
on sym ptom s a n d  side-effects in  g e n e ra l34, 38, 46, 48, 55, 58. In te rv e n tio n s  also focused 
on d is tre ss30, 34, 35, 40'42, 52, 58 an d  q u a lity  of life 32, 35, 37, 39, 46, 51, 56.
The e lem en ts  of th e  in te rv en tio n  v a r ie d  am ong th e  stud ies. Some 
in te rv e n tio n s  w ere b ased  on one or two e lem en ts, w hile  o th e rs  u sed  m ultip le  
techn iq ues. F o u r s tu d ies  focused on th e  expression  of em o tions30, 42, on providing 
social su p p o rt45, or a com bination  of th e se  tw o32. Yoga w as e v a lu a te d  in  two 
stud ies, w ith  e lem en ts  such as  m ed ita tion , an d  p hysica l s tre tch ing . Yoga also 
fa lls w ith in  com plem en tary  m edicine, b u t  as g en era l d iscussion  a n d  re lax a tio n  
w ere also p a r ts  of th e  in te rv en tio n , i t  w as decided to include  th e se  s tu d ie s37, 56. 
A ll o th e r s tu d ies  u se d  a com bination  of sev era l e lem en ts  in  th e  in te rv en tio n . 
Teaching, giving p a tie n ts  in fo rm atio n  an d  educa tion  on cancer a n d  tre a tm e n t  is 
often u se d  as  one of th e  elem en ts. In  two stu d ies  exercise w as ac tua lly  
p erfo rm ed 39, 51, b u t  ac tiv ities w ere m ore often  one of th e  topics, for exam ple 
ac tiv ity  m an ag em en t, or energy  conservation . R elaxation  or gu ided  im ag ery  w ere 
som etim es u sed  as  tech n iq u es to m an ag e  stress. P rob lem  solving or teach in g
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p a tie n ts  coping s tra teg ie s  w ere also e lem en ts  of sev era l in te rv en tio n s . In  four 
s tu d ies  cognitive (behavioural) th e ra p y  w as th e  in te rv e n tio n 34, 43, 44, or 
p sy ch o th e rap y 58.
C ontrol group.
In  18 s tu d ies  p a r tic ip a n ts  in  th e  contro l group did  no t receive th e  in te rv en tio n , 
b u t received  s ta n d a rd  care  an d  s ta n d a rd  in fo rm atio n 30, 32, 34, 35, 38'4°, 43, 47'49, 51, 53'58. 
In  th e  s tu d ies  of S av a rd  (2006)44 a n d  M oadel (2007)37 p a r tic ip a n ts  in  th e  control 
group w ere a ss ig n ed  to a w a itin g  list. O ne stu d y  d id  no t specify th e  control 
g roup45. In  six s tu d ies  th e  contro l condition  involved m ore th a n  s ta n d a rd  care. In  
th e  stu d y  of C lassen  (2001)41 p a r tic ip a n ts  w ere  p ro v ided  w ith  self-d irected  
educa tion  m a te ria ls . In  four s tu d ies  p a r tic ip a n ts  in  th e  contro l group received  an  
in te rv en tio n  w ith  th e  sam e n u m b er an d  d u ra tio n  of sessions, b u t  received 
d ifferen t in fo rm ation . In  th e  firs t s tu d y  th e  contro l condition  com prised  
supportive  d iscussion  a lone52. In  th e  second stu d y  p a r tic ip a n ts  in  th e  contro l 
group received  in fo rm atio n  on n u tr i t io n 50. In  th e  th ird  stu d y  th e  contro l condition 
w as a 'n e u tra l  w ritin g ' condition42. In  th e  fou rth  stu d y  p a r tic ip a n ts  received  
g en era l in fo rm atio n  on liv ing w ith  can ce r36. In  one s tu d y  p a r tic ip a n ts  in  the  
contro l group h a d  m ore m om en ts of con tact th a n  in  th e  in te rv en tio n  g roup46. 
P a r tic ip a n ts  in  th e  contro l group received  ro u tin e  te n  m in u te  w eekly 
ap p o in tm en ts  for p a tie n ts  w ith  b lad d er cancer, or te n  m in u te  tw o-w eekly 
ap p o in tm en ts  for p a tie n ts  w ith  p ro s ta te  cancer, led  by physicians.
O utcom es
S tu d ies  w ere only inc luded  w hen  th ey  w ere RCTs. T hus, a ll th e  s tu d ies  h a d  
a b ase lin e  asse ssm en t an d  a p o s t-in te rv en tio n  assessm en t. H ow ever, th e  to ta l 
n u m b er of a sse ssm en ts  v a r ie d  b etw een  two an d  six a ssessm en ts , w ith  a m ed ian  
of th ree . S tu d ies  w ith  m ore th a n  two m easu rem en ts , also a ssessed  p a rtic ip a n ts  
du rin g  th e  in te rv en tio n , or h a d  a follow-up m easu rem en t. Twelve s tu d ies  h a d  one 
or m ore follow-up m e a su re m e n ts30, 34-36, 40, 42, 43, 49, 50, 52, 53, 58, a n d  te n  stud ies 
a ssessed  p a r tic ip a n ts  once or m ore d u rin g  th e  in te rv e n tio n 32, 38, 39, 41, 43, 45, 47, 48, 55,
58.
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The tim in g  of th e  m ea su re m e n ts  v a r ie d  a lo t across th e  stud ies. In  m ost 
s tu d ies  p a r tic ip a n ts  w ere a ssessed  im m ed ia te ly  or w ith in  a few days a fte r th e  
in te rv e n tio n  w as com pleted. In  two stu d ies  th e  tim e betw een  th e  en d  of the  
in te rv en tio n  an d  th e  asse ssm en t of p a r tic ip a n ts  w as longer; one m o n th 48 an d  six 
w eeks40 a fte r th e  in te rv en tio n . The a c tu a l tim e b e tw een  th e  en d  of the  
in te rv en tio n  a n d  th e  asse ssm en t w as no t obvious in  five s tu d ie s30, 36, 46, 49, 50. In  
two of th e se  s tu d ies  th e  a c tu a l tim e betw een  th e  en d  of th e  in te rv en tio n  a n d  the  
follow-up asse ssm en t w as also u n c le a r46, 50. In  B arsev ick  (2004) a n d  Y ates (2005) 
th e  post- an d  follow-up asse ssm en t depen ded  on th e  tre a tm e n t  regim es, 
ra d io th e ra p y  or ch em o th erap y 36, 50. F ive s tu d ies  h a d  a sh o rt period  betw een  the 
p o s t-in te rv en tio n  asse ssm en t a n d  th e  follow-up, of fou r w eeks or le ss42, 49, 52, 53, 58. 
T hree  of th e se  five s tu d ies  h a d  ad d itio n a l follow-up m easu rem en ts  a t  e igh t 
w eeks53, a t  six, eigh t, a n d  te n  w eeks42, an d  n ine  m on th s a fte r  re c ru itm e n t49. In  
five o th e r s tu d ies  th e  tim e b e tw een  p o s t-in te rv en tio n  an d  follow-up w as longer 
v a ry in g  b etw een  th re e  to e ig h t m o n th s30, 34, 35, 40, 43.
F ive s tu d ies  explicitly  described  th a t  th e  p o s t-in te rv en tio n  a sse ssm e n t took 
place a fte r  p a r tic ip a n ts  f in ish ed  th e ir  cancer tre a tm e n ts  38, 47, 49, 53, 58, a n d  th re e  of 
th e se  s tu d ies  also h a d  a follow-up a sse ssm e n t49, 53, 58. In  two stu d ies  i t  w as 
described  th a t  p a r t  of th e  p a r tic ip a n ts  fin ish ed  cancer tre a tm e n t a t  th e  tim e of 
follow-up m e a su re m e n t36, 50.
M ost s tu d ies  u se d  one in s tru m e n t to m easu re  fa tigue , b u t  six s tu d ies  u sed  
two to four in s tru m e n ts 32, 36, 46, 49-51 (see T able 3: O utcom es). F ive in s tru m e n ts  
w ere u sed  in  m u ltip le  tr ia ls . The m ost freq u en tly  u se d  in s tru m e n t w as th e  
PO M S sub-scale fa tig u e /in e rtia , a n d  w as u se d  in  12 s tu d ies  to m easu re  fa tig u e 30, 
32, 35, 40-43, 45, 50-52, 54. The VAS w as u sed  in  five s tu d ie s38, 46, 49, 51, 57 an d  th e  EORTC 
QLQ-C3032, 39, 46, 49, 53, 56 w as u sed  in  six stud ies. The FA CT-F 36, 47 an d  th e  M F I44,
49 w ere u sed  in  two stud ies. All o th e r in s tru m e n ts  w ere only u se d  in  a single 
study.
A m ino rity  of th e  stud ies, only five, u se d  specific q u es tio n n a ire s  designed  to 
m easu re  fa tigue , such as  th e  M FI, SCFS, GFS, FSI, PFS . The m ost freq u en tly  
u sed  in s tru m e n ts  w ere u sed  to m easu re  m ood sta te s , or q u a lity  of life. F a tig u e  in  
th e se  in s tru m e n ts  w as m e a su re d  w ith  a sub-scale, or w ith  only one item .
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O th er stu d y  ch a rac te r is tic s
The sam ple size of th e  27 inc luded  s tu d ies  v a r ie d  b etw een  30 a n d  396, w ith  a 
to ta l  of 3324 p a r tic ip a n ts . M ost s tu d ies  described  th e  sam ple a t  ran dom isa tion . 
F ive s tu d ies  described  th e  n u m b er of p a r tic ip a n ts  a t  b a se lin e36, 43, or u se d  for 
an a ly s is34, 38, 54. The m ean  sam ple size w as 123 (s ta n d a rd  dev ia tion  (s.d.) 87). 
Tw elve s tu d ies  h a d  a sam ple size sm alle r th a n  100 34, 35, 40, 42-45, 47, 49, 52, 54, 56, an d  
te n  s tu d ies  be tw een  100 a n d  20036-38, 41, 46, 48, 51, 55, 57, 58. F ive s tu d ies  h a d  a la rg e r 
sam ple th a n  20 0 30, 32, 39, 50, 53.
Methodological Quality
The re s u lts  of th e  m ethodological q u a lity  a sse ssm en t a re  described  in  Table 
4: Q u ality  A ssessm ent. A m ajo rity  of th e  s tu d ies  scored one or two on th e  Oxford 
Q uality  Scale26 w ith in  th e  ran g e  of one to five. O nly th re e  s tu d ies  scored th re e 36, 
48, 57. O n th e  D elph i L is t27 seven s tu d ies  scored above th re e  30, 32, 34, 36, 38, 50, 57 and  
none of th e se  w ere  p u b lish ed  before th e  y ear 2000. Looking a t  th e  scores on 
in te rn a l  v a lid ity  as sug gested  by V an  T u ld er (1997)28, only one stu d y  h a d  a good 
ev a lu a tio n  w ith  a score of five36. All o th e r s tu d ies  scored low er th a n  five.
The m ajo rity  of th e  s tu d ies  h a d  a m oderate  m ethodological quality , vary ing  
betw een  te n  an d  17. In  th re e  s tu d ies  th e  q u a lity  w as g ra d ed  a nine, being 
reg a rd e d  as poor39, 45, 46. The m ethodological q u a lity  of th e  s tu d y  of B arsev ick  
(2004)50 w as ra te d  as  18, being  good.
One of th e  item s of th e  Q u ality  R a tin g  Scale w as concealm en t of allocation  
an d  th e  ev a lu a tio n  is described  in  T able 5: C h a ra c te r is tic s  of inc luded  stud ies. 
E ig h t s tu d ies  sug gested  th a t  concealed a llocation  w as u se d 32, 36, 44, 46-49, 57 an d  in  
five s tu d ies  th e  a llocation  w as concealed ad eq u a te ly 36, 46, 48, 57, w ith  one study  
chang ing  th e  p ro cedure  d u rin g  re c ru itm e n t49. In  th e  rem a in in g  s tu d ies  i t  w as no t 
described  w hich p ro cedu re  w as u sed  to conceal allocation.
B arsev ick  (2004) w as th e  only stu d y  in  w hich an  in te n tio n -to -tre a t ana ly sis  
w as u se d 50. Two o th e r s tu d ies  described  th a t  in te n tio n -to -tre a t an a ly sis  w as 
used, how ever, th is  re m a in e d  u n c lea r from  th e  described  an a ly sis  an d  re s u lts 32, 
39. In  m ost s tu d ies  th e  an a ly sis  w as perfo rm ed  w ith  p a r tic ip a n ts  w ho com pleted  
a ll assessm en ts .
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T hree  s tu d ies  explicitly  described  th a t  ac tions w ere ta k e n  to p rev en t 
con tam ina tion . In  th e  stu d y  of S an d g ren  (2003) n u rse s  gave bo th  in te rv en tio n s, 
b u t th e  a u th o rs  a tte m p te d  to avoid co n tam in a tio n  by info rm ing  th e  n u rse s  about 
th e  r isk s  of co n tam in a tio n 30. In  two o th e r s tu d ies  it  w as explicitly  m en tioned  th a t  
th e  p e rso n s ad m in is te rin g  th e  in te rv en tio n  w ere d ifferen t from  th e  p e rso n s in  
con tac t w ith  p a r tic ip a n ts  in  th e  contro l cond ition36- 57. In  th e  s tu d y  th a t  ev a lu a ted  
m edical qigong, p a tie n ts  in  th e  contro l group w ere a sk ed  to re f ra in  from  jo in ing  
an  ou tside  qigong c lass56.
An im p o rta n t aspect w hen  ev a lu a tin g  th e  effectiveness of psychosocial 
in te rv e n tio n s  is  th e  adherence  of p a tie n ts , how ever, in  only 12 s tu d ies  th is  w as 
described. In  e ig h t s tu d ies  th e  a tten d a n ce  of p a r tic ip a n ts  jo in ing  th e  sessions w as 
described32- 36’ 37’ 41 42’ 49’ 51 53 an d  in  four s tu d ies  adherence  w as a ssessed  in  o ther 
w ays. Two stu d ies  m easu red  if  p a r tic ip a n ts  u se d  th e  b eh av io u rs  le a rn e d  during  
th e  in te rv e n tio n 36- 50. Two stu d ies  a sk ed  p a r tic ip a n ts  if  th ey  re a d  th e  provided  
b ro ch u re s53, or p rac ticed  a t hom e34.
Risk of bias in included studies
The possib ility  of b ia s  could be found  in  th e  c h a rac te r is tic s  of th e  sam ple. The 
exclusion c r ite ria  v a r ie d  a lo t be tw een  th e  inc luded  stud ies, for exam ple some 
stu d ies  excluded  p a tie n ts  w ith  o th e r com orbidities, w hile  som e stu d ies  d id  not 
describe ad d itio n a l exclusion c rite ria . T he m ethodological q u a lity  m igh t also 
cause  a b ias, how ever, th is  is  described  in  th e  d iscussion  in  m ore detail.
Effects of interventions
Seven of th e  inc luded  s tu d ies  rep o rted  a sign ifican t effect of th e  in te rv e n tio n s  on 
fa tig ue  a t  a  0.05 level. The seven s tu d ies  a n d  th e ir  re s u lts  a re  b riefly  described  in  
p a r t  A an d  B of T able 6: S u m m ary  of find ings: E ffective stud ies. The effect sizes 
v a r ie d  betw een  0 .1750 an d  1.0734. The sm alle s t effect size w as found  in  th e  study  
of B arsev ick  (2004), b u t th is  could be due to th e  use of in te n tio n -to -tre a t ana ly sis  
no t ap p lied  in  o th e r s tu d ie s50. In  two stu d ies  i t  w as no t possib le to o b ta in  all 
re le v a n t d a ta  to ca lcu la te  effect sizes45’ 58.
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O f th e  seven s tu d ies  w hich  found  a sign ifican t effect of th e  in te rv e n tio n s  on 
fatigue , th re e  found  sign ifican t tim e-by-group in te ra c tio n  effects a t  follow-up 34, 49
50 on a t  le a s t one in s tru m e n t th a t  m easu red  fatigue. In  th e  s tu d ies  of A rm es 
(2007) an d  B arsev ick  (2004) th e  follow-up period  w as short, up  to one m o n th 49, 50. 
The follow-up period  in  th e  stu d y  of Cohen (2007) w as longer, la s tin g  four 
m o n th s34. In  th e  s tu d y  of A rm es (2007) p a r tic ip a n ts  w ere m easu red  ad d itionally  
a t  n in e  m o n th s a fte r re c ru itm e n t49. O f th e se  seven s tu d ies  two stu d ies  found a 
sign ifican t effect im m ed ia te ly  post-in te rv en tio n , b u t th ese  re s u lts  w ere  not 
m a in ta in e d  a t follow -up36, 58. In  th e  stu d y  of Spiegel (1981) sign ifican t re su lts  
w ere found  post-in te rv en tio n , b u t  no follow-up a sse ssm e n t w as described45. The 
stu d y  of R eam  (2006) found a sign ifican t effect on fatigue com paring  th e  p o s t­
in te rv en tio n  scores w ith  a t- te s t  w ith o u t con tro lling  for b ase lin e  differences. No 
follow-up m e asu rem en t w as ca rried  out. T he use  of a  - e s t  w as ju s tif ie d  in  th is  
s tu d y  as  b ase lin e  fatigue scores of th e  contro l an d  th e  in te rv en tio n  group w ere 
no t sign ifican tly  d iffe ren t57. These seven s tu d ies  a re  fu r th e r  re fe rre d  to a s  the  
'effective' s tu d ie s34, 36, 45, 49, 50, 57, 58.
The rem a in in g  20 in c lu d ed  s tu d ies  w ere re g a rd e d  as no t effective. In  17 
s tu d ies  no sign ifican t effects of th e  in te rv en tio n  on fa tig u e  w ere  found, a lthoug h  
in  fou r of th ese  17 s tu d ies  th e  a u th o rs  concluded th a t  th e  re s u lts  w ere in  the 
expected  d irec tion32, 55, 56 or sign ifican t on a 0.1 level52. T hree  of th e  20 stud ies 
found  a sign ifican t effect of th e  in te rv en tio n  w hen  m e a su re d  w ith  a - e s t ,  
im m ed ia te ly  p o s t-in te rv en tio n 38, 54 or a t  fo llo w u p 40. In  th e  f irs t  study, G asto n ­
Jo h an sso n  (2000) rep o rted  th a t  th e  d ifference betw een  th e  in te rv en tio n  group 
a n d  contro l group d isap p ea red  a fte r  con tro lling  for dem ographic  v a riab le s  an d  
fa tig ue  a t b a se lin e38. In  th e  second s tu d y  of D ecker (1992) a s ta tis tic a lly  
sign ifican t d ifference in  th e  pre- v e rsu s  p o s t-te s t scores w as found, w here  control 
p a tie n ts  becam e m ore fa tig ued . H ow ever, no sign ifican t re s u lts  on t re a tm e n t  by 
re p e a te d  m easu re s  in te rac tio n  w ere found  on fa tigue . In  add ition , w hen  looking 
a t th e  re s u lts  fa tigue scores w ere  h ig h e r in  th e  ex p e rim en ta l group com pared  to 
th e  contro l group, a t b ase lin e  an d  p o s t-in te rv en tio n 54. In  th e  th ird  study, Faw zy 
(1995) found  sign ifican t re s u lts  on fa tig u e  on th e  w ith in -g roup  an a ly sis  an d  the 
betw een-group  analysis , b u t re p o rte d  no sign ifican t re s u lt  of th e  an a ly sis  of
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covariance on fa tig u e40. T hus, u sin g  a t- te s t  to ev a lu a te  th e  in te rv en tio n  w as not 
ju s tif ie d  in  th e  la s t  th re e  s tu d ies  a n d  th erefo re  w e concluded th a t  in  20 stud ies 
th e  in te rv en tio n  w as no t effective for fatigue.
Comparing effective and non-effective interventions for fatigue
The q u a lity  of th e  seven effective s tu d ies  d id  no t differ from  th e  non-effective 
s tu d ies  (P = 0.231). The m ean  q u a lity  score of th e  effective s tu d ies  w as 14.0 (s.d. 
3.6) com pared  to 12.2 (s.d. 2.0) of th e  non-effective stud ies. No difference w as 
found  in  th e  m ean  n u m b er of p a r tic ip a n ts  (P = 0.598). The m ean  n u m b er of 
p a r tic ip a n ts  of th e  effective s tu d ies  w as 138 (s.d. 115) com pared  to 118 (s.d. 78) of 
th e  non-effective studies.
The psychosocial in te rv e n tio n s  could be d is tin g u ish ed  in to  in te rv en tio n s  
specific for fa tig u e  an d  in te rv e n tio n s  no t specific for fa tigue . The effectiveness of 
in te rv e n tio n s  specific for fa tig u e  w as sign ifican tly  h ig h e r a t  80% (four ou t of five) 
com pared  to in te rv e n tio n s  no t specific for fa tig ue  a t  14% (th ree  ou t of 22) (P < 
0.01). Two stu d ies  w ere specific in te rv e n tio n s  for p a in 53, an d  dep ressio n 44, b u t 
w ere no t effective for fa tigue . The o th e r in te rv e n tio n s  no t specific for fa tig u e  h a d  
a m ore g en era l app roach  a n d  focused on d istress , m ood s ta te s , q u a lity  of life, or 
sym ptom s or side effects in  genera l. O f th ese  20 stud ies, th re e  s tu d ies  w ere 
effective in  red u c in g  fa tig u e34, 45, 58.
The five specific in te rv e n tio n s  for fa tig ue  w ere sh o rt in te rv en tio n s, 
consisting  of th re e  in d iv id u a l sessions w ith  a d u ra tio n  v a ry in g  b e tw een  te n  an d  
60 m inu tes. T hese in te rv e n tio n s  w ere to a la rg e  e x te n t b a sed  on th e  sam e 
elem en ts. In  a ll in te rv e n tio n s  p a r tic ip a n ts  w ere; 1) ed u ca ted  abou t fa tigue; 2) 
ta u g h t in  self-care or coping techn iques; 3) ta u g h t ac tiv ity  m an ag em en t, le a rn in g  
to ba lance  betw een  ac tiv ities a n d  re s t. In  add ition  to th e se  e lem en ts  R eam  (2006) 
em p h asised  em otional su p p o rt57. In  th e se  five s tu d ies  (oncology) n u rse s  
ad m in is te red  th e  in te rv e n tio n s  a n d  w ere tra in ed . All s tu d ies  inc luded  
p a r tic ip a n ts  w ith  v a rio u s  m alignanc ies a n d  s tages of cancer. In  th e  study  
described  by A rm es (2007), th e  f irs t  a u th o r  w as also th e  n u rse  ad m in is te rin g  the 
in te rv e n tio n 49. The stu d y  of Godino (2006) w as th e  only in te rv e n tio n  specific for 
fa tigue , th a t  w as no t effective47. The m ost obvious d ifference betw een  th is  study
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a n d  th e  effective s tu d ies  is  th e  sm alle r n u m b er of p a r tic ip a n ts . Godino (2006) 
ran d o m ised  40 p a r tic ip a n ts , w hile th e  sam ple  size of th e  effective s tu d ies  w as 
b etw een  60 a n d  n ea rly  400 p a rtic ip an ts .
The th re e  effective s tu d ies  no t specific for fa tig u e  w ere longer in te rv e n tio n s  
com pared  to th e  in te rv e n tio n s  specific for fa tigue. The stu d y  of Cohen (2007) 
consis ted  of n ine  w eekly  sessions of 90 m in u te s34. T he s tu d y  of F o re s te r  (1985) 
consis ted  of te n  w eekly  30 m in u te  sessions58. The in te rv en tio n  in  th e  s tu d y  of 
Spiegel (1981) la s te d  a t le a s t a  year, in  w hich  p a r tic ip a n ts  m et w eekly  for 90 
m in u te s45. The d u ra tio n  of th e se  th re e  in te rv e n tio n s  fa ll w ith in  th e  ra n g e  of a ll 
o th e r in te rv e n tio n s  th a t  w ere no t specific for fa tigue, v a ry in g  betw een  four w eeks 
an d  a year. The con ten t of th e se  th re e  in te rv e n tio n s  v a r ie d  am ong each  other. 
The in te rv e n tio n  g roups in  th e  stu d y  of Spiegel (1981) w as p rim a rily  supportive 
an d  a im ed  to b enefit p a tie n ts  psychologically45. The in te rv e n tio n  of F o re s te r 
(1985) w as in d iv id u a l u n s tru c tu re d  supportive  p sy ch o th e rap y  designed  to reduce 
p a tie n ts  em otional d is tre ss  an d  physica l sym ptom s, reg a rd in g  t r e a tm e n t58. 
Cohen (2007) s tu d ied  th e  effects of two group in te rv e n tio n s  on psychological 
d is tre ss  an d  p hysica l sym ptom s34. T he f irs t  w as a cognitive beh av io u r group 
in te rv en tio n  an d  th e  second consis ted  of re lax a tio n  a n d  gu ided  im agery . O nly the  
re lax a tio n  a n d  gu ided  im ag ery  in te rv e n tio n  a p p ea red  to be effective on fatigue. 
In  th e  s tu d ies  of C ohen (2007) a n d  F o re s te r  (1985) th e  f irs t  a u th o rs  w ere also the 
only care  p ro v ider giving th e  in te rv e n tio n 34, 58. The effectiveness of th e  th ree  
s tu d ies  p robab ly  cou ldn 't be ex p la in ed  by a la rg e r sam ple size or by  a b e tte r  
quality . The q u a lity  scores of th e  s tu d ies  by  C ohen (2007), F o re s te r  (1985), and  
Spiegel (1981) ra n g e d  betw een  n ine  a n d  13, w hile  th e  q u a lity  score of th e  n o n ­
effective s tu d ies  no t specific for fa tig u e  ra n g e d  from  n in e  to 1734, 45, 58. T hus the 
qu a lity  scores w ere w ith in  th e  ra n g e  of th e  effective s tu d ies  no t specific for 
fa tigue , a n d  even a b it lower. The n u m b er of p a r tic ip a n ts  of th e  th re e  effective 
s tu d ies  ran g e d  betw een  86 an d  114, an d  w as w ith in  th e  ra n g e  of 30 to 313 of the 
non-effective s tu d ies  no t specific for fatigue.
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The aim  of th is  rev iew  w as to provide a n  overview  of psychosocial in te rv en tio n s  
for fa tig ue  d u rin g  cancer tre a tm e n t, an d  to ev a lu a te  th e  effectiveness of these  
in te rv en tio n s . In  our sea rch  27 psychosocial in te rv e n tio n s  w ere found, in  w hich 
th e  effect on fa tig ue  w as te s te d  in  a  RCT. The sam ple size of th e  27 included  
s tu d ies  v a r ie d  b e tw een  30 an d  396, w ith  a to ta l  of 3324 p a r tic ip a n ts . The qua lity  
w as gen era lly  ev a lu a te d  as m oderate .
In  genera l, th e re  is  lim ited  evidence th a t  psychosocial in te rv e n tio n s  during  
t re a tm e n t  a re  effective in  red uc ing  fa tig ue  in  cancer p a tie n ts . In  only seven 
s tu d ies  w ere th e  psychosocial in te rv e n tio n s  effective in  red uc ing  fatigue. In  only 
th re e  s tu d ies  w as th e  effect of th e  in te rv e n tio n  on fatigue m a in ta in e d  d u rin g  th e  
follow-up p e rio d 34’ 49 50. The q u a lity  a n d  th e  m ean  n u m b er of p a r tic ip a n ts  of the  
effective s tu d ies  d id  no t differ from  th e  non-effective stud ies. The effect sizes of 
th e  effective s tu d ies  w ere g enera lly  m ed ium 59. In  th e  s tu d ies  w ith  a la rg e  effect 
size, th e  in te rv en tio n  w as prov ided  by only one care  provider, also being  th e  firs t 
a u th o r34' 49.
O vera ll th e  27 s tu d ies  w ere v ery  he te ro g en eo u s on m ost asp ec ts  of the  
stud ies, on p a tie n t  an d  t re a tm e n t ch a rac te ris tic s , types of in te rv en tio n s , and  
outcom e m easu res . T his m ade i t  d ifficult to e s tab lish  if  c e r ta in  types of 
in te rv en tio n  or e lem en ts  could be e sse n tia l for red uc ing  fatigue. A ttem p ts  w ere 
m ade to d raw  ad d itio n a l conclusions abou t ce r ta in  types of in te rv e n tio n s  or 
subgroups of p a tie n ts . F o r exam ple a lo t of s tu d ies  w ere  ca rried  ou t w ith  only 
b re a s t  cancer p a tie n ts , b u t th e se  s tu d ies  w ere also too he te ro g en eo u s to draw  
ad d itio n a l conclusions abou t in te rv e n tio n s  for th is  specific group. Psychosocial 
in te rv e n tio n s  for p a tie n ts  w ith  p ro s ta te  cancer or o th e r com m on types of cancer, 
a re  less o ften  te s te d  in  RCTs, a s  also p rev iously  e s ta b lish e d 14. H ow ever, i t  w as 
possib le to d is tin g u ish  in te rv e n tio n s  th a t  w ere  specifically designed  to t r e a t  
fa tig u e  d u rin g  cancer tre a tm e n t, a n d  in te rv en tio n s  no t specific for fatigue.
T h is rev iew  show ed th a t  th e  effectiveness of in te rv e n tio n s  specific for 
fatigue w as sign ifican tly  h ig h e r th a n  in te rv e n tio n s  no t specific for fatigue. To
DISCUSSION
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conclude, a t  p re se n t psychosocial in te rv e n tio n s  specifically for fa tig ue  is th e  m ore 
p ro m ising  type  of in te rv e n tio n  for red uc ing  fa tigue d u rin g  cancer tre a tm e n t. 
H ow ever, th e re  is  c u rren tly  no solid evidence for th e  effectiveness of 
in te rv e n tio n s  no t specific for fatigue.
O f th e  five in te rv e n tio n s  specific for fa tigue , four w ere effective in  red ucing  
fa tig u e  d u rin g  cancer t r e a tm e n t36, 49 50, 57. In  two stu d ies  th e  effects w ere 
m a in ta in e d  in  th e  follow-up p erio d  th a t  la s te d  up to a m o n th 49, 50. O ne stu d y  w as 
no t effective47, b u t th e  sm all sam ple size m igh t be a n  ex p lan a tio n  w hy no 
sign ifican t re s u lt  w as found.
I t  seem s p ro m ising  th a t  four ou t of five in te rv e n tio n s  specifically designed  
for fa tig u e  w ere effective, b u t th e  s tab ility  of th e  evidence is  q u estionab le  for 
th re e  reasons. F irs t, in  two stu d ies  th e re  w as only an  im m ed ia te  effect on fa tig ue  
a fte r th e  in te rv en tio n , b u t  th e  effect d isap p ea red  a t  follow -up36, or no follow-up 
a sse ssm en t w as p erfo rm ed 57. Second, w hen  m ore th a n  one in s tru m e n t w as u sed  
to assess  fatigue, th e  effects w ere  no t v isib le  on all in s tru m e n ts . T hird , in  the  
stu d y  of A rm es (2007)49 th e  in te rv e n tio n  w as p rov ided  by only one care  giver, also 
being  th e  firs t au tho r.
Looking a t th e  ch a rac te r is tic s  of th e  five s tu d ies  th a t  ev a lu a ted  
in te rv e n tio n s  specifically designed  to t r e a t  fa tigue , rev ea led  two obvious fea tu res. 
F irstly , th e se  s tu d ies  in c lu d ed  p a tie n ts  w ith  v a rio u s  m alignancies an d  s tag es of 
cancer. Secondly, th ese  in te rv e n tio n s  w ere brief, consisting  of th re e  sessions 
la s tin g  up to 60 m in u te s  each, an d  con ta in ing  to a la rg e  ex ten t th e  sam e 
elem en ts. In  a ll in te rv e n tio n s  p a r tic ip a n ts  w ere; 1) ed u ca ted  abou t fa tigue; 2) 
ta u g h t in  self-care or coping techn iques; 3) ta u g h t abou t ac tiv ity  m anagem en t, 
le a rn in g  to ba lan ce  betw een  ac tiv ities  a n d  res t. B ased  on th is  lim ited  n u m b er of 
five s tu d ies  it  could no t be e s tab lish ed  w hich  form at or e lem en ts  of an  
in te rv en tio n  w ere e sse n tia l for red uc ing  fatigue. F or exam ple, i t  could no t be 
e s ta b lish e d  if  sessions shou ld  be b ased  on face-to-face contact, or i f  te lephone 
sessions m igh t be an  a lte rn a tiv e .
T hree  ou t of 22 psychosocial in te rv e n tio n s  no t specially  designed  to m anage 
fa tigue w ere effective in  red uc ing  fa tigue d u rin g  cancer t r e a tm e n t34, 45, 58. In  one 
stu d y  th e  effect on fa tig u e  w as m a in ta in e d  d u rin g  th e  four m o n th  follow-up
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period. These th re e  in te rv e n tio n s  h a d  a m ore g en era l app roach  a im ed  a t 
psychological d is tress , m ood a n d  physica l sym ptom s. T here  is  no obvious rea so n  
w hy th ese  th re e  in te rv e n tio n s  w ere effective, w hile  19 o th e r s tu d ies  w ere  not. No 
ex p lan a tio n  could be fou nd  in  th e  sam ple size, th e  q u a lity  of th e  s tu d ies  or 
c h a rac te r is tic s  of th e  in te rv en tio n s.
T here  a re  sev era l rea so n s  th a t  su p p o rt th e  conclusion th a t  in te rv en tio n s  
w ith  a g en era l app roach  a re  ra re ly  effective. F irs t, in  th e  s tu d ies  of C ohen (2007) 
an d  F o re s te r (1985) th e  f irs t  a u th o r  w as also th e  care  p ro v ider ad m in is te rin g  the 
in te rv e n tio n 34, 58. Second, in  only one stu d y  th e  effect w as m a in ta in e d  a t  follow- 
up. In  add ition , one of th e se  th re e  s tu d ies  w as a n  ea rly  stu d y  of Spiegel (1981)45 
an d  w as rep lica ted  in  la te r  s tu d ie s32' 41. H owever, th e  effect on fatigue 
d e m o n s tra ted  by Spiegel (1981), w as no t confirm ed in  th e  la te r  two stu d ies45.
In te rv e n tio n s  th a t  d id  no t focus on fatigue, for exam ple in te rv e n tio n s  th a t  
a im ed  to red uce  depression  or pa in , show ed th a t  fa tig ue  d id  no t decrease  w ith  
d epression  or pa in , an d  th ere fo re  we can  conclude th a t  th e se  in te rv e n tio n s  are  
no t effective for red uc ing  fa tigue.
Limitation of the studies
D uring  th e  ev a lu a tio n  of th e  inc luded  s tu d ies  sev era l shortcom ings w ere noticed. 
In  m ost s tu d ies  i t  w as difficult to get a  c lear p ic tu re  of th e  com plete cancer 
t re a tm e n t  p a r tic ip a n ts  received, such as  types of tre a tm e n ts  a n d  to ta l  dura tion . 
As a re s u lt  i t  also re m a in e d  u n c lea r w h en  d u rin g  cancer t re a tm e n t  the  
a sse ssm en ts  an d  th e  sessions took place. O ften  i t  w as u n c e r ta in  if  p a r tic ip a n ts  
co n tin u ed  w ith  cancer t re a tm e n t  a fte r  th e  in te rv en tio n .
The ev a lu a tio n  of th e  q u a lity  of th e  inc luded  s tu d ies  rev ea led  ad d itio n a l 
lim ita tio n s. In  th e  m ajo rity  of th e  s tu d ies  i t  w as no t described  if  a  p ro cedure  w as 
u sed  to conceal allocation , no t even in  th e  m ost rec en t pub lica tions. In  addition, 
only one s tu d y  ap p lied  a n  in te n tio n -to -tre a t analysis . R ecom m endations for 
im proving  th e  q u a lity  of R CTs a re  p rov ided  in  th e  CONSO RT g u ide lines60.
S evera l m ethodological e lem en ts  of th e  psychosocial in te rv en tio n  stud ies 
could be im proved. F o r exam ple, avoiding th e  r is k  of co n tam ina tion , a n d  te s tin g
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th e  ad h eren ce  of p a rtic ip a n ts . T ra in in g  th e  care  prov iders, sup erv isin g  them , and  
apply ing  an  in te g r ity  check w ould  help  im prove an  in te rv e n tio n  study.
In  som e stu d ies  th e  in te rv en tio n  w as prov ided  by only one care  p ro v ider also 
being  th e  au th o r, b u t th e re  m igh t be a conflict of in te re s t  in  perfo rm in g  the  
in te rv en tio n  a t  th e  one h an d , an d  p u b lish in g  th e  re s u lts  a t  th e  o ther. The care 
p ro v ider m igh t w ork  h a rd  to get positive outcom es, re su ltin g  in  a la rg e  effect size. 
D esp ite  th e  good in te n tio n s  of rea lis in g  a good in te rv en tio n , w ith  only one 
p ra c tis in g  care  p ro v ider i t  could be difficult to tra n s fe r  th e  in te rv e n tio n  to o thers , 
a n d  to rep lica te  th e  study. T hus i t  is  recom m ended  th a t  th e  in te rv e n tio n  should  
be given to p a r tic ip a n ts  by m ore th a n  one person.
Limitation of the review
A lim ita tio n  of th is  rev iew  is  th a t  RCTs w ere excluded  w hen  i t  w as u n c lea r if 
cancer p a tie n ts  w ere receiv ing  t re a tm e n t  a t  th e  tim e  of th e  in te rv en tio n . To 
clarify  th is  issu e  w e con tac ted  th e  ex p erts  an d  re se a rc h e rs  w ho perfo rm ed  th e  
stud ies. In  add ition  th e  possib ility  re m a in s  th a t  t r ia ls  w ith  n egativ e  re su lts  
m igh t no t h av e  been  p u b lish ed  a t  all, a n d  the re fo re  a re  m issed  d u rin g  our search . 
A lthough  we a re  u n a w a re  th a t  re le v a n t s tu d ies  w ere m issed, th e  possib ility  th a t  
a  re le v a n t stu d y  ex is ts  canno t be ru le d  out.
AUTHORS' CONCLUSIONS 
Implications for practice
W hen cancer p a tie n ts  experience fa tig u e  d u rin g  cancer t re a tm e n t  th e re  are 
sev era l op tions to t r e a t  fatigue. In  clin ical p rac tice  an  in te rv en tio n  w ith  a gen era l 
app roach  is  u su a lly  chosen w h en  in te rv en in g  for fatigue, a lth o u g h  a t  p re se n t 
th e re  is  no solid evidence for th e  effectiveness of psychosocial in te rv e n tio n s  no t 
specific for fatigue. T his rev iew  show ed th a t  in te rv e n tio n s  w ith  a gen era l 
app roach  w ere ra re ly  effective in  red uc ing  fatigue, an d  th ese  in te rv en tio n s  
focused on psychological d is tress , m ood an d  physica l sym ptom s. W hen o th e r 
types of psychosocial in te rv e n tio n  a re  offered to cancer p a tie n ts , for exam ple w ith
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th e  a im  of red uc ing  depression  or pa in , i t  is  no t likely  th a t  sym ptom s of fa tigue 
au to m a tica lly  decrease w ith  depression  or pain .
The effectiveness of psychosocial in te rv e n tio n s  specifically designed  to t r e a t  
fa tigue w as sign ifican tly  h ig h e r th a n  in te rv e n tio n s  no t specific for fatigue, a n d  is 
c u rre n tly  th e  m ore p ro m ising  type  of in te rv e n tio n  for red uc ing  fa tigue d u ring  
cancer tre a tm e n t. The in te rv e n tio n s  specific for fa tigue contained , to a  la rg e  
ex ten t, th e  sam e elem en ts. In  a ll in te rv e n tio n s  p a tie n ts  w ere: 1) ed u ca ted  about 
fa tigue; 2) ta u g h t in  self-care or coping techn iques; 3) ta u g h t  activ ity  
m an ag em en t, le a rn in g  to ba lance  betw een  ac tiv ities a n d  re s t. H owever, c u rren tly  
w ith  only a l im ited  n u m b er of s tu d ies  i t  could no t be e s tab lish ed  w hich  form at or 
e lem en ts  a re  e sse n tia l  to red uce  fatigue d u rin g  cancer tre a tm e n t.
I t  is  im p o rta n t to note th a t  psychosocial in te rv e n tio n s  d u rin g  active cancer 
t re a tm e n t  w ere  th e  focus of th is  review . O ur re s u lts  a re  th ere fo re  no t applicable 
to cancer p a tie n ts  w ho have com pleted  th e ir  cancer tre a tm e n t.
Implications for research
T his rev iew  show ed th a t  th e re  is  lim ited  su p p o rt for psychosocial in te rv en tio n s  
for fa tigue d u rin g  cancer tre a tm e n t. A t p re se n t th e  effectiveness of psychosocial 
in te rv e n tio n s  specifically designed  to t r e a t  fa tigue is  h igh , b u t th e re  is  no solid 
evidence for th e  effectiveness of psychosocial in te rv e n tio n s  no t specific for 
fatigue.
As th e  RCTs w ere v ery  h e te rogen eous in  n a tu re , a n d  th e  n u m b er of 
psychosocial in te rv e n tio n s  specific for fa tigue w ere lim ited , th e re  a re  still some 
questions th a t  n eed  to be answ ered . F irs t, i t  is im p o rta n t to know  w hy  some 
psychosocial in te rv e n tio n s  w ork, an d  th ere fo re  in te rv e n tio n s  shou ld  p re fe rab ly  be 
b ased  on a th eo ry  or model. To find e sse n tia l com ponents th a t  a re  necessa ry  to 
red uce  fatigue i t  is  adv isab le  to assess  if  factors th a t  a re  expected  to reduce 
fa tigue also change d u rin g  th e  in te rv en tio n . In  add ition , th e  op tim al d u ra tio n  of 
th e  in te rv en tio n  needs to be estab lish ed , a n d  th e  b es t m ethod  to provide the  
in te rv en tio n . F or exam ple, i t  is  u n c lea r if  te lepho ne or face-to-face sessions a re  
equally  effective. Also th e re  a re  no RCTs th a t  e v a lu a te d  th e  effectiveness of 
group in te rv e n tio n s  specific for fatigue.
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As th e  inc luded  s tu d ies  w ere v ery  h e te rogen eous i t  w as no t possib le to 
id en tify  h ig h  r is k  groups. T hus, th e  question  re m a in s  w h e th e r p a tie n ts  w ith  
specific m alignancies, or p a tie n ts  receiv ing  specific types of tre a tm e n ts  a re  a t  
r isk  of becom ing m ore fatigued, a lth o u g h  som e s tu d ies  po in t in  th a t  d irec tion24. 
Som e stu d ies  found th a t  th e  p revalence  of fa tigue depen ded  on th e  diagnosis. For 
exam ple, p a tie n ts  w ith  p ro s ta te  carcinom a rep o rted  th e  le a s t severe fa tigue 
du rin g  ra d io th e ra p y  an d  p a tie n ts  w ith  lung , a lim en ta ry , an d  h e a d  an d  neck 
carc inom a re p o rte d  th e  m ost severe fa tig ue61. Levels of fa tigue also depen ded  on 
d iagnosis in  p a tie n ts  receiv ing chem otherapy . In  a group of cancer p a tie n ts  
receiv ing  cytotoxic tre a tm e n t, lu n g  a n d  b re a s t  cancer p a tie n ts  experienced  the  
h ig h e s t degree of fa tig ue62.
T here  a re  also in d ica tio n s th a t  th e  p revalence  of fa tigue depen ds on th e  type 
of tre a tm e n t  cancer p a tie n ts  receive. F o r exam ple, b re a s t  cancer p a tie n ts  who 
h a d  a m astec tom y  op era tio n  w ere m ore fa tig ued  th a n  w om en w ho u n d e rw e n t a 
lum pectom y. R eceiving ra d io th e ra p y  su p p lem en ta ry  to ch em o th erap y  led  to an  
in c rease  in  fa tigue in  w om en w ith  b re a s t  cancer63.
In  add ition  th e  course of fa tigue ap p e a rs  to depend  on th e  type  of t re a tm e n t 
cancer p a tie n ts  receive. F o r exam ple, th e  course of fa tig u e  in  p a tie n ts  receiv ing 
ch em o th erap y  seem s to be d ifferen t from  th e  course of fa tigue in  p a tie n ts  
receiv ing  rad io th e rap y . A fter th e  s ta r t  of ch em o th erap y  th e  p revalence  of fa tigue 
in creases, re m a in in g  s tab le  d u rin g  ch em o th erap y  t re a tm e n t63, 64. D uring  
ra d io th e ra p y  th e  occurrence of fa tigue in c reases w ith  th e  n u m b er of w eeks 
p a tie n ts  a re  tre a te d  w ith  ra d io th e ra p y 61, 65.
I f  h ig h  r isk  g roups can  be id en tified  i t  is  im p o rta n t to know  if th ese  g roups 
n eed  ad a p te d  psychosocial in te rv en tio n s . In  c u r re n t  g u idelines for CRF, 
in te rv e n tio n s  for p a tie n ts  on active t re a tm e n t  a re  d is tin g u ish ed  from 
in te rv e n tio n s  for p a tie n ts  a t  th e  en d  of life4 althoug h , th e  effectiveness of 
in te rv e n tio n s  specific for fa tigue in  th is  sam ple still needs to be dem o n stra ted .
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Table 1: Characteristics of excluded studies
Study Reason for exclusion
Badger 20 0 566 In a previous study of Badger 2001, partic ipan ts  were random ised 
betw een six conditions, five experim ental groups and a control 
group. In th is  study partic ipan ts of the  five experim ental groups 
were tak en  together as one, and com pared w ith  the  control group 
on fatigue. This was not considered to be a RCT.
B ennet 20 0767 In tervention  was conducted after cancer trea tm en t was 
completed.
Berglund 199468 In tervention  was conducted after cancer trea tm en t was 
completed.
Boesen 200569 In tervention  was conducted after cancer trea tm en t was 
completed.
B urns 200870 No psychosocial intervention. P artic ipan ts were educated about 
the  use of music im agery and relaxation. Thus no feedback was 
given on th e ir behaviour.
Campbell 200571 No psychosocial intervention. The em phasis was placed on 
exercise.
Campbell 200772 In tervention  was conducted after cancer trea tm en t was 
completed.
Carlson 200573 In th is  study the re  was no control or norm al care group.
Cim prich 199374 Fatigue was not m easured.
Cim prich 200375 Fatigue was not m easured.
C lark 200676 No psychosocial intervention. D uring the  intervention  
partic ipan ts listened to music, b u t no feedback was received on 
th e ir behaviour.
Cohen 20 0477 Most partic ipan ts (71%) did not receive cancer trea tm en t during 
the  intervention.
Courneya 200378 U nclear if partic ipan ts received cancer tre a tm en t during the  
intervention.
Crooks 200479 P artic ipan ts were not random ised betw een the  conditions.
Culos-Reed 200680 In tervention  was conducted after cancer trea tm en t was 
completed.
Daley 200481 In tervention  was conducted after cancer trea tm en t was 
completed.
D alton 200482 Fatigue was not m easured.
Dimeo 199983 No psychosocial intervention. The em phasis was placed on 
exercise.
Dimeo 200484 In tervention  was conducted after cancer trea tm en t was 
completed.
Doorenbos 20 0585 Fatigue was m entioned as one of the  sym ptom s. R esults on the 
to ta l num ber of symptom s were described, and not separated  for 
fatigue.
Fawzy 199086 Cancer partic ipan ts undergoing trea tm en t were excluded.
G ielissen 20 0687 The in terven tion  was conducted after cancer tre a tm en t was 
completed
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Table 1: Characteristics of excluded studies
Study Reason for exclusion
Given 200488 Fatigue was m entioned as one of the  symptoms. R esults on the 
to ta l num ber of symptom s were described, and  not separated  for 
fatigue.
Given 20 0589 No psychosocial intervention. The effect of neu tropen ia  was 
tested.
H aase 200590 No psychosocial intervention. This study evaluated  guided 
im agery and group relaxation. P artic ipan ts were provided w ith 
tapes and instructions, bu t no feedback on th e ir behaviour was 
given.
H ack 20 0391 C onsultation was recorded and partic ipan ts received an 
audiotape.
H anna 200892 In th is  study the re  was no control or usua l care group.
H oekstra  200693 No psychosocial intervention . This study evaluated  a symptom 
monitor. P a rtic ipan ts m onitored th e ir symptoms, bu t no 
additional feedback on th e ir  behaviour was provided.
Houborg 200694 Not only cancer partic ipan ts were included (participants 
undergoing colorectal surgery also included).
Jacobsen 20 0295 No psychosocial intervention. This study evaluated  two types of 
stress m anagem ent consisting of only one session. This 
in terven tion  is not a system atic process.
Kim 200296 No psychosocial intervention. In th is  in tervention  partic ipan ts 
received tapes w ith inform ation on self-help. Thus feedback was 
lacking.
Kim 20 0597 No psychosocial intervention. In th is  in tervention  partic ipan ts 
received tapes for exercise in bed and relaxation  breath ing  
exercise, bu t the re  was no additional feedback.
K orstjens 200898 In tervention  was conducted after cancer trea tm en t was finished.
Laidlaw  20 0 599 Less th a n  10 partic ipan ts for each condition (n = 7 self hypnosis 
group, n = 4 Johrei group, n = 3 control group).
Lindem alm  2008100 In tervention  was conducted after cancer trea tm en t was finished.
Mock 1994101 Less th a n  10 partic ipan ts for each condition (n = 9 experim ental 
group, n = 5 control group).
O llenschlager
1992102
No psychosocial intervention. The em phasis was placed on 
changing nu tritiona l behaviour.
Ovesen 1993103 Fatigue was not m easured.
O yam a 2000104 No psychosocial intervention. This study evaluated  a Bedside 
w ellness system , including arom atic oil and  v irtu a l reality  using 
sound system s. Thus feedback was lacking.
Persson 2002105 Four conditions were described, bu t partic ipan ts  were 
random ised betw een two of the  four groups. There was no control 
for these two groups.
Post-W hite 2003106 In th is  study the re  was no control or norm al care group.
Ravasco 2005107 No psychosocial intervention. The em phasis was placed on 
changing nu tritiona l behaviour.
Ravasco 2005a108 No psychosocial intervention. The em phasis was placed on 
changing nu tritiona l behaviour.
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Table 1: Characteristics of excluded studies
Study Reason for exclusion
Roscoe 2005109 No psychosocial in terv en tio n . T his s tudy  ev a lu a te d  po larity , b u t 
feedback on th e ir  b ehaviou r w as lacking.
S avard  2005110 In te rv en tio n  w as conducted  afte r cancer tre a tm e n t w as 
com pleted.
Sherw ood 2005111 F atigu e  w as m entioned  as one of th e  sym ptom s. R esu lts  on th e  
to ta l n um b er of sym ptom s w ere described, b u t w as no t sep a ra ted  
for fatigue.
Speca 2000112 U nclear if p a rtic ip a n ts  received cancer t re a tm e n t during  th e  
in terven tion .
S tan to n  2005113 In te rv en tio n  w as conducted  afte r cancer tre a tm e n t w as 
com pleted.
S tiegelis 2004114 In te rv en tio n  w as conducted  afte r cancer tre a tm e n t w as 
com pleted.
S trong  2008115 C ancer p a tie n ts  w ith  concu rren t chem otherapy  or rad io th e rap y  
w ere excluded.
Telch 1986116 U nclear if p a rtic ip a n ts  received cancer t re a tm e n t during  th e  
in terven tion .
Vos 2004117 U nclear if p a rtic ip a n ts  received cancer t re a tm e n t during  th e  
in terven tion .
W enzel 1995118 U nclear if p a rtic ip a n ts  received cancer t re a tm e n t during  th e  
in terven tion .
W illiam s 2004119 No psychosocial in terv en tio n . In  th is  in te rv en tio n  p a rtic ip a n ts  
w ere ed ucated  using  audio tapes. T hus feedback w as lacking.
W illiam s 2005120 No psychosocial in terv en tio n . In  th is  in te rv en tio n  p a rtic ip a n ts  
w ere ed ucated  using  audio tapes. T hus feedback w as lacking.
W ydra 2001121 No psychosocial in terv en tio n . T his in te rv en tio n  ev a lu a te d  self­
care m anag em en t giving p a rtic ip a n ts  an  in te rac tive  videodisc 
module, b u t received no feedback from  a  care  provider.
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Table 2: Characteristics of ongoing studies
Cohen 2004a
Study name M indfu lness re lax a tion  com pared  w ith  re lax ing  m usic and  
s ta n d a rd  sym ptom  m a n ag em e n t education  in tre a tin g  p a tie n ts  
who are  undergo ing  chem otherapy  for new ly d iagnosed  solid 
tum ors.
Methods R andom ized phase : P a tie n ts  a re  random ized  to 1 of 3 tre a tm e n t 
arm s; A rm  I: P a tie n ts  undergo  m indfu lness re lax a tion  th e ra p y  
(MR); A rm  II: P a tie n ts  lis ten  to  re lax ing  music; A rm  III: P a tie n ts  
receive s ta n d a rd  sym ptom  m anag em en t education. N au sea  and  
vom iting, m en ta l h e a lth  (anxiety, depression, and  d istress), and  
quality  of life (cancer-re la ted  sym ptom s, fatigue, sleep, and  pain) 
are  assessed  a t  baseline , in  th e  m iddle of chem otherapy  (course 2 
of a  4-course chem otherapy  protocol OR course 3 of a  6-course 
chem otherapy  protocol), a t  th e  end  of tre a tm e n t, and  th e n  a t  3 
m onths.
Participants P a tie n ts  who are  undergo ing  chem otherapy  for new ly diagnosed 
solid tum ors.
Interventions A rm  I: P a tie n ts  undergo  m indfu lness re lax a tion  (MR) th e ra p y  
com prising  lis ten in g  to  in s tru c tio n s  on b re a th in g  tech n iq ues and  
o th er m ind  and  body re lax a tion  p ractices on com pact disc for 30 
m in u tes before and  d uring  each chem otherapy  session and  a t 
le a s t once daily  for th e  e n tire  d u ra tio n  of chem otherapy  
tre a tm e n t.
A rm  II: P a tie n ts  lis ten  to re lax ing  m usic (w ith no in s tru c tio n s  on 
re lax a tion  techniques) for 30 m in u tes  before and  d uring  each 
chem otherapy  session an d  a t  le a s t once daily  for th e  en tire  
d u ra tio n  of chem otherapy  tre a tm e n t.
A rm  III: P a tie n ts  receive s ta n d a rd  sym ptom  m anag em en t 
education.
Outcomes C onditioned  n a u se a  and  vom iting  as m easu red  by M orrow 
assessm en t of n a u se a  and  em esis (MANE); D istress as m easu red  
by Im pact of E v e n t Scale (IES); F a tigu e  as m easu red  by b rie f 
fa tigue inven to ry  (BFI); A nxiety  as m easu red  by Spielberger 
S ta te /T ra it A nxiety  Scale (STAI); D epression  as m easu red  by 
C en ter for Epidem iology-D epression (CES-D); Sleep as m easu red  
by P ittsb u rg h  Sleep Q uality  Index  (PSQI); P a in  as m easu red  by 
b rie f p a in  inven to ry  (BPI); Q uality  of life as m easu red  by 
F un ction al A ssessm en t of C ancer T herapy.
Starting date M arch  2006
Contact information Lorenzo Cohen: U.T.M .D. A nderson  C ancer C en ter USA
Notes
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Cohen 2006
Study name E va lu a tion  of th e  effect of cognitive behav io r in te rv en tio n  on 
psychological d is tre ss  of cancer p a tie n ts  and  th e ir  fam ily 
m em bers.
Methods S tudy  Design: R andom ized, Active Control Study.
Q uestion na ire s will be answ ered  by th e  p a rtic ip a n ts  pre-, p o s t­
in te rv en tio n  and  afte r four m onths.
Participants C ancer p a tie n ts .
Interventions Cognitive behavior group in terven tion .
Outcomes B rief Sym ptom  Inventory , F a tigu e  inventory, M ini Sleep 
Q u estionna ire  and  rep ressio n -sensitiza tion  questionnaire .
Starting date Ju ly  2006
Contact information cohenm @ research.haifa.ac.il
Notes
Cohen 2007a
Study name Effects of T ibe tan  yoga on fa tigue an d  sleep in cancer.
Methods P a rtic ip a n ts  a re  random ly  assigned  to th re e  groups: a  T ibe tan  
Yoga (TY) group; s tre tch ing  group (SG); or a  u su a l care  group 
(UC). M easu res will be ob ta ined  p rio r to  ran do m izatio n  and  1 
week, 1 m onth , 6 m onths, and  12 m onths, a fte r th e  la s t 
in te rv en tio n  session.
Participants W om en w ith  b re a s t cancer undergo ing  chem otherapy .
Interventions P a rtic ip a n ts  in  th e  TY and  SG groups will p a rtic ip a te  in  seven 
w eekly group sessions (60 m inutes) or 4 sessions every  3  w eeks 
(90 m inutes).
TY: Deep b re a th in g  exercises and  perform ing  d ifferent s tre tch ing  
and  m ovem ent exercises.
SG: Sim ple s tre tch ing  exercises.
Outcomes F atigu e  an d  sleep d istu rbances.
Starting date N ovem ber 2006
Contact information Lorenzo Cohen: U.T.M .D. A nderson  C ancer C en ter USA
Notes
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Cohen 2007b
Study name Effects of yoga in  b re a s t cancer p a tie n ts .
Methods P a rtic ip a n ts  a re  random ly  ass igned  to  th re e  groups: a  Yoga group 
(YG) group; s tre tch ing  group (ST); or a  w aitlis t contro l group 
(WL). M easu res will be ob ta ined  p rio r to  random ization , a  b rie f 
assessm en t d uring  th e  m iddle of rad ia tio n  th e rap y , during  th e  
la s t  w eek of rad ia tio n  th e ra p y  and  1 m onth , 3 m onths, and  6 
m onths, a fte r th e  la s t rad ia tio n  session.
Participants W om en w ith  b re a s t cancer undergo ing  rad io therapy .
Interventions P a rtic ip a n ts  in  th e  YG and  ST groups w ill a tte n d  th re e  sessions 
(60 m inutes) each  w eek th ro u g h o u t th e ir  6 -week rad io th e rap y  
schedule. TY: Deep b re a th in g  exercises an d  perform ing  d ifferent 
m ovem ents an d  m ed ita tion .
SG: Sim ple s tre tch ing  exercises.
Outcomes F atigu e  and  sleep d is tu rbances  (self-report and  actig raphy).
Starting date M arch  2006
Contact information Lorenzo Cohen: U.T.M .D. A nderson  C ancer C en ter USA
Notes
G oedendorp 2005
Study name E va lu a tion  of in te rv en tio n  s tra teg ie s  to  m anage fa tigue during  
active tre a tm e n t and  to  p re v en t p e rs is te n t fa tigue a fte r cu rative  
tre a tm e n t for cancer.
Methods P a rtic ip a n ts  a re  random ly  ass igned  to  th re e  g roups: th e  m in im al 
in terven tion ; th e  CBT in terven tion ; an d  a  u su a l care group. 
P a tie n ts  w ill be assessed  before cancer tre a tm e n t (T0), shortly  
afte r cancer t re a tm e n t (a t lea s t 6 m onths a fte r baseline) (T1), and  
one y ea r a fte r T1.
Participants P a tie n ts  ju s t have been  d iagnosed for b re a s t cancer, colorectal 
cancer, cervix cancer, u te ru s  cancer, te s tis  cancer, H odgkin  and  
non-H odgkin  d isease. P a tie n ts  in  p re p a ra tio n  of receiv ing th e ra p y  
w ith  cu ra tive  in ten tion .
Intervention 1) The n u rs in g  in te rv en tio n  consists of a  booklet w ith  easily  
understood  gene ra l in fo rm ation  abou t tw o com ponents. In  tw o one 
h our session  th e  rese arch  n u rse  will exp lain  th e  booklet and  help 
th e  p a tie n t to  applicate  th is  to  th e ir  s itua tion . G en era l 
info rm ation  abou t fa tigue during  active t re a tm e n t will be given. 
The second com ponent consists of physical activ ity  ins truc tions. 
In  th e  second session also th e  adherence of th e  p a tie n ts  to  th e  
in s tru c tio n s  will be discussed.
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co n tin u ed  G oedendorp 2005
Interventions 2) CBT condition  w ill also get an d  d iscuss th e  booklet given in  th e  
m in im al in te rv en tio n  condition. A dditional th ey  get ind iv idual 
tre a tm e n t th a t  consists of 10 sessions w ith  a  p sych o th erap is t of 
th e  E x p ert C en tre  C hronic F a tigu e  in  abou t six m onths. P a tie n ts  
will; lea rn  to  cope w ith  em otions evoked by hav ing  a  life- 
th re a te n in g  disease; be th o u g h t how to get a  m ore reg u la r 
sleep/w ake cycle; lea rn  to  reg u la te  activ ities; lea rn  to  reg u la te  
supp o rt of o thers, em otionally  or in s tru m en ta lly ; engaging  in  
activ ities th a t  give m e n ta l re s t and  relief; in te g ra te  th e  lea rn ed  
w ay of th in k in g  and  behav ing  in daily  life.
Outcomes F atigu e  severity  will be m easu red  using  th e  C hecklist Ind iv idual 
S treng th .
Starting date 1-11-2005
Contact information m .goedendorp@ nkcv.um cn.nl; g.bleijenberg@ nkcv.um cn.nl
Notes
Oh 2008b
Study name R andom ized C linical Trial: The im pact of m edical qigong 
(trad itio n a l C hinese m edicine) on fatigue, qua lity  of life, side 
effects, mood s ta tu s  and  in flam m ation  of cancer p a tie n ts .
Methods P a rtic ip a n ts  a re  random ly  ass igned  to  tw o groups: a  contro l group 
th a t  receive u su a l h e a lth  care and  an  in te rv en tio n  group who 
p a rtic ip a te  in  a  M edical Qigong (MQ) p rogram  in  addition  to 
receiving u su a l h e a lth  care  a t th e  hosp ita l. R andom isation  w as 
s tra tif ied  by com pletion of cancer t re a tm e n t or u n d e r active 
cancer t re a tm e n t. P a tie n ts  com pleted  m easu res before and  afte r 
th e  program .
Participants P a tie n ts  d iagnosed w ith  a  ran ge  of cancers.
Interventions The 10 w eek MQ p ro g ram  consists of, coord ination  of gentle  
exercise and  re lax a tio n  th ro u g h  m ed ita tion  and  b re a th in g  
exercise b ased  on th e  C hinese M edicine theo ry  of energy  
channels.
Outcomes C ancer re la te d  fa tigue w as m easu red  by FACT-F, qua lity  of life 
and  sym ptom s w ere m easu red  by th e  FACT-G, mood s ta tu s  by 
POM S. The in flam m ato ry  m a rk e r seru m  C -reactive p ro te in  (CRP) 
w as also m onitored  serially .
Starting date U nclear. In  S ep tem ber 2008 alm ost 162 p a rtic ip a n ts  w ere 
recru ited .
Contact information byeongsangoh@ health .usyd .edu.au
Notes An a b s tra c t can  be found a t th e  A m erican  Society of C linical 
Oncology: 08-AB-32678-ASCOAM
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P u rce ll 2008
Study name A random ised  control t r ia l  inv estig a tin g  th e  effects of group 
education  and  su pp o rt in reducing  can cer-re la ted  fa tigue and  
im proving q uality  of life in  p a tie n ts  undergo ing  rad io therapy .
Methods P a tie n ts  will be random ised  in to  one of four group using  a  2x2 
factorial design. T hese groups will a t te n d  a  fa tigue education  and  
supp o rt (FES) group e ith e r  once a t th e  s ta r t  of tre a tm e n t, once a t 
th e  end  of t re a tm e n t or tw ice a t  both  th e  s ta r t  an d  end  of 
tre a tm e n t. T hese th re e  in te rv en tio n s  will be com pared to a 
control group who receive s ta n d a rd  care  (no F E S  group). P a tie n ts  
w ill be assessed  a t  th re e  tim e points; once a t  th e  s ta r t  of 
tre a tm e n t, once a t  th e  end  of tre a tm e n t, and  once six w eeks afte r 
th e  com pletion of tre a tm e n t.
Participants P a tie n ts  d iagnosed w ith  a  ran ge  of cancers.
Interventions P a rtic ip a n ts  receive education  abou t rad io th e rap y  process, w h a t 
to  expect from  tre a tm e n t, side effects and  s tra teg ie s  to  use to 
m in im ise side effects.
Outcomes F atigu e  u sing  th e  M ultid im ensional F a tigu e  Inventory .
Starting date 01-04-2008
Contact information A m anda_purcell@ health .q ld .gov.au
Notes
S av a rd  2008
Study name Self-Help t r e a tm e n t for in som nia  in  b re a s t cancer p a tie n ts .
Methods Study  Design: R andom ized, Active Control S tudy  w ith  th re e  
study  arm s: tw o form s of cognitive-behavioral th e ra p y  (CBT) and  
a  th e  control condition  (i.e., u su a l care). T im efram e: p re ­
tre a tm e n t, p o s t-trea tm e n t, 4 follow-up.
Participants C ancer p a tie n ts .
Interventions 1: p ro fessionally  ad m in is te red  cognitive-behavioral the rapy , 
consisting  of six w eekly sessions.
2: se lf-adm in is tered  form  of cognitive behav io ra l the rapy , 
consisting  of six sh o rt booklets and  v ideotapes.
Outcomes sleep d ia ry  indices, actig raphy , Insom nia  S everity  Index.
Starting date A pril 2008
Contact information josee.savard@ psy.u laval.ca; julie.villa@ crhdq .ulaval.ca
Notes
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Table 3: Outcomes
Author and year Instruments used to measure fatigue Number of 
instruments 
used to 
measure 
fatigue
A rm es 20 0 749 V isual A nalogue Scale (VAS-f) of global 
fatigue. E u ro pean  O rg an isa tio n  for 
R esearch  and  T re a tm e n t of C ancer Q uality  
of Life Q u estionna ire  C30 (EORTC QLQ- 
C30), sub-scale fatigue. M ultid im ensional 
F a tigu e  Inven to ry  (MFI).
3
B arsevick  200450 S hort F orm  of th e  Profile of Mood S ta tes  
(POMS), sub-scale F atigue. S chw artz 
C ancer F a tigu e  Scale (SCFS). G eneral 
F a tigu e  Scale (GFS).
3
B erg lund  200739 E uro pean  O rg an isa tio n  for R esearch  and  
T re a tm e n t of C ancer Q uality  of Life 
Q u estion na ire  C30 (EORTC QLQ-C30), 
sub-scale fatigue.
1
B row n 200651 Single item  L inea r A nalogue Self 
A ssessm en t (LASA). Profile of Mood S ta tes  
(POMS), F a tig u e -In e rtia  sub-scale. STAI 
question  26, Sym ptom  D istress  Scale (SDS) 
fa tigue question.
4
C lassen  200141 Profile of Mood S ta te s  (POMS), F atigue- 
In e r tia  sub-scale.
1
Cohen 200734 F atigu e  Sym ptom  Inven tory  (FSI). 1
C unn ingham  198952 Profile of Mood S ta te s  (POMS), F atigue- 
In e r tia  sub-scale.
1
D ecker 199254 Profile of Mood S ta te s  (POMS), F atigue- 
In e r tia  sub-scale.
1
De M oor 200242 Profile of Mood S ta te s  (POMS), F atigue- 
In e r tia  sub-scale.
1
De W it 199753 E uro pean  O rg an isa tio n  for R esearch  and  
T re a tm e n t of C ancer Q uality  of Life 
Q u estion na ire  C30 (EORTC QLQ-C30), 
sub-scale fatigue.
1
E delm an  199943 Profile of Mood S ta te s  (POMS), F atigue- 
In e r tia  sub-scale.
1
F aith fu ll 200146 V isual A nalogue Scale (VAS). E uropean  
O rg an isa tio n  for R esearch  an d  T re a tm e n t 
of C ancer Q uality  of Life Q uestionna ire  
C30 (EORTC QLQ-C30), sub-scale fatigue.
2
Faw zy 199540 Profile of Mood S ta te s  (POMS), F atigue- 
In e r tia  sub-scale.
1
F o res te r 198558 Schedule of Affective D iso rders and  
S ch izophren ia  (SADS), item  F atigue.
1
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Author and year Instruments used to measure fatigue Number of 
instruments 
used to 
measure 
fatigue
G aston-Johansson  20 0038 V isual A nalogue Scale (VAS). 1
G iven 2002BB Sym ptom  E xperience Scale (SES), item  
F atigue.
1
Godino 200647 F un c tion a l A ssessm ent of C ancer T herapy  
F a tigu e  (FACT-F).
1
Goodwin 200132 Profile of Mood S ta te s  (POMS), F atigue- 
In e r tia  sub-scale. E u ro pean  O rg an isa tio n  
for R esearch  and  T re a tm e n t of C ancer 
Q uality  of Life Q uestion na ire  C30 (EORTC 
QLQ-C30), sub-scale fatigue.
2
M oadel 20 0737 F un c tion a l A ssessm en t of C hronic Ilness 
T herapy  - F a tigu e  (FACIT-F).
1
Oh 2008B6 E uro pean  O rg an isa tio n  for R esearch  and  
T re a tm e n t of C ancer Q uality  of Life 
Q u estion na ire  C30 (EORTC QLQ-C30), 
sub-scale fatigue.
1
Raw l 20 0248 SF-36 V itality . 1
R eam  2006B7 V isual A nalogue Scale (VAS), SF-36 su b ­
scale v ita lity .
2
S andgren  20003B Profile of Mood S ta te s  (POMS), F a tigu e  
sub-scale.
1
S andgren  200330 Profile of Mood S ta te s  (POMS), F atigue- 
In e r tia  sub-scale.
1
S avard  20 0644 M ultid im ensiona l F a tigu e  Inven to ry  (MFI). 1
Spiegel 1 9 8 i4B Profile of Mood S ta te s  (POMS), F a tigu e  
sub-scale.
1
Y ates 200536 R evised P iper F a tigu e  Scale (PFS). 
F un c tion a l A ssessm ent of C ancer T herapy  
F a tigu e  (FACT-F). F ou r 11-point num eric  
fa tigue ra tin g  scales (NFRS) assessing  
levels of fa tigue a t  w orst, best, and  average 
in  th e  p a s t  week, and  cu rren tly .
6
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Table 4: Quality Assessment
Scales A rm e
s
200749
B arse
vick
200450
Bergl
und
200739
Brow
n
200651
Class
en
200141
Cohe
n
200734
C unni
ngh a
m
198952
ran do m isa tio n 1 1 1 1 1 1 1
concealm ent of allocation 0 0 0 0 0 0 0
b linded  outcom e assesso r 0 0 0 0 0 1 0
pow er calculation 1 0 0 0 0 0 0
in ten tio n  to  t r e a t 0 1 0 0 0 0 0
group sim ila rity  a t  baseline 0 1 1 0 1 1 1
specified eligib ility  c r ite r ia 1 1 1 1 1 1 0
drop-out 1 1 0 1 0 1
selective lost to  follow-up 0 1 0 0 0 0 0
co-in terven tion  avoided 1 1 1 1 1 1 1
com pliance 1 1 0 1 1 1 0
re lev an t m easu res 1 1 1 1 1 1 1
tim ing  a ssessm en ts 1 1 0 1 1 0 0
equally  tre a tm e n t 1 1 1 0 1 1 1
con tam ination 0 0 0 0 0 1
protocol 1 1 0 1 1 1 1
t ra in in g 1 1 0 1 0 0 0
in teg rity  check 1 1 0 0 0 0 0
adverse  effects 0 0 0 0 0 0
sam ple size 1 0 0 1 1 1
m issing  va lues 0 1 0 0 0 0 0
s ta n d a rd  deviation 1 1 0 0 0 1 0
desc. of index  & contro l 
in te rv en tio n
1 1 1 1 1 1 1
long te rm  follow-up 
m easu rem en t
1 1 1 1 0 1 1
superv ision 1 1 0 0 1 0 0
Oxford Q uality  Scale26 2 1 2 1 2 1 2
D elphi l is t27 2,5 3,5 2,5 1,5 2,5 3,5 1,5
In te rn a l V alid ity28 4,5 4,5 3,5 3,5 4,5 4,5 3,5
T otal (25) 17 18 9 10 13 13 11
Footnotes
Oxford Quality Scale26: randomisation, concealed allocation, drop-out (0-3).
Delphi list27: randomisation (0,5 points), concealed allocation (0,5 points), blinded outcome 
assessor, power calculation, intention to treat, group similarity at baseline, specified eligibility 
criteria (0-6).
Internal validity28: randomisation, concealed allocation, blinded outcome assessor, intention to 
treat, drop-out, co-intervention avoided, compliance, timing assessments. (0-8)
Yes= 1, No= 0, Not enough information to answer this question= 0 
desc. = description
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Table 4: Quality Assessment
Scales D ecker
199254
De Moor 
200242
De W it 
199753
E delm
an
199943
F a ith fu
ll
200146
Faw zy 
199 540
ran do m isa tio n 1 1 1 1 1 1
concealm ent of allocation 0 0 0 0 0 0
b linded  outcom e assesso r 1 0 0 0 0 0
pow er calculation 0 0 0 0 1 0
in ten tio n  to  t r e a t 0 0 0 0 0 0
group sim ila rity  a t  baseline 0 1 1 1 0 1
specified eligib ility  c r ite r ia 1 1 1 1 1 1
drop-out 0 1 1 1 0 0
selective lost to  follow-up 1 -1* 0 0 0
co-in terven tion  avoided 1 1 1 1 1 1
com pliance 0 1 1 0 0 0
re lev an t m easu res 1 1 1 1 1 1
tim ing  a ssessm en ts 1 1 1 1 1 0
equally  tre a tm e n t 1 1 1 1 1 1
con tam ination 0 0 0 0 0 0
protocol 1 1 1 1 0 1
t ra in in g 0 0 1 0 0 0
in teg rity  check 0 0 0 0 0 0
adverse  effects 0 0 0 0 0 0
sam ple size 0 0 1 1 1 0
m issing  va lues 0 0 0 0 0 0
s ta n d a rd  deviation 1 0 1 0 0 1
desc. of index  & contro l 
in te rv en tio n
1 1 1 1 1 1
long te rm  follow-up 
m easu rem en t
1 1 1 1 0 1
superv ision 1 0 0 0 0 0
Oxford Q uality  Scale26 1 2 2 2 1 1
D elphi l is t27 2,5 2,5 2,5 2,5 2,5 2,5
In te rn a l V alid ity28 3,5 4,5 4,5 3,5 2,5 2,5
T otal (25) 13 12 14 12 9 10
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Table 4: Quality Assessment
Scales Fores
te r
198558
G aston- 
Jo han sso  
n  20 0038
Given 
20 0255
Godin
o
200647
Good
w in
200132
M oad
el
200737
Oh
200856
ran do m isa tio n 1 1 1 1 1 1 1
concealm ent of allocation 0 0 0 0 0 0 0
b linded  outcom e assesso r 0 0 0 0 0 0 0
pow er calculation 0 1 0 0 1 1 0
in ten tio n  to  t r e a t 0 0 0 0 0 0 0
group sim ila rity  a t 
b aseline
1 1 1 0 1 1 0
specified eligib ility  
c rite ria
1 1 1 1 1 1 1
drop-out 0 0 0 1 1 1 1
selective lost to  follow-up 0 0 1 0 1 -1* 0
co-in terven tion  avoided 1 1 1 1 1 1 1
com pliance 0 0 0 0 1 1 0
re lev an t m easu res 1 1 1 1 1 1 1
tim ing  a ssessm en ts 1 1 0 1 1 1 1
equally  tre a tm e n t 1 1 1 1 1 1 1
con tam ination 0 0 0 0 0 0 0
protocol 0 1 1 1 1 0 0
t ra in in g 0 0 1 1 1 1 1
in teg rity  check 0 0 0 0 1 0 0
adverse  effects 0 0 0 0 0 0 0
sam ple size 1 1 1 1 1 1 1
m issing  va lues 0 0 0 0 0 0 0
s ta n d a rd  deviation 0 1 0 1 1 1 0
desc. of index  & contro l 
in te rv en tio n
1 1 1 1 1 1 1
long te rm  follow-up 
m easu rem en t
1 0 0 0 0 0 0
superv ision 0 0 0 0 0 0 0
Oxford Q uality  Scale26 1 1 1 2 2 2 2
D elphi l is t27 2,5 3,5 2,5 1,5 3,5 3,5 1,5
In te rn a l V alid ity28 2,5 2,5 2,5 3,5 4,5 4,5 3,5
T otal (25) 10 12 11 12 17 13 10
Footnotes
* -1: in this study selective lost to follow-up was present
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Table 4: Quality Assessment
Scales Raw l
200248
R eam
200657
S andgr
en
200035
S andgr
en
200330
S avard
200644
Spiegel
198145
Y ates 
20 0536
ran do m isa tio n 1 1 1 1 1 1 1
concealm ent of allocation 1 1 0 0 0 0 1
b linded  outcom e assesso r 0 0 0 0 0 0 0
pow er calculation 0 1 0 0 0 0 1
in ten tio n  to  t r e a t 0 0 0 1 0 0 0
group sim ila rity  a t 
b aseline
1 1 1 0 0 0 1
specified eligib ility  
c rite ria
1 1 1 1 1 0 1
drop-out 1 1 1 1 1 0 1
selective lost to  follow-up 0 0 0 1 0 0 0
co-in terven tion  avoided 1 1 1 -1 1 1 1
com pliance 0 0 0 1 0 0 1
re lev an t m easu res 1 1 1 0 1 1 1
tim ing  a ssessm en ts 1 1 1 1 1 0 1
equally  tre a tm e n t 0 1 1 1 1 0 1
con tam ination 0 0 0 1 0 0 0
protocol 1 1 0 1 0 1 1
t ra in in g 1 0 1 1 0 1 1
in teg rity  check 1 0 0 1 1 0 0
adverse  effects 0 0 0 0 0 0 0
sam ple size 0 1 1 0 1 1 1
m issing  va lues 0 0 0 0 0 1 0
s ta n d a rd  deviation 0 1 0 0 1 0 1
desc. of index  & contro l 
in te rv en tio n
1 1 1 1 1 1 1
long te rm  follow-up 
m easu rem en t
1 0 1 1 1 0 1
superv ision 0 0 1 1 0 1 0
Oxford Q uality  Scale26 3 3 2 2 2 1 3
D elphi l is t27 3 4 2,5 3,5 1,5 0,5 4
In te rn a l V alid ity28 4 4 3,5 3,5 3,5 2,5 5
T otal (25) 13 14 13 15 12 9 17
Footnotes
* -1: in this study selective lost to follow-up was present
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Table 5: Characteristics of included studies
A rm es (2007)49
Methods RCT. O rig inally  s ta r tin g  w ith  m in im ization  on b asis  of age, sex, site, and  
stage of cancer, and  HADS scores. A fter 10 p a tie n ts  w ere allocated, sim ple 
random  p e rm u te d  block ran do m izatio n  w as im plem ented . S ixty 
p a rtic ip a n ts  w ere random ized , 30 to bo th  groups, th e  final sam ple size 
w as 55. O f th e  expe rim en ta l group (EG) 28 com pleted  baseline  
q uestio nn a ires  (T0 = cycle 3 of CT), 21 p a rtic ip a n ts  com pleted  T1 
a ssessm en t (end of cytotoxic tre a tm e n t) , 22 p a rtic ip a n ts  com pleted  T2 
a ssessm en t (4 w eeks a fte r th e  end  of cytotoxic tre a tm e n t) , and  17 
p a rtic ip a n ts  com pleted  T3 assessm en t (9 m onths a fte r rec ru itm en t). Of 
th e  control group (CG) 27 p a rtic ip a n ts  com pleted  T0, 16 com pleted  T1, 22 
com pleted  T2, 19 com pleted  T3. Non response ra te  v aried  across 
a ssessm en t from  16 to  5. A t T3 14 p a rtic ip a n ts  died and  5 w ere n o n ­
responders (EG 7 died, 4 non response; CG 7 died, 1 non response).
Participants P a tie n ts  who w ere a tten d in g  for chem otherapy  tre a tm e n t w ere screened  
for eligib ility  a t 2 cancer cen tres in  S ou th  London. P a tie n ts  w ere excluded 
who 1) w ere aged < 18 years; 2) did no t have h isto logically  proven  cancer 
or w ere no t aw are  of th e ir  cancer diagnosis; 3) w ere receiv ing th e  la s t  h a lf  
of th e  p la n n ed  course of cytotoxic tre a tm e n t; 4) w ere u nab le  to  sp eak  and  
u n d e rs ta n d  E nglish; 5) did no t rep o rt sign ifican t fatigue; 6) h ad  a  poor 
E a s te rn  C ooperative Oncology G roup perform ance s ta tu s  (>3); 7) h ad  a 
previous h is to ry  of psychotic disorder; 8) h ad  evidence of cognitive 
im p airm en t or cen tra l nervous system  m etastases ; 9) w ere receiving 
psycho therapy  or CBT; 10) w ere receiv ing cytokine tre a tm e n t; or 11) h ad  
an  uncontro lled  infection  a t th e  tim e of rec ru itm en t. The m ean  age of th e  
55 p a rtic ip a n ts  w as 59 years. A m ajo rity  w ere wom en (n=33) and  w ere 
w hite B ritish  (n=46). Of these , 27 h ad  a  d iagnosis of colorectal cancer, 44 
h ad  stage III or IV, and  42 h ad  a t lea s t 1 m e tastas is .
Interventions One tra in e d  rese arch  fellow (nurse) (first au tho r) p rovided  th e  
in terv en tio n , consisting  of 3 ind ividual, face-to-face, 60 m in u te  sessions a t 
3 to 4 w eekly in te rv a ls  (coinciding w ith  chem otherapy). The com ponents 
of th e  in te rv en tio n  w ere education  of CRF, w ritte n  in fo rm ation  on CRF, 
d iscussing  effectiveness of coping stra teg ies; goal se tting , activ ity  
scheduling, g raded  ta s k  m anagem ent, se lf m onitoring  and  m odification; 
d istraction , cognitive re s tru c tu rin g , p ra ise  and  encouragem ent. The 
control group received s ta n d a rd  care.
Outcomes T hree p rim ary  outcom es w ere m easured . F a tigu e  w as assessed  u sing  a 
VAS of global fatigue, physical function ing  (sub-scale of EORTC-QLQ- 
C30), fa tigu e-re la ted  d is tre ss  w as m easu red  w ith  a  F a tigu e  O utcom e 
M easure  designed  specifically for th e  study . Secondary  outcom es w ere 
M FI, HADS, and  th e  EORTC-QLQ-C30.
Notes The d u ra tio n  of th e  cy tosta tic  tre a tm e n t is no t described.
Allocation
concealment.? Yes, N ot concealed a t  th e  s ta r t  of th e  s tudy  (see m ethods)
Footnotes: CBT: cognitive behavioural therapy; CRF: cancer related fatigue
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Table 5: Characteristics of included studies
B arsev ick  200450
Methods RCT. P a rtic ip a n ts  w ere s tra tif ied  by job s ta tu s  (w orking v ersus 
N onw orking), type of tre a tm e n t (CTX versus. rad io th e rap y  v ersus 
concu rren t the rapy ), and  d iagnosis (b reast v e rsus n on -b reast cancer). 
Q uestion na ire s w ere ad m in is te red  a t th re e  points. B ase line assessm en t 
occurred  before th e  s ta r t  of cancer tre a tm e n t. For p a rtic ip a n ts  receiving 
CTX or co ncu rren t th e ra p ie s  a ssessm en t occurred  48 h ou rs a fte r th e  
second and  th ird  CTX. For p a rtic ip a n ts  receiv ing RT a ssessm en t occurred 
d uring  th e  la s t  w eek of t re a tm e n t an d  one m onth  a fte r com pletion of 
tre a tm e n t. 396 p a rtic ip a n ts  w ere inc luded  in  th e  study.
Participants Ind iv iduals  w ere eligible if  th ey  w ere cu rren tly  beg inn ing  tre a tm e n t 
in ten d e d  for cure of local control, for b reast, lung, colorectal, advanced  
p ro sta te , gynaecologic, or te s tic u la r  cancer or lym phom a and  if  th ey  
p la n n ed  to receive > 3 cycles of h igh-dose chem otherapy  (CTX), 6 w eeks of 
ra d io th e rap y  (RT) or c u rre n t RT and  CTX. O the r tre a tm e n t o th er th a n  
su rgery  h ad  to be com pleted  one m onth  previously. Exclusion c r ite r ia  
w ere if  th e  t r e a tm e n t p lan  inc luded  stem  cell tra n sp la n ta tio n , 
in te rleu k in s , in terfe rons, or tu m o u r necrosis factor, p a tie n ts  w ith  chronic 
fa tigue syndrom e, p a tie n ts  who enrolled  on to  o th er s tu d ies involving 
psycho-educational in terv en tio ns , p a tie n ts  w ith  a  p sych ia tric  disorder, 
and  p a tie n ts  receiv ing t re a tm e n t for a n aem ia  or depression. The m ean  
age of th e  396 p a rtic ip a n ts  w as 56.3 years, th e  m ajo rity  w ere fem ale 
(85%), C aucasian  (91%) and  college educated  (65%). The s tudy  w as 
conducted  a t a  u n iv e rs ity  h e a lth  science cen tre  an d  a  com prehensive 
cancer cen tre.
Interventions P a rtic ip a n ts  allocated  to th e  energy  conservation  and  activ ity  
m anag em en t (ECAM) condition  received th re e  te lephone sessions from  a 
tra in e d  oncology nurse . P a rtic ip a n ts  w ere given in fo rm ation  on cancer- 
re la te d  fa tigue and  lea rn ed  energy  conservation  skills. An energy  
conservation  p lan  w as c rea ted  (coping stage), ev a lu a te d  and  rev ised  
(ap p ra isa l stage). The control group received th re e  te lephone sessions 
w ith  in fo rm ation  on n u tritio n , inform ing  and  d iscussing  m ain ten ance  of a 
h ea lth y  diet, u se of v itam in s  and  m inerals. P lan n ed  d u ra tio n  for both  
conditions of th e  firs t tw o sessions w as 30 m in u tes  and  th e  th ird  session 
15 m inutes. For p a rtic ip a n ts  receiv ing CTX or co ncurren t th e ra p y  th e  
in te rv en tio n  w as ad m in is te red  during  th e  firs t 3 w eeks of tre a tm e n t. For 
p a rtic ip a n ts  receiv ing RT th e  in te rv en tio n  occurred  d uring  w eek 3 to 5 of 
tre a tm e n t.
Outcomes F atigu e  w as m easu red  w ith  th re e  scales (POM S-sf, SC FS and  GFS). An 
o th er outcom e w as functional perform ance (FPI).
Notes How m any  p a tie n ts  w ere random ised  to  th e  tw o conditions and  how  m any  
w ere lost to  follow up is no t described. In  add ition  a  descrip tion  w h a t w as 
done w ith  m issing  va lues is lacking.
Allocation
concealment? U nclear
Footnotes: ECAM: energy conservation and activity m anagement
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Table 5: Characteristics of included studies
B erg lu n d  200739
Methods RCT. A fter s tra tif ica tio n  on stage of d isease, cu ra tive  tre a tm e n t an d  age, 
211 p a rtic ip a n ts  w ere random ised  to  Physical tra in in g  (Phys) (n=53), 
In fo rm ation  (Info) (n=55), in fo rm ation  p lu s physical tra in in g  (PhysInfo) 
(n=52) or a  control group (C) (n=51). Q uestion na ire s w ere com pleted  by 
194 p a rtic ip a n ts  a t baseline , 166 p a rtic ip a n ts  a t 6 m on ths follow-up, and  
158 p a rtic ip a n ts  a t  12 m onths follow-up. Some p a rtic ip a n ts  (n=23) 
dropped-out a fte r random isa tion , o th ers  in  a  la te r  stage for th e  following 
reasons; d issa tisfied  w ith  group ass ignm en t, could no t a rran g e  
tra n sp o rta tio n . In  addition  some q uestio nn a ires  w ere no t re tu rn ed , a t  6 
m onths follow-up or a t 12 m onths follow-up.
Participants W ith in  six m onths a fte r d iagnosis p ro s ta te  cancer w ere inc luded  a t  th e  
u n iv e rs ity  h osp ita l in U ppsala , Sw eden. P a rtic ip a n ts  w ere excluded if 
th e y  h a d  a n o th e r cancer diagnosis, p a rtic ip a te d  in  o th er stud ies, w ere 
p a tie n ts  in  o th er care  p rogram m es, h ad  severe h ea rin g  or vision  
im p airm en t, w ere no t Sw edish  speaking , or w ere physically  or m en ta lly  
d isabled . O verall 20% of th e  p a rtic ip a n ts  h a d  m e ta sta s is , th e  m ost 
freq u en t cu ra tive  t r e a tm e n t w as rad ica l p ro sta tec to m y  (24%), and  36% 
did no t h ad  active t r e a tm e n t (w atchful w aiting). The average age w as 69 
years, 80% w as m a rrie d  an d  24% h ad  a  u n iv e rs ity  degree.
Interventions E ach  in te rv en tio n  p ro g ram  included  7 w eekly  sessions, w ith  group sizes 
vary ing  from  3 to  10 p a rtic ip an ts . Phys: A p h y s io th e rap is t led 60-m inute 
physical tra in in g  session followed by a  15 m inu te  coffee b reak . The 
p rogram m e included  ligh t physical tra in in g  w ith  m ovem ent and  fitness 
tra in in g , re lax a tion  and  b re a th in g  exercises. A booster session w as held  2 
m onths a fte r th e  conclusion of th e  tra in in g  exercises. Info: A n u rse  led  60 
m in u te  in fo rm ation  sessions followed by a  15 m inu te  coffee break . 
E m p has is  w as la id  on giving th e  info rm ation  abou t p ro s ta te  cancer, its  
tre a tm e n t (lecture given by an  urologist) and  p o ten tia l side effects and  
how to  deal w ith  side effects. PhysInfo: com bination  of P hys and  Info 
p rogram s. P a rtic ip a n ts  w ere given physical tra in in g  an d  th e n  info rm ation  
in  th e  sam e session, consisting  of seven 135-m inute sessions. The control 
group received s ta n d a rd  care, i.e. th e  info rm ation  and  care  th a t  w as 
availab le  a t  th a t  tim e.
Outcomes The HADS an d  EORTC-QLQ-C30 w ere used. F a tigu e  w as assessed  w ith  
th e  fa tigue sub-scale of th e  EORTC QLQ-C30.
Notes U nclear how m any  p a tie n ts  com pleted  q uestio nn a ires  a t 12 m onths 
follow-up as n um b ers  in  th e  figure are  d ifferen t from  th e  tab les.
Allocation
concealment? U nclear
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B row n 200651
Methods RCT: s tra tif ica tio n  for tu m o u r type, age, gender, and  ECO G  score. Of th e  
115, 57 w ere random ised  to  th e  ex pe rim en ta l condition  58 to  th e  control 
condition. Before a ssessm en t 3 p a rtic ip a n ts  cancelled  due to  illness. 55 
p a rtic ip a n ts  in  th e  expe rim en ta l condition com pleted  baseline  
a ssessm en t, 57 in  th e  contro l condition. O f th e  expe rim en ta l condition  46 
com pleted  th e  a ssessm en t a t  w eek 4, 6 w ere found inelig ible due to  lack 
of session a tten dan ce . O f th e  contro l condition  54 com pleted  th e  
assessm en t a t w eek 4.
Participants Eligible p a rtic ip a n ts  w ere ad u lt advanced  cancer p a tie n ts  scheduled  to 
undergo  rad ia tio n  the rapy , rec ru ited  a t  th e  division of ra d ia tio n  oncology 
m ayo clinic R ochester. P a rtic ip a n ts  h ad  to  be d iagnosed w ith  cancer in 
th e  p a s t  12 m onths, have an  expected  su rv ival of a t  le a s t 6 m onths, b u t a 
5-year su rv ival p robab ility  of no m ore th a n  50%, and  recom m ended  
rad io th e rap y  for a t  lea s t tw o weeks. E xclusion c r ite r ia  w as a  MMSE- 
score less th a n  20, an  ECO G  perform ance score of 3 or more, active 
alcohol or su bstance  dependence, active th o u g h t d isorder, su ic idal p lans, 
or p a rtic ip a tio n  in  a  psychosocial tr ia l. The m ean  age of th e  115 
p a rtic ip a n ts  w as 59.6 an d  66 of th e  p a rtic ip a n ts  w ere m ale.
Interventions In  th e  s tru c tu re d  m u ltid isc ip lin ary  in te rv en tio n  p a rtic ip a n ts  a tten d ed  
eig h t 90-m inute sessions over th e  firs t 4 w eeks a fte r en ro lm ent. A 
p sy c h ia tr is t or a  psychologist led each session; depending  on th e  them e 
(m ental, em otional, physical, social, spatial), an  advanced  practice  nurse , 
a  chap la in , or a  social w orker co-facilitated  each  session. Sessions began  
w ith  20 m in u tes  of exercise conducted  by a  physical th e ra p is t  followed by 
ed ucatio na l inform ation, cognitive-behavioral stra teg ies, d iscussion, and  
support. Sessions concluded w ith  a  10 to  20 m inu te  guided  re lax ation  
exercise. P a rtic ip a n ts  received a  m a n u a l and  specific education  
brochures. The contro l group received s ta n d a rd  m edical care.
Outcomes F atigu e  w as assessed  as a  secondary  outcom e, m easu red  w ith  LASA, 
POM S, and  SDS a t base line  and  a t  w eek 4, 8, 27 and  STAI a t  baseline . 
In  add ition  raw  scores w ere tran sfo rm e d  to  a  0 to  100 p o in t scale as 
fa tigue QOL.
Notes N ot described  how m any  p a tie n ts  com pleted  th e  a ssessm en t a t  w eek 8 
an d  27.
Allocation
concealment?
U nclear
72
Review: Psychosocial intervention for fatigue during cancer treatm ent.
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C lassen  200141
Methods On com pletion of base line  testing , p a rtic ip a n ts  w ere random ised  to 
in te rv en tio n  or control conditions using  th e  adap tive  ran do m isa tio n  b iased  
coin-design m ethod. The adap tive ran do m isa tio n  m ethod  u sed  th e  
following variab les: 1 d om inan t site  of m e ta s ta s is  a t s tu dy  en try , 2 
estrogen  recep to r s ta tu s , 3 d isease-free in terva l, m e ta s ta s is  or recurrence, 
4 age a t s tudy  en try , 5 system ic tre a tm e n t received since m e ta sta s is , 6 
in s titu tio n . 102 w om en w ere inc luded  in  th e  d a ta  analysis , w ith  p a tie n ts  
who com pleted  a  p re -rand om isa tion  base line  m easu re  and  a t lea s t 1 post 
base line  assessm en t. 23 of th e  125 w om en random ised  in to  th e  stu dy  did 
no t com plete any  post-baseline  assessm en ts: 15 of these  23 p a rtic ip a n ts  
w ere too ill to  com plete q uestio nn a ires  (4 tre a tm e n t and  11 control 
p a rtic ip an ts), 2 w ere too busy  (both control p a rtic ip an ts), 4 w ithd rew  from  
th e  stu dy  because th ey  w ere no t assigned  to  a  supp o rt group, 1 w ithdrew  
because she did no t like th e  supp o rt group, and  1 assigned  to  th e  
tre a tm e n t condition w ithd rew  for no s ta te d  reason . 64 wom en w ere 
random ised  to  th e  in te rv en tio n  a rm  of th e  stu dy  and  61 to th e  control arm . 
P ost-base line  a ssessm en ts  w ere conducted  every  4 m onths during  th e  firs t 
y ea r and  every  6 m onths th e rea fte r.
Participants W om en w ith  confirm ed m e ta s ta tic  or locally re c u rre n t b re a s t  cancer w ere 
rec ru ited  th ro u g h  th e  Oncology D ay C are C en ter a t  S tan fo rd  U n iversity  
M edical C enter. P a tie n ts  w ere eligible if th e y  h ad  a  K arnofsky  score of a t 
le a s t 70%, w ere p ro ficien t enough in  E ng lish  to  be able to  respond  to 
q uestio nn a ires  and  p a rtic ip a te  in a  su pp o rt group. W om en w ere not 
inc luded  w ith  positive su p rac lav icu la r lym ph nodes as th e  only m e ta s ta tic  
lesion a t th e  tim e of in itia l diagnosis; active cancers w ith in  th e  p a s t  10 
y ea rs  o th er th a n  b re a s t cancer, b asa l cell or squam ous cell carc inom as of 
th e  skin, in s itu  cancer of th e  cervix, or m elanom a w ith  a  B reslow  depth  
less th a n  0.76 mm; or concu rren t m edical conditions likely  to  affect sh o r t­
te rm  survival. At s tu dy  en try  41% of th e  control group received 
chem otherapy  and  84% horm one the rapy . O f th e  t r e a tm e n t group 43% 
received chem otherapy  and  81% received horm one the rapy . The m ean  age 
of th e  control group w as 54, th e  m ean  education  w as 19 years, and  80% 
w as w hite. The m ean  age of th e  tre a tm e n t group w as 53, th e  m ean  
education  w as 16 years, and  91% w as w hite.
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Interventions P a rtic ip a n ts  in  th e  t r e a tm e n t group, th e  size ran g in g  from  3 to  15, m et 
w eekly for 90-m inute sessions. The in ten ded  d u ra tio n  of t re a tm e n t w as 1 
year. The th e ra p y  sessions w ere fac ilita ted  by 2 th e ra p is ts . T h e rap is ts  
inc luded  a  p sy ch ia tris t, psychologists, and  social w orkers. The supportive- 
expressive th e ra p y  m odel involved th e  c rea tion  of a  supportive 
en v iro nm ent in  w hich p a rtic ip a n ts  w ere encouraged  to  confront th e ir  
problem s, s tre n g th e n  th e ir  re la tion sh ip s, and  find  en hanced  m eaning  in 
th e ir  lives. Psycho education  w as provided  in  a  s im ila r fashion, w ith  
group m em bers sh a rin g  know ledge th ey  g a th e re d  abou t th e  illness and  
re la te d  issues. The in te rv en tio n  w as u n s tru c tu red , n e ith e r  coping 
s tra teg ie s  nor psycho education  w as ta u g h t in  a  d idactic m anner. E ach  
session ended  w ith  a  self-hypnosis exercise to  help p a rtic ip a n ts  m anage 
s tre ss  an d  deal w ith  pain . P a rtic ip a n ts  w ere encouraged  to  use th is  
exercise a t  home. All p a rtic ip a n ts  (also from  th e  control group) w ere 
offered self-d irected  education  m a te ria ls . They w ere given a  lis t of 
m a te ria ls  to select from  and  to  ta k e  hom e on loan. The selection  of 30 
books, 15 pam p h le ts , 5 v ideo tapes, and  7 au d io tapes covered a  wide range  
of topics re la te d  to  b re a s t cancer.
Outcomes The Profile of Mood S ta te s  (POMS) w as u sed  to  assess mood d istu rbance , 
inc luding  th e  sub-scale fatigue. The Im pact of E ven t Scale (IES) w as used  
to assess tr a u m a  sym ptom s.
Notes R esu lts  of th e  six m onths follow-up m e asu rem en ts  a fte r th e  in te rv en tio n  
are  no t described.
Allocation
concealment? U nclear
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Methods RCT. The n um b er of p a rtic ip a n ts  w as 38 in th e  cognitive-behavior (CB) 
group, 39 in  th e  re lax a tio n  and  guided  im agery  (RGI) group, and  37 in  th e  
control group (CG). P a rtic ip a n ts  com pleted  q uestio nn a ires  a t th re e  tim e 
point: p re -in terv en tion , p ost-in terven tion , and  a t th e  end  of a  4 -m onth  
follow-up a fte r th e  CB and  RGI groups concluded. S everal w om en did not 
com plete th e  p ost-in te rv en tio n  or follow-up questionnaires: 3 from  th e  
RGI group, 1 from  th e  CB group, and  6 from  th e  CG.
Participants B reas t cancer p a tie n ts , s tag es I and  II, who w ere 2 to  12 m onths since 
su rgery  an d  receiving tre a tm e n t (chem otherapy  or rad io therapy ) w ere 
inv ited  to  p a rtic ip a te  in th e  o u tp a tie n t u n it  of th e  oncology cen tre. 
Inclusion  c r ite r ia  w ere fluen t spoken H ebrew  and  absence of a  p sych iatric  
illness know n to th e  oncology staff. The m ean  age of th e  w om en w as 55.9 
(CB), 51.8 (RGI), an d  52.9 (CG). The m ean  education  in  y ears w as 13.5 
(CB), 13.2 (RGI) and  12.8 (CG). The m ajo rity  w ere m a rrie d  76.3% (CB), 
64.1% (RGI), an d  81.1% (CG). The tim e since d iagnosis w as 6.9 (CB), 7.2 
(RGI), 6.5 (CG) m onths. A m ajo rity  received chem otherapy  60.5 (CB), 64.1 
(RGI), 56.8 (CG).
Interventions The in te rv en tio n s  w ere conducted  by th e  firs t au tho r, a  sen ior social 
w orker and  ex pe rt in  psycho-oncology, w ith  tra in in g  and  experience in  CB 
techniques. E ach  group of 6 to  8 p a rtic ip a n ts  m et weekly, for n ine 90- 
m in u te  sessions. CB: Cognitive com ponents focused on lea rn in g  to  elicit 
negative th in k in g  p a tte rn s  and  re s tru c tu re  th e m  in to  adap tive p a tte rn s  
and  s tress-redu cing  tho ug h ts. In  add ition  m en ta l d istraction , p ro b lem ­
solving, and  decision-m aking s tra teg ie s  w ere ta u g h t. B ehav io ral 
com ponents focused on activ ity  scheduling, g raded  ta s k  ass ig n m en t and  
behav io ra l d istraction . P rac tic ing  a t hom e w as em phasized , w ith  
hom ew ork exercises, and  w ritte n  m a te ria l w as provided. RGI: S ystem atic  
lea rn ing  of deep RGI, p rac tic ing  deep b re a th in g  and  au togenic re laxation . 
E xperience of p ractice  a t  hom e w as d iscussed  to  give re assu ra n ce  and  
w ork on problem s in  th e  re lax a tio n  process. P a rtic ip a n ts  also p racticed  
anxiety , pain , and  n a u se a  reduction , and  s tra teg ie s  to  overcome sleep 
problem s. P a rtic ip a n ts  w ere provided w ith  RGI audio  casse ttes  or 
com pact d isks for ac tiv ity  a t  home. P a tie n ts  in  th e  contro l group received 
s ta n d a rd  care in  th e  oncology unit.
Outcomes The F a tigu e  Sym ptom  Inven to ry  (FSI) w as u sed  to m easu re  fatigue. 
O the r in s tru m e n ts  u sed  w ere th e  B rief Sym ptom  Inventory , th e  Perceived 
S tre ss  Scale, th e  M ini Sleep Q uestionnaire , and  th e  M ultid im ensional 
H ea lth  Locus of Control.
Notes The tw o in te rv en tio n s  could overlap  in  th e  use of a  behav io ra l s tra teg y  
such as d is trac tion . G roup processes, such as m u tu a l support, exchange of 
inform ation, and  expression  of feelings, took place in  both  groups.
Allocation
concealment? U nclear
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Methods RCT. 60 p a rtic ip a n ts  w ere random ly  assigned  in to  one of th e  two 
tre a tm e n t arm s: (30 to  both  groups). T hey  w ere s tra tif ied  by th e  au th o rs  
according to  age, sex and  a p p a re n t seriousness of d isease. Seven dropped 
ou t of th e  th e ra p y  (th ree  dying during  th e  program , th re e  being  too ill to 
a tten d , an d  one for unknow n reasons), leav ing  53, 28 in  th e  psycho 
educationa l th e ra p y  p lu s  supportive  discussion, 25 in supportive 
d iscussion  only. All a ssessm en ts  w ere being ad m in is te red , by th e  au tho rs, 
a t  th e  beg inn ing  of th e  firs t w eekly session of each in terv en tio n , a t  th e  
end  of th e  la s t w eekly session, and  for a  th ird  tim e 2 to 3 w eeks la ter.
Participants T he p a rtic ip a n ts  w ere consecutive adm issions to an  ongoing coping skills 
tra in in g  p ro g ram  a t a  large m etro po litan  cancer cen tre. They w ere 
re fe rred  by a  v a rie ty  of h e a lth  professionals, or self-referred. The group 
w as he terogeneous in  dem ographic and  d isease ch arac teris tics , abou t h a lf  
hav ing  re c u rre n t d isease, and  h a lf  being on some form  of m edical 
tre a tm e n t (chem otherapy, rad io th e rap y  or horm one tre a tm e n t)  a t th e  
tim e th e  in te rv en tio n s  began. O f th e  psycho educations group (n=28), 20 
w ere fem ale, th e  m ean  age w as 48, 13 h ad  b re a s t cancer, an d  16 did not 
receive tre a tm e n t a t  s ta r t  of th e  groups. O f th e  d iscussion  contro l group 
(n=25), 19 w ere fem ale, th e  m ean  age w as 49, 12 h ad  b re a s t  cancer, and  
12 did no t receive tre a tm e n t a t  s ta r t  of th e  groups.
Interventions B oth in te rv en tio n s  occupied 6 weekly, 2-hour sessions w ith  groups from  7 
to 10 p a rtic ip a n ts  an d  a  single leader. The psycho educationa l 
in te rv en tio n  inc luded  in  addition  to supportive  discussions, education  in 
coping skills. The tra in in g  com prised  tw o sessions of re laxation , two 
sessions on th e  use of positive m e n ta l im agery  and  one session each 
cen tred  a ro un d  goal-se tting  and  on gene ra l lifestyle m anagem ent. W here 
coping tech n iq ues w ere ta u g h t, th ey  w ere p ra c tised  firs t in  th e  group afte r 
w hich p a rtic ip a n ts  w ere asked  to  continue th e  p rac tice  a t  hom e w ith  th e  
aid  of a  w orkbook and  tw o audio tapes. T hese groups w ere conducted  by 
th e  firs t au tho r, a t  th a t  tim e a  g ra d u a te  s tu d e n t in clinical psychology. 
The control in te rv en tio n  consisted  of supportive  d iscussion, v en tila tio n  of 
feelings, gene ra l problem  solving an d  in fo rm ation  sharing . The lead er w as 
th e  second au tho r, a  sen ior nurse .
Outcomes The PO M S w as used, including  th e  sub-scale fatigue. The sym ptom  
check lis t (SCL-90-R) w as also used.
Notes
Allocation
concealment?
U nclear
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Methods RCT. On th e  day of th e  firs t vaccine tre a tm e n t, 42 p a rtic ip a n ts  
com pleted  q uestio nn a ires  and  w ere th e n  random ly  ass igned  to  an 
expressive w riting  (EW) group or a  n e u tra l w riting  (NW) group using  
m in im ization . P a tie n t  ch a rac te ris tic s  u sed  for ass ig n m en t were: gender, 
n um b er of m e tastases , and  non-lung  m e ta s ta tic  involvem ent. 
P a rtic ip a n ts  com pleted  follow-up a ssessm en ts  on th e  day of th e  fou rth  
w riting  session and  4, 6 , 8 an d  10 w eeks la te r. O f th e  21 p a rtic ip a n ts  in 
th e  EW  group 2 dropped  ou t p rio r to  th e  follow-up, and  one p a rtic ip a n t 
died during  th e  study. O f th e  21 p a rtic ip a n ts  in  th e  NW  group 3 dropped 
ou t and  tw o died during  th e  study.
Participants P a tie n ts  w ith  new ly d iagnosed stage IV ren a l cell carc inom a w ere 
rec ru ited  from  a  P hase  II tr ia l. Inclusion  c rite r ia  for th e  P h a se  II tr ia l  
w ere th a t  all p a rtic ip a n ts  h ad  a  life expectancy  of > 4 m onths, a  Zubrod 
perform ance s ta tu s  of 2, no serious in te rc u rre n t illnesses, an d  no b ra in  
m e tastases . P rio r to  en ro lm en t p a rtic ip a n ts  could no t have received any 
chem otherapy , or im m unotherapy . P a rtic ip a n ts  u n d e rw en t a 
nephrectom y and  vaccine tre a tm e n t. In  bo th  groups, th e  average age 
w as 56 years, 86% w ere m ale, and  76% h a d  tw o or m ore m e tastases . 
P a rtic ip a n ts  w ith  non-lung  involvem ent w as 76% in  th e  EW  group and  
71% in  th e  NW  group.
Interventions The w riting  sessions for bo th  groups w ere conducted  a t  each  of th e  firs t 
four w eekly clinic v is its  w hile th e  p a rtic ip a n ts  w aited  to  receive th e ir  
vaccine tre a tm e n t. P a rtic ip a n ts  w ere given v erbal an d  w ritten  
in s tru c tion s. P a rtic ip a n ts  in  th e  EW  group w ere in s tru c te d  to  w rite  for 
15 m in u tes  abou t th e ir  deepest th o u g h ts  and  feelings abou t th e ir  cancer. 
The in s tru c tio n s  rem ained  essen tia lly  th e  sam e for each  assignm ent. 
The p a rtic ip a n ts  in  th e  NW  group w ere in s tru c te d  to  w rite  abou t a 
d ifferen t h e a lth  b ehav iou r a t each  session, w hich com prised  diet, 
physical activ ity , su bstance  use and  sleep.
Outcomes The outcom e m easu res w ere sym ptom s of d is tre ss  (IES), perceived  s tre ss  
(PSS), mood d is tu rbance  (POMS), and  sleep d is tu rbances (PSQI). 
F a tigu e  w as m easu red  w ith  a  sub-scale of th e  POMS.
Notes The re su lts  re p resen ted  th e  overall group m eans averaged  across th e  
five follow-up m easu res, for both  groups. In  addition  it w as no t described 
how m any  p a rtic ip a n ts  th e  s ta tis tic a l ana lysis  w as perform ed  upon.
Allocation
concealment? U nclear
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Methods C ancer p a tie n ts  who w ould receive d is tr ic t n u rs in g  a t  hom e and  p a tie n ts  
who w ould no t receive d is tr ic t n u rs in g  w ere s tu d ied  separa te ly . B oth 
p a tie n t g roups w ere random ly  assigned  to  a  contro l or an  in te rv en tio n  
group, a fte r s tra tify in g  for th re e  variab les: gender, age, and  m e ta s ta tic  
sites. S um m arizing, four s tudy  groups w ere d istingu ished: 1) a  control 
group w itho u t d is tric t n u rs in g  (n=103); 2) an  in te rv en tio n  group w itho u t 
d is tr ic t n u rs in g  (n=106); 3) a  control group w ith  d is tr ic t n u rs in g  (n=5l); 
and  4) an  in te rv en tio n  group w ith  d is tr ic t n u rs in g  (n=53). P a tie n ts  w ere 
approached  to  p a rtic ip a te  a fte r adm ission  to th e  hosp ita l. All 
p a rtic ip a n ts  w ere followed up by te lephone a t 2 (T l), 4 (T2), and  8 w eeks 
postd ischarge (T3). (Group (l) T l:  N=94, T2: N =86, T3: N=78. G roup (2) 
T l: N=100, T2: N=97, T3: N=85. G roup (3) T l: N=44, T2: N=43, T3: 
N=41. G roup (4) T l: N=39, T2: N=33, T3: N=31).
Participants The stu dy  w as ca rried  ou t in  th e  A ntoni van  L eeuw enhoek  H ospital, 
A m sterdam , th e  N eth erlan ds. The following inclusion  and  exclusion 
c r ite r ia  w ere used: 1) p a in  re la te d  to  cancer, cancer th e rap y , or illness; 2) 
p a in  d u ra tio n  of a t  le a s t 1 m onth; 3) life expectancy  of a t  le a s t 3 m onths; 
(4) able to re a d  an d  sp eak  D utch; (5) accessible by telephone; an d  (6) not 
resid ing  in  a  n u rs in g  hom e or re tire m e n t home. P a rtic ip a n ts  h ad  various 
types of p rim ary  tu m o u rs  and  ex ten t of th e  d isease. At base line  22.4% of 
th e  p a rtic ip a n ts  did no t receive cancer tre a tm e n t, 62.6% w ere fem ale, 
25.9% h ad  a  h ig he r education  and  th e  m ean  age w as 55.5 years.
Interventions T hree n u rses  gave th e  P a in  E ducation  P rog ram  (PEP). The P E P  consists 
of th re e  com ponents:l) E nhancing  p a tie n ts ' know ledge abou t p a in  and  
p a in  tre a tm e n t. A p a tie n t w as in s tru c te d  abou t a  specific p a in  topic only 
w hen  th a t  topic w as assessed  as applicab le to  th e  p a tie n t, and  only w hen 
th e  p a tie n t 's  know ledge abou t p a in  and  p a in  t r e a tm e n t w as assessed  as 
insufficien t. T his ta ilo red  in fo rm ation  w as provided on a  one-to-one 
se ttin g  la s tin g  betw een  30 and  60 m inutes. The v erbal in s tru c tio n  w as 
accom panied by a  p a in  brochure  consisted  of tw o p arts : (A) a  section 
w ith  gene ra l in fo rm ation  aim ed a t  all cancer p a in  p a tie n ts , an d  (B) a 
loose-leaf p a r t  g iven to  p a tie n ts  w hen  applicable, including  
su p p lem en ta ry  sh eets  w ith  in fo rm ation  abou t d ifferent cancer p a in  
tr e a tm e n ts .2) P a rtic ip a n ts  w ere in s tru c te d  on how  to re g is te r th e ir  
P re se n t P a in  In te n s ity  tw ice daily  in a  p a in  d ia ry  for a  period  of 2 
m onths. In  addition , p a rtic ip a n ts  w ere in s tru c te d  to  docum ent changes 
on type of p a in  an d  use of (non-)pharm acological p a in  tre a tm e n t. 3) 
S tim u la tin g  p a tie n ts ' help-seeking  behavior. P a rtic ip a n ts  w ere 
in s tru c te d  on how to  use sim ple non-pharm acological p a in  m anag em en t 
techniques, such as cold, h ea t, re laxation , and  m assage, a t  hom e w hen 
p a in  re lie f  w as insufficien t. They w ere encouraged  to  contac t h e a lth  care 
prov iders if  necessary.
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Continuation
Interventions B esides th e  in s tru c tio n  provided  in  th e  hosp ita l, p a rtic ip a n ts  w ere called a t  hom e a t  3 and  7 days post-d ischarge by th e  sam e n u rse  to d eterm ine 
w h eth e r th e  in s tru c tio n  w as fully understood, and  to  offer th e  
opportun ity  to  a sk  questions. T hese phone calls took 5 to  15 m in u tes 
each
Outcomes P a in  experience w as m easu red  w ith  th e  M CGill P a in  Q u estionna ire  
D utch  L anguage V ersion (MPQ-DLV). P re se n t an d  A verage P a in  
In te n s ity  w as m easu red  w ith  a  n um eric  ra tin g  scale. P a in  know ledge 
w as m easu red  w ith  PKQ-DLV. Q uality  of life w as m easu red  w ith  th e  
EORTC-QLQ. F a tigu e  w as m easu red  w ith  th e  sym ptom  lis t of th e  
EORTC-QLQ.
Notes Drop ou t ra te  in  th e  in te rv en tio n  group w ith  d is tric t n u rs in g  w as m uch 
h ig he r com pared to  th e  o th er th re e  groups, th u s  possible selective d rop­
out.
Allocation
concealment? U nclear
D ecker 199254
Methods RCT. B ase line a ssessm en t took place p rio r to  rad ia tio n  th e rap y . The post 
in te rv en tio n  assessm en t took place a t th e  six th  session, for bo th  groups. 
34 p a rtic ip a n ts  of th e  re lax a tion  group com pleted  th e  post-in terv en tio n  
assessm en t, 29 of th e  contro l group.
Participants Eligible p a rtic ip a n ts  w ere recen tly  d iagnosed cancer p a tie n ts  scheduled  to 
receive ex te rn a l beam  rad ia tio n . P a tie n ts  w ith  p rio r cancer w ere excluded, 
those who received p rio r rad ia tio n  th e rap y , in -p a tien ts , or those w ith  
su icidal ideas. 74 w ere tre a te d  w ith  cu ra tive  in ten t, 8 w ith  pa llia tiv e  
in ten t. Of th e  82 p a tie n ts  random ised  30 w ere m ales, th e  m ean  age w as 
61 years.
Interventions P a rtic ip a n ts  receiving re lax a tion  tre a tm e n t m et ind iv idually  for six 1- 
hou r sessions w ith  a  g ra d u a te  s tu d e n t superv ised  by th e  firs t au tho r. In 
addition  to  re lax a tion  tra in in g , supp o rt focused on concerns re la te d  to 
cancer ra d ia tio n  tre a tm e n t and  its  effects on physical and  em otional 
sensations. P a rtic ip a n ts  w ere in s tru c te d  to perform  re lax a tio n  each  day a t 
hom e and  w ere provided w ith  a  re lax a tion  tap e  and  w ritte n  in s tru c tion s. 
The contro l group com pleted  th e  a ssessm en t and  received s ta n d a rd  
education  an d  su pp o rt along w ith  th e  rad ia tio n  the rapy . All p a rtic ip a n ts  
received th e  u su a l services d uring  rad ia tio n  the rapy .
Outcomes F atigu e  w as m easu red  w ith  th e  PO M S sub-scale fatigue.
Notes
Allocation
concealment? U nclear
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E d elm an  199943
Methods RCT. For every  20 p a rtic ip a n ts  th a t  w ere rec ru ited  a  block ran do m isa tio n  
p rocedure  took place, w ith  te n  to each condition. O f th e  124 p a rtic ip a n ts  
rec ru ited  32 w ere classified  as d ropouts (16 died, 10 due to  illness, 3 w ere 
found no t have m e ta s ta tic  d isease, 3 o th er reasons. N inety-tw o com pleted 
b ase line  q uestionnaires, 43 in  th e  CBT group and  49 in  th e  control group 
(CG). The 3 m onth  a ssessm en ts  w as com pleted  by 36 CBT and  37 CG. The 
6 m onth  a ssessm en t w as com pleted  by 31 CBT an d  32 CG.
Participants T his s tudy  focused on m e ta s ta tic  b re a s t cancer p a tie n ts  rec ru ited  from  
th e  Royal N orth  Shore H ospita l Sydney. E lig ib ility  c rite r ia  included: 
ab ility  to a t te n d  group sessions; no concu rren t p sych ia tric  disorder, 
o rgan ic b ra in  d isorder or drug/alcohol dependency; ab ility  to  speak  and  
re a d  E nglish; and  aged betw een  30 and  65 years. O f th e  rec ru ited  
p a rtic ip a n ts  47% w ere betw een  41 and  50 y ea rs  old, 63% w as m arried . It 
w as no t described w h e th e r p a rtic ip a n ts  received  t re a tm e n t d uring  th e  
in terven tion .
Interventions T herapy  rec ip ien ts  a tten d ed  eig h t w eekly sessions of group CBT, followed 
by a  fam ily  n igh t, and  th re e  fu r th e r  m onth ly  sessions. The p rogram m e 
w as led by tw o th e ra p is ts  and  incorpora ted  th e  use of cognitive and  
b ehav iou ra l techniques, encourag ing  th e  expression  of feelings and  
build ing  of group support. P a rtic ip a n ts  received a  m anual, h an d o u ts  and  
hom ew ork exercises a t  every  session. In  th e  firs t few sessions p a rtic ip a n ts  
w ere ta u g h t basic cognitive skills, inc luding  how to iden tify  and  challenge 
m aladap tive  th o u g h ts  and  beliefs. B ehav ioura l tech n iq ues w ere 
in troduced  in  th e  second sessions, w ith  a  d iscussion  on deep 
re lax a tion /m ed ita tio n  as a  tool for m anag ing  anxiety . P a rtic ip a n ts  
received a  re lax a tio n  ta p e  an d  w ere encouraged  to  p rac tise . The no ­
th e ra p y  control group received s ta n d a rd  oncological care.
Outcomes The PO M S w as u sed  to  m easu re  mood, inc luding  th e  sub-scale fatigue. 
The C oopersm ith  Self-esteem  Inven tory -A dult form  w as also u sed  to 
m easu re  self-esteem .
Notes
Allocation
concealment? U nclear
Footnotes: CBT: cognitive behavioural therapy
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F a ith fu ll 200146
Methods RCT. 115 m en w ere random ised  and  s tra tif ie d  to  provide a  balanced  
rep re se n ta tio n  of m en w ith  p ro s ta te  and  b ladd er cancer. B oth groups 
w ere assessed  w ith in  th e  firs t w eek of s ta r tin g  RT, w eek 3, 6, and  a t  12 
w eeks following s ta r t  of RT. T here  w as a  decrease in  com pletion of 
q uestio nn a ires  over tim e (88% a t w eek 6). 81% of th e  EORTC QLQ w as 
re tu rn e d  a t  w eek 12.
Participants M en inc luded  in  th e  stu dy  w ere those  undergo ing  rad ica l (g rea ter th a n  60 
Gy) rad io th e rap y  for p ro s ta te  (83%) or b ladd er cancer (17%). The m ean  
age of th e  m en w as 70 in  both  groups.
Interventions The nu rse-led  care  (in terven tion) w as o rgan ised  for w ith in  th e  firs t w eek 
and  la s t w eek of RT. A ppo in tm en ts w ere for 20 m in u tes and  fu rth e r  
ap po in tm en ts  could be n ego tia ted  as required . The n u rse  explored th e  
ind iv idual's  u n d e rs ta n d in g  of th e ir  d iagnosis, sym ptom s and  th e  m eaning  
of th e  illness. The in te rv en tio n  provided p a rtic ip a n ts  w ith  info rm ation  
and  p rac tica l advice on how to recognise ea rly  sym ptom s, w h a t to  expect 
from  tre a tm e n t and  how to  m anage ex isting  problem s. The n u rse  also 
p rovided  m en and  th e ir  fam ilies w ith  leafle ts on h ea lth y  eating , RT and  
how to  m anage u rin a ry  sym ptom s d uring  RT. The control group received 
conventional care  consisting  of ro u tin e  m edical ap po in tm en ts las tin g  10 
m inutes. T hese w ere a rran g e d  a t th e  s ta r t  of RT, continu ing  w eekly for 
p a tie n ts  w ith  b ladd er cancer, or 2-weekly for p a tie n ts  w ith  p ro sta te  
cancer, th ro u g h o u t th e  d u ra tio n  of RT, an d  led w ith  a  group of 6 
physicians.
Outcomes D a ta  collected w ere observ er-ra ted  toxicity  scores (RTOG/EORTC), self­
a ssessm en t of sym ptom s (VAS), q uality  of life (EORTC QLQ-C30), 
sa tisfac tion  w ith  clinical care (based on N ew castle sa tisfac tion  w ith  
n u rs in g  scale), costs. F a tigu e  w as m easu red  w ith  a  VAS and  a  sub-scale of 
EORTC QLQ-C30.
Notes M issing d a ta  w ere rem oved from  analysis . T herefore th e  n um b er of 
p a rtic ip a n ts  varies from  56 a t  w eek 1 to 25 a t  w eek 12, in  th e  in te rv en tio n  
group (SES)
Allocation
concealment? Yes, ad eq uate
Footnote: RT: Radiotherapy
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Faw zy 199540
Methods RCT. S tage I p a tie n ts  w ere rec ru ited  a t  tim e of th e ir  postopera tive  
checkup and  stage II p a tie n ts  w hen  th e y  began  im m un o the rapy  protocols. 
A t re c ru itm en t p a rtic ip a n ts  w ere ask ed  to  fill in  th e  baseline 
q uestionnaires. At base line  (t0) 31 p a rtic ip a n ts  w ere random ised  to th e  
in te rv en tio n  group and  32 to th e  control group. Follow-up Q uestion na ire s 
w ere m ailed  to  all p a rtic ip an ts , six w eeks (t1) and  3 m onths (t2) a fte r 
com pletion of th e  in terven tion . A t t2  th re e  p a rtic ip a n ts  w ere lost to  follow- 
up, leav ing  28 p a rtic ip a n ts  in  th e  in te rv en tio n  group an d  32 in  th e  control 
group.
Participants T his s tudy  focused on p a tie n ts  w ith  m a lig n a n t m elanom a, stage I or II. 
A ny B reslow  dep th  an d  C lark  levels I-V w ere acceptable. P a rtic ip a n ts  had  
to be a t  lea s t 18 and  no o lder th a n  70, able to  sp eak  and  re a d  E ng lish  and  
have no p revious h is to ry  of cancer or p sych ia tric  tre a tm e n t. The m ean  age 
of th e  expe rim en ta l condition  (n=29) w as 42, all w ere w hite, 15 w ere 
m ales, and  24 h a d  a  college degree or h igher. The m ean  age of th e  control 
group (n=33) w as 46, 30 w ere w hite, 19 w ere m ales, and  19 h ad  a  college 
degree or h igher.
Interventions P a rtic ip a n ts  random ised  to  th e  psycho ed ucatio na l n u rs in g  in te rv en tio n  
received an  educationa l m an u a l and  3 h ou rs  of ind iv idualized  teach ing  on 
tw o se p a ra te  occasions from  an  oncology n u rse . The firs t session w as afte r 
b ase line  testing , th e  second w as m ade coinciding w ith  th e  p a tie n ts ' nex t 
clinic visit. The in te rv en tio n  consisted  of th re e  specific n u rs in g  goals and  
stra teg ies . H ea lth  education , s tre ss  m anagem ent, including  teach ing  
abou t s tress , s tre ss  m onitoring  and  re lax a tio n  exercises, and  
en hancem en t of coping skills. P a rtic ip a n ts  w ere called  by th e  n u rse  p rio r 
to th e  second ap po in tm en t to  rem in d  th e m  of th e  ap po in tm en t an d  to  do 
th e  read ing  and  re lax a tion  exercises. The control group did no t receive th e  
in te rv en tio n  b u t com pleted  th e  questionnaires.
Outcomes Affective s ta te  w as m easu red  w ith  th e  BSI and  POM S, w hich includes th e  
sub-scale fa tigu e/ine rtia . The D ealing  w ith  Illness Inven tory  w as u sed  to 
asses h e a lth  seeking  and  coping behaviours.
Notes The n um b ers  of p a tie n ts  p a rtic ip a tin g  is no t clear. D ifferen t n um b ers are 
described  a t  baseline , and  th e  n um b ers  a t  t 1 a re  no t described.
Allocation
concealment? U nclear
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F o re ste r  198558
Methods RCT. 48 p a rtic ip a n ts  w ere random ly  selected  from  th e  100 p a tie n ts  to 
receive p sycho therapy, th e  o th er 52 p a rtic ip a n ts  served  as control 
subjects. A ssessm en ts w ere m ade a t  five points, a t  base line  (week 0), 
m idpo int in  rad io th e rap y  (RT) (week 3), end  of RT (week 6), 4 w eeks afte r 
RT (week 10), 8 w eeks a fte r RT (week 14).
Participants P a rtic ip a n ts  w ere random ly  selected  before th ey  received 6 w eeks of 
rad io th e rap y  for cancer. P a tie n ts  w ith  abdom inal cancer w ere excluded. 
T he m ean  age of th e  p a rtic ip a n ts  given p sycho therapy  w as 62.4 years 
(n=52), 54% w ere m en and  71% w as m arried ; of th e  control group (n=48) 
th e  m ean  age w as 61.5 years, 46% w ere m en and  67% w ere m arried .
Interventions P a rtic ip a n ts  given th e  in te rv en tio n  w ere given w eekly  supportive 
p sycho therapy  for 10 w eeks (4 w eeks beyond com pletion of RT). The 
sessions w ere provided  by th e  firs t au th o r and  la s te d  30 m inutes. The 
co n ten t w as u n s tru c tu re d  and  focused on perceived  p a tie n ts  needs, 
help ing  th e m  deal w ith  th e ir  em otions reg ard in g  tre a tm e n t. F or th e  
m ajo rity  th e  sessions w ere com posed of supportive  p sycho therapy  w ith  
explanatory , educational, in te rp re tive , and  ca th a rtic  com ponents. The 
control group received only RT.
Outcomes The outcom e m easu re  w as a  SADS in terv iew  m easu rin g  em otional 
sym ptom s, physical sym ptom s, including  a  anorex ia, n a u se a  and  
vom iting, and  a  fa tigue scale.
Notes I t  seem s th a t  of th e  100 p a rtic ip a n ts  all a ssessm en t w ere available. 
N o th ing  is m entioned  on m issing  d a ta  or loss to  follow up.
Allocation
concealment?
U nclear
Footnote: RT: Radiotherapy
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G asto n -Jo h an sso n  200038
Methods RCT. The fina l sam ple w as 110 p a rtic ip a n ts  w ith  52 in th e  in te rv en tio n  
group (IG) an d  58 in  th e  control group (CG). The p a rtic ip a n ts  com pleted 
th e  q uestio nn a ires  a t baseline , 2 days before autologous bone 
m arro w /pe rip h era l blood stem  cell tra n sp la n ta tio n  (ABMT), and  7 days 
a fte r th e  ABMT provided  by th e  BM T clinical n u rse  specialist.
Participants E lig ib ility  c r ite r ia  for th e  p a rtic ip a n ts  req u ired  a  d iagnosis of stage II, III 
or IV b re a s t cancer; a  scheduled  ABM T a t  an  u rb a n  N ational C ancer 
In s titu te -d es ig n a ted  com prehensive cancer centre; age of 18 y ears or 
older; and  ab ility  to re a d  and  w rite  E nglish . M ost p a rtic ip a n ts  w ere 
betw een  41 and  50 y ears old (50% in th e  IG an d  56% in th e  CG). M ost 
p a rtic ip a n ts  h ad  a  college or g ra d u a te  degree (65% in th e  IG and  51% in 
th e  CG) an d  w ere w h ite  (89% in  th e  IG and  83% in th e  CG).
Interventions The com prehensive coping s tra te g y  p ro g ram  (CCSP) w as ta u g h t to 
p a rtic ip a n ts  by a  clinical social w orker a t lea s t 2 w eeks before h osp ita l 
adm ission  for t r e a tm e n t w ith  high-dose chem otherapy  an d  ABMT. 
D uring  th e  in te rv en tio n  p re p a ra to ry  info rm ation  w as p re sen ted  
explain ing  th a t  ad eq ua te  control of p a in  can  lead  to  decreased  
psychological d is tre ss  and  a  decrease in  physical sym ptom s such as 
fatigue. S everal h an d o u ts  w ere given explain ing  theo re tica l 
considerations and  th e  use of re lax a tio n  exercise w ith  guided  im agery, 
an d  coping se lf-sta tem en ts . Cognitive re s tru c tu rin g  info rm ation  focused 
on th e  avoidance of ca ta s tro p h is in g  d is to rted  th in k in g . R elaxation  w ith  
guided  im agery  w as p re sen ted  v ia  live m odel and  p a rtic ip a n ts  w ere given 
an  aud io tape  and  recorder w ith  earp ho nes to guide th e m  th ro u g h  th e  
re lax a tio n  exercise. P a rtic ip a n ts  w ere in s tru c te d  to  use it  every  day and  
before s tressfu l even ts. The CCSP w as reinforced by an  ABMT oncology 
nu rse , th e  p rin c ipa l inv estig a to r or th e  pro ject director, on th e  day 
p a tie n ts  w ere ad m itted  to hosp ita l, 2 days a fte r com pleting  of 
chem otherapy , and  7-9 days a fte r ABMT. The contro l group did not 
receive CCSP.
Outcomes The outcom e m easu res  w ere p a in  (POM), n a u se a  (VAS), fa tigue (VAS), 
psychological d is tre ss  (anxiety  (STAI) and  depression  (BDI)).
Notes
Allocation
concealment?
U nclear
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G iven 200255
Methods RCT. 113 p a rtic ip a n ts  w ere random ised , 53 to  th e  ex pe rim en ta l condition 
(EG), 60 to  th e  control group (CG), an d  w ere in terv iew ed  for baseline  
assessm en t, w ith in  e ig h t w eeks of th e  p a rtic ip a n ts  in itia tin g  
chem otherapy . The second interv iew , 10 w eeks following base line  w as 
com pleted  by 42 p a rtic ip a n ts  of th e  EG  and  48 of th e  CG. The th ird  
in terv iew , 20 w eeks following base line  w as com pleted  by 35 p a rtic ip a n ts  
of th e  EG  an d  43 of th e  CG.
Participants P a rtic ip a n ts  w ere eligible w hen  th e y  w ere w ith in  56 days of th e  firs t cycle 
of chem otherapy , a fte r a  new  cancer diagnosis, for colon, b re ast, lung 
cancer, non-H odgkin  lym phom a or o th er solid tum ours. P a rtic ip a n ts  had  
to  be a t  lea s t 40 y ears of age, an d  h ad  to  rep o rt both  p a in  and  fa tigue a t 
baseline . In  addition  p a rtic ip a n ts  h a d  to  be cognitive in tac t an d  able to 
re a d  E nglish . P a tie n ts  w ere excluded w hen th ey  w ere no t expected  to 
survive th e  d u ra tio n  of th e  study. F o u r o u t-p a tien t cancer tre a tm e n t sites 
w ere u sed  for th is  study. Two sites  w ere affilia ted  w ith  com prehensive 
cancer cen tres, and  tw o w ere com m unity  cancer t r e a tm e n t clinics. The 
m ean  age of th e  sam ple w as 58 years, 28% w as m ale, an d  73% h ad  some 
college education . A bout 70% h ad  advanced  cancer (stages III of IV).
Interventions The in te rv en tio n  given by n u rse s  w ith  a  certification  in  oncology, w as a 
20-w eek d uring  in te rv en tio n  w ith  10 sessions a t  tw o w eeks in terva l. Six 
sessions w ere in  person, la s tin g  one hour, and  four w ere v ia  telephone, 
la s tin g  20 m inutes. W ith  th e  use of a  com puter a ss is ted  protocol, 
sym ptom s w ere assessed, including  fatigue. For each  problem atic  
sym ptom  an  in te rv en tio n  s tra teg y  w as c rea ted  and  in  la te r  sessions 
m odified, changed  or dele ted  depending  on th e  resu lt. In te rv en tio n  
s tra teg ie s  w ere categorized  as teach ing , counselling  and  support, 
coord ination  and  com m unication . The contro l group did no t receive th e  
in terv en tio n , b u t did com pleted  th e  in terv iew  assessm en ts.
Outcomes Sym ptom s, th e  p rim ary  outcom es, w ere m easu red  w ith  th e  SES, w ith  
fa tigue as one of th e  sym ptom s. F unction ing  w as m easu red  w ith  th e  SF- 
36 (short-form ) as secondary  outcome.
Notes
Allocation
concealment? U nclear
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Godino 200647
Methods RCT. P a rtic ip a n ts  w ere s tra tif ie d  b ased  on d iagnosis an d  t re a tm e n t w ith  
m ono-chem o th e ra p y  or m u lti-chem otherapy  schedule. 40 p a rtic ip a n ts  
w ere random ised , 23 to  th e  in terv en tio n , 17 to  th e  contro l condition. A 
second assessm en t w as availab le  from  16 p a rtic ip an ts , from  th e  
ex pe rim en ta l condition  only. The th ird  a ssessm en t w as available from  13 
p a rtic ip a n ts  who received th e  in te rv en tio n  and  7 p a rtic ip a n ts  from  th e  
control condition. P a r t  of th e  p a rtic ip a n ts  w ere lost to follow-up because 
th e y  declined in  h ea lth . The th re e  a ssessm en t w ere ca rried  ou t a t  th e  
sam e tim e as th e  sessions of th e  in terven tion .
Participants Eligible p a rtic ip a n ts  w ere d iagnosed  w ith  gastric  or colon cancer, and  
who w ere undergo ing  chem otherapy  a t tim e of th e  study. O the r inclusion 
c rite r ia  w ere K arnofsky  Index  >70 and  w illing to sign  th e  consen t form. 
E xclusion c rite r ia  w ere p revious cancer tre a tm e n t, including  surgery , 
rad io th e rap y  or chem otherapy; p resence of resp ira to ry ; card iac  or hepa tic  
dysfunctions; lea rn ing  d isab ility  and  cen tra l nervous system  m etastasis . 
The m ean  age of th e  ex pe rim en ta l group w as 58.5 y ears (30 to 75), of th e  
23 p a rtic ip a n ts  12 w ere m en and  11 h ad  p rim ary  school as education . The 
m ean  age of th e  contro l group w as 62.7 years, of th e  17 p a rtic ip a n ts  w ere 
9  m en and  8 h ad  p rim ary  school as education . The stu dy  w as ca rried  out 
in  a  com prehensive cancer cen tre  in  B arcelona.
Interventions The expe rim en ta l group received an  ind iv idualised  in te rv en tio n  over 
th re e  sessions given by an  experienced  nurse . The firs t session d uring  th e  
firs t cycle of chem otherapy , th e  second session d uring  th e  second cycle of 
chem otherapy , th e  th ird  session  one m onth  a fte r fin ish ing  tre a tm e n t. The 
issu es d iscussed  d uring  th e  sessions inc luded  n u tritio n , s tress 
m anagem ent, re s t an d  sleep, activ ity  to  m a in ta in  energy, lifestyle 
changes and  ad ju stm en t. Fam ily  m em bers could a t te n d  an d  w ritten  
in fo rm ation  w as p rovided  to  p a rtic ip an ts . Control group received th e  
u su a l in fo rm ation  provided to  p a tie n ts  by cancer n u rses  and  d a ta  w ere 
collected d uring  th e  firs t and  th e  th ird  session.
Outcomes F atigu e  w as m easu red  w ith  th e  FACT-F as p rim ary  outcom e. S atisfaction  
w ith  th e  n u rs in g  in te rv en tio n  w as assessed  w ith  a  self-com pleted 
q uestio nn a ire  consisting  of 10 item s.
Notes The differences in  fa tigue scores w ere no t significant, b u t re su lts  a re  not 
described.
Allocation
concealment? Yes, no t adequate
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Goodwin 200132
Methods R andom isation  w as perform ed cen tra lly  w ith  th e  use of sea led  envelopes 
con tain ing  allocations form  a  com puter g en e ra ted  tab le  of random  
num bers, w as s tra tif ied  according to  th e  cen tre  (7 sites) and  th e  p resence 
or absence of v isceral m e tastases . A 2:1 ra tio  (in terven tion/contro l) w as 
used. O f th e  237 w om en random ly  assigned. Two of th e m  w ere found 
inelig ible - one w om an (control group) did no t have m e ta stases , and  one 
w om an (in terv en tio n  group) h ad  a  carcino id  tum ou r. T hese wom en w ere 
excluded from  th e  analysis . The analyses included  th e  218 w om en who 
com pleted  base line  questio nn a ires d uring  th e  four m onths before 
ran do m isa tio n  (146 in  th e  in te rv en tio n  group and  72 in th e  control 
group). A fter one year, 102 com pleted  th e  PO M S in  th e  in te rv en tio n  
group, and  45 in  th e  control group.
Participants Inclusion  crite ria : histologic confirm ation  of b re a s t cancer a t th e  tim e of 
diagnosis, p resence of m e ta s ta tic  d isease  outside of th e  b re a s t and  
ip s ila te ra l axilla, consen t of th e  m ost responsib le  tre a tin g  physician. 
E xclusion criteria : cen tra l nervous system  m etastases , life expectancy of 
less th a n  3 m onths as assessed  by th e  tre a tin g  oncologist; active 
psychosis, u n tre a te d  m ajor depression, or severe c h a rac te r disorder; 
inab ility  to  speak  and  read  E nglish; p la n n ed  p a rtic ip a tio n  in  a  th e rap is t-  
led  supp o rt group for p a tie n ts  w ith  m e ta s ta tic  b re a s t cancer outside of 
th e  stu dy  centre; and  residence of m ore th a n  1 hou r from  th e  s tudy  
cen tre. A t ran do m isa tio n  73.9% of th e  w om en in th e  in te rv en tio n  group 
w ere c u rren tly  m arried , and  th e  m ean  age w as 49.5. C u rre n tly  41.1% 
received chem otherapy , 43.0% horm one th e rap y , and  3.2% rad io therapy . 
In  th e  contro l group 69.3% of th e  w om en w ere cu rren tly  m arried , and  th e  
m ean  age w as 51.5. an d  14.3% did no t h ad  active tre a tm e n t. C u rren tly  
39.0% received chem otherapy , 46.8% horm one th e rap y , and  6.5% 
rad io the rapy .
Interventions W om en in th e  in te rv en tio n  group p a rtic ip a te d  in  a  w eekly 90-m inute 
th e ra p is t- le d  group of supportive-expressive the rapy . E ach  group 
consisted  of 8 to 12 w om en and  tw o leaders. The lead ers w ere 
p sy ch ia tris ts , psychologists, social w orkers, or n u rse  c lin ic ians who w ere 
experienced  in  lead ing  group the rapy .
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Interventions The supportive-expressive th e ra p y  w as in ten d e d  to  foster su pp o rt am ong 
group m em bers and  to  encourage th e  expression  of em otions abou t cancer 
an d  its  b road  rang ing  effects on th e ir  lives. W om en w ere encouraged  to 
in te ra c t w ith  each  o th er an d  to supp o rt each o th er outside of th e  group 
sessions. P a rtic ip a n ts  w ere given th e  oppo rtun ity  and  supp o rt to speak  
abou t th e  effects of th e  illness, its  tre a tm e n t, and  changes in  th e ir  self­
im age, roles, and  re la tio n sh ip s  w ith  fam ily  m em bers, friends, cow orkers, 
h e a lth  care  providers, an d  o thers. The w om en also d iscussed  th e  life- 
a lte rin g  n a tu re  of th e  illness and  s tra teg ie s  for coping and  
com m unicating . They w ere asked  to a t te n d  th e  group sessions for a t lea s t 
one year. A m onth ly  90-m inute session  w as provided for fam ily  and  
friends. W om en in  th e  control a rm  did no t p a rtic ip a te  in a  supp o rt group. 
E very  6 m onths, a ll w om en received educationa l m a te ria ls  abou t b re a s t 
cancer and  its  tre a tm e n t, re laxation , and  n u tritio n .
Outcomes The p rim a ry  outcom e for th is  t r ia l  w as survival. Psychosocial function  
w as assessed  by self-reported  q uestio nn a ires  inc luding  th e  PO M S fatigue- 
in e r tia  sub-scale. P a in  and  suffering  w as m easu red  w ith  a  VAS.
Notes
Allocation
concealment?
Yes, no t adequate
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M oadel 200737
Methods RCT: A fter base line  assessm en t, p a rtic ip a n ts  w ere random ly  assigned  to 
s ta r t  classes e ith e r  im m edia te ly  or in  3 m onths. The base line  assessm en t 
w as conducted  in person , th e  follow-up a ssessm en t by te lephone on a  day 
w hen  p a rtic ip a n ts  did no t a t te n d  a  yoga class p revious to  th e  assessm en t. 
164 wom en consented  to  p a rtic ip a te . R andom  ass ig n m en t w as in  a  2:1 
ra tio  to in te rv en tio n  (n=108) or contro l (n=56) a fte r s tra tif ica tio n  by 
tre a tm e n t (chem otherapy  or an tie s tro g en  therapy ). 128 (78%) com pleted 
th e  baseline  and  follow-up a ssessm en t (yoga=84, control=44). In  th e  yoga 
group 24 p a rtic ip a n ts  w ere s tudy  drop-out, 16 w ere lost to  follow-up, 5 
refused, and  3 h ad  a  change in  h e a lth  s ta tu s . In  th e  control group 12 
p a rtic ip a n ts  w ere stu dy  drop-out, 8 w ere lost to  follow-up, 3 refused , and  1 
h ad  a  change in  h e a lth  s ta tu s .
Participants E lig ib ility  inc luded  age > 18 years, n ew /recu rren t (stage I to III) b re a s t 
cancer d iagnosis w ith in  previous 5 years, h igh  perform ance s ta tu s  
(E as te rn  C ooperative Oncology G roup perform ance s ta tu s  of < 3), ab ility  
to speak  E ng lish  or S panish , an d  no t actively  p rac tic ing  yoga. T hroughout 
th e  s tudy  48% of th e  p a rtic ip a n ts  w ere receiv ing m edical tre a tm e n t. Of 
th e  sam ple (n=128) 27 received CT, 30 received an tie s tro g en  th e ra p y  and  
10 received rad ia tio n  tre a tm e n t a t  baseline . P a rtic ip a n ts  w ere 42% 
A frican A m erican, 31% H ispanic, an d  23% w hite; m ean  age w as 54,8 
years, and  69% of p a tie n ts  w ere no t cu rren tly  m arried . T hree q u a r te rs  of 
th e  sam ple e a rn ed  up to, b u t no g re a te r  th a n , a  h igh  school degree.
Interventions The yoga in te rv en tio n  consisted  of 12 1,5-hour w eekly classes. 
P a rtic ip a n ts  w ere p e rm itte d  to a t te n d  m ore th a n  one class p e r week. The 
yoga in te rv en tio n  w as developed for use w ith  b re a s t cancer p a tie n ts  by 
one of th e  co -authors (C.S.), an  oncologist and  certified  yoga in s tru c to r, in 
co nsu lta tion  w ith  expe rts  in  In d ia  and  th e  USA. B ased  on H a th a  yoga 
techniques, th e  in te rv en tio n  incorporated  th e  following th re e  m ajor yoga 
com ponents: physical s tre tch es  and  poses; b re a th in g  exercises; and  
m edita tion . P a rtic ip a n ts  w ere asked  to  p rac tice  yoga a t  hom e daily  and  
given an  audio tape/com pact d isk  for guidance. The contro l group s ta r te d  
classed  a fte r 3 m onths.
Outcomes QOL w as m easu red  w ith  FACT. The FA C IT -fatigue w as u sed  to  assess 
lim ita tion s in daily  activ ity  and  energy  level. The FA C IT -sp iritua l w as 
u sed  to  assess sp iritu a l and  ex is ten tia l well-being. A D istressed  Mood 
Index  w as developed u sing  19 fee lings-sta te  descrip tive adjectives from  
th e  Profile of Mood S tates.
Notes
Allocation
concealment? U nclear
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Methods RCT: 30 p a rtic ip a n ts  w ere random ly  ass igned  in to  th e  in te rv en tio n  group 
(n=15), and  th e  contro l group (n=15). The ran do m izatio n  w as s tra tif ie d  by 
t re a tm e n t a t  baseline  (cu rren tly  ongoing chem otherapy  or com pleted  th e  
cancer tre a tm e n t). R andom ization  w as done by a  com puter p rogram . 18 
p a rtic ip a n ts  com pleted  th e  study, 8 from  th e  in te rv en tio n  group (MQ) and  
10 from  th e  contro l group. R easons w ere th e  tim e schedule w as not 
su itab le  (n=3), fam ily  holiday  (n=2) and  sickness (n=2). Five p a rtic ip a n ts  
of th e  control group did no t respond  to  th e  q uestio nn a ires  and  w ere not 
reachab le  to provide reasons. At th e  end  of th e  p rogram  all p a rtic ip a n ts  
w ere assessed.
Participants Inclusion  c rite r ia  were: a  confirm ed d iagnosis of cancer a t any  stage, 18 
y ea rs  of age or older, an  E a s te rn  C ooperative Oncology G roup (ECOG) 
perform ance s ta tu s  of 0-3, an  expected  su rv ival len g th  of m ore th a n  12 
m onths, and  ab ility  to  com plete all q uestionnaires. E xclusion c r ite r ia  
were: d iagnosis of o th er m ajor m edical or p sych ia tric  d isorders, a  h is to ry  
of epilepsy, b ra in  m e ta sta s is , delirium  or dem entia , m edical 
co n tra in d ica tio n  for exercise and  a lread y  p rac tic ing  Qigong. P a rtic ip a n ts  
ran g ed  in  age from  35 to  75 y ea rs  old (m ean  54, s.d. 9). M ost w ere fem ales 
(75%), living w ith  a  p a r tn e r  (67%), and  of C aucasian  e th n ic ity  (84%). Of 
th e  p a rtic ip a n ts  53% w ere on active tre a tm e n t.
Interventions The in te rv en tio n  w as a  M edical Qigong (MQ) group th e ra p y  program , 
m odified to  specifically ta rg e t  th e  needs of cancer p a tie n ts  to  control 
em otion and  s tre ss  as well as im prove physical function . The MQ group 
w as lead  by an  experienced  MQ in s tru c to r. P a rtic ip a n ts  a tten d ed  class 
once or tw ice a  w eek for e igh t w eeks th a t  la s te d  to ta lly  90 m inutes, and  it 
w as recom m ended  th a t  th ey  ca rried  ou t p rac tice  a t hom e every  day for a t 
le a s t an  hour. E ach  session consisted  of 15 m in u tes  of g enera l discussion, 
inc luding  th e  philosophy and  princip le  b eh ind  th e  in terven tion , p a tie n ts ' 
feelings and  experiences of t re a tm e n t; 30 m in u tes  of s tre tch ing  an d  body 
m ovem ents; 15 m in u tes  m ovem ent in  sea ted  postu re; and  30 m in u tes  of 
b re a th in g  exercise, m ed ita tion  and  v isualization . The control group 
received u su a l care  an d  w ere ask ed  to  re fra in  from  jo in ing  an  outside 
Qigong class.
Outcomes P a rtic ip a n ts  com pleted  th e  EORTC QLQ-C30, including  th e  sym ptom  
scales (fatigue, pa in , and  n a u se a  and  vom iting).
Notes C hange scores of side effects w ere only te s te d  w ith in  groups. N ot betw een  
groups. C hange scores for th e  MQ group and  th e  contro l group w ere not 
sign ifican t for fatigue.
Allocation
concealment? U nclear R andom ization  w as done by a  com puter program .
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R aw l 200248
Methods RCT. 120 p a rtic ip a n ts  w ere random ised , 31 did no t continue in  th e  s tudy  
(21 in  th e  in te rv en tio n  group (IG), 10 in  th e  s ta n d a rd  care group (CG)). 
109 p a tie n ts  p rovided  d a ta  for analysis , a t  baseline , 94 (55 IG, 54 CG), 94 
a t  tim e 2, w hich w as m idw ay th ro u g h  th e  in te rv en tio n  (9 weeks), and  77 
a t  tim e 3 w hich w as one m onth  post in te rv en tio n  (24 weeks). Group 
a ss ig n m en t w as g en e ra ted  v ia  com puter and  s tra tif ied  according to, site 
of rec ru itm en t, site  of th e  p a tie n ts ' cancer, an d  care g ivers' em ploym ent 
s ta tu s .
Participants P a tie n ts  new ly d iagnosed w ith  b reast, colorectal, or lung  cancer who w ere 
undergo ing  chem otherapy  w ere approached  w ith in  56 days of in itia tin g  
chem otherapy , in a  te rtia ry -c an c e r cen tre  or a  com m unity-based  cancer 
cen tre. P a rtic ip a n ts  w ere eligible if  th e y  w ere 18 or o lder and  spoke 
E ng lish . O f th e  109 p a rtic ip a n ts  91% w ere C aucasian , 77% w ere fem ale. 
51% h ad  b re a s t cancer, 23% colorectal cancer, an d  27% lung cancer. The 
average age w as 55.7 years. The sam ple w as d is tr ib u ted  evenly  betw een  
early  (stage I or II) and  la te  (stage III or IV) cancers. E ducation  levels 
w ere fa irly  heterogeneous.
Interventions The in te rv en tio n  w as a  com puter-based  n u rs in g  in te rv en tio n  and  
occurred  over 18 w eeks consisting  of n ine v is its  (five in  person  (1 hour) 
an d  four v ia  te lephone (20 m inutes) w ith  a  m a ste rs '-p rep a red  oncology 
n u rse  specialist. I t w as a  m enu-driven  com puter p rogram  th a t  guided 
clinical assessm en t, p roblem  identification , selection  of in terv en tio ns , and  
m e asu rem en t of outcom es. Sym ptom  experience w as assessed  for 38 
sym ptom s, inc luding  frequency, severity, lim ita tions, and  level of d istress. 
In te rv en tio n s  w ere ta ilo red  ind iv idually  to  ad d ress up to  four sym ptom s 
th a t  w ere p rio ritise d  as p roblem s by th e  p artic ip an t. The n u rse  provided 
objective in fo rm ation  abou t th e  m anag em en t and  m onitoring  of th e  
sym ptom , b u t also provided  em otional su pp o rt an d  counselling  during  
each  session. Control group p a rtic ip a n ts  received any  education  norm ally  
delivered  during  chem otherapy .
Outcomes The M edical O utcom es S tudy  S ho rt F orm  (SF-36) w as used. The sub-scale 
v ita lity  w as u sed  to  m easu re  fatigue. O the r in s tru m e n ts  w ere also used. 
The C en ter for Epidem iological S tud ies D epression-20 scale and  th e  
S ta te -T ra it A nxiety  Inventory .
Notes
Allocation
concealment? Yes, adequate
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R eam  200657
Methods RCT. P a rtic ip a n ts  w ere s tra tif ied  according to  th e  cen tre  th ey  w ere 
tre a te d  and  th e  chem otherapy  reg im en  th ey  w ere given. 103 p a rtic ip a n ts  
w ere random ised , 48 a llocated  to  th e  in terv en tio n , 55 to  th e  control 
condition. In  th e  in te rv en tio n  condition 5 p a rtic ip a n ts  w ere lost to follow- 
up (1 w ithdrew , 4 declined in  health ). In  th e  contro l condition 12 
p a rtic ip a n ts  w ere lost to  follow-up (3 w ithdrew , 9 declined in  health ). In 
bo th  conditions 43 p a rtic ip a n ts  w ere availab le  for analysis . P re ­
in te rv en tio n  m e asu rem en t took place p rio r to  th e  chem otherapy . The 
p ost-in te rv en tio n  m e asu rem en t took place p rio r to  th e  fou rth  tre a tm e n t 
cycle.
Participants Eligible p a rtic ip a n ts  h a d  been  d iagnosed w ith, non-H odgkin 's lym phom a 
or g astro in te s tin a l, non-sm all cell, lung, colorectal, b re ast, or unknow n 
p rim a ry  cancer, an d  w ere chem otherapy-naive. They h ad  to  u n d e rs tan d , 
speak, read , an d  w rite  E nglish . P a tie n ts  w ere excluded w hen  tre a te d  for 
p sych ia tric  illness. The m ean  age of th e  sam ple w as 56.5 y ears (18 to 70) 
an d  55% w as m ale. P a rtic ip a n ts  w ere rec ru ited  from  th e  in p a tie n t or 
o u tp a tie n t service p rio r to  com m encing th e ir  f irs t cycle of tre a tm e n t.
Interventions The in te rv en tio n  p rogram  w as provided by an  experienced  cancer n u rse  
v isiting  p a rtic ip a n ts  a t  hom e, over th e  firs t th re e  t re a tm e n t cycles (3 
sessions). The in te rv en tio n  com prised: assessm en t/m on ito ring  of fatigue; 
education  on fa tigue including  an  inv estiga to r-designed  info rm ation  pack; 
coaching in  self-care; and  provision of em otional support. C ontrol group 
received u su a l care and  fa tigue assessm en ts.
Outcomes F atigu e  (four VAS'), as p rim ary  outcom e. O th e r outcom es w ere E m otional 
w ell-being (HADS), G eneral h e a lth  s ta tu s  (SF-36) and  coping (VAS and  
COPE).
Notes
Allocation
concealment?
Yes, adequate .
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S an d g ren  200035
Methods RCT. P a rtic ip a n ts  f irs t com pleted  base line  q uestionnaires. For w om en in 
th e  expe rim en ta l group, te lephone th e ra p y  began  th e  w eek following th e  
re tu rn  of th e  q uestionnaires. Q uestion na ire s w ere m ailed  a t 1 m onth  (not 
p resen ted ), 4 and  10 m onth  in terv a ls . D a ta  p re se n te d  cam e from  53 of th e  
orig inal 62 p a rtic ip an ts , 24 th e ra p y  p a rtic ip a n ts  and  29 control 
p a rtic ip an ts . F ou r w om en failed  to com plete m easu res  a t some in terva ls , 
an d  five dropped ou t of th e  stu dy  (one died, o th ers  unknow n).
Participants W om en w ith  stage I or II b re a s t cancer in itia lly  w ere rec ru ited  th ro u g h  a 
te r t ia ry  cancer tre a tm e n t cen tre  serv ing  ru ra l  e a s te rn  N orth  D ak o ta  and  
w este rn  M inneso ta . W om en d iagnosed w ith in  th e  p rio r th re e  to  four 
m onths w ere eligible. All b u t five w om en u n d erw en t ad ju v an t tre a tm e n t, 
an d  w ere in  th e  m idst of such tre a tm e n t d uring  th e  study . All had  
com pleted  chem otherapy  an d  rad ia tio n  before th e  10-m onth  follow-up. 
Ages ran ged  from  30 to  82 (m ean 51). N early  all (92%) of th e  sam ple had  
com pleted  h igh  school, and  30% com pleted  a  college education  (m ean 13.5 
years). All p a rtic ip a n ts  w ere C aucasian  except for one N ative A m erican.
Interventions T re a tm e n t p a rtic ip a n ts  received up to  10 te lephone calls (m ean=9). 
T h e ra p y  w as ad m in is te red  once a  w eek for four w eeks and  th e n  every  
o th e r w eek for six m ore sessions (4 m onths). P hone sessions la s te d  up to 
30 m inutes, averag ing  20 to  25 m inutes. T he rapy  inc luded  providing 
support, teach ing  coping skills, m anag ing  anx ie ty  and  stress, and  helping  
to  solve p a tie n ts -g e n e ra te d  problem s. Cognitive re s tru c tu rin g  w as used, a 
tech n iq ue  th a t  involves identify ing  erroneous beliefs, over-generalization , 
or ca ta s trop h ic  th in k in g . T h e ra p is ts  also encouraged  em otional 
expression, an d  re lax a tion  techniques. T h ree  fem ale clinical psychology 
m a ste r 's  can d id a tes conducted  th e  th e rap y . The contro l group had  
a ssessm en ts  only.
Outcomes The PO M S w as u sed  to  m easu re  d istress. I t a ssesses six moods, including  
fatigue. The Coping R esponse Indices-R evised scale w as u sed  to  m easu re  
coping, and  th e  M edical O utcom e Scale (MOS) short-form  w as u sed  to 
m easu re  q uality  of life.
Notes
Allocation
concealment? U nclear
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S an d g ren  200330
Methods RCT. O f th e  235 p a rtic ip a n ts  who began  th e  s tudy  13 dropped out. A to ta l 
of 222 p a rtic ip a n ts  com pleted  th e  study. R andom  ass ig n m en t to  a 
condition  w as b ased  on a  2:2:1 ra tio . 55 p a rtic ip a n ts  in  th e  s ta n d a rd  care 
com pleted  th e  study, 78 of th e  h e a lth  education  in terv en tio n , and  89 of 
th e  em otional expression  in terv en tio n . P a rtic ip a n ts  w ere blocked by 
cancer stage. M easu res w ere collected im m ediate ly  before th e  
in terv en tio n , w hich w as typ ically  a fte r surgery , b u t  during  ad ju v an t 
tre a tm e n t. Follow-up took place approx im ately  5 m onths la ter.
Participants E lig ib ility  c r ite r ia  inc luded  d iagnosis of s tages I-III b re a s t cancer, ab ility  
to  sp eak  E ng lish  an d  to  ta lk  by phone, absence of serious com orbid 
conditions, and  undergo ing  ad ju v an t tre a tm e n t. A d juvan t tre a tm e n t 
inc luded  any  com bination  of chem otherapy , rad io the rapy , and  horm one 
th e rap y . P a tie n ts  w ere rec ru ited  from  tw o cancer tre a tm e n t clinics, 1-3 
m onths a fte r diagnosis. The average age of th e  sam ple w as 54.5 years, 
m ost p a rtic ip a n ts  (78%) w ere m a rrie d  and  C aucasian  (97%).
Interventions B oth  in te rv en tio n s  inc luded  5 w eekly 30 m in phone calls, w ith  a  six th  
follow-up 3 m onths la ter, abou t th e  tim e ad ju v an t chem otherapy  typ ically  
ended. P a rtic ip a n ts  in  th e  h e a lth  education  in te rv en tio n  received a 
s tru c tu re d  cu rricu lum . The topics inc luded  u n d e rs ta n d in g  b re a s t cancer 
an d  t re a tm e n t (chem otherapy, rad ia tio n  th e rap y , and  horm one therapy ), 
m anag ing  post-su rg ica l changes and  t re a tm e n t side effects and  fatigue, 
an d  m a in ta in in g  a  h e a lth y  lifestyle. P a rtic ip a n ts  in  th e  em otional 
expression  w ere asked  to  ta lk  abou t tho ug h ts, feelings and  em otional 
issu es and  s tressfu l experiences. T ra ined  n u rse s  p a rtic ip a te d  in  both  
t re a tm e n t conditions. P a rtic ip a n ts  in  th e  control group received s ta n d a rd  
care  in  w hich th e  u su a l n u rse  help line w ould be available.
Outcomes O utcom e m easu res  included  qua lity  of life (FACT-B) an d  additionally  
POM S. F a tigu e  w as m easu red  as th e  fa tig u e /in e rtia  sub-scale of th e  
POM S.
Notes N ot described  how m any  p a rtic ip a n ts  w ere random ised  and  w h a t w as 
done w ith  any  m issing  values.
Allocation
concealment? U nclear
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S av a rd  200644
Methods P a rtic ip a n ts  w ere firs t s tra tif ied  according to th e  cancer clinic th e y  w ere 
rec ru ited  to. 45 p a rtic ip a n ts  w ere th e n  random ly  assigned  e ith e r  to th e  
CT (25) or WLC (20) condition. P re -tre a tm e n t m easu res  w ere com pleted 
by 21 p a rtic ip a n ts  of th e  CT and  16 of th e  WLC. P o s t- tre a tm e n t m easu res 
w ere com pleted  by 15 (CT) and  13 (WLC). 3 -m onth  follow-up m easu res 
w ere com pleted  by 14 (CT) and  10 (WLC). 6 -m onth  follow-up m easu res 
w ere com pleted  by 12 (CT) an d  9 (WLC). R easons for lost to  follow-up 
w ere, s tu dy  or th e ra p y  too burdensom e, lost in te re s t, due to 
chem otherapy  side effects, te rm in a l stage or death .
Participants Inclusion  criteria : 1) a  d iagnosis of m e ta s ta tic  b re a s t cancer (stage IV) 
an d  2) a  score of 7 or m ore on th e  HADS-D or 15 or m ore on th e  BDI. 
E xclusion c rite ria : 1) life expectancy of less th a n  2 m onths, 2) m eeting  
DSM -IV c rite r ia  for a  severe p sych ia tric  d isorder o th er th a n  m ajor 
depression , 3) p re sen tin g  severe su icidal ideas w ith  a  r isk  of acting  out, 4) 
h av ing  recen tly  s ta r te d  an  a n tid e p re ssa n t m edication  or recen tly  a lte red  
th e  dosage, 5) cu rren tly  receiving a  psychological in te rv en tio n  ta rg e tin g  
depression. P a rtic ip a n ts  w ere rec ru ited  in  th re e  cancer clinics. All 
p a rtic ip a n ts  w ere C aucasian . In  th e  ex pe rim en ta l condition 57% w as 
m arried , 48% com pleted  u n iv e rs ity  an d  th e  m ean  age w as 51. In  th e  
w aiting -lis t contro l condition  50% w ere m arried , 31% com pleted 
u n iv e rs ity  an d  th e  m ean  age w as 52. (not described  how m any  
p a rtic ip a n ts  received trea tm e n t).
Interventions Cognitive th e ra p y  (CT) w as ad m in is te red  ind iv idually  and  involved eigh t 
w eekly sessions of 60 to  90 m inutes, w ith  th re e  booster sessions of CT 
every  3 w eeks following tre a tm e n t. Two psychologists w ith  experience in 
th e  application  of CT conducted  th e  sessions. The u ltim a te  goal w as to 
develop an  optim istic  b u t  rea lis tic  a tti tu d e  tow ards th e ir  s itua tion . CT 
began  w ith  th e  p re se n ta tio n  of a  cognitive theo ry  of em otions. T hen  
p a rtic ip a n ts  w ere encouraged  to inc rease  th e ir  level of daily  activ ities. 
P a rtic ip a n ts  w ere th e n  tra in e d  to  identify  th e ir  negative th o u g h ts  and  to 
use cognitive re s tru c tu rin g  to  modify dysfunctional or irra tio n a l 
cognitions. P a rtic ip a n ts  w ere th e n  encouraged  to  redefine th e ir  life goals. 
F inally , fu tu re  h ig h -risk  s itu a tio n s  w ere identified, as well as s tra teg ie s  
to  cope w ith  them . P a tie n ts  in  th e  w aiting -lis t contro l (WLC) condition 
w ere scheduled  10 w eeks la te r  for CT.
Outcomes F atigu e  w as m easu red  w ith  th e  M FI. O th e r in s tru m e n ts  u sed  w ere 
H osp ita l A nxiety  and  D epression  Scale, Beck D epression  Inventory , 
In som nia  S everity  Index, Q uality  of life q uestio nn a ires : QLQ-C33, QLQ 
BR-23, and  L ist of Life E vents.
Notes
Allocation
concealment? Yes, no t adequate
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Table 5: Characteristics of included studies
Spiegel 198145
Methods RCT. 109 wom en w ere re fe rred  to  th e  s tudy  by th e ir  oncologists, and  86 
com pleted  th e  firs t questionnaire . M ore p a rtic ip a n ts  w ere random ised  to 
th e  ex pe rim en ta l group (EG=50) th a n  to  th e  contro l group (CG=36). Of 
th e  EG  14 w ere too w eak  or too ill to p a rtic ip a te  and  2 m oved away. Of 
th e  CG 12 p a rtic ip a n ts  w ere lost; 4 w ere too ill, 2 died, 4 refused, 2 w ere 
ou t of contact. The final EG  consisted  of 34 women, an d  th e  final CG of 24 
wom en. Follow-up te s tin g  w as done a t  fou r-m onth  in te rv a ls  for a  to ta l of 
a  year. The an alysis  considered  16 (EG) and  14 (CG) th a t  com pleted  all 
four assessm en ts.
Participants P a rtic ip a n ts  w ith  docum ented  m e ta s ta tic  carcinom a of th e  b re a s t w ere 
included. The average age of th e  tre a tm e n t group w as 54 years, an d  th e  
control group 55 years. 75% of th e  tre a tm e n t group and  70% of th e  control 
group w ere m arried . Two m em bers of th e  t re a tm e n t group an d  th re e  of 
th e  contro l group lived alone. The average len g th  of tim e since d iagnosis 
of recu rren ce  w as 54 m onths for th e  tre a tm e n t group and  68 m onths for 
th e  control group. M em bers of th e  t re a tm e n t and  contro l group received 
eq u iv a len t am oun ts of chem otherapy  d uring  th e  period  of study . A t onset 
of th e  s tudy  it  w as no ted  th a t  th e  m em bers of th e  tre a tm e n t group w ere of 
sign ifican tly  h ig h e r social s ta tu s  th a n  w ere m em bers of th e  control group.
Interventions The psychological su pp o rt g roups m et w eekly in  o u tp a tie n t se ttin g s  for 1 
1/2 h ou rs and  w ere com posed of seven to  te n  women. A lthough  th e  period 
of m e asu rem en t w as one year, no te rm in a tio n  tim e w as set for th e  
groups. T hree groups w ere form ed; each  group h ad  tw o leaders, a 
p sy c h ia tr is t or a  social w orker and  a  counsellor who h ad  h a d  b re a s t 
cancer. The groups w ere designed  p rim arily  to  be supportive . T here w as a 
h igh  degree of cohesion and  re la tive ly  little  confron tation  and  here-and- 
now  in te rp e rso n a l exploration . In te ra c tio n  in  th e  group often  contained  a 
considerab le am ou n t of se lf d isclosure and  sh arin g  of m u tu a l fears  and  
concerns. U nlike a  th e ra p y  group, th e re  w ere few process in te rp re ta tio n s; 
th e  focus w as m ore on conten t, w hich inc luded  discussion  of d ea th  and  
dying, re la te d  daily  problem s, d ifficulties in ob tain ing  tre a tm e n t, issues of 
com m unication  w ith  physicians, and  living as richly  as possible in  th e  
face of a  te rm in a l illness.
Outcomes F atigu e  w as m easu red  w ith  th e  PO M S sub-scale fatigue. In  addition  
H e a lth  Locus of control, M aladap tive  coping response an d  den ial w as 
m easu red . Self-esteem  w as assessed  w ith  th e  Jan is-F ie ld  Scale and  
Phobias w ith  a  checklist.
Notes No descrip tion  of th e  contro l condition.
Allocation
concealment? U nclear
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Table 5: Characteristics of included studies
Y ates 200536
Methods RCT: B ase line a ssessm en ts  w ere com pleted  a t  th e  firs t tre a tm e n t v isit 
(week1) (53 of th e  in te rv en tio n  group (IG) an d  57 of th e  control group 
(CG)). The firs t follow-up a ssessm en t (t2) w as conducted  a t  th e  th ird  
course of chem otherapy  (CT) (w eek 7-9) (50 of IG and  54 of CG). The 
second follow-up (t3) w as conducted  a t th e  fou rth  course of CT or for 
p a rtic ip a n ts  receiv ing rad io th e rap y  (RT) a ssessm en t w as conducted  on 
th e  firs t day of RT (week10-13) (50 of IG and  50 of CG). The th ird  follow- 
up (t4) w as conducted  a t  th e  fifth  course of CT or for p a rtic ip a n ts  
receiv ing rad io th e rap y  (RT) a ssessm en t w as conducted  on th e  firs t day of 
RT. P a rtic ip a n ts  receiving RT a t  t3, a ssessm en t w as conducted  tw o w eeks 
a fte r RT (week 13-21) (49 of IG  and  48 of CG).
Participants W om en more th a n  18 y ears of age w ith  stage I or II b re a s t cancer who 
w ere com m encing ad ju v an t chem otherapy  a t  one of 5 d ay -trea tm en t u n its  
w ere approached  an d  a d m itted  if  th ey  h ad  an  EC O G  perform ance ra tin g  
of one or tw o and  th e ir  haem oglobin  level w as a t le a s t 11.6 g/m L a t 
rec ru itm en t. The m ean  age of th e  p a rtic ip a n ts  w as 49.4, and  
approxim ately  65% of th e  sam ple h a d  post-h igh  school qualifications. 
M ost of th e  wom en w ere m arried  (77% in th e  IG and  73% in  th e  CG).
Interventions The psycho educationa l in terv en tio n , given by an  oncology n u rse  (2), 
a im ed to im prove p a tie n ts  know ledge and  sk ills  in  perform ing  self-care 
b ehav iou rs to  m inim ize fatigue, b ased  on G reen 's PR E C ED E  m odel of 
h e a lth  behaviours. Effective s tra teg ie s  to  reduce fa tigue included  
prom oting: sleep and  res t, a  balance betw een  ac tiv ity  and  exercise, 
conserving energy, and  re s to ra tiv e  activ ities. The firs t session, a  face to 
face contac t of 20 m inutes, focused on th e  p a rtic ip a n ts  specific needs and  
to  ta rg e t  influencing  these  factors. The second and  th ird  session, a 
te lephone call of 10 m inutes, w ere aim ed to  review  th e  p a tie n ts ' fa tigue 
m an ag em en t p lan , and  re inforcem ent. The in te rv en tio n  w as given a t th e  
s ta r t  of th e  second cycle of chem otherapy  w ith  one w eek betw een  each 
session. In  addition  p a tie n ts  received a  booklet w ith  specific inform ation. 
P a rtic ip a n ts  in  th e  contro l group received g enera l cancer education  
sessions equ iv alen t in  n um b er an d  tim ing  an d  also given by th e  sam e 
oncology n u rses . The education  focused on ta lk in g  abou t gene ra l issues 
associa ted  w ith  living w ith  cancer. P a rtic ip a n ts  also received a  booklet 
w ith  gene ra l inform ation.
Outcomes The p rim ary  end  po in ts  for th e  stu dy  inc luded  use of fa tigu e-m anag em en t 
behaviours, confidence w ith  m anag ing  fatigue, and  fa tigue experiences 
(levels of fa tigue a t  w orst, best, average in  th e  p a s t  w eek and  cu rren tly , 
PFS, and  FACT-F).
Notes N ot described  w h a t w as done w ith  m issing  values.
Allocation
concealment? Yes, adequate
Footnote: RT: Radiotherapy
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Table 6: Summary of findings: Effective studies Part A
Author Intervention D uration Patients Quality
(0-25)
N
(total)
A rm es 
20 0 749
A b rie f behaviora lly  o rien ted  
in te rv en tio n  for cancer-re la ted  
fatigue, given by one n u rse  (the 
firs t au thor).
T hree ind ividual, face-to-face, 60 
m in u te  sessions a t 3 to  4 w eekly 
in te rv a ls  (coinciding w ith  
ch em o therapy ).
C ancer p a tie n ts  who 
w ere a tten d in g  for 
chem otherapy  
tre a tm e n t.
17 60
B arsevick
2004B0
ECAM  in te rv en tio n  for cancer 
re la te d  fatigue.
T hree 3 te lephone sessions w ith  an  
oncology nurse , during  th e  firs t 3-5 
w eeks of tre a tm e n t. D u ra tion  of 
th e  firs t tw o sessions w as 30 
m inutes, th e  th ird  session 15 
m inutes.
C ancer p a tie n ts  
cu rren tly  beginning  
chem otherapy , 
rad io the rapy , or both, 
in ten ded  for cure.
18 i .t .t 396
Cohen
200734
Two group interventions^ 
cognitive-behaviour group, and  
RGI group. Goal decreasing  
psychological d is tre ss  and  
physical sym ptom s (general 
approach).
T he in te rv en tio ns  w ere conducted  
by a sen ior social w orker (the firs t 
au thor). E ach  group of 6-8 
p a rtic ip a n ts  m et weekly, for n ine 
90-m inute sessions.
B reas t cancer p a tie n ts , 
s tages I and  II, 
receiving chem otherapy  
or rad io therapy .
13 114
F ores te r 
198 558
U n s tru c tu re d  ind iv idually  
supportive  psycho therapy  
provided by a p sy c h ia tr is t (first 
au thor), focusing on em otions 
and  physical sym ptom s (general 
approach).
T he 30 m in u te  sessions w ere given 
w eekly, for 10 w eeks (4 w eeks 
beyond com pletion of 
rad io therapy ).
Cancer p a tie n ts  before 
th ey  received 6 w eeks of 
rad io the rapy . P a tie n ts  
w ith  abdom inal cancer 
w ere excluded.
10 100
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Table 6: Summary of findings: Effective studies Part A
Author Intervention D uration Patients Quality
(0-25)
N
(total)
R eam  
20 0657
The supportive  in te rv en tio n  for 
fa tigue w as provided  by a cancer 
n u rse  who v is ited  ind iv idual 
p a tie n ts  a t home.
T hree sessions, over th e  firs t 3 
t r e a tm e n t cycles, d u ra tio n  not 
described.
Cancer p a tie n ts  during  
chem otherapy .
14 103
Spiegel
1981*
Psychological supp o rt g roups (3 
groups). E ach  group h ad  two 
leaders, a p sy c h ia tr is t or a 
social w orker and  a counsellor, 
(genera l approach).
T he groups m et w eekly for 1 1/2 
hours, d u ring  a t  lea s t one year.
P a tie n ts  w ith  
m e ta s ta tic  b re a s t 
cancer
9 86
Y ates
200536
An ind iv id ual psycho 
educationa l in te rv en tio n  for 
fatigue, given by an  oncology 
nurse .
T hree sessions. The firs t session, 
w as a face to  face contac t of 20 
m inutes, th e  second and  th ird  
session  w as a te lephone call of 10 
m inutes. The in te rv en tio n  w as 
given a t  th e  s ta r t  of th e  second 
cycle of chem otherapy  w ith  one 
w eek betw een  each  session.
W om en receiving 
ad ju v an t chem otherapy  
for early  stage b re a s t 
cancer (stage I & II).
17 110
Footnotes
TO = pre-intervention, T1 = post-intervention, T2 = follow-up, T3 = second follow-up.
- = not assessed, n.s. = not significant, n.a. = not applicable, S.E.M. = Standard error of the mean. 
RGI = relaxation and guided imagery.
ECAM = energy conservation and activity management.
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Table 6: Summary of findings: Effective studies Part B
Author Results Instruments* Fatigue scores 
mean 
(s.d.) TO
Fatigue 
scores 
mean 
(s.d.) T1
Fatigue
scores
mean
(s.d.) T2
Fatigue
scores
mean
(s.d.) T3
Effect size 
post­
intervention
(Tl)
Effect size 
follow-up 
(T2)
Effect size 
follow-up
<T3)
Armes 
20 0 749
An in te raction  betw een 
group and  tim e for MFI- 
fatigue, (P = 0.03).
MFI
physical
fatigue.
EG 15,4 
(3,7) CG 
15,2 (3,7) 
(NA)
EG 14,3 
(4,6) CG 
14,6 (3,6)
EG 12,3 
(4,5) CG 
14,7 (3,3)
EG 10,2 
(4,6) CG 
13,5 (4,2)
T1 = 0 T2=0,61
(MFI
physical
fatigue)
(follow-up
period 4
weeks).
T3=0,75 (MFI 
physical 
fatigue) (follow- 
up period 9 
m onths after 
recru itm ent)
B arsevick 
20 0450
A group-by-tim e 
in te raction  effect was 
found on GFS (P < 0.01), 
SCFS (P < 0.05) and 
POMS-F (< 0.05), 
exam ined in a sep ara te  
repeated-m easures 
ANOVA, w ith  cancer 
trea tm e n t as covariate. 
A fter bonferroni 
correction+ only GFS was 
significant.
GFS EG 3,3 
(1,8) CG 
3,3 (1,8)
EG 4,6 
(2,2) CG 
4,6 (2,0)
EG 4,1 
(2,2) CG 
4,7 (2,1)
T l  = 0 T2=0,28 
(follow-up 
period up to 
4 weeks)
POMS EG 1,9 
(0,72) 
CG 1,9 
(0,76)
EG 2,5 
(1,1) CG 
2,5 (1,1)
EG 2,4 
(1,1) CG 
2,6 (1,1)
T l  = 0 T2= 0,17
SCFS EG 1,8 
(0,70) 
CG 1,8 
(0,73)
EG 2,4 
(0,95) 
CG 2,4 
(0,94)
EG 2,3 
(0,99) 
CG 2,5 
(1,0)
T l  = 0 T2= 0,20
Cohen 
20 0 734
R epeated  m easures 
MANOVA (3 group x 3 
tim es x 6 variables) 
revealed  significant group 
x tim e effects. For fa tigue 
P < 0.001. Only the 
reduction  in  the  RGI 
group from  pre-to post- 
in te rven tion  was 
significant.
FSI RGI 4,89 
(0,96)
CG 4,50 
(1,30)
RGI 3,01 
(1,13)
CG 4,32 
(1,31)
RGI 2,86 
(0,89)
CG 3,72 
(1,19)
RGI T l  = 1,07 RGI T2= 
0,82
100
Review: Psychosocial intervention for fatigue during cancer treatm ent.
Table 6: Summary of findings: Effective studies Part B
Author Results Instruments* Fatigue scares 
mean 
(s.d.) TO
Fatigue 
scares 
mean 
(s.d.) T1
Fatigue 
scares 
mean 
(s.d.) T2
Fatigue
scares
mean
(s.d.) T3
Effect size 
post-
intervention
(Tl)
Effect size 
follow-up
CT2)
Effect size 
fdlow-up 
CT3)
F orester 
198 558
For fa tigue a significant 
effect was found a t T1 (P 
= < 0.01) found w ith 
rep ea ted  m easures, 
analysis of variance. No 
significant effect was 
found a t T2.
SADS EG 3,8 
CG 4,0 
(s.d. not 
reported)
EG 2,3 
CG 3,3
EG 3,1 
CG 3,5
? (unknow n 
s.d.)
n.s.
Ream  
20 0657
Significant re su lts  on t- 
te s t  for betw een-group 
(1 i(Terences post 
in tervention . VAS P = 
0.04, SF36 P = < 0.05.
VAS EG 38,8 
(28,9) 
CG 42,6 
(28,8) P 
= 0.51
EG 30,6 
(27,7) 
CG 41,6 
(29,4)
T l  = 0,39
SF36
vita lity
M ean 
ra n k  EG 
46,3 CG 
42,6 P = 
0.53
EG 47,1 
CG 38,2
? (unknow n 
s.d.)
Spiegel 
198146
For fa tigue a significant 
effect was found after one 
year (completers) P < 
0.05. A dditional slope 
analysis of p a tien ts  who 
com pleted two 
assessm ents, show ed a 
significant effect (P < 
0.01).
POMS Slopes: EG: -1,06 
(s.e.m 0,34) CG 1,55 
(s.e.m. 0,45)
? (no m ean 
and  s.d. 
described)
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Table 6: Summary of findings: Effective studies Part B
Author Results Instruments* Fatigue scores 
mean 
(s.d.) TO
Fatigue 
scores 
mean 
(s.d.) T l
Fatigue
scores 
mean 
(s.d.) T2
Fatigue
scores
mean
(s.d.) T3
Effect size 
post­
intervention
(Tl)
Effect size 
follow-up
CT2)
Effect size 
follow-up 
CT3)
Y ates 200536 On 4 of th e  6 fatigue 
m easures a significant 
effect was found a t T l. 
(Analysis of covariance of 
the  change scores 
controlling for baseline  
values). Follow-up 
m easures were not 
significant.
NFRS 
fa tigue at 
worst in  thè 
p a st week.
EG 2,6 
(3,0) CG 
1,8 (2,5)
EG 3,5 
(3,2) CG 
4,5 (3,1)
T l  = 0,32 n.s.
NFRS 
average 
fa tigue in  
thè  p ast 
week.
EG 2,0 
(2,5) CG 
1,2 (1,7)
EG 2,9 
(2,8) CG 
3,5 (2,5)
T l  = 0,22 n.s.
PFS su b ­
scale fatigue 
severity.
EG 1,8 
(2,6) CG 
0,9 (1,4)
EG 2,7 
(3,0) CG 
3,6 (3,0)
T l  = 0,30
FACT-F EG 1,1 
(0,3) CG 
1,0 (0,4)
EG 1,1 
(0,4) CG 
1,3 (0,6)
T l=  0,39 n.s.
Footnotes
* = the instrum ents and abbreviations are explained in Table 3: Outcomes
Bonferroni correction* = This correction is applied for multiple testing. In this study three separate ANOVA's were preformed. Results on all three 
outcomes significant on a 0.05 level.
After Bonferroni correction (0.05/3) only the result on GFS was significant.
TO = pre-intervention, T1 = post-intervention, T2 = follow-up, T3 = second follow-up.
- = not assessed, n.s. = not significant, n.a. = not applicable, S.E.M. = Standard error of the mean.
EG = experimental group, CG = control group.
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Appendix 1
M E D L IN E  sea rch  s tra teg y  
M E D L IN E  (via OVID)
1. Exp N EOPLA SM S
2. BO NE M ARROW  TRAN SPLA NTA TIO N
3. Exp STEM  CELL TRANSPLANTATION
4. (neoplas$  or cancer$  or carcinom a$  or tu m o u r$  or adenocarcinom a$  or leukem i$  
or leu k aem ia$  or lym phom a$ or tu m o r$  or m a lig n an $  or m elanom a$  or sarcom a$ 
or "bone m arrow  tra n sp la n t$ "  or "stem  cell tran sp lan t$ ")
5. OR/1-4
6. FA TIG U E/
7. (fatigue$ or a s th e n ia  or a s th en ic  or asthen i$ )
8. (ex haustion  or exhau sted )
9. ((loss ad j4  energy) or (loss ad j4  v ita lity ))
10. (w eary  or w ea rin ess  or w eakness)
11. (ap a th y  or a p a th e tic  or la ss itu d e  or le th a rg ic  or le thargy )
12. (sleepy or sleep iness or drow sy or drow siness)
13. (tired  or tired n ess)
14. OR/6-13
15. Exp PSYCHOLOGY, SOCIAL/
16. Exp PSY CHO TH ERA PY /
17. (psychosocial$ or psycho-social$)
18. (counsel$ or (behaviour$  ad j4  th e rap $ ) or "au togenic  tra in in g "  or (behavior$ 
adj4  th e rap $ ) or (relax$ ad j4  th e rap $ ) or (relax$ ad j4  tre a tm e n t$ )  or (support$  
adj4  group$) or im agery  or "energy conservation" or "s tre ss  m anagem en t"  or 
p sy cho th erapy$  or "self care" or "self help" or b iofeedback or educa ti$  or 
p sychoeducat$  or re lax a tio n  th e ra p $  or "nu rs ing  in te rv en tio n "  or "nursing  
support")
19. OR/15-18
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20. ran d o m ized  con tro lled  tria l.p t.
21. con tro lled  clin ical tria l.p t.
22. ran d o m ized  con tro lled  tria ls .sh .
23. ran d o m  allocation .sh .
24. double b lin d  m ethod .sh .
25. single b lin d  m ethod .sh .
26. or/1-6
27. (ANIM ALS no t H UM A N S).sh.
28. 7 no t 8
29. clin ical tria l.p t.
30. Exp CLIN ICA L TRIALS
31. (clin$ adj25 tria l$ ).ti,ab .
32. ((singl$ or doubl$ or treb l$  or trip l$ ) adj25 (blind$ or m ask$)).ti,ab .
33. p lacebos.sh .
34. placebo$.ti,ab .
35. ran dom $ .ti,ab .
36. re se a rc h  design.sh .
37. or/10-17
38. 18 no t 8
39. 19 no t 9
40. 9 or 19
41. 5 AND 14 AND 19 AND 40
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Chapter 3
Severe fatigue and related factors in cancer 
patients before the initiation of treatm ent
B ritish  Jou rn al o f  Cancer (2008) 99, 1408 — 1414.
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Marlies Peters, Gijs Bleijenberg.
ABSTRACT
I t  is  gen e ra lly  know n th a t  fa tig ue  is  a  com m on sym ptom  d u rin g  cancer 
tre a tm e n t, an d  in  cancer survivors. H owever, fa tig u e  w as nev er s tu d ied  afte r 
diagnosis, before cancer tre a tm e n t  w as in itia ted . T h is stu d y  in v es tig a ted  the 
p revalence  of severe fa tigue , an d  re la te d  fac tors, in  cancer p a tie n ts  before the 
in itia tio n  of tre a tm e n t. O ne h u n d re d  an d  sev en ty -n ine  p a tie n ts  w ith  vario u s 
m alignancies w ere a ssessed  before s ta r t  of tre a tm e n t  w ith  cu ra tiv e  in ten tio n , 
inc lud ing  th e  C hecklist In d iv id u a l S tren g th , S ickness Im p ac t Profile, Beck 
D epression  In v en to ry  P rim a ry  C are, Sym ptom  C hecklist-90, an d  six N um eric  
R a tin g  Scales to m easu re  fa tigue , p a in  an d  p hysica l activ ity . To te s t  w hich 
fac to rs co n trib u te d  to severe fa tig ue  a logistic  reg ress io n  an a ly s is  w as perform ed. 
In  to ta l  23.5% p a tie n ts  w ere severely  fatigued , v a ry in g  betw een  diagnoses; 
p ro s ta te  cancer (14.3%), b re a s t  cancer (20.3%), g a s tro in te s tin a l cancer (28.1%). 
C u rren tly  low er physica l ac tiv ity  (P  = 0.013), m ore depressive  m ood (P  = 0.014), 
im p a ired  sleep an d  re s t  d u rin g  th e  day  an d  n ig h t (P  = 0.045), an d  fa tig u e  1 year 
before d iagnosis (P = 0.005) co n trib u te d  to severe fa tigue . R ela tive ly  la rg e  
n u m b ers  of cancer p a tie n ts  a lread y  experience severe fa tig ue  before in itia tio n  of 
tre a tm e n t, v a ry in g  betw een  14-28%. T he fac to rs th a t  co n trib u te d  to severe 
fa tig u e  a t th is  s tage  w ere physica l activ ity , depressive  mood, im p a ired  sleep an d  
res t, an d  fa tig ue  1 y ea r before d iagnosis.
INTRODUCTION
F a tig u e  is  a  f req u en t re p o rte d  sym ptom  in  cancer p a tie n ts  an d  w h en  severe, i t  is 
a d is tre ss in g  sym ptom  in te rfe rin g  w ith  daily  function ing . C ancer p a tie n ts  
experience fa tig u e  a t d ifferen t s tag es  d u rin g  th e ir  illness. The p revalence  of 
fa tig ue  d u rin g  cancer t re a tm e n t  ra n g e s  from  25% to 99% in  d ifferen t sam ples1. 
A fter successful cancer tre a tm e n t  severe fa tig ue  re m a in s  p ro b lem atic  in  19 - 38% 
of th e  d isease  free  cancer su rv ivors1, 2.
I t  is g en era lly  th o u g h t th a t  d u rin g  th e  active period  of cancer tre a tm e n t, 
sym ptom s of fa tig u e  a rise  as a consequence of th e  cancer itse lf, an d  the  
tre a tm e n ts  p a tie n ts  receive, such as surgery , ch em o th erap y  an d  rad io th e rap y . 
O th er fac to rs a re  also sug gested  to in fluence fa tig ue  d u rin g  cancer tre a tm e n t. 
Psychological d is tress , such as  depression , som atisa tion , anxiety , an d  also sleep 
q u a lity  w ere p rev iously  found  to re la te  w ith  fa tig u e1, 3. I t  is  sug gested  th a t  th e  
experience of receiv ing  cancer t re a tm e n t in  i tse lf  co n trib u te s  to th e  developm ent 
of fa tig u e4.
F a tig u e  in  cancer p a tie n ts  p rio r to t re a tm e n t  h a s  seldom  been  inv estig a ted . 
Som e s tu d ies  in v e s tig a te d  fa tig u e  before s ta r t  of ch em o th erap y 5-7 or 
ra d io th e ra p y 4, 8, 9, b u t looking a t th e se  s tu d ies  m ore closely rev ea led  th a t  m ost 
p a tie n ts  w ere  no t tre a tm e n t  naive. The m ajo rity  of p a tie n ts  a lread y  received 
t re a tm e n t  th a t  could have co n trib u te d  to fa tigue , such  as surgery , horm one 
th e rap y , or chem otherapy .
R esu lts  of th re e  q u a lity  of life s tu d ies  in d ica te  th a t  fa tig u e  m igh t be 
p ro b lem atic  in  t re a tm e n t  na ive  cancer p a tie n ts10-12. T he f irs t  s tu d y  found  th a t  
lu n g  cancer p a tie n ts  before su rg ery  re p o rte d  sign ifican t m ore fa tig ue  com pared  
w ith  age-m atched  contro l sub jects11. Two o th e r s tu d ies  concluded th a t  fa tig ue  
co n trib u te d  to in c rea sed  d is tre ss  a n d  im p a ired  q u a lity  of life in  new ly d iagnosed  
cancer p a t ie n ts 10- 12.
C ancer p a tie n ts  re p o rt th a t  th e  p erio d  of d iagnosis w as v ery  d is tress in g , an d  
re se a rc h  does confirm  th is . A t d iagnosis em otional function ing , anxiety , an d  sleep 
p rob lem s w ere th e  m ost p ro b lem atic  in  p a tie n ts  w ith  o ra l an d  o ro p h ary n g ea l 
c an ce r13. In  new ly d iagnosed  b re a s t  cancer p a tie n ts , d is tu rb an ces  in  m ood s ta te s
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a n d  in so m n ia  w ere also found, in  add ition  to loss of co n ce n tra tio n 10. T hus, new ly 
d iagnosed  cancer p a tie n ts  h av e  been  s tu d ied  in  th e  p as t, b u t  re se a rc h  specifically 
a im ed  a t fa tig u e  in  th is  group is  lacking.
The firs t  objective of th is  s tu d y  is to d e te rm in e  how m any  cancer p a tie n ts  
rep o rt severe fa tig u e  a fte r  being  d iagnosed, b u t before in itia tio n  of an y  m edical 
t re a tm e n t  for cancer. I f  p a tie n t  do re p o rt severe fa tigue , th e  second objective is  to 
e s ta b lish  w hich  fac to rs co n trib u te  to severe fa tig u e  before cancer tre a tm e n t, an d  
w h e th e r mood, such as  an x ie ty  an d  depression , an d  sleep p rob lem s co n trib u te  to 
fa tigue.
MATERIALS AND METHODS 
Patients and procedure
P a tie n ts  w ere  re c ru ite d  from  one u n iv e rs ity  h o sp ita l an d  six reg io n a l h o sp ita ls  in  
th e  period  from  N ovem ber 2005 u n til  A ugust 2007. P a tie n ts  w ere inc luded  in  th is  
s tu d y  a fte r  be ing  d iagnosed  w ith  a p r im a ry  tu m o u r an d  before in itia tio n  of 
t re a tm e n t  w ith  cu ra tiv e  in ten tio n . T re a tm e n t could be surgery , rad io th e rap y , 
chem otherapy , or a com bination  of these . P a tie n ts  could ad d itiona lly  receive 
horm one th e rap y . In  concordance w ith  n a tio n a l a n d  reg io n a l g u idelines of the  
com prehensive cancer cen tre , th e  cu rab ility  of a  p a tie n t  w ith  cancer w as 
determ ined , a n d  th e  tre a tm e n t  p ro cedure  w as chosen. All t re a tm e n t  op tions w ere 
d iscussed  in  th e  m u lti d isc ip lin ary  w ork ing  p a r ty  for th e  specific tu m o u r group, 
before th e  t re a tm e n t  p ro cedure  w as decided. P a tie n ts  in  th is  s tu d y  w ere 
re c ru ite d  as p a r t  of a  la rg e r ongoing in te rv e n tio n  stu d y  for fa tig ue  d u rin g  cancer 
tre a tm e n t, an d  p re v en tin g  chronic fa tig u e  a fte r fin ish in g  cancer tre a tm e n t. To 
m in im ize drop ou t an d  exclusion d u rin g  th e  ongoing study, p a tie n ts  w ith  lung  
cancer, an d  h e a d  an d  neck  cancer w ere no t included . P a tie n ts  w ere  inc luded  if 
th ey  w ere betw een  18 a n d  75 y ea rs  old, a n d  able to speak, re a d  an d  w rite  D utch. 
P a tie n ts  w ere excluded w hen  h av in g  a co-m orbidity  th a t  could cause  fatigue , or 
w hen  p a tie n ts  in d ica ted  to be severely  fa tig u ed  for sev era l y ea rs  or have  been  
seeking t re a tm e n t  for th e ir  fa tigue . In  add ition , p a tie n ts  w ho w ere receiv ing 
p sy ch ia tric  of psychological t re a tm e n t  in  th e  la s t  3 m o n th s w ere excluded.
117
E lig ib le  p a tie n ts  w ere in fo rm ed  abou t th e  stu d y  by th e ir  p hysic ians an d  
w ere a sk ed  if  a  re se a rc h e r  could app roach  them . W hen a specialised  cancer u n it 
w as p re se n t in  a hosp ita l, such as  a m am m a care  or colon care  u n it, specialised  
n u rse s  checked for e lig ib ility  an d  in fo rm ed  p a tie n ts . W hen p a tie n ts  ag reed  the  
p hysic ian  in fo rm ed  th e  re sea rch e r. P a tie n ts  w ho ag reed  to be app roached  
received  w ritte n  in fo rm atio n  on th e  stu d y  an d  w ere con tac ted  by te lepho ne by th e  
re se a rc h e r or a  te s t-a ss is ta n t. W hen p a tie n ts  ag reed  to p a r tic ip a te  an  
a p p o in tm en t w as m ade for th e  b ase lin e  a ssessm en t. T he b ase lin e  a sse ssm en t 
took place, a t  th e  E x p e rt C en tre  C hronic F a tig u e  of th e  R adboud  U n iv e rs ity  
N ijm egen M edical C entre , a t  th e  h o sp ita l w here  p a tie n ts  w ould  receive 
tre a tm e n t, or a t  th e  p a tie n ts ’ hom e. All p a r tic ip a n ts  gave th e ir  w ritte n  in form ed 
consen t before b ase lin e  assessm en t. T he e th ics  com m ittees from  all seven 
involved h o sp ita ls  gave app roval for th e  study.
T he d a ta  p re se n te d  in  th is  stu d y  a re  b ased  on cancer p a tie n ts  w ho w ere 
t re a tm e n t  naive, an d  w ere assessed  before in itia tio n  of tre a tm e n t.
INSTRUMENTS
In fo rm ation  on age, gender a n d  d iagnosis w as p ro v ided  by th e  p a t ie n t’s physic ian  
from  p a tie n ts  w ho ag reed  to be approached , also from  p a tie n ts  w ho did  no t 
p a r tic ip a te  even tually . F rom  all p a r tic ip a tin g  cancer p a tie n ts  dem ographic  an d  
m edical ch a rac te r is tic s  w ere g a th e re d  by self-report using  q uestionnaires. 
In fo rm atio n  on m a ri ta l  s ta tu s  an d  level of ed u ca tio n  w ere collected as  p a r t  of th e  
dem ographic  d a ta . T he following in fo rm atio n  on m edical ch a rac te r is tic s  w as 
ob tained : m ed ica tion  use  in  th e  p a s t  m onth , an d  m edical h is to ry  on co­
m orbid ities, an d  receiv ing  psychological an d  p sy ch ia tric  tre a tm e n t  d u ring  
p a tie n ts ’ lifetim e.
F a tig u e  sev erity  w as a ssessed  by th e  subscale  fa tig u e  of th e  C hecklist 
In d iv id u a l S tre n g th  (C IS)14, 15. The CIS is a  w ell-va lida ted  in s tru m e n t am ong 
p a tie n ts  w ith  chronic fa tig u e  syndrom e (CFS) a n d  in  th e  w ork ing  p o p u la tio n 16’ 17. 
The fa tig u e  subscale  consists of e ig h t item s scored on a seven-point L ik e rt scale, 
w ith  scores ran g in g  from  e ig h t to 56. B ased  on re se a rc h  w ith  CFS p a tie n ts  a
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score of 35 or h ig h er ind ica te  severe fa tig u e 15. A score betw een  27 (m ean score for 
h e a lth y  ad u lts  p lu s  one s.d.) an d  35 in d ica te  a h e ig h ten ed  experience of fa tig u e 14. 
The CIS w as u sed  in  ea rlie r re sea rch  in v es tig a tin g  cancer su rv ivo rs18-21.
D epression  w as assessed  w ith  th e  Beck D epression  In v en to ry  P rim ary  C are 
(BDI-PC)22. This is  a seven item  qu estio n n a ire  w ith  scores ran g in g  from  zero to
21. A score of four or h ig h er on th e  BDI-PC is ind ica tive  for a clinical 
dep ression23. The BDI-PC is  b ased  on a set of non-som atic  item s from  th e  BDI- 
II24.
D epressive mood w as m easu red  w ith  th e  Sym ptom  C hecklist-90 (SCL-90)25, 
subscale depression. S ix teen  item s m easu re  depressive mood, w ith  scores rang ing  
from  16 to 80. H igher scores in d ica ted  a stronger depressive mood.
A nxiety  w as m easu red  w ith  th e  SCL-90 subscale anxiety . Ten item s 
m easu re  anx ie ty  w ith  scores from  10 to 50. H igher scores in d ica ted  m ore anxiety.
Q uality  of n o c tu rn a l sleep w as m easu red  w ith  th e  SCL-90 subscale sleep. 
T hree item s m easu re  sleep w ith  scores from  th ree  to 15. H igher scores ind ica ted  
low er q u a lity  of sleep. In  addition , th e  im pact of th e  d isease on sleep an d  re s t 
du ring  th e  n ig h t an d  day w as m easu red  w ith  th e  subscale s leep /rest of the  
Sickness Im pac t Profile —8 (SIP)26, 27. H igher scores on th is  subscale w as an  
ind ica tion  of m ore im p a irm en t on sleep /rest. Seven item s m easu red  im p a irm en ts  
on sleep /rest, w ith  scores ran g in g  from  zero to 499.
P hysica l ac tiv ity  w as m easu red  w ith  an  11-point N um eric  R atin g  Scale 
(NRS) ran g in g  from  zero to 10. P a tie n ts  w ere ask ed  how physically  active they  
w ere in  th e  period  since d iagnosis. Zero in d ica ted  ‘no t physically  active' an d  ten  
‘physically  very  active’.
P a in  w as also m easu red  w ith  an  11-point NRS. P a tie n ts  w ere ask ed  how 
m uch p a in  th ey  h a d  experienced  in  th e  period  since diagnosis, on a scale from  
zero to 10. Zero in d ica ted  ‘no p a in ’ a n d  te n  ‘very  m uch p a in ’.
P a tie n ts  w ere ask ed  add itiona lly  to ind ica te  th e ir  level of fatigue, physica l 
activity , an d  p a in  before d iagnosis re trospectively , 1 year before d iagnosis an d  3 
years  before diagnosis. Thus, in  to ta l six 11-point N R S’ w ere used, ran g in g  from  
zero to 10.
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Statistical analysis
All d a ta  an a ly sis  w as perfo rm ed  w ith  SPSS (version 14.0). D ifferences betw een 
p a rtic ip a tin g  an d  n o n -p artic ip a tin g  cancer p a tie n ts  w ere te s te d  w ith  x 2. For the 
f irs t objective descrip tive s ta tis tic s  w ere u sed  to describe dem ographic 
ch a rac te ris tic s  of tre a tm e n t naive cancer p a tie n ts , an d  th e  d a ta  on th e  p resence 
of severe fa tigue. D ifferences on dem ographic  an d  m edical ch a rac te ris tic  betw een  
severely an d  non-severely  fa tig u ed  cancer p a tie n ts  w ere te s te d  w ith  x 2. For the  
second objective, to find  th e  co n tribu ting  factors, two steps w ere tak en . The firs t 
step w as to te s t  th e  d ifferences betw een  severely  fa tig u ed  cancer p a tie n ts  an d  
non-severely  fa tig u ed  cancer p a tie n ts  on th e  co n trib u tin g  fac to rs w ith  a ¿"test for 
in d ep en d en t sam ples. For th e  second step  a logistic reg ression  an a ly sis  w as 
p erfo rm ed  using  Stepw ise F o rw ard  m ethod. This m ethod  w as chosen, as i t  w as 
an  exp lo ra to ry  d a ta  analysis. S ign ifican t fac to rs found  in  th e  f irs t step  w ere p u t 
in  th e  logistic reg ression  as in d ep en d en t variab les , w ith  sign ifican t dem ographic 
an d  m edical v a riab le s  as covariates. The d im ensions of depression  an d  sleep w ere 
each m easu red  w ith  two in s tru m e n ts , a lthough  m easu rin g  d ifferen t aspects. 
W hen bo th  in s tru m e n ts  show ed sign ifican t re su lts  in  th e  f irs t step, th e  
in s tru m e n t w ith  th e  la rg e s t s ign ifican t difference w as p u t in to  th e  logistic 
reg ression . V ariab les th a t  app lied  to th e  period  before d iagnosis w ere en te red  
in to  th e  f irs t block, an d  v a riab les  th a t  app lied  to th e  c u rre n t period  w ere en te red  
in to  th e  second block. Two p e rsons w ith  m issing  d a ta  on th e  BDI-PC or SCL-90 
w ere excluded from  th e  analysis. A tw o-sided P <  0.05 w as considered  significant.
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Figure 1: Flow c h a rt show ing th e  accrua l of p a tien ts .
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RESULTS
In  to ta l 477 p a tie n ts  ag reed  to be app roached  an d  w ere con tac ted  by telephone. 
D uring  th e  te lephone conversa tions an  ad d itio n a l 82 p a tie n ts  w ere excluded who 
did  no t m eet th e  e lig ib ility  c rite ria . The m ost com m on reaso n s for exclusion were: 
hav ing  a co-m orbidity  th a t  could cause fatigue, an d  being severely  fa tig u ed  for 
severa l years. O f th e  395 p a tie n ts  who m et th e  inclusion  c rite ria  155 re fu sed  to 
p a rtic ip a te  for d ifferen t reaso n s (see F igu re  1). In  to ta l 240 p a tie n ts  p a rtic ip a ted  
an d  com pleted  base line  assessm en ts . The ch a rac te ris tic s  of p a rtic ip a n ts  w ere 
com pared  w ith  n o n -p artic ip an ts  (see Table 1).
Table 1: D ifferences betw een  p a r tic ip a n ts  an d  n o n -partic ipan ts.
Characteristics Participants Non-participants P-value
Total (n) 240 155
Mean (s.d.) Mean (s.d.)
Age (years) 56.8 (11.1) 59.7 (10.9) 0.010
n (%) n (%)
Sex 0.219
Male 92 (38.3) 50 (32.3)
Female 148 (61.7) 105 (67.7)
Diagnosis“ 0.310
Breast cancer 109 (45.4) 81 (52.3)
Prostate cancer 57 (23.8) 28 (17.4)
Other tumours 76 (31.7) 47 (30.3)
Gastrointestinal 33 26
Urogenital 16 9
Gynaecological 13 10
Lymphomas 7 0
Sarcoma 3 2
Melanoma 2 0
Thyroid carcinoma 2 0
a Three patients were diagnosed with both bladder and prostate cancer and were categorized as 
urogenital tumours of the other tumours. A two-sided P  < 0.05 was considered significant.
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R esu lts  show ed th a t  cancer p a tie n ts  who re fu sed  to p a rtic ip a te  w ere significantly  
older com pared  to p a tie n ts  who p a rtic ip a ted . No differences w ere found  on 
gender or d iagnosis betw een  p a r tic ip a n ts  an d  non-p artic ip an ts . P a tie n ts  u sua lly  
s ta r t  w ith  cancer tre a tm e n t re la tiv e ly  fa s t a fte r being diagnosed. As a 
consequence of th is  sh o rt tim e  span  base line  a sse ssm en ts  som etim es took place 
w hen  cancer tre a tm e n t h a d  ju s t  s ta rted . For exam ple, some b re a s t cancer 
p a tie n ts  w ere a ssessed  a fte r surgery , b u t before ad ju v an t rad io th e rap y  or 
chem otherapy .O f th e  240 p a rtic ip a n ts  61 p a tie n ts  w ere a ssessed  w hen  th e ir  
cancer tre a tm e n ts  h a d  ju s t  s ta rted , b u t th e ir  d a ta  w ere not u sed  in  th e  analysis. 
T hus d a ta  p re se n te d  in  th is  s tu d y  are  b ased  on 179 cancer p a tie n ts  who w ere 
tre a tm e n t naive.
Patient Characteristics
M ost of th e  179 p a tie n ts  w ere d iagnosed w ith  b re a s t cancer or p ro s ta te  cancer, 
54% w ere fem ale, an d  82% w ere m arried  (see Table 2). The m ean  age of the  
sam ple w as 56.6 (s.d. 10.9) years, an d  th e  m ean  education  level w as 4.1 (s.d. 1.7) 
ran g in g  betw een  one an d  seven (data  no t shown). No differences w ere found 
betw een  severely an d  non-severely  fa tig u ed  cancer p a tie n ts  on dem ographic 
v a riab les  such as sex, age, education  or m a rita l s ta tu s , a lth o u g h  th e  difference 
betw een  m ales an d  fem ales n ea rly  reach ed  significance. In  addition , differences 
w ere te s te d  on severa l m edical v a riab le s  be tw een  severely  fa tig u ed  cancer 
p a tie n ts  an d  non-severely  fa tig u ed  cancer p a tien ts . No sign ifican t differences 
w ere found  on c u rre n t m edication  use, a n d  on th e  m edical h is to ry  of co­
m orbidities, a n d  receiving psychological or p sy ch ia tric  tre a tm e n t in  p a tie n ts ’ 
lifetim e (all P  > 0.971) (d a ta  no t shown).
The presence of severe fatigue in cancer patients before treatment
In  th e  to ta l sam ple 23.5% of th e  cancer p a tie n ts  w ere severely  fa tigued , b u t th is  
p ercen tag e  v a ried  betw een  diagnoses (see Table 2). The p resence  of severe fa tigue 
w as th e  low est in  p a tie n ts  w ith  p ro s ta te  cancer (14.3%), b u t h ig h e r in  b re a s t 
cancer p a tie n ts  (20.3%).
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Table 2: D a ta  of dem ographic v ariab les, d iagnosis a n d  presence  of severe fatigue.
Characteristics
Total
sample
n
Non-severely 
fatigued cancer 
patients 
n (%)
Severely 
fatigued 
cancer 
patients 
n (%)
Difference»
P-value
Total 179 137 (76.5) 42 (23.5)
Sex 0.064
Male 82 68 (82.9) 14 (17.1)
Female 97 69 (71.1) 28 (28.9)
Age (years) 0.237
Younger age group (< 57 years) 88 64 (72.7) 24 (27.3)
Older age group (> 58 years) 91 73 (80.2) 18 (19.8)
Education level 0.269
Lower education (< 4) 111 88 (79.3) 23 (20.7)
Higher education (>4) 68 49 (72.1) 19 (27.9)
Marital status 0.568
Married / cohabiting 146 113 (77.4) 33 (22.6)
Other status 33 24 (72.7) 9 (27.3)
(unmarried/divorced/ widowed)
Diagnosis b 0.044
Breast cancer 64 51 (79.7) 13 (20.3)
Prostate cancer 49 42 (85.7) 7 (14.3)
Other tumours 68 46 (67.7) 22 (33.3)
Gastrointestinal 32 23 (71.9) 9 (28.1)
Urogenital 14 6
Gynaecological 10 3
Lymphomas 5 2
Sarcoma 3 1
Melanoma 2 1
Thyroid carcinoma 2 1
“Difference between severely and non-severely cancer patients, tested with x2.
bTwo patients were diagnosed with both bladder and prostate cancer and were categorized as
urogenital tumours of the other tumours. A two-sided P <  0.05 was considered significant.
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In  th e  group of p a tie n ts  w ith  o th e r tu m o u rs  th e  presence  of severe fa tigue  w as 
th e  h ig h es t (33.3%). W hen p a tie n ts  w ith  g a s tro in te s tin a l cancer w ere considered 
as a sep a ra te  group, fa tigue  in  th is  specific group w as 28.1%. In  p a tie n ts  w ith  
o th e r tu m o u rs  w ith o u t g a s tro in te s tin a l cancer severe fa tigue  even rose to 38.2%. 
A sign ifican t overall effect of d iagnosis on severe fa tigue  w as found  using  th e  x 2 
te s t  (P  = 0.044). In  addition, we te s te d  if  th e  m eans of th e  th re e  d iagnosis groups 
w ere d ifferen t on th e  CIS using  ANOVA, an d  also a sign ifican t overall effect w as 
found  (P  = 0.014). U sing a p o s t hoc  te s t we te s te d  w hich of th e  th re e  groups 
(b reast cancer (m ean 23.5, s.d. 12.4), p ro s ta te  cancer (m ean 19.9, s.d. 12.0), or 
o th e r tu m o u rs  includ ing  g a s tro in te s tin a l cancer (m ean 27.1, s.d. 13.9)) differed 
from  each o ther, an d  found one sign ifican t difference. P a tie n ts  w ith  p ro s ta te  
cancer w ere sign ifican tly  less fa tig u ed  com pared  w ith  th e  group of p a tie n ts  w ith  
o th e r tu m o u rs  (P  = 0.011) (d a ta  not shown).
Contributing factors to severe fatigue before cancer treatment
In  Table 3 th e  d ifferences on co n tribu ting  factors betw een  severely  fa tigued  
cancer p a tie n ts  an d  non-severely  fa tig u ed  cancer p a tie n ts  a re  described.
Severely  fa tig u ed  cancer p a tie n ts  rep o rted  to have  m ore fa tigue  in  the 
period  before diagnosis, m ore pain , an d  being less physically  active. These 
differences w ere sign ifican t for bo th  periods, 1 an d  3 years  before diagnosis. 
Severely fa tig u ed  cancer p a tie n ts  also rep o rted  cu rren tly  m ore p a in  an d  being 
less physically  active, th a n  non-severely  fa tig u ed  cancer p a tien ts . In  addition, 
th ey  rep o rted  sign ifican tly  m ore sleeping problem s, an d  m ore feelings of 
depression  an d  anxiety.
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Table 3: C o n tr ib u tin g  fa c to rs  to  se v ere  fa tig u e  befo re  c a n c e r  t r e a tm e n t  te s te d
w ith  a t t e s t .
Factors
Non-severely 
fatigued 
mean (s.d.)
Severely 
fatigued 
mean (s.d.) t df P
Period before diagnosis
Fatigue 1 year before diagnosis“ 1.71 (2.43) 3.86 (2.89) 4.786 177 <0.001
Fatigue 3 years before diagnosis 1.32 (2.14) 2.93 (2.67) 3.563 177 0.001
Physical activity 1 year before 7.06 (2.34) 6.17 (2.66) -2.094 177 0.038
diagnosis
Physical activity 3 years before 7.28 (2.24) 6.17 (2.63) -2.711 177 0.007
diagnosisa
Pain 1 year before diagnosis 0.89 (1.91) 1.95 (2.68) 2.391 177 0.020
Pain 3 years before diagnosis® 0.73 (1.66) 1.76 (2.43) 2.577 177 0.013
Current period before cancer treatm ent 
Paina 1.28 (2.14) 3.24 (3.04) 3.900 177 <0.001
Anxietya 13.1 (3.77) 17.0 (6.91) 3.502 176 0.001
Sleep quality (SCL-sleep) 4.91 (2.23) 6.91 (2.93) 4.061 176 <0.001
Impairments on sleep/rest (SIP-SR)a 34.7 (46.4) 85.1 (70.4) 4.358 177 <0.001
Physical activitya 6.66 (2.42) 4.69 (2.37) -4.636 177 <0.001
Depressive mood (SCL-90)a 20.8 (5.86) 27.5 (9.54) 4.360 176 <0.001
Clinical depression (BDI-PC)b
% (n)
2.9 (4)
% (n)
17.1 (7) 0.004
aFactors tha t were put into the logistic regression analysis as separate factors.
bDifference on clinical depression was tested with Fisher’s Exact Test.
The re su lts  of th e  logistic reg ression  a re  described  in  Table 4. F our factors 
co n trib u ted  un iquely  to severe fa tigue  in  cancer p a tie n ts  before tre a tm e n t. F irs t 
fa tigue  1 year before d iagnosis co n trib u ted  significantly . T hree fac to rs of the 
c u rre n t period  co n trib u ted  sign ifican tly  to severe fa tigue. Lower physica l activ ity  
co n trib u ted  th e  m ost, followed by depressive m ood an d  im p a irm en ts  on sleep and  
rest.
126
Severe fatigue before the in itiation of cancer treatm ent.
Two factors, d iagnosis an d  physica l ac tiv ity  3 y ears  before diagnosis, d id  not 
co n tribu te  sign ifican tly  to severe fa tigue. A nxiety  an d  p a in  w ere no t p a r t  of the  
l in e a r  regression .
Table 4: C o n tribu ting  factors to severe fa tigue
Contributing factors B (SE) Exp b P-value 95% CI
Diagnosis group 0.374
Diagnosis group (1) (breast cancer) 0.783 (0.609) 2.187 0.199 0.663 -  7.218
Diagnosis group (2) (prostate cancer) 0.270 (0.606) 1.310 0.656 0.399 -  4.297
Period before diagnosis
Fatigue 1 year before diagnosis 0.218 (0.077) 1.244 0.005 1.070 -  1.446
Physical activity 3 years before 
diagnosis 
Current period before treatm ent
0.020 (0.111) 1.020 0.855 0.822 -  1.267
Depressive mood (SCL-90) 0.076 (0.031) 1.079 0.014 1.015 -  1.147
Impairments on sleep/rest (SIP-SR) 0.008 (0.004) 1.008 0.045 1.000 -  1.015
Physical activity -0.284 (0.115) 0.752 0.013 0.601 -  0.943
Constant -2.986 (1.040) 0.051 0.004
(R2 was 0.274 (Cox & Snell) and 0.412 (Nagelkerke)). A two-sided P  < 0.05 was considered 
significant.
DISCUSSIO N
T his is th e  f irs t s tudy  specifically a im ed  a t in v estig a tin g  fa tigue  in  p a tie n ts  who 
w ere recen tly  being d iagnosed  w ith  cancer, before in itia tio n  of any  tre a tm e n t for 
cancer. The f irs t goal of th is  s tudy  w as to e s tab lish  how m any  cancer p a tie n ts  
rep o rt severe fa tigue  before receiv ing tre a tm e n t. In  th e  w hole sam ple 24% of the 
cancer p a tie n ts  w ere severely fa tigued , ran g in g  from  14 to 28%. The p resence  of 
severe fa tigue  w as th e  low est in  p a tie n ts  w ith  p ro s ta te  cancer (14%), b u t h igher 
in  b re a s t cancer p a tie n ts  (20%), a n d  g a s tro in te s tin a l cancer p a tie n ts  (28%).
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The p revalence of severe fa tigue  in  our study  is  su rp ris in g ly  h igh, in  
perspective to re su lts  in  o th e r sam ples. R eview ing th e  re su lts  of seven d ifferen t 
s tud ies fa tigue  in  cancer surv ivors ap p ea rs  to v a ry  betw een  16 an d  38%, 
com pared  w ith  10 - 11% in  a control g roup28. The p revalence of severe fa tigue  in  
cancer surv ivors w ith  vario u s cancer d iagnoses w as abou t 22 18, 19, 29. T hus severe 
fa tigue  in  cancer p a tie n ts  before tre a tm e n t seem s tw o tim es as h igh  com pared  
w ith  people w ith o u t a h is to ry  of cancer, an d  reach in g  th e  level of severe fa tigue  
in  cancer surv ivors long a fte r cancer tre a tm e n t.
As p a tie n ts  in  th is  s tu d y  w ere re c ru ite d  as  p a r t  of a la rg e r in te rv en tio n  
study, th e  question  rise s  if  th is  could be a b iased  sam ple. In  th e  g en era l D utch 
popu la tion  m ore m ales a re  d iagnosed  w ith  cancer th a n  fem ales. In  addition, 
b re a s t cancer is th e  m ost com m on type of cancer, followed by colorectal cancer, 
lung  cancer, a n d  p ro s ta te  cancer30. So th e  sam ple in  th is  s tudy  does no t reflect 
th e  incidence an d  types of cancer in  th e  D utch  population , as  m ore fem ales w ere 
inc luded  an d  p ro s ta te  cancer w as m ore com m on th a n  g a s tro in te s tin a l cancer in  
th is  sam ple. T hese d ifferences canno t be exp la ined  from  th e  ch a rac te ris tic s  of th e  
p a tie n ts  who re fu sed  to p a rtic ip a te , as no sign ifican t d ifferences w ere found 
betw een  p a rtic ip a n ts  an d  n o n -p artic ip an ts  on sex an d  diagnosis. The following 
reaso n s m igh t exp la in  th ese  differences. One reaso n  m igh t be, because th is  
sam ple is  a selected  group of cancer p a tie n ts  who w ould be tre a te d  w ith  cu ra tive  
in te n t. A no ther reaso n  m igh t be th a t  p a tie n ts  w ith  colorectal cancer a re  m ore 
often d iagnosed  in  an  acu te  p h ase  req u estin g  im m ed ia te  tre a tm e n t, w h ereas  
p a tie n ts  w ith  b re a s t or p ro s ta te  cancer receive tre a tm e n t in  a m ore p lan n ed  
m anner. P a tie n ts  d iagnosed  a n d  tre a te d  in  th is  acu te  p h ase  w ere m ore difficult 
to approach  a n d  to include in to  th e  study. This also exp la ins th e  sm all n u m b ers  
of p a tie n ts  w ith  te s tis  cancer in  th is  study, who also receive su rgery  in  an  acute 
phase . The o rg an isa tio n  of th e  re c ru itm e n t m igh t also exp la in  th e  differences 
betw een  our sam ple a n d  th e  D utch  population . For exam ple, in  m ost h o sp ita ls  
specialised  m am m a care  u n its  w ere involved w ith  rec ru itin g  p a tie n ts , w hich 
m igh t exp lain  th e  la rg e  n u m b ers  of p a tie n ts  w ith  b re a s t cancer.
128
Severe fatigue before the in itiation of cancer treatm ent.
The question  rose if  severe fa tigue  w as m ore com m on in  th is  sam ple as 
p a tie n ts  w ere re c ru ite d  for an  in te rv en tio n  study  on fa tigue  du ring  cancer 
tre a tm e n t. We do no t expect th a t  p a tie n ts  w ith  severe fa tigue  are  over­
re p re se n te d  in  th is  sam ple. F irstly , physic ians excluded p a tie n ts  w ith  co­
m orb id ities th a t  could have caused  fatigue, for exam ple p a tie n ts  w ith  rh eu m a tic  
a r th r i t is  or h e a r t  d isease. Secondly, p a tie n ts  w ere in fo rm ed  th a t  p rev en tio n  of 
severe fa tigue  w as th e  m ain  goal of th e  study, an d  p a tie n ts  who in d ica ted  seeking 
help  for severe fa tigue  w ere no t inc luded  in  th e  study. Thirdly, a lthough  p a tie n ts  
w ere excluded w hen  receiv ing psych ia tric  or psychological tre a tm e n t in  th e  la s t  3 
m on ths b ased  on self-report, p a tie n ts  w ere no t excluded b ased  on tak in g  
psychotropic m edicines. H ow ever, only one p a rtic ip a n t took psychotropic 
m edicine, so it  is im probable  th a t  th is  is  an  exp lan a tio n  for th e  p revalence of 
severe fa tigue. The p revalence  of severe fa tigue  m igh t even be u n d erestim a ted . 
M ore p a tie n ts  w ith  p ro s ta te  cancer (who a re  less freq u en tly  severely  fatigued), 
an d  less p a tie n ts  w ith  colorectal cancer (who are  m ore often severely  fatigued) 
p a rtic ip a te d  in  th is  study, com pared  w ith  th e  D utch  population.
O ur second goal w as to in v estig a te  w hich fac to rs in fluenced  severe fa tigue 
before cancer tre a tm e n t, a n d  four fac to rs w ere found. M ore fa tigue  1 year before 
diagnosis, cu rren tly  low er physica l activity , depressive mood an d  m ore im p a ired  
sleep an d  re s t  ap p ea red  to be re la te d  to fa tigue  p rio r to tre a tm e n t. A lthough 
d ifferences w ere found in  th e  p revalence of severe fa tigue  am ong v a rio u s groups 
of diagnoses, re su lts  show ed th a t  d iagnosis did no t un iquely  con tribu te  to severe 
fa tigue. In  lig h t of th is  re su lt, TNM  classification  of each  tu m o u r w as considered 
no t useful. F u r th e r  c lassification  w ould in crease  th e  n u m b er of subgroups, 
m aking  i t  even h a rd e r  to d em o n stra te  a p o ten tia l re la tio n sh ip  betw een  diagnosis 
an d  fa tigue. The four m en tioned  fac to rs are  th u s  stronger re la te d  to severe 
fa tigue  th a n  diagnosis, an d  also stronger th a n  anxiety, p a in  or physica l ac tiv ity  3 
years  before diagnosis.
Low er physica l ac tiv ity  w as re la te d  to fa tigue  in  cancer p a tie n ts  during  
tre a tm e n t31-33 a n d  in  cancer su rv iv o rs19- 26 as prev ious s tud ies revealed .
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A new  find ing  is th a t  th is  re la tio n sh ip  betw een  physica l ac tiv ity  an d  fa tigue  w as 
now found in  cancer p a tie n ts  before in itia tio n  of tre a tm e n t.
Two stud ies th a t  in v es tig a ted  th e  q u a lity  of life in  new ly d iagnosed  cancer 
p a tie n ts  found th a t  sleeping problem s affected p a tie n ts  before cancer t r e a tm e n t10, 
13; how ever, i t  rem a in ed  un c lea r w hich aspects  of sleep w ere affected. Looking a t 
our re su lts  on th e  subscale sleep /rest of th e  S IP  m ore closely rev ea led  four 
differences betw een  severely  an d  non-severely  fa tig u ed  cancer p a tie n ts . Severely 
fa tig u ed  cancer p a tie n ts  in d ica ted  to sleep less a t n igh t, sleep or nap  m ore during  
th e  day, sit d u rin g  m uch of th e  day, an d  lie down to re s t  m ore often du ring  the  
day. Thus, no t only th e  n o c tu rn a l sleep w as affected in  severely  fa tig u ed  cancer 
p a tien ts , b u t th e ir  daily  sleep an d  re s t  w as affected too.
One of th e  sym ptom s of clin ical depression  can be fatigue. H owever, the 
p revalence of clin ical depression  in  our sam ple is low (6.2%) a n d  w ith in  the 
no rm al ran g e  of th e  a d u lt D utch  popu la tion  (5.7 — 6.6%)34. Thus, clinical 
depression  canno t be an  exp lan a tio n  for th e  h ig h  p revalence of severe fa tigue  in  
th is  study. In  add ition  our re su lts  show ed th e  necessity  to d is tin g u ish  clinical 
depression  from  depressive mood, w ith  th e  la t te r  c learly  being a mood sta te . 
A lthough no s tru c tu re d  psy ch ia tric  in terv iew  w as u sed  to diagnose mood 
disorders.
F a tig u e  1 year before d iagnosis w as ev a lu a ted  re tro spective ly  by p a tien ts , 
an d  no t m easu red  a t th a t  specific tim e. This ev a lu a tio n  probab ly  reflects 
p a tie n ts ’ recollection of fa tigue  1 year before diagnosis, r a th e r  th a n  ac tu a l fa tigue 
a t th a t  tim e.
C o n tra ry  to w h a t w as expected  an x ie ty  w as no t found as  a fatigue- 
co n tribu ting  factor. R eceiving th e  d iagnosis cancer can  inflict s trong  feelings of 
a n x ie ty 10, 35, a lthough  th ese  h igh  levels ap p ea red  to decrease w ith in  2 w eek s13. 
T his tre n d  w as also found  in  p a tie n ts  receiv ing chem otherapy . H igh level of 
anx ie ty  p rio r to chem otherapy  decreased  as soon as in d iv idua ls  s ta rte d  
tre a tm e n t36, 37. Thus, feelings of an x ie ty  are  a com m on reac tion  on being 
d iagnosed w ith  cancer, an d  th e  p rospect of receiv ing chem otherapy , b u t feeling of 
anx ie ty  a re  no t re la te d  to severe fa tigue  in  tre a tm e n t naive cancer p a tien ts .
No prev ious re sea rch  w as done to in v estig a te  th e  re la tio n sh ip  betw een
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fa tigue  an d  p a in  in  tre a tm e n t naive cancer p a tien ts , b u t no evidence w as found 
th a t  p a in  con trib u ted  to severe fa tigue  in  th is  study.
One of th e  lim ita tio n s  in  th is  s tu d y  is  th e  re liance  on cross-sectional data . 
Therefore, we canno t m ake any  claim s for cau sa lity  betw een  fa tigue  an d  the 
re la te d  factors, im p a ired  sleep an d  re s t, depressive mood, an d  physica l activity.
In  th is  s tu d y  q u es tio n n a ires  w ere u sed  to m easu re  physica l activ ity , b u t 
ask ing  people to e s tim a te  th e ir  level of physica l ac tiv ity  h a s  i ts  lim ita tions. 
P rev ious re sea rch  show ed th a t  th e re  is a lack  of correspondence betw een  self­
rep o rted  physica l ac tiv ity  an d  objective physica l ac tiv ity38, 39. P robably  the 
percep tion  of physica l ac tiv ity  does no t alw ays reflect th e  ac tu a l level of physical 
activity . T hus in  our study  it  is  m ore likely  th a t  th e  perceived  level of physical 
ac tiv ity  w as re la te d  to severe fa tigue  ra th e r  th a n  th e  ac tu a l level.
In  sum m ary , it  is  genera lly  know n th a t  m ost cancer p a tie n ts  w ill experience 
fa tigue  d u ring  tre a tm e n t, b u t fa tigue  in  tre a tm e n t naive cancer p a tie n ts  w as not 
p rev iously  in vestiga ted . This study  show ed th a t  a la rg e  n u m b er of cancer 
p a tie n ts  a lread y  experience severe fa tigue  before in itia tio n  of cancer trea tm en t. 
O ne m igh t expect th a t  th e  course of fa tigue  d u rin g  an d  a fte r cancer tre a tm e n t 
could be d ifferen t for p a tie n ts  w ith  severe fa tigue  or p a tie n ts  w ith o u t severe 
fa tigue  before cancer tre a tm e n t. In  addition , i t  rem a in s  a question  if  p a tie n ts  
w ith  severe fa tigue  before cancer tre a tm e n t should  receive a k in d  of ea rly  fa tigue 
in te rv en tio n  a t  th is  stage. T hese w ill be topics for fu tu re  research .
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Is increasing physical activity necessary to 
diminish fatigue during cancer treatment? 
Comparing cognitive behavior therapy and 
a brief nursing intervention with usual care 
in a multicenter randomized cntrolled 
trial
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ABSTRACT
Background. Two in te rv en tio n s  for fa tigue  w ere given du ring  cu ra tiv e  cancer 
tre a tm e n t. The aim  of th is  m u lticen te r random ized  contro lled  t r ia l  (RCT) w ith  
th ree  conditions w as to d em o n stra te  th e  efficacy an d  to de te rm ine  the 
con tribu tion  of physica l activity.
M ethods. R ecru ited  from  seven hosp ita ls , 220 p a tie n ts  w ith  v a rio u s m alignancies 
p a rtic ip a te d  in  a RCT. The b rie f  n u rs in g  in te rv en tio n  (BNI) consisted  of two one- 
ho u r sessions, th ree  m o n ths ap a rt, given by 12 tra in e d  n u rses , focusing only on 
physica l activity . Cognitive behav io r th e ra p y  (CBT) consisted  of up to te n  one- 
ho u r sessions, w ith in  six m onths, p rov ided  by tw o th e ra p is ts , focusing on 
physica l ac tiv ity  an d  psychosocial e lem ents. The control group received  only 
u su a l care  (UC). A ssessm en ts took place before an d  a t le a s t two m on th s after 
cancer tre a tm e n t, w hen  p a tie n ts  h a d  recovered  from  acu te  fa tigue. F a tig u e  w as 
th e  p rim ary  outcom e. Efficacy w as te s te d  u sing  ana ly ses  of covariance. A
n o n p a ram e tric  bo o tstrap  approach  w as u sed  to te s t  w h e th e r th e  effect on fa tigue 
w as m ed ia ted  by physica l activity .
Results. The CBT group w as sign ifican tly  less fa tig u ed  th a n  th e  UC group. 
B etw een  th e  B N I an d  th e  UC groups, no sign ifican t difference w as found  in  
fa tigue. The m edia tion  h y po thesis  w as rejected.
Discussion. CBT given d u ring  cu ra tiv e  cancer tre a tm e n t proved  to be an  effective 
in te rv en tio n  to reduce fa tigue  a t  le a s t two m o n ths a fte r cancer tre a tm e n t. The 
B N I w as no t effective. C o n tra ry  to w h a t w as expected, physica l ac tiv ity  d id  not 
m edia te  th e  effect of CBT on fatigue. Thus, th e  reduction  in  fa tigue  elic ited  by 
CBT w as rea lized  w ith o u t a la s tin g  in crease  in  physica l activity.
INTRODUCTION
F a tig u e  is  one of th e  m ost com m on an d  d is tre ss in g  sym ptom s in  cancer p a tien ts , 
an d  w hen  severe i t  h a s  a la rg e  im pact on daily  function ing  an d  q u a lity  of life1-3. 
I t  is  assu m ed  th a t  levels of fa tigue  a re  low before th e  s ta r t  of cancer tre a tm e n t 
an d  h igh  du ring  cancer tre a tm e n t. P revalence e s tim a te s  of fa tigue  during  
tre a tm e n t are  in  th e  ran g e  of 25%—75%, in  d ifferen t sam ples an d  m easu red  w ith  
d ifferen t q u es tio n n a ire s4. S evera l s tud ies even rep o rted  a p revalence > 90%B'9. 
F a tig u e  con tinues to be p rob lem atic  for m any  p a tie n ts  a fte r cancer tre a tm e n t is 
fin ished, because th e  n u m b er of p a tie n ts  w ith  su b s ta n tia l fa tigue  is  h ig h e r th a n  
th a t  in  control g roups4- 10. Therefore, it  is  im p o rta n t to in te rv en e  d u ring  active 
cancer tre a tm e n t in  order to reduce severe fa tigue  a fte r cancer tre a tm e n t. 
B ecause n ea rly  a ll cancer p a tie n ts  experience fa tigue  d u rin g  active cancer 
tre a tm e n t, we assu m ed  th a t  m ost p a tie n ts  could benefit from  an  in te rv en tio n  for 
fatigue.
E xercise an d  psychosocial in te rv en tio n s  have  th e  s tro n g est evidence base  for 
m anag ing  fa tigue  d u ring  cancer t r e a tm e n t11, b u t c learly  no t a ll in te rv en tio n s 
g en era te  sim ilar effects. Psychosocial in te rv en tio n s  specifically a im ed  a t fa tigue 
d u ring  cancer tre a tm e n t w ere found  to be m ore effective th a n  psychosocial 
in te rv en tio n s  no t a im ed  a t fa tig u e 12-14. H owever, th e  n u m b er of random ized
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controlled  t r ia l  (RCT) in te rv en tio n s  specifically for fa tigue  d u ring  cancer 
tre a tm e n t is lim ite d 13.
Review s d em o n stra te  th a t  in te rv en tio n s  for fa tigue  an d  asse ssm en ts  tak e  
p lace d u ring  d ifferen t p h ases  of cancer tr e a tm e n t12-14. For exam ple, in  some 
RCTs, p a rtic ip a n ts  s till received  chem otherapy  a fte r th e  p o stin te rv en tio n  
a sse ssm e n t15-17. S uch  a design  is u n su itab le  to d em o n stra te  w h e th e r th e  level of 
fa tigue  a fte r fin ish ing  cancer tre a tm e n t re tu rn s  to th e  p re tre a tm e n t level. To the  
b est of our know ledge, th e re  is no fa tigue  in te rv en tio n a l RCT d uring  cancer 
tre a tm e n t th a t  a ssessed  p a tie n ts  a t  clinically  re le v a n t m om ents—before th e  s ta r t  
of cancer tre a tm e n t an d  shortly  a fte r fin ish ing  cancer tre a tm e n t.
E xercise in te rv en tio n s  a re  solely a im ed  a t physica l activity , w h ereas  
psychosocial in te rv en tio n s  often have  a physica l ac tiv ity  com ponent, such as 
ac tiv ity  m anagem en t. In te rv en in g  w ith  physica l ac tiv ity  to reduce  fa tigue  is 
b ased  on th e  assu m p tio n  th a t  a lack  of physica l ac tiv ity  an d  deconditioning 
d u ring  cancer tre a tm e n t can w orsen  fa tig u e 18. W hen p a tie n ts  are  d iagnosed  w ith  
cancer, th e ir  ac tiv ity  p a tte rn  changes an d  th ey  becom e physically  less active, 
possible lead ing  to decondition ing19. This is  th e  re su lt  of a nega tive  spiral, 
because w hen  p a tie n ts  becom e physically  less active th ey  becom e m ore easily  
fa tigued , a n d  w hen  p a tie n ts  experience fa tigue  th ey  re a c t by becom ing physically  
even less active. Exercise can b re a k  th is  cycle by im proving to lerance  for physica l 
ac tiv ity 11. Therefore, increasin g  physica l ac tiv ity  is  an  im p o rta n t e lem en t in  
reducing  fa tigue  du ring  cancer tre a tm e n t. However, th e  m ed ia ting  role of 
physica l ac tiv ity  in  in te rv en tio n s  aim ed  a t reducing  fa tigue  d u rin g  cancer 
tre a tm e n t h a s  never been d em onstra ted .
In  th e  c u rre n t RCT, two in te rv en tio n s  for fa tigue  du ring  cancer tre a tm e n t 
w ere com pared  w ith  u su a l care  (UC). The firs t in te rv en tio n  w as a m in im al 
in te rv en tio n  perfo rm ed  by nu rses. The b rie f  n u rs in g  in te rv en tio n  (BNI) w as 
a im ed  a t advising  p a tie n ts  how to avoid deconditioning. There is  evidence th a t  
such b rie f  in te rv en tio n s  for fa tigue  given by n u rse s  a re  effective15-17. 
F u rth e rm o re , i t  is  recognized th a t  oncology n u rse s  can  p lay  sign ifican t ro les in  
th e  tra n s la tio n  of can ce r-re la ted  fa tigue  gu idelines by teach ing  p a tie n ts  and  
decreasing  b a r r ie r s 19. The second in te rv en tio n  w as an  ex tensive in te rv en tio n
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aim ed  a t fa tigue  b ased  on cognitive behavior th e ra p y  (CBT). This CBT 
in te rv en tio n  w as, in  add ition  to avoiding deconditioning, b ased  on e lem en ts  such 
as chang ing  dysfunctional cognitions abou t fa tigue, changing  a d is to rted  sleep— 
w ake rh y th m , a n d  coping w ith  th e  consequences of hav ing  cancer.
The f irs t aim  of th is  RCT w as to d e te rm in e  th e  efficacy of th e se  two 
in te rv en tio n s  com pared  w ith  UC. The m om ent of p o stin te rv en tio n  assessm en t 
(T2) w as chosen a t  a clinically  re le v a n t point. T2 w as chosen p o stin te rv en tio n  
an d  also a fte r a recovery period  from  th e  d irect effects of cancer tre a tm e n t. A 
p rev ious study  found th a t  th e  im m ed ia te  effects of surgery , chem otherapy , or 
ra d io th e ra p y  on fa tigue  d isap p ear a fte r six w eeks20. Therefore, the  
p o stin te rv en tio n  assessm en t w as com pleted  a t le a s t tw o m on th s a fte r cancer 
tre a tm e n t fin ished. I t  w as expected  th a t  p a tie n ts  in  th ese  two in te rv en tio n  
g roups w ould be less fa tig u ed  a t  le a s t two m on ths a fte r cancer tre a tm e n t th a n  
p a tie n ts  given UC. In  addition , i t  w as expected  th a t  p a tie n ts  in  th e  in te rv en tio n  
g roups w ould  have  h ig h er levels of functioning, less psychological d istress, an d  a 
b e tte r  q u a lity  of life.
O ur second aim  w as to de te rm ine  th e  role of physica l ac tiv ity  in  reducing  
fa tigue  du ring  cancer tre a tm e n t. I t  w as expected  th a t  a reduc tion  in  fa tigue  w as 
m ed ia ted  by en h an ced  physica l activity.
METHODS
Patients and procedure 
Sample
P a tie n ts  w ere re c ru ite d  from  th e  R adboud U n iversity  N ijm egen M edical C entre 
an d  six reg iona l h o sp ita ls  from  N ovem ber 2005 u n til  A ugust 2007. P a tie n ts  w ere 
inc luded  a fte r being d iagnosed  w ith  a p rim ary  tu m o r an d  scheduled  to receive 
tre a tm e n t w ith  cu ra tiv e  in ten t. P a tie n ts  h a d  to be 18—75 y ea rs  of age an d  able to 
speak, read , an d  w rite  D utch. To m inim ize d ropout an d  exclusion du ring  the  
study, p a tie n ts  w ith  lung  cancer an d  w ith  h e a d  an d  neck cancer w ere excluded. 
Exclusion c rite r ia  w ere: com orbidities causing  fa tigue, seeking tre a tm e n t for p re ­
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ex isting  chronic fa tigue, an d  receiv ing psy ch ia tric  or psychological tre a tm e n t in  
th e  p reced ing  th re e  m onths. The eth ics com m ittees from  a ll seven hosp ita ls  
approved  th e  study. In form ed consent w as ob ta ined  from  a ll p a rtic ip an ts .
Design and procedure
Eligible p a tie n ts  w ere app roached  by th e ir  physic ian  or specialized  n u rse  a t the  
tim e th ey  w ere in fo rm ed  abou t th e ir  d iagnosis a n d  tre a tm e n t p lan . The 
re c ru itm e n t procedure is  described  in  d e ta il e lsew here21. P a tie n ts  w ith  in itia l 
in te re s t received w ritte n  in fo rm ation  an d  su p p lem en ta ry  in fo rm ation  by 
telephone. S ubsequently , p a tie n ts  who consen ted  com pleted  th e  baseline 
assessm en t (T1) by com puter or p ap e r an d  pencil depending  on th e ir  preference. 
T1 w as com pleted  before th e  s ta r t  of cancer tre a tm e n t. S ubsequen tly , 
p a r tic ip a n ts  w ere random ly  a llocated  to one of th e  th re e  groups: BNI, CBT, or 
UC. R andom ization  w as perfo rm ed  in  blocks sep ara te ly  for each  hosp ita l, using  
labe led  card s  in  n u m b ered  closed envelopes p re p a re d  by a s ta tis tic ia n  not 
involved in  th e  study. T est a s s is ta n ts  b linded  to th e  ran d o m iza tio n  sequence 
opened th e  envelopes an d  in fo rm ed  th e  p a rtic ip an ts . The follow-up assessm en t 
(T2) w as in itia lly  p lan n ed  for six m on ths a fte r T1. I f  p a tie n ts  received surgery, 
chem otherapy , or rad io th e rap y  in  th e  fifth  or six th  m onth , th ey  w ere assessed  
two m on ths a fte r th ese  tre a tm e n ts  w ere fin ished.
Interventions
The UC group received  tre a tm e n t for cancer as  p roposed by th e  m u ltid isc ip linary  
w orking  p a r ty  for th e ir  specific tu m o r group, conform ing to th e  gu idelines of the  
com prehensive cancer cen ter. N one of th e  h o sp ita ls  a lread y  offered supportive 
care for fa tigue  du ring  cancer tre a tm e n t.
BNI
The B N I consisted  of two one-hour sessions an d  a booklet. In  th e  f irs t session, th e  
n u rse  exp la ined  how to b re a k  th e  negative  sp ira l of low physica l activ ity  an d  
fatigue. To d em o n stra te  th is , th e  p a tie n t’s level of physica l ac tiv ity  w as 
d e te rm in ed  before d iagnosis an d  in  th e  prev ious week. These levels w ere
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e s tim a ted  w ith  th e  q u estio n n a ire  physica l ac tiv ity  (QPA). C onsequently , p a tie n ts  
w ere adv ised  to in crease  th e ir  physica l ac tiv ity  level stepw ise (five m in u tes  per 
w eek, up to one ho u r p er day, for five days a week, by w alk ing  or cycling) up to 
300 m in u tes  p er week. P a tie n ts  who w ere physically  active a t th is  level w ere 
encouraged  to m a in ta in  it. A dditionally , how to rem a in  physically  active during  
cancer tre a tm e n t w as d iscussed, an d  w h a t to do if  com plications occurred. The 
second session w as p lan n ed  for th ree  m on ths la te r . D urin g  th a t  session, th e  level 
of physica l ac tiv ity  w as d e te rm in ed  again  a n d  difficulties an d  so lu tions for 
becom ing active or m a in ta in in g  ac tiv ity  w ere d iscussed. In fo rm ation  an d  
recom m endations on physica l ac tiv ity  could be re re a d  in  th e  booklet. All n u rse s  
received  a protocol. To im prove in teg rity , n u rse s  w ere tra in e d  an d  superv ised  by 
G.B. an d  C.V. about every  two m onths, an d  th ey  w ere req u es ted  to send  a 
checklist to th e  re sea rch er a fte r each  session. The checklist con ta ined  questions 
on how m uch tim e w as spen t a t  th e  c u rre n t level of physica l ac tiv ity  an d  on 
discussing  difficulties.
CBT
P a rtic ip a n ts  in  th e  CBT group received  up to te n  one-hour sessions du ring  six 
m onths. The n u m b er of sessions a n d  th e  tim e spend  on each  e lem en t v a ried  
am ong in d iv id u a l p a tien ts , depending  on problem s encountered . The m ethods 
u sed  w ere: re s tru c tu r in g  of cognitions an d  beliefs, education  an d  behav io ra l 
in stru c tio n s, an d  providing em otional support. The in te rv en tio n  focused on six 
e lem ents. (a) P hysica l activity: p a tie n ts  received  th e  sam e in fo rm ation  an d  
booklet as prov ided  in  th e  BNI; in  addition , ac tiv ity -re la ted  cognitions w ere 
d ispu ted . (b) F a tig u e -re la ted  cognitions: dysfunctional cognitions w ere changed  to 
m ore help fu l ones. (c) S leep—w ake rh y th m : p a tie n ts  w ere m o tivated  to m a in ta in  
fixed bedtim es, tak in g  th e  p h ase  of cancer tre a tm e n t in to  account; napp ing  
d u ring  th e  day  w as d iscouraged. (d) Effects of cancer an d  tre a tm e n t: th e  
consequences of hav ing  cancer an d  th e  side effects of cancer w ere discussed, 
aim ed  a t he lp ing  p a tie n ts  to cope an d  accept th e se  (e.g., stom a, am p u ta tion ). (e) 
C ancer in  contact w ith  o thers: unh e lp fu l cognitions w ere changed  a n d  coping 
s tra teg ie s  for dealing  w ith  hav ing  cancer in  contact w ith  o thers, such as fam ily  or
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colleagues, w ere discussed; for exam ple, “W ith  w hom  do you w an t to sh a re  your 
em otions?” or “How do I te ll th e  k ids?” (f) P lan s  for th e  fu tu re : p a tie n ts  w ere 
ask ed  to th in k  abou t th e  fu tu re , an d  to m ake a p lan; for exam ple, a concrete p lan  
for re tu rn in g  to w ork. O bstacles, fears, an d  so lu tions w ere d iscussed. T h erap is ts  
w ith  prev ious CBT experience in  tre a tin g  chronically  fa tig u ed  cancer surv ivors 
gave th e  CBT22. A protocol w as developed an d  th e  th e ra p is ts  received  tra in in g  
an d  superv ision  every  two w eeks by G.B., d u rin g  w hich each  case w as discussed.
INSTRUM ENTS
D em ographic ch a rac te ris tic s  w ere g a th e re d  by self-report using  questionnaires. 
In fo rm ation  on d iagnosis w as ob ta ined  from  th e  p a tie n t’s physician .
F a tig u e  severity  w as th e  p rim a ry  outcom e an d  w as assessed  using  the  
fa tigue  subscale of th e  C hecklist In d iv id u a l S tre n g th  (CIS)23, 24. The CIS is  a well- 
v a lid a ted  in s tru m e n t25, 26. The fa tigue  subscale (CIS-fat) consists of e igh t item s 
w ith  scores in  th e  ran g e  of 8—56. A cutoff score > 35 in d ica tes  severe fa tig u e24. I t  
h a s  been  used  in  prev ious re sea rch  in v estig a tin g  fa tigue  in  cancer surv ivors an d  
h a s  show n sensitiv ity  to detect change3, 22, 27, 28.
As a secondary outcom e, function ing  w as assessed  u sing  th e  H ea lth  S urvey  
S hort Form -36 (SF-36). The D utch  language version  of th e  SF-36 h a s  been  proven 
to be a re liab le  an d  v a lid  in s tru m e n t in  th e  g en era l popu la tion  an d  in  chronic 
d isease popu la tio n s29. The Sym ptom  C hecklist-90 (SCL-90) w as u sed  to m easu re  
psychological d istress. The SCL-90 h a s  good re liab ility  an d  d isc rim ina ting  
v a lid ity 30. Q uality  of life w as assessed  using  th e  Q uality  of Life Q uestio n n a ire  of 
th e  E u ro p ean  O rgan iza tion  for R esearch  an d  T rea tm en t of C ancer (EORTC QLQ- 
C30), version  3.0. The EORTC-QLQ C30 is an  in te rn a tio n a lly  v a lid a ted  
q u es tio n n a ire31, 32.
To te s t for m ediation , physica l ac tiv ity  w as assessed  using  th re e  d ifferen t 
in s tru m e n ts . For a ll in s tru m e n ts , h ig h e r scores ind ica te  h ig h er levels of physica l 
activity . P hysica l ac tiv ity  w as m easu red  w ith  ac tig rap h y  using  an  actom eter, 
w hich h a s  been u sed  in  cancer su rv ivo rs33. An ac tom eter is a m otion-sensing 
device b ased  on a piezoelectric sensor, w ith  h igh ly  rep roducib le  re a d in g s34. I t
143
records th e  n u m b er of m ovem ents in  five-m inute  in te rv a ls . A t baseline, 
p a r tic ip a n ts  w ore an  ac tom eter from  th e  a ssessm en t to th e  s ta r t  of cancer 
tre a tm e n t, for up to 12 days an d  n igh ts. A t T2, th e  ac tom eter w as w orn  for 12 
consecutive days an d  n igh ts. The m ean  daily  physica l ac tiv ity  score across all 
w orn days an d  n ig h ts  w as th e  p a ra m e te r  u sed  to assess  th e  level of physica l 
activity.
D uring  th e  sam e period, p a r tic ip a n ts  w ere ask ed  to com plete th e  D aily 
O bserved A ctivity  (DOA), scoring th e ir  level of physica l ac tiv ity  four tim es a day. 
A m ean  daily  score w as calcu lated , v ary ing  in  th e  ran g e  of 0 —16. The DOA h as  
p rev iously  been  used  in  cancer su rv ivors35.
To m easu re  w h e th e r p a tie n ts  com plied w ith  advice concerning physica l 
activity , th e  QPA w as developed. P a tie n ts  w ere a sk ed  w h e th e r th ey  h a d  p rac ticed  
sports, w alked, or cycled in  th e  p a s t w eek for a t  le a s t 30 m inu tes. They w ere 
ask ed  how m any  days an d  for how long th ey  h a d  perfo rm ed  th ese  activ ities. The 
to ta l d u ra tio n  w as ca lcu la ted  in  m inu tes. C riterion  va lid ity  w ith  th e  actom eter 
w as m odera te  (S pearm an’s p =.31); how ever, i t  w as sim ilar to th e  In te rn a tio n a l 
P hysica l A ctivity  Q uestio n n a ire  w ith  th e  ac to m ete r36.
Statistical methods
The d a ta  an a ly sis  w as perfo rm ed  w ith  SPSS, version  16.0 (SPSS Inc, Chicago, 
IL). D ata  w ere u sed  from  p a rtic ip a n ts  w ho m et th e  elig ib ility  c rite r ia  a t bo th  T1 
an d  T2. A ccording to F ergusson  e t a l.37, p a tie n t d a ta  can  be excluded from  
analy sis  w ith o u t risk in g  b ias w hen  inelig ib le p a tie n ts  a re  m istak en ly  random ized  
in to  a tria l.
An a p rio ri pow er analy sis  in d ica ted  th a t  48 p a tie n ts  w ould  be req u ired  in  
each group, b ased  on th e  following assum ptions. A change of 8 po in ts  w as 
expected on th e  C IS-fat22. An a  of .017 (.05/3) an d  tw o-sided significance level 
w ere u sed  to y ield  an  80% power. This s tudy  w as overpow ered as a re su lt  of the  
fact th a t  few er p a tie n ts  w ere excluded d u rin g  th e  s tu d y  th a n  expected.
B aseline d ifferences am ong th e  th re e  conditions w ere te s te d  w ith  a t-tes t or 
X2 te s t  for in d ep en d en t sam ples. S ignifican t d ifferences w ere en te re d  as 
covaria tes in  a ll fu r th e r  analyses. To te s t for an  overall s ign ifican t difference
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am ong m ean  scores for th e  th re e  conditions, ana ly ses  of covariance (ANCOVA) 
w ere perfo rm ed  for th e  outcom e m easu res, w ith  base line  scores e n te re d  as 
covaria tes an d  condition as a fixed factor. W hen an  overall effect w as significant, 
a c o n tra s t an a ly sis  w as perfo rm ed  to com pare th e  in te rv en tio n  g roups (level 2 
an d  3) w ith  th e  UC group (level 1). To te s t  w h e th e r th e re  w as a clinically  
sign ifican t difference, th e  d ifferences am ong th e  p roportions of severely fa tig u ed  
p a r tic ip a n ts  in  th e  th re e  g roups w ere te s te d  w ith  a logistic reg ression  analy sis  
u sing  th e  e n te r  m ethod. A tw o-sided p  < .05 w as considered  significant.
P rim a ry  outcom e d a ta  w ere m issing  from  two p a r tic ip a n ts  a t T2. To avoid 
o verestim ation  of th e  effects of th e  in te rv en tio n s, m issing  d a ta  w ere su b s titu te d  
w ith  th e  m ean  score of th e  UC group. A sensitiv ity  analy sis  show ed th a t  en te rin g  
th e  m issing  d a ta  w ith  th e  m ean  score of th e  UC group added  w ith  one or two 
s ta n d a rd  dev ia tions (SDs) did no t in fluence th e  re su lts .
An in te n tio n -to -tre a t an a ly sis  w as perfo rm ed  for a ll outcom es except for the  
ac tom eter an d  th e  DOA. C om pleters w ere u sed  for th ese  m easu res, because less 
th a n  h a lf  th e  p a rtic ip a n ts  wore th e  ac tom eter a n d  com pleted  th e  DOA a t  both 
assessm en ts.
The m ed ia tion  h y po thesis  w as te s te d  w ith  a n o n p a ram e tric  boo tstrap  
approach. This approach  w as chosen because i t  gives m ore pow er to detect 
s ign ifican t d ifferences in  sm all, non-norm ally  d is tr ib u te d  sam ples. A macro 
expansion, consisting  of a sy n tax  file for SPSS, w as in tro d u ced  by P reach e r an d  
H ay es38 to te s t for m ed ia tion  according to th e  gu idelines of B aron  an d  K enney39. 
The m acro g en e ra te s  a m ean  m edia tion  effect w ith  a 95% confidence in te rv a l (CI) 
by random ly  resam p lin g  th e  observed  d a ta se t 5.000 tim es w ith  rep lacem en t. The 
m edia tion  h y po thesis  w as accepted w hen  th e  95% CI inc luded  zero38.
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RESULTS
F igu re  1 illu s tra te s  th e  flow of p a rtic ip an ts . A to ta l of 395 eligible cancer p a tie n ts  
w ere approached, an d  155 re fu sed  to p a rtic ip a te . “P a rtic ip a tin g  w ould tak e  too 
m uch tim e” w as th e  m ost com m on reason . N o n p artic ip an ts  w ere older th a n  
p a rtic ip an ts , b u t no sign ifican t difference w as found  for sex or type of 
m alignancy21. B ecause of th e  sho rt tim e span  betw een  th e  d iagnosis an d  s ta r t  of 
tre a tm e n t, no t a ll p a r tic ip a n ts  could be assessed  before th e  s ta r t  of tre a tm e n t. 
T w enty  six p e rcen t of th e  p a r tic ip a n ts  w ere a ssessed  a fte r su rgery  or th e  s ta r t  of 
horm one th e rap y , b u t alw ays before a d ju v an t chem otherapy  or rad io th e rap y . Of 
th e  240 p a rtic ip an ts , 77 w ere assigned  to th e  B N I group, 82 w ere assig n ed  to the  
CBT group, an d  81 w ere assigned  to th e  UC group. The m ajo rity  w ere rec ru ited  
from  th e  u n iv e rs ity  h o sp ita l (n = 158). T w enty p a tie n ts  w ere excluded 
postrandom ization . In ten tio n -to -trea t ana ly ses  w ere b ased  on 220 p a r tic ip a n ts—
72 in  th e  B N I group, 76 in  th e  CBT group, a n d  72 in  th e  UC group. Two 
p a r tic ip a n ts  dropped  out. T2 w as com pleted  by 162 p a rtic ip a n ts  six m on ths after 
T1. F ifty  six p a r tic ip a n ts  who received  cancer tre a tm e n t for a longer period  
com pleted  T2 two m on ths a fte r th e ir  cancer tre a tm e n t w as fin ished.
Interventions 
BNI
Of th e  68 p a tie n ts  who s ta r te d  th e  BNI, 66 a tte n d e d  bo th  sessions. M ost sessions 
w ere face to face; 10% w ere te lephone sessions. All b u t two of th e  check lists w ere 
re tu rn e d  by th e  n u rses . The m ean  tim e betw een  th e  two sessions w as 4.5 m onths 
(SD, 2.5 m onths). In  to ta l, 12 n u rse s  gave th e  BNI. The m ean  h o u rs  of tra in in g  
an d  superv ision  w ere 7.8 (SD, 4.9 hours), v ary ing  in  th e  ran g e  of 2—12 hours. In  
th e  u n iv e rs ity  hosp ita l, tw o n u rse s  ad m in is te red  th e  B N I to 20 an d  26 
p a r tic ip a n ts  each. In  th e  reg iona l hosp ita ls , n u rse s  gave th e  B N I to one to seven 
p a rtic ip an ts . T here w as no sign ifican t difference betw een  p a r tic ip a n ts  tre a te d  in  
th e  u n iv e rs ity  h o sp ita l by th e  m ore experienced  n u rse s  an d  those tre a te d  in  th e  
reg iona l h o sp ita ls  for level of fa tigue  an d  physica l ac tiv ity  a t  T2 (d a ta  no t shown).
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Eligible for trial 
(n = 395)
Refused to participate 
(n = 155)
Assessed and randomized 
(n = 240)
BNI CBT Usual Care
T1 (n = 77) T1 (n = 82) T1 ( n = 81)
Excluded from trial Excluded from trial
( n = 5) ( n = 6)
- Died (n = 1) - Died (n = 2)
- Treated for - Treated for
secondary tumor secondary tumor
(n = 1) ----► (n = 1)
- Received palliative - Received palliative
treatm ent (n = 2) treatm ent (n = 2)
- Severe - Severe
comorbidity complications
during the study during the study
(n = 1) (n = 1)
Excluded from trial
( n = 9)
- Died (n = 3)
- Received palliative 
treatm ent (n = 2)
- Diagnosed with 
metastases during 
the study (n = 1)
- Severe 
comorbidity 
during the study 
(n = 1)
- Diagnose was 
benign (n = 2)
Intention to treat 
( n = 72)
BNI
Received BNI (68)
Did not start BNI (n =
- BNI considered not 
beneficial (n = 1)
- Unknown (n = 3)
4)
CBT
Received CBT (73)
Did not start CBT (n = 3)
- CBT considered too time 
consuming and not beneficial
- Other priorities
- Unknown
T2 ( n = 72) T2 ( n = 75) T2 ( n = 71)
Drop-out: (n = 1) Drop-out: (n = 1):
- CBT considered too time - Family circumstances
consuming and not
beneficial
Figure 1: P a rtic ip a n t flow diagram .
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Table 1: Baseline characteristics for the three groups
Characteristics Total (n= 220) BNI (n=72) CBT(n=76) UC(n=72) P-value
n % n % n % n %
Sex Male 81 37 28 39 28 37 25 35 .874
Female 139 63 44 61 48 63 47 65
Age (years) Mean
(s.d.)
56.7
(10.8)
57.1
(10.0)
55.6
(11.3)
57.3
(11.1)
.562
Education 
(l=low -  7 high)
Mean
(s.d.)
3.99
(1.71)
4.31
(1.87)
3.93
(1.59)
3.74
(1.63)
.127
Marital status
Married / cohabiting 178 81 65 90 61 80 52 72 .022
Other status 42 19 7 10 15 20 20 28
Diagnosis (*)
Breast cancer 105 48 35 49 36 47 34 47 .822
Prostate cancer 51 23 19 26 15 20 17 24
Other tumors 64 29 18 25 25 33 21 29
Gastrointestinal 27 7 10 8
Urogenital 15 3 7 5
Gynecological 12 6 3 3
Lymphomas 6 1 3 2
Sarcoma 3 1 1 1
Melanoma 1 1
Thyroid carcinoma 2 1 1
Treatment type (**)
Surgery 201 93 66 92 71 97 64 90 .207
Chemotherapy 67 31 22 31 28 38 17 24 .173
Radiotherapy 128 59 42 58 44 60 42 59 .972
Hormone therapy 65 30 22 31 20 28 23 32 .833
Treatment before no 164 74 49 68 57 79 58 76 .282
assessment yes 56 26 23 32 15 21 18 24
Time between T1 
and T2 (months)
Mean
(s.d.)
7.42
(1.56)
7.40
(1.54)
7.52
(1.52)
7.35
(1.64)
.787
BNI: brief nursing intervention, CBT: Cognitive Behavior Therapy, UC: usual care, T1: baseline 
assessment, T2: follow-up assessment. (*) Two patients were diagnosed with both bladder and 
prostate cancer and were categorized as other tumors. One was allocated to the control group, the 
other to CBT. (**) The total is more than 100%, as several combinations of treatm ent regimes 
were given to patients.
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CBT
S eventy  th re e  p a tie n ts  s ta r te d  w ith  CBT. The m ean  d u ra tio n  w as 7 m on ths (SD, 
2.6 m onths). The m ean  n u m b er of sessions w as 6.2 (SD, 1.9; range, 2—11). One 
person  received  11 sessions. F ifty  n ine  p e rcen t of th e  p a r tic ip a n ts  h a d  only face- 
to-face sessions; 41% com bined face-to-face sessions w ith  te lephone sessions. 
M ost of th e  sessions (80%) w ere given face to face. No re la tio n sh ip  w as found 
betw een  change in  fa tigue  severity , an d  th e  n u m b er of sessions an d  type of 
contact. Two th e ra p is ts  tre a te d  34 an d  39 p a tie n ts  each. No th e ra p is t effect w as 
found  on fa tigue  a t  T1 (p = .937) or a t  T2 (p = .991), or on o th e r outcom e 
m easu res  (d a ta  no t shown).
Baseline comparison
No base line  sign ifican t d ifferences w ere found  am ong th e  th re e  g roups in  te rm s 
of diagnosis, cancer tre a tm e n t, or fa tigue  (Tables 1, 2, an d  3). S ignifican tly  more 
p a r tic ip a n ts  in  th e  B N I group th a n  in  th e  UC group w ere m arried . For the  
secondary  outcom es, a sign ifican t difference (p = .029) w as found  on th e  cognitive 
function ing  subscale of th e  EORTC-QLQ C30 betw een  th e  CBT group (mean, 
86.0; SD, 19.5) an d  th e  UC group (m ean, 92.8; SD, 12.5). In  addition , a significant 
d ifference w as found  for th e  QPA betw een  th e  B N I group an d  th e  UC group 
(Table 4). T hese th re e  sign ifican t d ifferences w ere e n te re d  as covaria tes in  
fu r th e r  analyses.
Effect of the interventions
The re su lts  of th e  ANCOVA on fa tigue  a re  show n in  Table 2. P a r tic ip a n ts  in  the  
CBT group w ere sign ifican tly  less fa tig u ed  th a n  those in  th e  UC group. F rom  T1 
to T2, fa tigue  in c reased  in  th e  UC group, w h ereas  fa tigue  decreased  in  th e  CBT 
group. This re su lte d  in  a m ean  difference betw een  th e  tw o conditions of 5.6 
p o in ts  on th e  CIS-fat. T here w as no sign ifican t difference in  fa tigue  betw een  the 
B N I group an d  th e  UC group (p = 1.000). The proportion  of severely  fa tigued  
cancer p a tie n ts  w as sign ifican tly  low er in  th e  CBT group th a n  in  th e  UC group ( p  
= .019) (Table 3). No sign ifican t differences w ere found  for th e  secondary  
outcom es (d a ta  availab le  upon request).
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T able 2 : M eans an d  s ta n d a rd  deviation  of fa tigue  a t T1 an d  T2 an d  re su lts  of the 
ANCOVA show ing th e  overall effects a n d  c o n tra s t analy sis  of the 
in te rv en tio n s  on fa tigue
Overall effect BNI CBT UC F P-value
n 72 76 72
T1 mean (s.d.)
CIS- fat
T2 mean (s.d.)
21.5 (12.7) 
23.3 (14.6)
25.3 (14.0) 
21.0 (11.6)
23.4 (12.4) 
25.9 (13.5)
1.568
4.255
.211
.015
Contrast analysis
Covariate adjusted 
Mean difference
95% CI P-value
UC - BNI
CIS- fat T2
UC - CBT
1.30
5.60
-3.74 -  6.34 
0.69 -  10.5
1.000
.019
BNI: Brief Nursing Intervention, CBT: Cognitive Behavior Therapy, UC: Usual Care, CIS-fat: 
Checklist Individual Strength subscale fatigue, T1: baseline assessment, T2: follow-up 
assessment, CI: Confidence Interval.
T able 3: P e rcen tag es severe fa tigue  in  th e  th ree  conditions a t T1 an d  T2 and  
re su lts  of th e  logistic reg ression  analysis.
Percentage severely fatigued 
cancer patients
B (SE) Exp b P-value 95% CIn T1 T2
UC 72 19% 31% 0.020
BNI 72 19% 22% -.393 (.418) .675 0.348 .297- 1.53
CBT 76 26% 15% -1.30 (.467) .272 0.005 .109 - .680
Constant 1.94 (1.03) 6.93 0.061
(R2 was 0.127 (Cox & Snell) and 0.195 (Nagelkerke)). A two-sided P <  0.05 was considered 
significant. BNI: Brief Nursing Intervention, CBT: Cognitive Behavior Therapy, UC: Usual Care, 
CI confidence interval, T1: baseline assessment, T2: follow-up assessment
R esu lts  of ANCOVA show ed no sign ifican t d ifferences in  physica l activ ity  
betw een  th e  two in te rv en tio n  g roups com pared  w ith  th e  UC group (Table 4). The 
b oo tstrap  approach  show ed th a t, a t m ost, 3.4% of th e  effect of CBT on fatigue
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could be explained by physical activity (Table 5). The 95% CI of the mean 
m ediation effect included zero, rejecting the m ediation hypothesis.
Table 4: M eans and standard deviation of physical activity at T1 and T2 and 
results of the ANCOVA showing the overall effects and contrast 
analysis of the interventions on physical activity.
Outcome BNI CBT UC F P-value
n 35 30 25
Actometer T1 mean (s.d.) 68.4 (17.4) 69.4 (31.1) 69.1 (24.1) 0.015 .986
T2 mean (s.d.) 65.9 (21.3) 71.6 (25.0) 69.1 (22.9) 0.825 .442
DOA n 34 29 31
T1 mean (s.d.) 4.4 (2.2) 4.5 (1.5) 4.8 (2.0) 0.251 .779
T2 mean (s.d.) 4.8 (1.9) 4.9 (1.5) 4.6 (1.9) 0.405 .668
QPA n 72 76 72
T1 mean (s.d.) 248 (270) 203 (197) 140 (174) 4.527 .012
T2 mean (s.d.) 273 (303) 322 (277) 211 (223) 2.830 .061
Contrast analysis
Covariate adjusted Mean 
difference
95% CI P-value
QPA T1
UC - BNI 
U C - CBT
-108
-63.5
-196 -  -21.0 
-150 -  22.6
.009
.229
BNI: Brief Nursing Intervention, CBT: Cognitive Behavior Therapy, UC: Usual Care, DOA: Daily 
Observed Activity, QPA: Questionnaire Physical Activity, T1: baseline assessment, T2: follow-up 
assessment, CI: Confidence Interval.
Table 5: R esults of the m ediation effect of physical activity in the CBT group 
compared to UC, according to the Bootstrap approach
Actometer DOA QPA
mean mediation effect -0.006 0.015 0.058
CI (95%) -0.250 - 0.215 -0.322 - 0.430 -0.067 - 0.212
Percentage of total treatm ent effect -0.29% 0.92% 3.40%
CBT: Cognitive Behavior Therapy, UC: Usual Care, DOA: Daily Observed Activity, QPA: 
Questionnaire Physical Activity, CI: Confidence Interval.
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The f irs t aim  of th is  s tu d y  w as to ev a lu a te  tw o in te rv en tio n s  for fa tigue  during  
cu ra tiv e  cancer tre a tm e n t— CBT a n d  th e  BNI. O ur re su lts  show ed th a t  CBT w as 
effective. CBT sign ifican tly  red u ced  fa tigue  shortly  a fte r cancer tre a tm e n t. Also, 
sign ifican tly  few er p a rtic ip a n ts  w ere severely  fa tig u ed  a t le a s t two m on ths a fte r 
cancer tre a tm e n t, d em o n stra tin g  i ts  clin ical re levance. The B N I did  no t reduce 
fa tigue  com pared  w ith  UC. The u n iq u en ess  of th is  s tudy  w as th a t  th e  CBT 
in te rv en tio n  proved  to be effective a t  a clinically  re le v a n t tim e, th a t  is, a fte r a 
recovery period  from  th e  d irect effects of cancer tre a tm e n t.
C o n tra ry  to our expectations, physica l ac tiv ity  d id  no t m ed ia te  th e  reduction  
in  fa tigue  rea lized  by CBT, w h e th e r physica l ac tiv ity  w as m easu red  w ith  
ac tig rap h y  or q u estionna ires. The find ing  th a t  th e re  w as no effect of the  
in te rv en tio n s  on physica l ac tiv ity  a lread y  show ed th a t  m edia tion  w as absen t, b u t 
because m edia tion  ana ly ses  req u ire  a la rg e  pow er, a bo o tstrap  analy sis  w as 
perform ed. The lack  of m edia tion  w as a su rp ris in g  find ing  because increasing  
physica l ac tiv ity  is  an  im p o rta n t th e ra p e u tic  com ponent. O ur find ings ind ica te  
th a t, w ith  CBT, i t  w as possible to rea lize  a sign ifican t reduction  in  fa tigue  
w ith o u t a la s tin g  in crease  in  physica l activity .
A n u m b er of lim ita tio n s  should  be considered. The m ajo rity  of the  
p a r tic ip a n ts  w ere re c ru ite d  from  th e  u n iv e rs ity  hosp ita l. This could have  ra ise d  
th e  question  of sam ple b ias, b u t we found no difference betw een  th e  u n iv e rs ity  
h o sp ita l an d  th e  reg ional h o sp ita ls  for fatigue. The fact th a t  th is  w as a 
m u lticen te r tr ia l  in c reases  th e  gen era lizab ility  of th e  findings.
C on tam ina tion  could have  occurred, a lth o u g h  p reven tive  actions w ere 
tak en . The th e ra p is ts  an d  n u rse s  who gave th e  in te rv en tio n s  w ere no t involved 
in  rec ru itin g  p a r tic ip a n ts  or in  UC.
No effect on secondary outcom es w as found. This could be exp la ined  by the  
fact th a t  th e  m ean  a n d  SD for th e  SCL-90 a n d  SF-36 w ere s im ila r to those  in  the 
gen era l D utch  popu la tion  a t b ase lin e29, 30. Therefore, i t  w as difficult to rea lize  an  
im provem ent.
DISCUSSION
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One could a rgue  th a t  an  effect of th e  B N I failed  to occur for several 
reaso n s,— because i t  consisted  of only tw o sessions, because th e  tim e  betw een  
th e  la s t session an d  T2 w as longer th a n  in  th e  CBT condition, or because the  
n u rse s  w ere less experienced  th a n  th e  th e ra p is ts . H owever, th e  m ore in tensive  
CBT also failed  to show an  in c reased  level of physica l activity.
A fo rm al in te g rity  check, such as record ing  of sessions, d id  no t tak e  place. 
S ev era l actions w ere ta k e n  to en su re  th a t  n u rse s  a n d  th e ra p is ts  w orked 
according to protocol, such as tra in in g  an d  supervision. A lm ost a ll checklists 
w ere re tu rn e d  by th e  n u rses , d em o n stra tin g  good adherence.
We did  no t control for level of a tten tio n . I t  could be th a t  p a r t  of th e  effect of 
CBT on fa tigue  can  be exp la ined  by a tten tio n , b u t i t  is  im probable  th a t  th e  effect 
is caused  by a tte n tio n  alone. For exam ple, we could no t find  a dose-response 
effect for CBT. F u rth e rm o re , no effect of an  a tte n tio n  placebo group on fatigue 
w as found  in  p a tie n ts  w ith  chronic fa tigue  syndrom e (CFS)40, 41.
A ctom eter an d  daily  self-observation  d a ta  w ere no t o b ta in ed  from  all 
p a rtic ip an ts . T his could ra ise  concerns abou t possible d ifferences betw een  those 
who did  an d  those  who did  no t com plete th ese  evaluations. However, no 
difference in  fa tigue  a t T1 a n d  T2 or condition w as found  betw een  com pleters an d  
noncom pleters.
The assu m p tio n  th a t  in creasin g  physica l ac tiv ity  reduces fa tigue  is 
w idespread , b u t no t a lw ays em pirically  supported . Som e rev iew s found no effect 
of exercise on reducing  fa tig u e42, 43. In  addition , some exercise s tud ies d id  no t find  
an  effect on fatigue, even th ough  physica l fitn ess  in creased 44-46. O ther 
in te rv en tio n  s tud ies w ith  m edia tion  an a ly ses  support our findings, 
dem o n stra tin g  th a t  increasin g  physica l ac tiv ity  is  no t necessary  to reduce  fatigue 
in  CFS p a tie n ts 47.
B ecause no in te rm ed ia te  a sse ssm en ts  w ere perform ed, i t  could no t be ru le d  
ou t if  a tem p o ra ry  in crease  in  physica l ac tiv ity  co n trib u ted  to low er fatigue. 
H owever, i t  is m ore likely  th a t  o th e r factors, such as fatigue- an d  cancer-re la ted  
cognitions or s tre ss  reduction , an d  no t physica l condition, m ed ia ted  th e  fa tigue  
reduction . R esu lts  of a g rad ed  exercise RCT for C FS also d em o n stra ted  th a t
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sym ptom  focusing, no t physica l condition, m ed ia ted  th e  im provem en t in  
fa tig u e48.
As expected, th e  n u m b er of p a tie n ts  w ith  severe fa tigue  in c reased  in  th e  UC 
group. However, a find ing  no t expected befo rehand  w as th a t  a t  T1 more 
p a r tic ip a n ts  th a n  expected w ere a lread y  severely  fatigued . T h is canno t be 
a ttr ib u te d  to preceding  cancer tre a tm e n t, because no difference w as found  in  
fa tigue  betw een  cancer tre a tm e n t—naïve p a tie n ts  an d  p a tie n ts  a ssessed  before 
a d ju v an t th e rap y . Type of m alignancy  w as also no t found  to be a con tribu ting  
factor to severe fa tigue  before th e  in itia tio n  of cancer tre a tm e n t21.
A lthough fa tigue  w as no t a ssessed  d u ring  active cancer tre a tm e n t, m any 
p a tie n ts  in  th e  UC group w ere no t severely fa tig u ed  a fte r cancer tre a tm e n t 
fin ished. A pparen tly , th e  group of p a tie n ts  w ith o u t severe fa tigue  m anaged  
w ith o u t a specific in te rv en tio n  for fa tigue, im ply ing  th a t  no t a ll cancer p a tie n ts  
need  CBT for fa tigue  d u rin g  cu ra tiv e  cancer tre a tm e n t. F u tu re  s tud ies should 
iden tify  p a tie n ts  a t r isk  for severe fa tigue  shortly  a fte r cancer tre a tm e n t, and  
in te rv en tio n s  should  focus on th ese  r isk  groups.
SUMMARY
U n til now, th e re  w as no in te rv e n tio n a l RCT for fa tigue  d u rin g  cu ra tiv e  cancer 
tre a tm e n t th a t  a ssessed  p a tie n ts  before th e  s ta r t  of cancer tre a tm e n t an d  shortly  
a fte r cancer tre a tm e n t, a fte r p a tie n ts  recovered  from  acu te  effects. O ur RCT 
show ed th a t  p a r tic ip a n ts  who received  CBT for fa tigue  d u ring  cancer tre a tm e n t 
w ere less fa tig u ed  th a n  p a tie n ts  who received  UC a t le a s t two m on ths after 
cancer tre a tm e n t. The B N I w as no t effective.
U nexpectedly, physica l ac tiv ity  d id  no t m ed ia te  th e  redu c tio n  in  fatigue. 
Thus, w ith  CBT it w as possible to rea lize  an  im provem en t in  fa tigue  w ith o u t a 
la s tin g  increase  in  physica l activity.
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Chapter 5
Moderators and long-term effectiveness of 
cognitive behaviour therapy for fatigue 
during cancer treatm ent
Psycho-Oncology (in press)
Martine Goedendorp, Marieke Gielissen, 
Marlies Peters, Stans Verhagen, Gijs Bleijenberg.
ABSTRACT
Objective. A ran d o m ised  controlled  tr ia l  (RCT) d em o n stra ted  th a t  cognitive 
behav iou r th e ra p y  (CBT) for fa tigue  d u rin g  cu ra tiv e  cancer tre a tm e n t w as 
effective sho rtly  a fte r cancer tre a tm e n t. T his study  aim ed  to iden tify  w hich 
p a tie n t ch a rac te ris tic s  p red ic t fa tigue  im provem en t a fte r CBT. A dditionally  the  
long te rm  effectiveness w as in vestiga ted .
M ethods. P a tie n ts  w ith  v a rio u s m alignancies p a rtic ip a te d  in  th e  RCT (n=210). 
P a r tic ip a n ts  w ere a ssessed  before cancer tre a tm e n t (T1), p o st-in te rv en tio n  (T2), 
w hich w as a t  le a s t two m on ths a fte r cancer tre a tm e n t an d  a fte r one year follow- 
up (T3). M onth ly  fa tigue  asse ssm en ts  w ere com pleted  betw een  T2 an d  T3. A 
reg ression  an a ly sis  w ith  in te rac tio n s  w as perfo rm ed  to de te rm ine  if  dom ains of 
q u a lity  of life (EORCT-QLQ-C30) function ing  (SF-36) or psychological d is tress  
(SCL-90) m od era ted  th e  effect of CBT on fatigue. ANCOVAs w ere u sed  to study  
th e  long te rm  effectiveness of CBT.
Results. F a tig u e  a t  T2 w as p red ic ted  by a sign ifican t in te rac tio n  betw een  self­
rep o rted  cognitive function ing  an d  CBT. No in te rac tio n s  w ere found  betw een  
o th e r dom ains of q u a lity  of life, function ing , psychological d is tre ss  an d  CBT. At 
T3 no sign ifican t difference on fa tigue  w as found  betw een  CBT an d  u su a l care. 
E xp lo ra to ry  ana ly ses  show ed th a t  th e  difference n ea rly  reach ed  significance 
u n til  seven m on ths post-in terven tion .
Conclusions. P a tie n ts  who experienced  m ore concen tra tion  an d  m em ory 
problem s a t T1 benefited  m ore from  CBT for fa tigue  a n d  are  ind ica to rs. A fter a 
year follow-up th e  effect of CBT for fa tigue  w as no longer observed, th e  effect on 
fa tigue  seem ed to be d im in ished  seven m on ths p o st-in te rven tion . The 
im plication  is th a t  CBT for fa tigue  should  be offered to cancer p a tie n ts  w ith  the  
h ig h es t chance to benefit.
INTRODUCTION
F a tig u e  is  one of th e  m ost freq u en tly  rep o rted  sym ptom s d u ring  cancer 
tre a tm e n t1, 2. U n fo rtu n a te ly  not a ll cancer p a tie n ts  recover from  fa tigue  after 
cancer tre a tm e n t is fin ished . M any cancer surv ivors rem a in  severely  fa tigued  
for y ea rs  a fte r fin ish ing  cancer tre a tm e n t w ith  profound  effects on daily 
function ing  an d  quality  of life1-3.
T here a re  strong  ind ica tio n s th a t  psychosocial in te rv en tio n s  specifically 
aim ed  a t fa tigue  du ring  cancer tre a tm e n t have  a h igh  probab ility  of being 
effective in  reducing  fa tig u e4. F ive5'9 of th e  six in te rv e n tio n s5-10 (83%) rep o rted  
in  th e  l i te ra tu re  specifically designed  to reduce fa tigue  w ere effective. Three 11 
13 ou t of 22 (14%) psychosocial in te rv en tio n s  w ith  a g en era l approach, a im ed  a t 
im proving psychological d istress, mood an d  physica l sym ptom s have show n 
efficacy for fa tigue. M ost in te rv en tio n s  specifically a im ed  a t  reducing  fatigue 
w ere brief, consisting  of th ree  in d iv id u a l sessions, p rovided  by (oncology) 
n u rse s5, 6, 8, 9. One in te rv en tio n  w as m ore in tensive . P a tie n ts  received  12 
sessions of cognitive behav iou r th e ra p y  an d  hypnosis for six w eeks supp o rted  by 
a th e ra p is t7. Long te rm  effectiveness of th ese  in te rv en tio n s  w as seldom 
in v es tig a ted  a n d  none of th e se  s tud ies te s te d  w hich fac to rs m od era ted  the  
effectiveness of th e  in te rv en tio n s.
R ecently  we perfo rm ed  a ran d o m ised  controlled  t r ia l  (RCT) in  w hich two 
in te rv en tio n s  specifically a im ed  a t  fa tigue  d u rin g  cu ra tiv e  cancer tre a tm e n t 
w ere com pared  to u su a l care  (UC)14. The s tre n g th  of th is  RCT w as th e  tim ing  of 
th e  assessm en ts , as th ese  took place a t  clinically re le v a n t m om ents. F irs t, the  
b ase line  a sse ssm en ts  (T1) w ere com pleted  before th e  s ta r t  of cancer tre a tm e n t. 
T his is  a clinically  re le v a n t m om ent, because a t  th is  stage fa tigue  can’t  be
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a ttr ib u te d  to oncological tre a tm e n t. Second, th e  p o st-in te rv en tio n  assessm en t 
(T2) took place a t  le a s t two m on ths a fte r cancer tre a tm e n t w as fin ished. A 
p rev ious study  found th a t  th e  im m ed ia te  effects of surgery , chem otherapy  or 
rad io th e rap y  on th e  p resence  of fa tigue  d isap p eared  w ith in  six w eek s15. T2 w as 
th u s  chosen a t a clinically  re le v a n t m om ent, a fte r a recovery period  from  the  
d irect effects of cancer tre a tm e n t.
The in te rv en tio n s  ev a lu a ted  in  our recen t RCT w ere a b rie f n u rsin g  
in te rv en tio n  (BNI) an d  cognitive behav iou r th e ra p y  (CBT) for fa tig u e 14. The 
B N I consisted  of two one-hour sessions w ith  a n u rse  an d  a booklet a im ed  a t 
in creasin g  an d  m a in ta in in g  physica l activ ity . R esu lts  show ed th a t  com pared  to 
UC th e  B N I h a d  no effect on fatigue.
The CBT in te rv en tio n  consisted  of, on average, six one-hour ind iv idual 
sessions w ith  a cognitive beh av io u ra l th e ra p is t  in  abou t seven m on ths d u ring  
cancer tre a tm e n t. In  add ition  to in creasin g  an d  m ain ta in in g  physica l activ ity  
th e  CBT in te rv en tio n  w as d irec ted  tow ard  chang ing  severa l dysfunctional 
cognitions abou t fa tigue, cancer, cancer tre a tm e n t, th e  fu tu re , a n d  about 
re la tio n s  w ith  o th e r people (self efficacy, ca tastro p h ic  cognitions, unh e lp fu l 
a ttr ib u tio n s  an d  expectations). M ethods u sed  inc luded  cognitive re s tru c tu rin g , 
education  an d  b eh av io u ra l in stru c tio n s, w ith  hom ew ork assignm en ts, an d  
exposure. The in te rv en tio n  focused on six e lem ents. 1) P hysica l activity: 
P a tie n ts  received  th e  sam e in fo rm ation  an d  booklet as p rovided  in  th e  BNI. In  
addition , dysfunctional ac tiv ity -re la ted  cognitions w ere challenged. 2) F a tigue  
re la te d  cognitions: dysfunctional cognitions w ere changed  to m ore help fu l ones 
an d  excessive focusing on fa tigue  w as m inim ized. 3) S leep-w ake rhy thm : 
P a tie n ts  w ere encouraged  to m a in ta in  re g u la r  bed  an d  w ake up tim es an d  
napp ing  du ring  th e  day w as discouraged, tak in g  th e  p h ase  of cancer tre a tm e n t 
in to  account. 4) Effects of cancer an d  tre a tm e n t: The consequences an d  side 
effects of hav in g  cancer w ere d iscussed  (e.g. stom a, am pu ta tion ), w ith  th e  aim  
to help  p a tie n ts  to cope an d  accept them . 5) C ancer a n d  fa tigue  in  contact w ith  
o thers: dysfunctional cognitions w ere changed  an d  m ore help fu l coping 
s tra teg ie s  to use  in  in te ra c tin g  w ith  o th e rs  (family, colleagues) concerning 
h av ing  cancer w ere d iscussed. 6) P lan s  for th e  fu tu re : P a tie n ts  w ere a sk ed  to
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allow them selves to th in k  abou t th e  fu tu re , an d  to m ake fu tu re  p lans; obstacles 
an d  fea rs  reg a rd in g  doing so, an d  w ays to overcom e them , w ere discussed. 
R esu lts  of th e  RCT show ed th a t  a t le a s t two m on th s a fte r cancer tre a tm e n t, 
significantly  few er p a r tic ip a n ts  w ere severely fa tig u ed  in  th e  CBT group 
com pared  to U C 14.
D esp ite  find ing  th a t  th e  CBT in te rv en tio n  proved  to be effective in  
reducing  fa tigue, th e  re su lts  of our study  also im plied  th a t  some p a r tic ip a n ts  in  
th e  UC group m an ag ed  fa tigue  very  w ell w ith o u t a specific in te rv en tio n  for 
fatigue. B ased  on th e  find ing  th a t  65% of th e  p a tie n ts  in  th e  UC group w ere not 
severely fa tig u ed  bo th  before th e  s ta r t  of cancer tre a tm e n t (T1) a n d  two m onths 
a fte r cancer tre a tm e n t w as fin ish ed  (T2), we conclude th a t  th ese  p a tie n ts  m ay 
not n eed  a fa tigue  in te rv en tio n . Therefore, i t  is  not u n reaso n ab le  to assum e 
th a t  abou t th e  sam e percen tag e  of th e  CBT group could have  recovered 
spon taneously  from  fa tigue  an d  m ay th u s  have  been  o v ertrea ted . T herefore an  
im p o rta n t question  is  who w ould benefit m ost from  our CBT in te rv en tio n ?  In  
o ther w ords w h a t are  th e  ind ica to rs  for CBT for fa tigue  d u ring  cancer 
tre a tm e n t?  To an sw er th ese  questions i t  is  im p o rta n t to iden tify  fac to rs th a t  
m odera ted  th e  effectiveness of CBT.
A lthough severa l RCTs d em o n stra ted  th e  effectiveness of a psychosocial 
in te rv en tio n  for fa tigue  du ring  cancer tre a tm e n t, th e re  is  a lack  of in te rac tio n  
m odels of fa tigue  in  contro lled  in te rv en tio n  stud ies. U sing lin ea r  reg ression  
analysis, A rm es e t al., (2007) iden tified  mood d is tu rb an ce  an d  com orbid 
d iso rders as confounders of fa tig u e5. Cohen e t al., (2009) found  tre a tm e n t w ith  
chem otherapy  p red ic ted  less change in  fa tig u e 11.
The f irs t aim  of th is  study  w as to explore w hich base line  factors m odera ted  
th e  effect of our CBT in te rv en tio n  on fa tigue  m easu red  tw o m on ths a fte r cancer 
tre a tm e n t. B esides base line  ch a rac te ris tic s  such as age, gender, a n d  type of 
cancer tre a tm e n t, we explored  w h e th e r any  of th e  secondary outcom es of our 
RCT, such as fu n c tiona l im p a irm en ts , psychological d is tre ss  an d  q u a lity  of life 
before th e  s ta r t  of cancer tre a tm e n t m od era ted  th e  effect of CBT on fatigue.
Long te rm  effects of psychosocial in te rv en tio n s  specifically for fa tigue  
d u ring  cancer tre a tm e n t a re  seldom  d em o n stra ted 4. O f th e  e ig h t psychosocial
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in te rv en tio n  s tu d ies  d em o n stra tin g  effectiveness for fa tigue  du ring  cancer 
tre a tm e n t, only tw o RCTs d em o n stra ted  long te rm  effectiveness a t  four an d  
seven m on ths follow -up5, n . The o th e r six s tud ies h a d  no follow-up assessm en t 
a t all, or only a sho rt follow-up period  of abou t 4 w eeks post-in terven tion . To 
our know ledge th e re  is no RCT th a t  exam ined  th e  effect of a psychosocial 
in te rv en tio n  for fa tigue  d u ring  cancer tre a tm e n t beyond seven m on ths follow- 
up. Therefore th e  second aim  of th is  s tu d y  w as to d e te rm in e  if  th e  effect of CBT 
for fa tigue  d u ring  cu ra tive  cancer tre a tm e n t w ould  be m a in ta in e d  a fte r a year 
follow up. I t  w as h ypo thesized  th a t  a t  one year follow up p a rtic ip a n ts  in  the 
CBT group w ould  be sign ifican tly  less fa tig u ed  com pared  to th e  UC group.
MATERIALS AND METHODS 
Patients and Procedure
Sample
P a tie n ts  w ere re c ru ite d  a fte r being d iagnosed w ith  a p rim ary  tu m o u r an d  
scheduled  to receive tre a tm e n t w ith  cu ra tiv e  in te n t. P a r tic ip a n ts  h a d  to be 
betw een  18 an d  75 years  of age. Exclusion c rite r ia  were: com orbidity th a t  could 
cause fatigue; rece ip t of p sy ch ia tric  or psychological tre a tm e n t in  th e  preced ing  
th ree  m onths; an d  u n ab le  to speak, re a d  or w rite  D utch. P a tie n ts  w ere not 
inc luded  in  th e  study  if  th ey  rep o rted  severe fa tigue  for severa l years  or 
in d ica ted  seeking tre a tm e n t for p re-ex isting  chronic fa tigue. As th is  
in te rv en tio n  study  w as a im ed  a t fa tigue  in  p a tie n ts  w ho w ould  receive 
tre a tm e n t w ith  cu ra tiv e  in te n t p a tie n ts  exh ib iting  d isease  progression  or 
recu rren ce  d u rin g  th e  study  w ere excluded. To m inim ize exclusion an d  drop-out 
d u ring  th e  study, p a tie n ts  w ith  lung  or h e a d  an d  neck cancers w ere not 
included.
P a tie n ts  w ere re c ru ite d  from  th e  R adboud U n iv ersity  N ijm egen M edical 
C en tre  an d  six reg iona l h o sp ita ls  from  N ovem ber 2005 th ru  A ugust 2007. The 
eth ics com m ittees from  all seven h o sp ita ls  gave th e ir  approval for th e  study. 
In fo rm ed  consent w as o b ta ined  from  all p a rtic ip a tin g  p a tien ts .
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Eligible p a tie n ts  who ag reed  to p a rtic ip a te  com pleted  th e  base line  assessm en t 
(T1) before th e  s ta r t  of cancer tre a tm e n t an d  w ere subsequen tly  random ized  to 
one of th e  th ree  conditions: BNI, CBT or UC. The p rocedu res for re c ru itm e n t16 
an d  ran d o m iza tio n 14 a re  described  in  d e ta il e lsew here. The sho rt te rm  follow-up 
assessm en t (T2) took place six m on th s a fte r T1 an d  a t le a s t two m on ths after 
cancer tre a tm e n t w as fin ished. Thus, p a rtic ip a n ts  who received  surgery, 
chem otherapy  or rad io th e rap y  m ore th a n  four m on th s a fte r T1 w ere assessed  
two m on ths a fte r th ese  tre a tm e n ts  w ere fin ished. The long te rm  follow-up 
assessm en t (T3) w as com pleted  one year a fte r T2. B etw een  T2 an d  T3 
p a r tic ip a n ts  w ere a sk ed  to com plete th e  C hecklist In d iv id u a l S tre n g th  (CIS) a t 
hom e each m onth .
INSTRUM ENTS
D em ographic, m edical, an d  cancer tre a tm e n t ch a rac te ris tic s  w ere g a th e red  
from  all p a rtic ip a tin g  p a tie n ts  by self-report questionna ire . In fo rm ation  on the 
type of m alignancy  w as prov ided  by th e  p a tie n t’s physician . The in s tru m e n ts  
u sed  to assess  th e  secondary outcom es in  our RCT w ere u sed  in  th is  study  for 
th e  exp lo ra to ry  m odera to r analyses.
C hecklist Ind ividua l S tren g th 11- 18. The C hecklist In d iv id u a l S tre n g th  
(CIS) consists of four subscales: fa tigue  severity  (8 item s), concen tra tion  
problem s (5 item s), decreased  m otivation  (4 item s) an d  decreased  activ ity  (3 
item s). E ach  item  on th e  fa tigue  severity  subscale is scored on a seven-point 
L ik ert scale. The CIS w as com pleted  a t  T1, T2, T3 an d  eleven tim es (m onthly) 
betw een  T2 an d  T3. The CIS is  a w ell-valida ted  in s tru m e n t,19, 20 sensitive  to 
d etect change an d  w as u sed  in  p rev ious re sea rch  in v es tig a tin g  fa tigue  in  cancer 
p a tie n ts21-24. Scores on th e  fa tigue  severity  subscale (CIS-fat) ran g e  from  8 to 
56. A score of 35 or h ig h er in d ica tes  severe fa tigue  a n d  a score betw een  27 and  
34 in d ica tes  h e ig h ten ed  fatigue.
The H ealth S u rvey  Sh o rt Form-36 (SF-36) w as u sed  to assess  functional 
im p a irm en t in  d ifferen t dom ains w ith  e ig h t m u lti-item  scales: physical 
functioning, social functioning, role lim ita tio n s  due to physica l h e a lth  problem s,
Design and Procedure
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role lim ita tio n s  due to em otional problem s, bodily pain , v ita lity , gen era l h e a lth  
perceptions, an d  gen era l m en ta l h ea lth . The D utch  language  version  of th e  SF- 
36 h a s  proven  to be a prac tica l, re liab le , an d  v a lid  in s tru m e n t in  th e  g en era l 
popu la tion  an d  in  chronic d isease popu la tio n s25.
The Q uality o f  L ife  Questionnaire o f  the European Organisation for 
Research a nd  Treatm ent o f  Cancer (EORTC QLQ-C30) version 3.0  co n ta in s five 
function ing  scales (physical functioning, role functioning, em otional 
functioning, cognitive functioning, social functioning), th re e  sym ptom  scales 
(fatigue, pain , n a u se a  an d  vom iting) an d  one scale a ssessing  global q u a lity  of 
life. The EORTC-QLQ C30 is  an  in te rn a tio n a lly  v a lid a ted  q u es tio n n a ire26, 27.
The Sym ptom  Checklist-90  (SCL-90)28 is a 90 item  questio n n a ire  
consisting  of e igh t subscales, anxiety , agoraphobia, depression, som atisation , 
obsessive-com pulsive behaviour, in te rp e rso n a l sensitiv ity , h o s tility  an d  sleeping 
problem s. The to ta l score on th e  SCL-90 w as u sed  to m easu re  psychological 
d istress. The SCL-90 h a s  good re liab ility  an d  d isc rim in an t validity .
Statistical method
SPSS, version  16.0 (SPSS Inc, Chicago, IL) w as u sed  for a ll d a ta  analyses.
One sign ifican t difference (m arita l s ta tu s)  w as found  betw een  th e  th ree  
study  g roups a t  base line . M a rita l s ta tu s  w as th u s  u sed  as a covariate  in  all 
analyses.
This s tu d y  w as pow ered to d em o n stra te  effectiveness of in te rv e n tio n s14, 
b u t no t pow ered for m odera to r analyses. Pow ering for m odera to r ana ly ses  w as 
not possible, as no m odera to rs could be h ypo thesized  beforehand . The 
m odera to r ana ly ses  w ere exploratory .
Moderator analysis
Two steps w ere ta k e n  to in v estig a te  w hich fac to rs m o d era ted  th e  effect of CBT 
on fatigue. F irs t, u sing  P earso n  correlations, i t  w as te s te d  if  fa tigue, q u a lity  of 
life, functional im p a irm en ts  an d  psychological d is tre ss  in  severa l dom ains a t T1 
sign ifican tly  co rre la ted  w ith  fa tigue  severity  a t  T2. Second, lin e a r  reg ression  
analy sis  w as perfo rm ed  to te s t  for sign ifican t in te rac tio n s. The m ethod  of A iken 
an d  W est (1991) w as chosen to te s t for in te rac tio n s. W ith  th is  m ethod  p o ten tia l
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m ultico llinearity  can  be g rea tly  reduced  by cen te ring  v a ria b le s29. Two dum m y 
v ariab les  rep re sen tin g  th e  in te rv en tio n  v a riab le  w ere e n te re d  in  th e  firs t block. 
In  addition , Z-scores for sign ifican tly  co rre la ted  fac to rs a t  T1 w ere en te re d  in  
th e  firs t block. Z-scores of th ese  fac to rs a t T1 m u ltip lied  by study  condition  w ere 
en te red  in  th e  second block. F a tig u e  severity  a t  T2 w as th e  dep en d en t variab le .
Long term effect of CBT
To exam ine th e  long te rm  effect of CBT, an a lysis  of covariance (ANCOVA) w as 
p erfo rm ed  w ith  fa tigue  severity  as th e  dependen t variab le . B aseline scores w ere 
en te red  as covaria tes a n d  study  condition w as u sed  as a fixed factor. C on trast 
ana ly ses  w ere perfo rm ed  to com pare th e  in te rv en tio n  groups (level 2 an d  3) 
ag a in s t u su a l care (level 1). In te n tio n -to -tre a t analy sis  w as used. A tw o-sided p  
< .05 w as considered  significant. To avoid o verestim ation  of in te rv en tio n  effects, 
m issing d a ta  on fa tigue  w ere rep laced  by th e  m ean  fa tigue  score of th e  UC 
group.
RESULTS
In  to ta l 395 eligible cancer p a tie n ts  w ere approached , an d  155 re fu sed  to 
p a rtic ip a te . The flow of p a r tic ip a n ts  th ro u g h  each  stage  of th e  study  is 
i l lu s tra te d  in  F igu re  1. The re c ru itm e n t p rocedure an d  th e  flow of p a r tic ip a n ts  
th ro u g h  th e  study  u n til  T2 a re  described  in  m ore d e ta il e lsew h ere16. A fter T2, 
10 inelig ib le p a r tic ip a n ts  w ere excluded. W hen inelig ib le p a tie n ts  are  
random ized  m istak en ly  in to  a tr ia l, th e ir  d a ta  can be excluded p o s t­
rand o m iza tio n  w ith o u t risk in g  b ia s30. T hese p a r tic ip a n ts  no longer m et 
e lig ib ility  c rite r ia  because of, for exam ple, d isease progression  or cancer 
recu rren ce  d u rin g  th e  study  (see F igu re  1).
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Eligible for tria l (n = 395)
Refused to participate (n = 155)
Assessed and randomized (n = 240)
Excluded from trial
(n = 5)
- Died (n = 1)
- Treated for secondary 
tumor (n = 1)
- Received palliative 
treatm ent (n = 2)
- Severe comorbidity 
during the study 
(n = 1)
Intention to treat 
(n = 72)
BNI
Received BNI (n = 68) 
Not s tarted  BNI (n = 4)
- BNI considered not 
beneficial (n = 1)
- Unknown (n = 3)
1 r
T2 assessm ent (n = 72)
Excluded from trial 
(n = 3)
- M etastases developed 
during the study
(n = 2)
- Cure was not realised 
(n = 1)
Intention to treat* 
(n = 69)
T3 assessm ent (n = 69)
Excluded from trial
(n = 6)
- Died (n = 2)
- Treated for secondary 
tumor (n = 1)
- Received palliative 
treatm ent (n = 2)
- Severe complications 
during the study
(n = 1)
Intention to treat 
(n = 76)
CBT
Received CBT (n = 73)
Not s tarted  CBT (n = 3)
- CBT considered too time 
consuming and not beneficial
- O ther priorities
- Unknown
T2 assessm ent (n = 76).
Completed: n = 75
Drop-out: n = 1 (CBT considered too
time consuming and not beneficial)
Excluded from trial
(n = 3)
- Disease recurrence (n =
- Diagnosed with 
metastases during the 
study (n = 1)
Intention to treat* 
(n = 73)
T3 assessm ent (n = 68)
Drop-out: (n = 5)
- Refused to answer 
questionnaires (n = 1)
- Too confronting (n = 1)
- Questionnaires and intervention 
too burdensome (n = 2)
- Unknown (n = 1)
F igu re  1. C onsort d iagram .
*intention to t re a t  including drop-out
1 r 1r 1 r
BNI (n = 77) CBT (n = 82) U sual Care (n = 81)
Excluded from tria l (n = 9).
- Died (n = 3)
- Received palliative 
treatm ent (n = 2)
- Diagnosed with 
m etastases during the 
study (n = 1)
- Severe comorbidity 
during the study (n = 1)
- Diagnose was benign 
(n = 2)
Intention to treat
(n = 72)
T2 assessm ent (n = 72) 
Completed: n = 71 
Drop-out: n = 1 (family 
circumstances)
Excluded from trial
(n = 4)
- Disease recurrence 
(n = 2)
- Diagnosed with 
m etastases during 
the study (n = 1)
- Diagnosed with 
secondamreytamsatalisgensancy 
(n = 1)
Intention to treat* 
(n = 68)
T3 assessm ent (n = 67) 
Drop-out: (n = 1)
- Family circumstances
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In  to ta l, th e  n u m b er of p a r tic ip a n ts  in  th is  s tu d y  w as 210; 69 in  th e  B N I group,
73 in  th e  CBT group, an d  68 in  th e  UC group. B aseline ch a rac te ris tic s  are 
described  in  Table 1. T here w ere no sign ifican t base line  d ifferences betw een  the  
th ree  study  g roups except for m a rita l s ta tu s . M ore p a r tic ip a n ts  in  th e  BN I 
group w ere m arried  com pared  to th e  UC (p=.008).
N ot a ll p a r tic ip a n ts  could be assessed  before th e  s ta r t  of cancer tre a tm e n t 
because of th e  sh o rt tim e  span  betw een  th e  d iagnosis an d  s ta r t  of tre a tm e n t. 
Thus, 27% of th e  p a r tic ip a n ts  w ere assessed  a fte r su rg ery  or s ta r t  of horm one 
therapy , b u t a lw ays before beg inn ing  ad ju v an t chem otherapy  or rad io th erap y . 
T2 w as com pleted  by 156 p a r tic ip a n ts  6 m on ths a fte r T1. Fifty-tw o p a rtic ip an ts , 
who received  cancer tre a tm e n t for a longer period  com pleted  T2 two m on ths 
a fte r cancer tre a tm e n t w as fin ished. D rop-out in  th is  s tudy  w as low. Two 
p a r tic ip a n ts  d id  no t com plete bo th  T2 an d  T3, an d  an  ad d itio n a l four 
p a r tic ip a n ts  d id  no t com plete T3.
M ost p a r tic ip a n ts  (88%, n=185) com pleted  all m onth ly  fa tigue  assessm en ts  
betw een  T2 an d  T3 or m issed  one assessm en t a t m ost. The m ed ian  n u m b er of 
m onth ly  asse ssm en ts  com pleted  w as 11. E ig h t p e rcen t of p a r tic ip a n ts  (n=17) 
did no t com plete any  of th e  m onth ly  fa tigue  assessm en ts.
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Table 1: Baseline characteristics for the three study groups
Characteristics Total 
(n= 210) 
n %
BNI
(n=69)
n
CBT 
(n=73) 
% n
UC 
(n=68) 
% n %
P-
value
Sex Male 74 35 26 38 26 36 22 32 .805
F emale 136 65 43 62 47 64 46 68
Age (years) Mean 56.5 57.2 55.6 56.9 .629
(s.d.) (10.9) (10.1) (11.6) (11.1)
Education Mean 3.99 4.30 3.97 3.69 .109
(1=low -  7 high) (s.d.) (1.71) (1.87) (1.61) (1.61)
M arital status
Married / cohabiting 169 81 62 90 58 80 49 72 .031
Other status 41 19 7 10 15 20 19 28
Diagnosis (*)
Breast cancer 102 49 34 49 35 48 33 49 .780
Prostate cancer 49 23 19 28 15 21 15 22
Other tumors 59 28 16 23 23 31 20 29
Gastrointestinal 27 7 8 7
Urogenital 15 2 7 5
Gynecological 12 6 3 3
Lymphomas 6 1 3 2
Sarcoma 3 0 1 1
Melanoma 1 1
Thyroid carcinoma 2 1 1
Treatment type (**)
Surgery 193 94 63 91 70 97 63 93 .311
Chemotherapy 62 30 20 29 25 35 17 25 .414
Radiotherapy 123 59 40 58 44 60 39 57 .933
Hormone therapy 64 31 22 32 20 29 22 32 .871
BNI: brief nursing intervention, CBT: Cognitive Behaviour Therapy, UC: usual care, T1: 
baseline assessment, T3: follow-up assessment,
(*) Two patients were diagnosed with both bladder and prostate cancer and were categorized as 
other tumors. One was assigned to the control group, the other to CBT,
(**) The total is more than 100%, as several combinations of treatm ent regimes were given to 
patients,
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Moderator analysis
R esu lts  of th e  lin ea r  reg ressio n  an a ly sis  show ed th a t  th e  in te rac tio n  betw een 
CBT th e  E0R TC -Q LQ -C 30 cognitive function ing  subscale score w as significant 
(Table 2). Specifically, p a tie n ts  in  th e  CBT group who rep o rted  m ore im p aired  
cognitive function ing  a t  T1 h a d  less fa tigue  a t T2 com pared  to th e  UC group . 
CIS-fat scores (p=.810), SCL-90 to ta l or subscale score (all p>.194), an d  SF-36 
subscale score (all p>.139) a t b ase lin e  d id  no t sign ifican tly  in te ra c t w ith  CBT on 
fa tigue  a t T2.
T able 2 : R esu lts  of lin e a r  reg ression  analyses, w ith  sign ifican t m odera to rs for 
th e  effect of CBT on fatigue.
Independent variables B Std. error B P-value
Step  1
(Constant) 21.99 1.02 .000
Condition CBT -6.48 2.07 -.228 .002
Condition BNI -2.48 2.07 -.087 .234
z- score CIS-fat 5.93 0.95 .433 .000
z-score EORTC-QLQ C30 CF -.41 0.94 -.030 .666
Step  2
(Constant) 22.27 1.01 .000
Condition CBT -6.46 2.06 -.228 .002
Condition BNI -2.92 2.08 -.102 .161
z-score CIS-fat 5.53 .952 .404 .000
z-score EORTC-QLQ C30 CF -.55 1.08 -.041 .611
z-score EORTC-QLQ C30 CF x CBT 4.77 2.20 .175 .031
R2 = .026 for Step 1; AR2 = .251 for Step 2. A two-sided P-value < 0.1 was considered significant.
BNI: Brief Nursing Intervention, CBT: Cognitive Behaviour Therapy, CIS-fat: subscale fatigue 
severity of the Checklist Individual Strength, EORTC-QLQ C30 CF: Quality of life 
questionnaire subscale cognitive functioning
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Long term effect of CBT
R esu lts  of th e  ANCOVA show ed no sign ifican t d ifferences betw een  th e  CBT and  
UC groups on fa tigue  a t  T3 (see Table 3). Thus, th e  effect of CBT on fa tigue  w as 
not m a in ta in e d  a t one y ear follow-up.
T ab le  3: M eans an d  s ta n d a rd  deviation  for fa tigue  a t th e  m onth ly  an d  T3
assessm en ts, m ean  differences betw een  th e  in te rv en tio n  an d  u su a l 
________ care groups, an d  p-values for th e  ANCOVA’s______________________
Assessment Groups N Mean (s.d.) F Overallp-value
Mean
difference p-value*
CIS-fat 1 UC 62 25.0 14.3) 2.677 .071
CBT 64 21.6 12.6) 4.6 .080
CIS-fat 2 UC 62 25.0 13.8) 1.443 .239
CBT 64 22.5 13.3) 3.7 .274
CIS-fat 3 UC 59 27.3 13.0) 2.441 .090
CBT 63 23.1 13.4) 4.8 .088
CIS-fat 4 UC 61 26.4 13.0) 2.730 .068
CBT 63 22.3 13.1) 4.8 .065
CIS-fat 5 UC 61 25.6 12.9) 2.148 .120
CBT 63 22.2 13.0) 4.1 .162
CIS-fat 6 UC 60 24.4 13.1) 4.627 .011
CBT 62 20.0 12.8) 5.0 .069
CIS-fat 7 UC 60 24.0 12.6) 4.266 .015
CBT 62 20.1 13.4) 4.7 .096
CIS-fat 8 UC 60 23.9 13.4) 1.616 .202
CBT 62 21.2 13.3) 3.4 .378
CIS-fat 9 UC 60 23.6 13.2) 0.456 .635
CBT 61 22.1 13.7) 2.0 1.000
CIS-fat 10 UC 60 23.7 13.7) 0.228 .797
CBT 61 23.3 14.9) 0.9 1.000
CIS-fat 11 UC 58 23.0 13.4) 1.290 .278
CBT 60 20.6 12.7) 3.1 .476
T3 UC 67 24.2 14.7) 1.273 .282
CBT 68 22.0 13.5) 3.0 .472
BNI: Brief Nursing Intervention, CBT: Cognitive Behaviour Therapy, UC: Usual Care, CIS: 
Checklist Individual Strength, T1: baseline assessment, T2: follow-up assessment, CI: 
Confidence Interval.
*p-values of contrast analyses: first p-value is the difference between the BNI and UC, the 
second p-value is the difference between the CBT and UC. P-values <.100 in italics indicated a 
trend.
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As fatigue w as assessed  m onthly, explo ra to ry  an a ly ses  w ere perfo rm ed  to 
inv estig a te  how long th e  effect of CBT w as m a in ta in ed  a fte r  T2. R esu lts  of 
th ese  ANCOVA an alyses an d  th e  d ifferences betw een  th e  UC group an d  the  
CBT in te rv en tio n  a re  show n in  Table 3. A t th e  six th  an d  sev en th  m on th  post-T2 
asse ssm en ts  a  s ign ifican t overall effect w as found on fatigue. U n til th e  seven th  
m on th  th e  difference betw een  th e  CBT an d  th e  UC groups h ad  a  p-value 
sm alle r th a n  0.100, in d ica tin g  a  tren d . The m ean  m onth ly  fa tigue  scores for the 
CBT an d  UC groups a re  also illu s tra te d  in  F igu re  2. T his figure d em o n stra te s  
th a t th ro u g h o u t the y ea r be tw een  the T2 an d  T3 asse ssm en ts  fa tigue in  the 
CBT group rem ain ed  low er th a n  th e  UC group. A lthough  fatigue h ad  roughly  a 
p a ra lle l course u n til  the sev en th  m onth , a fte r th is  po in t the d ifferences betw een  
th e  CBT an d  th e  UC group d isappeared . The difference betw een  th e  BNI and  
the UC group on fatigue w as no t sign ifican t a t  T3 or any  of the m onth ly  
a ssessm en ts  (all p=1.000).
F igu re  2. M ean  fatigue scores from  T2 to T3.
CIS-fatigue: fatigue severity, UC: usual care, CBT: cognitive behavior therapy, T2: 
post-intervention assessment, T3: one year follow-up assessment.
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The firs t aim  of th is  s tudy  w as to d e te rm in e  who w ould benefit th e  m ost from 
cognitive behav iou r th e ra p y  (CBT) for fa tigue  d u rin g  cu ra tiv e  cancer tre a tm e n t, 
i.e., iden tify  m odera ting  factors. O ur re su lts  show ed th a t  self-reported  
im p a irm en ts  in  cognitive function ing  before th e  s ta r t  of cancer tre a tm e n t 
m odera ted  th e  effect of CBT on fa tig u e . Thus, p a rtic ip a n ts  who experienced  
m ore concen tra tion  an d  m em ory problem s benefited  m ore from  CBT for fa tig u e . 
No o th e r m odera to rs of CBT includ ing  psychological d istress, global q u a lity  of 
life, fa tigue, pain , n a u se a  an d  vom iting, or s ta tu s  in  o th e r dom ains of 
function ing  could be iden tified  in  th is  s tudy .
This exp lo ra to ry  study  w as a firs t step  to d e te rm in e  clin ical ind ica tions for 
CBT specifically a im ed  a t fa tigue  d u ring  cu ra tiv e  cancer tre a tm e n t. C u rren tly  
th e re  a re  no o th e r s tud ies th a t  de te rm in ed  w hich fac to rs m odera ted  th e  effect of 
a specific in te rv en tio n  for fa tigue  du ring  cancer tre a tm e n t. A lthough some 
in te rv en tio n  s tud ies iden tified  some fac to rs in fluencing  fatigue, such as receip t 
of chem otherapy , th ese  fac to rs w ere no t m odera to rs of CBT for fa tig u e . There 
could be o th e r m odera to rs for CBT for fa tigue  th a t  w eren ’t  found  in  th is  
explo ra to ry  s tu d y . S evere  fa tigue  before th e  s ta r t  of cancer tre a tm e n t could be 
th e  f irs t in d ica to r for CBT, because fa tigue  a t  T1 co rre la ted  sign ifican tly  w ith  
fa tigue  a t  T2. As th e re  is  also a group of p a r tic ip a n ts  who w ere severely 
fa tig u ed  a t T2 b u t no t a t  T1, we subseq u en tly  com pared  th is  group w ith  
p a r tic ip a n ts  who w ere no t severely  fa tig u ed  a t  T1 an d  T2. M aking  th is  
com parison w ith  p a tie n ts  for th e  UC an d  th e  B N I g roups rev ea led  th a t  poorer 
gen era l m en ta l h e a lth  an d  som atisa tion  before th e  s ta r t  of cancer tre a tm e n t 
m igh t be ind ica to rs  for CBT.
In  th is  s tudy  th e  long te rm  effect of CBT for fa tigue  du ring  cu ra tive  cancer 
tre a tm e n t w as also in v es tig a ted . R esu lts  show ed th a t  a fte r one year follow-up 
(T3) no sign ifican t difference w as found  betw een  th e  CBT an d  UC groups on 
fa tig u e . This re su lt ra ise d  th e  question  of how long th e  effect of CBT 
in te rv en tio n  on fa tigue  w as m a in ta in ed .
DISCUSSION
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S u b seq u en tly  th e  m onth ly  fa tigue  asse ssm en ts  w ere s tu d ied . These 
analyses d em o n stra ted  a tre n d  u n til  7  m on ths p o st-in te rven tion , b u t th e re a fte r  
th e  positive effect of CBT on fa tigue  d isap p eared  to ta lly .
O ne reaso n  w hy th e  effect of CBT for fa tigue  could no t be m a in ta in ed  for 
longer th a n  seven m on ths post-in te rv en tio n  could be exp la ined  by th e  fact th a t  
fa tigue  m ay decline n a tu ra lly  a fte r cancer tre a tm e n t is f in ish ed 31. Secondly, it 
w as probably  m ore difficult to d em o n stra te  a long te rm  effect because we 
o v e rtrea ted  our p a tie n ts  an d  th is  w eakened  th e  effects of our in te rv en tio n . W ith 
a la rg e r sam ple size th e  long te rm  effect of CBT on fa tigue  m igh t become 
sign ifican t. Clinically, it  is  p robably  m ore im p o rta n t th a t  CBT should  be offered 
to th e  p a tie n ts  who have th e  h ig h es t chance to benefit from  CBT for fatigue. To 
our know ledge th e re  is  only one in te rv en tio n  RCT th a t  h a s  d em o n stra ted  a long 
te rm  effect on fa tigue  a t seven m o n ths follow-up5. An im p o rta n t difference 
betw een  th is  study  an d  our RCT is  th a t  in  th is  s tudy  p a tie n ts  w ere only 
inc luded  w hen  th ey  rep o rted  sign ifican t fa tig u e . T hese re su lts  support our idea  
th a t  severe fa tigue  m igh t be a p o ten tia l ind ica tion  for CBT.
O ur study  h a d  some lim ita tio n s. F irs t, th e  study  w as no t pow ered for a 
m odera to r analysis, or pow ered to d e te rm in e  how long th e  effect of th e  CBT 
in te rv en tio n  w as m a in ta in ed . To pow er for th e se  types of ana ly ses  m any  m ore 
p a tie n ts  w ould  be req u ired  to p a r tic ip a te . Therefore concen tra tion  an d  m em ory 
problem s shou ldn’t  be ta k e n  as firm  ind ica tions for CBT for fa tigue, because our 
analyses could only be exp lo rato ry .
Second, i t  should  be n o ted  th a t  cognitive function ing  w as a ssessed  using  a 
questionnaire , th e  EORTC-QLQ C30. The subscale consists of two item s in  
w hich p a tie n ts  are  a sk ed  if  th ey  experience d ifficulties w ith  co n cen tra ting  an d  
rem em b erin g . Scores on q u estio n n a ires  a ssessing  cognitive im p a irm en ts  are  
often in co n sis ten t w ith  neuropsychological te s t scores. F u rth e rm o re , it  h a s  been 
d em o n stra ted  th a t  fa tig u ed  b re a s t cancer surv ivors also have  h ig h er self 
rep o rted  concen tra tion  an d  m em ory p rob lem s32.
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So an  in te rp re ta tio n  of our find ing  could be th a t  p a tie n ts  w ith  more 
concen tra tion  an d  m em ory problem s benefit m ore from  CBT because th ey  are 
m ore severely fa tigued . The corre la tion  betw een  fa tigue  an d  bo th  of th ese  self 
rep o rted  com plain ts m easu red  a t  base line  (T1) w as ra th e r  h igh  (r=.448).
B ecause of th e  sho rt tim e span  betw een  diagnosis an d  tre a tm e n t, 27% of 
th e  p a tie n ts  w ere no t tre a tm e n t naïve a t th e  T1 assessm en t. H owever, 73% 
w ere tre a tm e n t naïve an d  a ll p a tie n ts  w ere assessed  before beg inning  ad ju v an t 
cancer tre a tm e n t. The fact th a t  abou t a q u a r te r  of our sam ple w ere not 
tre a tm e n t naive a t  T1 m ost likely  d id  not in fluence our re su lts , because no 
sign ifican t difference w as found betw een  cancer tre a tm e n t naïve p a tie n ts  and  
p a tie n ts  a ssessed  before ad ju v an t th e ra p y  on fatigue.
F inally , no t a ll p a r tic ip a n ts  v o lu n tee red  to com plete th e  m onth ly  fatigue 
a sse ssm en ts  be tw een  T2 and  T3. T his m igh t ra ise  th e  question  of w h e th e r 
p a r tic ip a n ts  who com pleted th e  m onth ly  asse ssm en ts  differed in  th e ir  level of 
fa tigue  com pared to p a r tic ip a n ts  w ho did no t com plete th e  m onth ly  fa tigue  
a ssessm en ts. H ow ever, no sign ifican t difference on fa tigue  w as found a t T2 and  
T3 betw een  p a rtic ip a n ts  who com pleted th e  m onth ly  fa tigue  asse ssm en ts  and  
p a r tic ip a n ts  who com pleted none of th e  m onth ly  assessm en ts.
D espite  th ese  lim ita tio n s  th is  exp lo ra to ry  study  rev ea led  some im p o rtan t 
in sigh ts, re le v a n t for fu tu re  s tud ies an d  p ractice. P a tie n ts  who rep o rted  more 
concen tra tion  an d  m em ory problem s before th e  s ta r t  of cancer tre a tm e n t 
b enefited  th e  m ost from  CBT for fa tigue. In  th e  fu tu re  i t  is  im p o rta n t to avoid 
o v e rtre a tm en t w ith  CBT for fa tigue. If  CBT for fa tigue  d u ring  cancer tre a tm e n t 
can  be in d ica ted  for a specific r isk  group th e  in te rv en tio n  w ill have  a b e tte r  
chance to d em o n stra te  solid long te rm  effectiveness.
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Chapter 6
Development of fatigue in cancer survivors; 
a prospective follow-up study 
from diagnosis into the year after successful 
cancer treatm ent
Martine Goedendorp, Marieke Gielissen, Stans Verhagen, 
Gijs Bleijenberg.
ABSTRACT
Background. There is a lack of longitudinal studies investigating fatigue from 
prior to cancer treatm ent to long after successful cancer treatm ent. The aim of 
th is prospective follow-up study w as to determ ine the prevalence and predictors 
of persistent fatigue in cancer survivors in the first year after finishing cancer 
treatm ent.
M ethods. O ne-hundred-thirty-six patients w ith various m alignancies were 
assessed  before (T1), shortly after curative cancer treatm ent (T2) and one year 
later (T3). Fatigue w as assessed  m onthly between T2 and T3. Fatigue severity  
w as m easured using the subscale of the Checklist Individual Strength. 
Q uestionnaires were used to m easure im paired sleep and rest, physical 
activity, social support, fatigue catastrophising, somatic related attributions 
regarding fatigue. Linear regression analyses were performed to identify  
predictors of persistent fatigue.
Results. In total 21% survivors had severe  persistent fatigue over the last 6 
months in the first year after cancer treatm ent (prostate cancer 3%, breast 
cancer 23%, and 34% in other m alignancies). Fatigue at T1 or T2 predicted the 
severity of persistent fatigue. A nalyses w ithout fatigue showed that lower self­
reported physical activity, im paired sleep and rest, fatigue catastrophising and 
somatic fatigue related attributions at T2, were associated w ith higher levels of 
persistent fatigue.
Discussion. Twenty-one percent of the survivors had severe persistent fatigue in  
the year after successful cancer treatm ent. Fatigue and cognitive behavioural 
factors predicted persistent fatigue in the year after cancer treatm ent. The 
im plication is  that cognitive behaviour therapy for postcancer fatigue, aim ed at 
these perpetuating factors, could be offered from two m onths after successful 
cancer treatm ent.
INTRODUCTION
Almost all cancer patients experience fatigue during active treatm ent. 
Percentages of 90% or higher were found in  several stud ies1-4. Unfortunately not 
all cancer survivors recover from fatigue, but 16-38% rem ain severely fatigued5-
11. Fatigue in cancer survivors can become persistent for years w ith a major 
im pact on daily functioning and quality of life11-13. Cancer patients experience 
significantly more fatigue compared to individuals w ithout a history of cancer; 
before, during and also after cancer treatm ent14- 15. D ata on the occurrence of 
fatigue in cancer patients are often based on cross-sectional studies. Longitudinal 
studies investigating the course of fatigue in  cancer patients from end of cancer 
treatm ent are scarce. We do not know which patients are at risk for developing 
persistent fatigue after successful cancer treatm ent.
There are longitudinal studies that dem onstrated that the level of fatigue  
decreases after successful cancer treatm ent14’ 16 17, but there are also studies that 
found no change in  fatigue over tim e18, 19. This inconsistency could be the result of 
methodological flaws, such as fatigue not being assessed  frequently enough to 
detect fluctuations15. It is  reasonable to assum e that fatigue increases from pre­
treatm ent to the post-treatm ent period15, 2(0 21. However, to our knowledge there 
are no longitudinal studies that assessed  cancer patients prior to treatm ent, 
when they were still treatm ent naïve, and continue to assess fatigue frequently  
after cancer treatm ent w as finished.
Therefore in  th is prospective longitudinal study we assessed  fatigue prior to 
the oncological treatm ent for cancer, assessed  them  again at least two months 
after the end of cancer treatm ent and followed these patients up during the next 
12 months. There are only a few studies in treatm ent naïve cancer patients that
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give clues to hypothesize which pre-treatm ent factors might predict persistent 
fatigue. One could speculate that depressive mood22- 23, less physical activity20- 23, 
im paired sleep and rest23, and fatigue before in itiation22- 23 of cancer treatm ent 
m ight candidate predictors.
In long term cancer survivors, who finished cancer treatm ent longer than a 
year previously, there are at least six fatigue perpetuating factors24- 25; poor 
coping w ith cancer and treatm ent, excessive fear of disease recurrence, 
dysfunctional cognitions regarding fatigue, dysregulation of sleep, dysregulation  
of activity, low social support and negative social interactions. CBT for postcancer 
fatigue is directed at changing these fatigue perpetuating factors. It is  not known 
if  these six factors already assessed  shortly after cancer treatm ent can also 
predict persistent fatigue. This has never been tested. If th is is  the case it is  a 
plea that CBT for postcancer fatigue can be offered to fatigued cancer survivors 
shortly after cancer treatm ent.
Therefore we had three research questions: First, how m any cancer 
survivors suffer from severe persistent fatigue in the year after finishing  
treatm ent? Secondly, which pre-treatm ent variables might predict persistent 
fatigue in the year after cancer treatm ent? Thirdly, do the known perpetuating  
factors of fatigue in  long term cancer survivors also have a predictive value for 
persistent fatigue in  the year after cancer treatm ent? More specifically, can the 
six fatigue perpetuating factors assessed  shortly after cancer treatm ent predict 
persistent fatigue?
METHODS
Patients and Procedure
Sample
P atients were recruited after being diagnosed w ith a primary tumour and 
scheduled to receive treatm ent w ith curative intent. Participants had to be 
between 18 and 75 years. To minim ize drop-out and exclusion during the study, 
patients w ith lung cancer, and head and neck cancer were not included. Patients  
were not included in the study when they indicated to be severely fatigued for
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several years or indicated to seek treatm ent for chronic fatigue before cancer 
m anifested. Other exclusion criteria were: co-morbidity that could cause fatigue; 
receiving psychiatric or psychological treatm ent in  the preceding three months; 
not being able to speak, read or write Dutch.
P atients were recruited from the Radboud U niversity Nijm egen Medical 
Centre and six regional hospitals from November 2005 until August 2007. The 
ethics com m ittees from all seven hospitals gave their approval for the study. 
Informed consent w as obtained from all participating patients.
Design and Procedure
Data of the current study were drawn from a larger intervention RCT. In the 
RCT cognitive behaviour therapy and a brief nursing intervention (BNI) for 
fatigue during curative cancer treatm ent were compared with usual care. For 
th is study data were used of participants not influenced by the active arm of the 
RCT, thus data of participants assigned to the usual care group. In addition, data 
of participants assigned to the BNI were also used in the current study, because 
the BNI had no significant effect on fatigue compared to usual care21.
Eligible patients were approached for the study by their physician or 
specialized nurse. Patients w ith in itia l interest received w ritten information and 
supplem entary information by telephone (by the researcher (MMG) or a te s t­
assistant). Patients who agreed to participate completed the baseline assessm ent 
(T1) before the start of cancer treatm ent and were subsequently randomly 
assigned to one of the three conditions. The procedures for recruitm ent23 and 
random ization21 w as described in detail elsewhere. The short-term follow-up 
assessm ent (T2) took place at least 2  m onths after cancer treatm ent, when  
patients recovered from the direct effects of cancer treatm ent. At the end of the 
T2 assessm ent participants received a folder w ith 11 fatigue questionnaires and 
11 envelopes to cover the whole period of extended follow-up. Participants were 
requested to complete a fatigue questionnaire (the Checklist Individual Strength) 
each month and return it by mail. W hen participants forgot to send the  
questionnaire, they received rem inding letters and when necessary a telephone  
call. One year after T2 the final follow-up assessm ent (T3) took place. Thus,
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fatigue w as assessed  m onthly for 12 tim es, from 2 m onths until 14 m onths after 
cancer treatm ent w as finished.
INSTRUM ENTS  
Persistent fatigue
The last six m onthly fatigue assessm ents were used to determ ine persistent 
fatigue. A period of 6 m onths w as chosen in accordance with the definition of 
chronic fatigue26. Fatigue severity w as m easured w ith the subscale of the  
Checklist Individual Strength (CIS-fat)27, 28. The CIS-fat consists of eight item s 
scored on a seven-point Likert scale. Scores range from 8 to 56. The CIS is a well- 
validated instrum ent29, 30, w as used in several studies investigating fatigue in 
cancer patients and is  sensitive to detect change25, 31-33. The same 
operationalisation as used by Servaes et al., (2007) w as used to determ ine the 
prevalence of severe persistent fatigue and the severity of persistent fatigue34. 
The severity of persistent fatigue w as determ ined by calculating a m ean CIS-fat 
score over the last 6 m onthly fatigue assessm ents. W hen patients only had  
completed five fatigue assessm ents the mean of the 5 assessm ents was 
calculated. A mean score of 35 or higher over all 6 fatigue assessm ents indicated  
severe persistent fatigue.
Predictors of persistent fatigue
Demographic, medical, and cancer treatm ent related characteristics were 
gathered by self-report using questionnaires. Information on the type of 
m alignancy w as provided by the patient’s physician. To assess the pre-treatm ent 
factors the same instrum ents were used as in our earlier study23 being the 
following:
D epressive mood w as m easured w ith the subscale depression of the  
Symptom Checklist-90 (SCL-90). The SCL-90 is sensitive to change, has good 
internal consistency and the stability is high. In addition, the convergent, 
discrim inant and predictive valid ity of the SCL-90 were dem onstrated35.
Impaired sleep and rest w as m easured w ith the subscale sleep/rest of the 
Sickness Impact Profile —8 (SIP). The SIP has a high reliability, good construct,
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convergent and discrim inant validity and w as validated in  the Dutch  
population36- 37.
The level of physical activity before cancer treatm ent and fatigue one year 
before diagnosis (retrospective) were m easured w ith 11-point numeric rating  
scales (NRS) ranging from zero to ten.
The following questionnaires were used to assess the six aforementioned  
perpetuating factors of fatigue. These instrum ents were also used in  previous 
studies w ith long term cancer survivors24- 25 34 38. Coping w ith the cancer and 
treatm ent w as m easured w ith the Dutch version of the Impact of Event Scale 
(IES)39"41. Fear of disease recurrence w as m easured by two item s of the cancer 
acceptance scale (CAS)33. Impaired sleep and rest shortly after cancer treatm ent 
was m easured w ith the subscale sleep/rest of the Sickness Impact Profile —8 
(SIP). The level of physical activity shortly after cancer treatm ent was m easured  
with a NRS. Several dysfunctional cognitions regarding fatigue were measured. 
Somatic related attributions regarding fatigue were m easured using the Causal 
Attribution List (CAL)32, Self-efficacy regarding fatigue w ith the Self-Efficacy 
Scale (SES), and w as based on the self-efficacy scale used in CFS patien ts42, 
fatigue catastrophising w ith the Fatigue Catastrophising Scale (FCS)43. The 
Social Support Inventory w as used to m easure a discrepancy in  social support 
(SSL-D) and, negative social interactions (SSL-NI)44.
Statistical method
To determ ine if  there were differences on demographic and cancer-related  
characteristics between participants w ith severe persistent fatigue and 
participants w ithout severe persistent fatigue an independent sample t -test or a 
chi-square were performed. ANCOVA w as used to determ ine if  there w as a 
significant difference on the severity of persistent fatigue between the types of 
malignancy. To explore which pre-cancer treatm ent factors predicted the severity  
of persistent fatigue correlations betw een above m entioned factors and the 
severity of persistent fatigue were calculated w ith Pearson. These tests  were also 
performed for demographic factors. Subsequently significant factors were entered  
in a linear regression using enter method.
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A linear regression analysis was performed to determ ine if  the model of 
precipitating and perpetuating factors for fatigue in long term cancer survivors 
was applicable to cancer survivors in the year after cancer treatm ent. The 
aforementioned six perpetuating factors were entered in  a linear regression using  
enter method, w ith the severity of persistent fatigue as dependent variable. A 
two-sided p  < 0.05 w as considered significant. SPSS version 16.0 (SPSS Inc, 
Chicago, IL) w as used for all data analyses.
RESULTS
For the current study data from patients assigned to the BNI and UC from the  
larger RCT were used for analyses. D ata from the active intervention arm (CBT) 
were not used. In total 158 participants completed the baseline assessm ent (T1), 
from which 81 were consequently assigned to the UC and 77 to the BNI. No 
significant differences were found between the UC and the BNI group on the 
baseline characteristics and fatigue at T1, T2, T3 or any of the 11 monthly 
fatigue assessm ents (all p>.154). Twenty-one ineligible participants were 
excluded after T1 (fourteen between T1 and T2, and seven betw een T2 and T3). 
The most frequent reason w hy these participants no longer met the eligibility  
criteria w as because of disease progression. When ineligible patients are 
m istakenly randomized into a trial, their data can be excluded post­
random ization w ithout risking b ias45. In total 137 participants curatively treated  
for cancer were followed.
Twelve of the 137 participants completed less than 5 of the 12 monthly 
fatigue assessm ents (T3 and the 11 m onthly fatigue assessm ents) and were not 
used for data analyses. Of the 125 participant whose data were used for analyses  
91% completed all la st 6 fatigue assessm ents (n=117) or m issed only one (n=8).
B aseline demographic and treatm ent related characteristics of the total 
group are described in Table 1. Most patients in our sample were diagnosed with  
breast cancer (48%) or prostate cancer (26%) and most patients received surgery 
(92%) and/or radiotherapy (59%). The m ean age w as 57 years.
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Table 1: Data of demographic variables, diagnosis and presence of severe
persistent fatigue.
Characteristics Total
sample
n (%)
Survivors 
without 
severe 
persistent 
fatigue 
n (%)
Survivors 
with 
severe 
persistent 
fatigue 
n (%)
Difference1
P
Total 125 99 (79) 26 (21)
Sex
Male
Female
46 (37) 
79 (63)
42 (91) 
57 (72)
4 (9) 
22 (28)
.011
Age (years) .205
Mean 57.1 57.7 54.8
s.d. 10.4 10.1 11.2
Education level .146
Lower education (< 4) 81 (65) 61 (75) 20 (25)
Higher education (>4) 44 (35) 36 (86) 6 (14)
Marital .208
Married / cohabiting 102 (82) 83 (81) 19 (19)
Other status (unmarried/divorced/ 
widowed) 23 (18) 16 (70) 7 (30)
Diagnosis * .007
Breast cancer 61 (48) 47 (77) 14 (23)
Prostate cancer 32 (26) 31 (97) 1 (3)
Other tumours 32 (26) 21 (66) 11 (34)
Gastrointestinal 14 (11) 3
Urogenital 5 (4) 2
Gynaecological 7 (6) 3
Lymphomas 3 (2) 1
Sarcoma 1 1
Melanoma 1 1
Thyroid carcinoma 1 0
Cancer treatm ent **
Surgery 
Radiotherapy 
Chemotherapy 
Hormone therapy
115 (92) 
74 (59) 
32 (26) 
41 (33)
90 (78) 
62 (84) 
22 (69) 
32 (78)
25 (22) 
12 (16) 
10 (31) 
9 (22)
.380
.128
.091
.825
* One patient was diagnosed with both bladder and prostate cancer and was categorized as 
urogenital tumours of the other tumours.
** The total is more than 100%, as several combinations of treatm ent regimes were given to 
patients.
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Severe persistent fatigue
How many cancer survivors suffer from severe persistent fatigue in the year after 
finishing treatment?
R esults showed that 21% of the total sample had severe persistent fatigue during 
the last 6 m onths of the first year after finishing cancer treatm ent. The 
prevalence of severe persistent fatigue w as 3% in prostate cancer survivors, 23% 
in breast cancer survivors, and 34% in participants who were successfully treated  
for other m alignancies. Two significant differences were found on demographic 
and cancer related characteristics between cancer survivors w ith or w ithout 
severe persistent fatigue: diagnosis and sex. Participants who were male and 
participants who were curatively treated for prostate cancer had significantly  
less often severe persistent fatigue, compared to women and participants treated  
for other m alignancies (see Table 1).
Predictors of persistent fatigue in the year after successful cancer 
treatment.
Which pre-treatment factors predict persistent fatigue?
Five factors assessed  before the start of cancer treatm ent correlated significantly  
w ith persistent fatigue in  cancer survivors: depressive mood (r=.470, p=.000), 
im paired sleep and rest (r=.218, p=.015), higher levels of retrospectively reported 
fatigue one year before the diagnosis (r=.560, p=.000), higher levels of fatigue at 
T1 (r=.562, p=.000) and lower levels of self-reported physical activity before the 
start of cancer treatm ent (r=-.187, p=.037). The linear regression analysis with  
pre-treatm ent factors and cancer-related factors entered as independent factors 
showed that higher levels of fatigue at T1 and higher levels of fatigue reported 
one year before diagnosis predicted significantly higher levels of persistent 
fatigue in cancer survivors (Table 2).
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Table 2: R esults of linear regression analysis of pre-treatm ent and cancer-related  
factors on persistent fatigue
Unstandardized
Coefficients 95% CI
Persistent fatigue
B SE Beta
t P Lower
bound
Upper
bound
(Constant) 6.98 4.54 1.54 .127 -2.01 16.0
sex -.820 3.51 -.031 -.233 .816 -7.78 6.14
Prostate cancer (dummy) -3.35 3.19 -.115 -1.05 .296 -9.66 2.97
Breast cancer (dummy) .630 2.76 .025 .228 .820 -4.84 6.10
NRS -  physical activity 
one year before diagnosis
.240 .372 .050 .644 .521 -.497 .977
NRS - fatigue one year 
before diagnosis
2.08 .453 .366 4.59 .000 1.18 2.97
CIS-fatigue T1 .321 .122 .320 2.62 .010 .079 .564
SCL-90 depression T1 .254 .147 .155 1.74 .085 -.036 .545
SIP- sleep/rest T1 -.011 .019 -.049 -.558 .578 -.049 .028
Note R2=.460
NRS: Numeric Rating Scale, CIS: Checklist Individual Strength, SCL-90: symptom checklist 90, 
SIP: Sickness Impact Profile, T1: baseline assessment before the start of cancer treatment.
Do the known perpetuating factors of fatigue now assessed shortly after cancer 
treatment predict persistent fatigue?
The linear regression analysis w ith the six aforem entioned perpetuating factors 
assessed  shortly after cancer treatm ent (at T2) entered as independent variables 
showed that stronger somatic attributions regarding fatigue, more fatigue 
catastrophising, a lower level of self-reported physical activity and more im paired  
sleep, were factors significantly predicting higher levels of persistent fatigue  
(Table 3). This linear regression analysis w as performed w ithout fatigue at T2 as 
a predictor, because the level of fatigue at T2 significantly predicted persistent 
fatigue (beta= .484, p=.000).
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Table 3: R esults of linear regression analysis of perpetuating factors at T2 on
persistent fatigue
Unstandardized
Coefficients 95% CI
Persistent fatigue
B SE Beta
t P Lower
bound
Upper
bound
(Constant) 7.81 9.34 .836 .405 -10.7 26.3
Social support 
(SSL-I)
-.020 .060 -.023 -.334 .739 -.140 .100
Discrepancy social 
support (SSL-D)
.019 .120 .012 -.158 .875 -.219 .257
Negative interactions 
SSL-NI
.541 .364 .103 1.49 .140 -.179 1.26
Physical activity 
(NRS)
-1.15 .394 -.214 -2.91 .004 -1.93 -.366
Impaired sleep and rest 
(SIP-SR)
.035 .016 .167 2.20 .030 .003 .066
Somatic attributions 
(CAL)
.915 .443 .170 2.07 .041 .037 1.79
Fear of disease recurrence 
(CAS)
-.210 .684 -.027 -.307 .759 -1.57 1.14
Coping with cancer 
(IES)
.111 .081 .123 1.36 .177 -.051 .272
Self-efficacy
(SES)
-.057 .189 -.021 -.301 .764 -4.31 .318
Fatigue catastrophising 
(FCS)
8.11 2.59 .294 3.13 .002 2.97 13.2
Note R2=.580.
SSL-I: Sonderen Social Support Inventory, SSL-D: discrepancy in social support, SSL-NI negative 
social interactions, NRS-PA: Numeric Rating Scale-physical activity, SIP-SR; Impaired sleep & 
rest, CAL: Causal Attribution List, CAS: cancer acceptance scale, IES: Impact of Event Scale,
SES: Self-Efficacy Scale, FCS: Fatigue Catastrophising Scale.
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Persistent fatigue, established w ith m onthly assessm ents w as previously not 
investigated  in  the first year after successful cancer treatm ent. To our knowledge 
th is is  the first prospective longitudinal study that assessed  patients treated for 
various m alignancies before and shortly after cancer treatm ent and followed the  
course of fatigue m onthly for a year after successful cancer treatm ent. Our study 
revealed three im portant issues. First, 21% of the cancer survivors were severely 
persistent fatigued in the year after cancer treatm ent. Second, fatigue before the 
start of the oncological treatm ent w as the only risk factor found for persistent 
fatigue. Third, the known perpetuating factors for fatigue assessed  shortly after 
cancer treatm ent had predictive value for persistent fatigue in the year after 
successful cancer treatm ent.
First, our resu lts showed that 3% of the survivors of prostate cancer, 23% of 
the breast cancer survivors, and 34% of the participants successfully treated for 
other tum ours were severely persistent fatigued. The finding that prostate cancer 
patients had less fatigue than breast cancer patients w as also found in  elderly  
cancer patients who were followed for a year46. There are indications that the  
factors sex and age can be relevant. W ithin a large sample of survivors of 
Hodgkin lym phom a’s an effect of sex and age w as found on fatigue47. There is  
also evidence that patients who receive an intensive oncological treatm ent are 
more likely to rem ain persistently fatigued48, 49. For example, it has been found 
that fatigued breast cancer survivors were more likely to have been treated with  
a combination of chem otherapy and radiation therapy or w ith chemotherapy 
alone as adjuvant treatm ent than non-fatigued breast cancer survivors who 
received only radiation therapy48. There is  also evidence that patients who did 
not have to undergo adjuvant treatm ent at all, and for whom surgery w as 
without complications experienced less often persistent fatigue49. However, in  our 
study it w as not possible to draw separate conclusions about the effect of cancer 
treatm ent, diagnosis, age or sex on severe persistent fatigue, because further 
subgroup analyses were not possible due to the sm all numbers. The diagnosis 
groups were inherently related to the m alignancy and consequently on types of
DISCUSSION
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treatm ent, sex and age. For example, prostate cancer is confined to older men, 
who don’t receive chem otherapy as curative cancer treatm ent.
Another lim itation of our study is  that the sample did not reflect the 
incidence of m alignancies in  the Dutch population. In the Dutch population  
breast cancer is the most common type of cancer, followed by colorectal cancer, 
lung cancer, skin cancer and prostate cancer, but in our sam ple patients with  
breast cancer and prostate cancer were the largest groups. Thus the finding that 
21% of our sample had severe persistent fatigue can’t be generalized to the 
population of all cancer survivors in  the Netherlands. As it w as not a population  
study the resu lts on the prevalence of severe persistent fatigue are difficult to 
generalize to other cancer survivors. However, our percentage of persistent 
fatigue in the breast cancer survivors is surprisingly similar to percentages found 
in other studies. We found that 23% of the breast cancer survivors had severe 
persistent fatigue. This percentage is w ithin the same range as reported in 
longitudinal studies in breast cancer survivors long after cancer treatm ent (21- 
24%)34, 50.
Our exploratory analysis of predictors showed that fatigue before the start 
of oncological treatm ent w as the strongest predictor for persistent fatigue in  the 
year after cancer treatm ent. This strong association betw een fatigue during 
several phases of cancer treatm ent and thereafter w as also found in other 
studies47- 51 52. The current study suggests that cancer-related factors are no 
strong risk factors in developing persistent fatigue. This w as also found in  other 
studies w ith long term cancer survivors16’ 34. Although other studies found that 
depression w as related to persistent fatigue long after cancer treatm ent 5 7 we 
did not find that depressive mood w as a predictor of persistent fatigue in our 
m ultivariate analysis.
This study showed that the known perpetuating factors for fatigue in  long 
term cancer survivors also predict persistent fatigue in the year after successful 
cancer treatm ent when assessed  shortly after cancer treatm ent. Stronger somatic 
attributions regarding fatigue, more fatigue catastrophising, a lower level of self­
reported physical activity and more im paired sleep (more specifically, difficulties 
sleeping at night, sleeping and resting more during the day) could be identified
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prospectively as factors related to persistent fatigue. Several other studies also 
found these fatigue perpetuating factors in long term cancer survivors11, 12, 32, 53 
54. In the current study these factors were already identified shortly after cancer 
treatm ent, when the acute effects of cancer treatm ent had subsided. The fact that 
not all six factors significantly predicted persistent fatigue in our study might be 
explained by the fact that the number of patients w ith severe persistent fatigue 
w as rather low.
Other lim itation of th is study should also be acknowledged. The data were 
used from participants who received usual care only and from participants who 
received a brief nursing intervention (BNI) aim ed at fatigue. U sing the data both 
conditions w as justified to our opinion, as the BNI had no effect on fatigue 
compared to usual care21 and no significant differences were found between the 
two groups on the baseline characteristics and fatigue at any of the other 
assessm ents.
Furthermore, not all participants completed all m onthly fatigue  
assessm ents between T2 and T3. This might raise the question if  participants 
who adhered to completing the m onthly assessm ents differed in the level of 
persistent fatigue compared to participants who did not adhere. However, no 
significant difference on fatigue w as found at T2 and T3 between participants 
who were included in the data analyses (n=125) and participants who were not 
included in  the data analyses (n=12).
In our study we determ ined persistent fatigue over the last 6 m onths of our 
data collection. This period w as chosen as the definition of chronic fatigue states  
that severe fatigue should be present for at least 6 m onths26. One could reason  
that the results might be different w hen a different tim e frame w as chosen. 
However, we found the same results when persistent fatigue w as determined  
over a longer period of time, suggesting that the results are stable.
The clinical im plications of our findings are the following. It is  im portant to 
identify patients at risk shortly after cancer treatm ent is finished. Based on our 
results, patients w ith severe fatigue before and shortly after cancer treatm ent 
are probably the patients at risk to develop severe persistent fatigue. CBT for 
postcancer fatigue proved to be an effective treatm ent for severely fatigued long
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term cancer survivors24’ 25. The current study found that the perpetuating factors 
of fatigue assessed  shortly after cancer treatm ent had predictive value for 
persistent fatigue. So it would be advisable to offer CBT for postcancer fatigue to 
cancer patients suffering from severe fatigue shortly after cancer treatm ent is 
finished.
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Chapter 7
General discussion: learning points
In the studies of th is dissertation patients who just received the diagnosis cancer 
were followed until fourteen m onths after successful cancer treatm ent for various 
m alignancies. Patients were assessed  before start of the oncological treatm ent, 
shortly after the oncological treatm ent and one year later. In the year after 
cancer treatm ent fatigue w as assessed  m onthly for a year. During the curative 
cancer treatm ent patients participated in a random ized controlled trial (RCT) to 
evaluate two interventions for fatigue and compare these w ith usual care. Our 
studies revealed new and even some unexpected insights. In th is chapter we will 
start w ith briefly repeating the resu lts of the intervention RCT, because several 
new questions rose as a consequence of th is RCT. Thereafter we w ill describe the 
new findings in  each paragraph. We w ill describe w hy a particular research  
question rose, we w ill present the findings, and we w ill place the results in view  
of the current literature. We w ill finish each paragraph w ith the conclusions and 
clinical im plications. In th is chapter we w ill inevitably repeat some findings from 
the previous chapters, but we w ill try to place the findings in  a broader 
perspective and w ill use updated literature. We w ill not describe the used  
m ethods in detail here.
EVALUATING STRATEGIES TO MANAGE FATIGUE DURING ACTIVE 
TREATMENT AND TO PREVENT PERSISTENT FATIGUE AFTER  
CURATIVE TREATMENT FOR CANCER.
Fatigue is  one of the most common and distressing symptoms in cancer patients, 
and w hen severe it has a large impact on daily functioning and quality of life1-3. 
Almost all cancer patients experience fatigue during active cancer treatm ent. 
Prevalences of 90% or higher were even reported4-8. Fatigue continues to be 
problematic for m any patients after cancer treatm ent is finished. To reduce 
fatigue after cancer treatm ent it m ight be im portant to intervene as early as
possible. Therefore we w anted to intervene already during active cancer 
treatm ent. There are several psychosocial interventions given to patients during 
cancer treatm ent (see a system atic review in chapter two). However, the 
assessm ents of these RCTS were seldom performed at clinically relevant 
moments, but incongruent w ith the phase of the oncological treatm ent. For 
example, in  several intervention studies for fatigue part of the patients still 
continued receiving treatm ent for cancer after the post-intervention assessm ent9-
12. This design is  suitable to investigate the efficacy of an intervention, but is 
unsuitable to evaluate w hether the intervention had effect at the moment when  
the oncological treatm ent is finished. To our best knowledge there is no fatigue 
intervention RCT during cancer treatm ent that assessed  patients at clinical 
relevant moments; before the start of cancer treatm ent and shortly after 
finishing cancer treatm ent.
In the current RCT two interventions for fatigue during cancer treatm ent 
were compared to usual care (UC). The first intervention w as a m inim al 
intervention performed by nurses. The brief nursing intervention (BNI) focused 
only on regulating and increasing physical activity. The second intervention w as 
cognitive behaviour therapy (CBT). This intervention w as also focused on 
physical activity, but additionally changed fatigue related cognitions and 
behaviours, such as dysfunctional cognitions about fatigue, a distorted sleep- 
wake rhythm, and dysfunctional coping w ith the consequences of having cancer. 
The main aim of th is intervention RCT was, first to reduce fatigue shortly after 
successful cancer treatm ent and, secondly to prevent patients from becoming 
chronically fatigued long after cancer treatm ent.
P atients were recruited shortly after the diagnosis cancer and assessed  
before the start of cancer treatm ent w ith curative in tent (see chapter three). In 
total 240 patients were assessed  at baseline (T1) and consequently they were 
randomly assigned to one of the three conditions. The post-intervention  
assessm ent (T2) w as in itially  planned six m onths after T1. If patients received 
surgery, chem otherapy or radiotherapy in the fifth or sixth month, they were 
assessed  two m onths after these treatm ents were finished. Thus T2 took place at 
least two m onths after cancer treatm ent w as finished. The follow-up assessm ent
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(T3) took place one year after T2, and between T2 and T3 fatigue w as assessed  
monthly w ith the Checklist Individual S trength13, 14, a w ell validated  
instrum ent15, 16. Thirty patients were excluded post-random ization because of 
disease progression or other reasons.
Our results showed that CBT significantly reduced fatigue assessed  shortly 
after cancer treatm ent w as finished. Also significantly fewer participants were 
severely fatigued from two m onths after cancer treatm ent, dem onstrating the  
clinical relevance of th is outcome. The BNI did not reduce fatigue compared to 
UC. After one year follow-up the effect of CBT were not significant anymore. 
Further analyses showed that the CBT nearly had a significant effect on fatigue 
until seven m onths post-intervention, but thereafter the effect diminished. 
Overtreatm ent is probably one of the main reasons why we could not find an 
effect anymore of CBT at one year follow-up. This w ill be explained in the 
following paragraphs.
The current RCT did dem onstrate the effectiveness of CBT for fatigue 
during curative cancer treatm ent. Other im portant findings, the clinical 
im plications of our findings, and comparisons of our RCT w ith other intervention  
studies are described in the following paragraphs.
SURPRISINGLY LARGE NUM BERS OF CANCER PATIENTS ARE ALREADY  
SEVERELY FATIGUED BEFORE INITIATION OF CANCER TREATMENT.
Almost all patients experience fatigue during active cancer treatm ent17. 
Generally it is  thought that there are probably three factors contributing to 
fatigue during th is period; 1) the cancer itself, 2) the oncological treatm ent 
against cancer and side-effects, 3) the associated distress, such as regular v isits  
to the hospital or concerns about the future. Therefore it w as expected that the 
level of fatigue in cancer patients before the start of cancer treatm ent would be 
low. However, there w as no scientific evidence for these assum ptions. Before the  
current study w as performed there were three studies that indicated that fatigue  
could be a relevant issue prior to cancer treatm ent18-20. One study found that lung  
cancer patients before surgery reported significantly more fatigue compared with  
age-m atched control subjects19. Two other studies concluded that fatigue
205
contributed to increased distress and im paired quality of life in new ly diagnosed  
cancer p atien ts18- 20. There were no studies that focused on the occurrence and 
related factors of fatigue in treatm ent naïve cancer patients. Our first aim w as to 
determ ine how m any cancer patients reported severe fatigue after being 
diagnosed, but before initiation of any medical treatm ent for cancer.
Patients were included in  th is study after being diagnosed w ith a primary 
tumour and before initiation of treatm ent w ith curative intention. Treatment 
could be surgery, radiotherapy, chem otherapy, or a combination of these. 
Patients could additionally receive hormone therapy. D etailed information about 
inclusion criteria and recruitm ent procedure is  described in chapter three.
In total 24% patients appeared to be severely fatigued prior to cancer 
treatm ent, varying betw een diagnoses. The presence of severe fatigue w as the 
low est in  patients w ith prostate cancer (14%), but higher in breast cancer 
patients (20%), and the h ighest in  gastrointestinal cancer patients (28%)21.
Our study sample did not reflect the incidence and types of cancer in the 
Dutch population. In the N etherlands breast cancer is the most common type of 
cancer, followed by colorectal cancer, lung cancer and prostate cancer. In our 
sample more participants were diagnosed w ith prostate cancer, w ith low levels of 
fatigue, and fewer participants were diagnosed w ith gastro-intestinal cancer, 
w ith high levels of fatigue. So the found prevalence of 24% severe fatigue could be 
an underestim ation. A recently published study in a group of older cancer 
patients prior to surgery for various m alignancies confirmed our findings22. In 
th is study 28% of the cancer patients had moderate to severe fatigue (a score 
between 4 and 10 on the brief fatigue inventory23) two w eeks before planned  
surgery for m ostly breast cancer, gastrointestinal cancer and genitourinary  
cancers. Furthermore th is study found that moderate to severe fatigue prior to 
surgery increased the likelihood of having a post-surgical complication22. This 
indicates that fatigued cancer patients starting w ith oncological treatm ent might 
be a vulnerable group for ongoing problems. U nfortunately in our study we did 
not m easure complications of surgery or adjuvant treatm ent.
In the literature no indication can be found that postcancer fatigue is  
associated w ith type of m alignancy17. However, in the current study, in
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treatm ent naïve cancer patients, there is evidence that fatigue differs between  
diagnosis groups. The number of severely fatigue treatm ent naïve cancer patients 
w as the low est in patients diagnosed w ith prostate cancer. A more recent study 
even found no significant difference in fatigue betw een men w ith prostate cancer 
compared to a non-cancer m atched control group24. Prostate cancer is  often 
diagnosed after a screening test, and less often because patients seek treatm ent 
for symptoms. Consequently patients probably don’t have symptom s of fatigue at 
th is stage. Fatigue appears to be higher in patients who are diagnosed after 
presenting symptoms. For example, many patients get diagnosed w ith colon 
cancer after consulting w ith their physician when having symptoms, such as 
constipation or blood in  their stools. Our study showed that 28% of patients w ith  
gastrointestinal cancer were severely fatigued.
To conclude; it is  generally thought that fatigue arises when cancer patients 
start w ith oncological treatm ent. Consequently, we expected that fatigue levels  
would be low before initiation of treatm ent, but there were hardly any studies 
that investigated  fatigue in  treatm ent naïve cancer patients. Contrary to w hat 
was expected our study revealed that rather large num bers of cancer patients  
were already severely fatigued before the start of cancer treatm ent. The presence 
of severe fatigue varied betw een the diagnosis groups, the low est in patients w ith  
prostate cancer.
NOT TYPE OF MALIGNANCY BUT PSYCHOLOGICAL AND BEHAVIOURAL  
FACTORS CONTRIBUTE TO SEVERE FATIGUE BEFORE INITIATION OF 
CANCER TREATMENT.
As the first study showed that about a quarter of the participants had severe 
fatigue before initiation of cancer treatm ent we subsequently investigated which  
factors were associated w ith severe fatigue at th is stage. To our knowledge this  
has never been done before. We explored if  type of m alignancy, depressive mood 
and anxiety, sleep disturbances, pain, se lf reported physical activity and pre­
existing fatigue were associated w ith severe fatigue in treatm ent naïve cancer 
patients.
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Although statistically  significant differences were found in the prevalence of 
severe fatigue betw een various m alignancies in univariate analysis, resu lts of 
m ultivariate analyses showed that four other factors were more strongly related  
to severe fatigue prior to cancer treatm ent. These factors were higher levels of 
fatigue one year before diagnosis, currently lower levels of self reported physical 
activity, depressive mood and more im paired sleep and rest21. Thus, our findings 
dem onstrated that psychological and behavioural aspects were more strongly 
related to severe fatigue before cancer treatm ent, than type of malignancy.
THERE IS NO SOLID EVIDENCE FOR THE EFFECTIVENESS OF 
INTERVENTIONS NOT SPECIFIC FOR FATIGUE DURING CANCER 
TREATMENT.
Efforts to m anage fatigue in cancer patients should first focus on treating somatic 
causes for fatigue, such as anaem ia. Treating somatic causes of fatigue is  a 
discussion in itself, but lies beyond the scope of th is thesis. Often no other 
somatic causes can be identified other than the disease itse lf and the oncological 
treatm ents. Psychosocial interventions have been regarded as one of the most 
prom ising interventions to manage fatigue in  cancer patients, but there w as no 
system atic review evaluating the effectiveness of psychosocial interventions for 
fatigue during active cancer treatm ent. We investigated if  psychosocial 
intervention in  general were effective in reducing fatigue, and if  specific types of 
interventions were the most effective in  reducing fatigue during cancer 
treatm ent.
The system atic review, performed until September 2008, identified 27 RCTs 
of which only seven studies reported significant effects of the psychosocial 
intervention on fatigue. Thus, in general there w as lim ited evidence that 
psychosocial interventions during cancer treatm ent were effective in reducing 
fatigue. More specifically, we found no solid evidence for the effectiveness of 
interventions not specific for fatigue. These are interventions aimed at improving 
psychological distress, mood and physical symptoms. Contrary to this, 
psychosocial interventions specifically for fatigue can be seen as a prom ising type 
of intervention. The phrase ‘prom ising intervention’ w as chosen because the
208
G eneral discussion: learning points
number of RCTs is still lim ited. The effectiveness of interventions specific for 
fatigue w as significantly higher (80%) compared to interventions not specific for 
fatigue (14%). In five studies the interventions were specifically focused on 
fatigue, w ith four being effective. The five interventions, of which four were 
effective, were brief, consisting of three individual sessions, provided by 
(oncology) nurses. In general, during these interventions participants were 
educated about fatigue, were taught in  self-care or coping techniques, and 
learned activity m anagem ent.
A literature update of psychosocial interventions for fatigue during cancer 
treatment.
In the following paragraphs we w ill update the review on psychosocial 
interventions for fatigue during active cancer treatm ent. We would like to 
confirm if psychosocial interventions specifically for fatigue are the most effective 
type of intervention in reducing fatigue. Our aim is also to confirm that 
psychosocial interventions not specifically aimed at fatigue are rarely effective in  
reducing fatigue.
Betw een Septem ber 2008 and December 2010 five new RCT studies, 
including our own, were published evaluating psychosocial interventions during 
cancer treatm ent9, 10 25-27. Two RCTs dem onstrated the effectiveness of 
interventions specifically aim ed at fatigue. The other three RCTs evaluated  
interventions not specifically aimed at fatigue, but these interventions were not 
effective in reducing fatigue.
We describe each of the five intervention studies in  brief below. First, we 
discuss the intervention RCTs specifically aim ed at fatigue. One of the two 
intervention studies sp ec ifica lly aimed at fatigue during cancer treatm ent w as 
our own intervention study. This study is described in  detail in chapter four.
In the second RCT a psychological intervention combining cognitive-  
behavioural therapy and hypnosis (CBTH) for fatigue w as evaluated in breast 
cancer patients who received radiotherapy (n=42)27. The CBTH intervention  
consisted of a hypnosis session and a session teaching participants CBT skills on 
the pre-radiotherapy planning session. Participants received a CD w ith hypnosis
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intervention, a CBT workbook to review and worksheets. During radiotherapy  
the therapist met twice a w eek for a total of 12 sessions to go over the 
worksheets. A ssessm ent took place w eekly during the intervention and 
radiotherapy. A significant effect of the CBTH intervention on the rate of change 
in fatigue w as found, such that on average, CBTH participants’ fatigue did not 
increase over the course of treatm ent, w hereas control group participants’ fatigue 
increased linearly28. Cohen’s d of .82 w as reported, which indicates a large effect 
size.
The following three RCTs of M olassiotis et at., (2009), Berger et al. (2009), 
and Barsevick et al., (2010) evaluated psychosocial interventions n o t specifically 
aim ed at reducing fatigue during cancer treatm ent. M olassiotis et at., (2009)26 
assessed  the effectiveness of a symptom-focused home care program by a nurse 
compared w ith standard care. The intervention w as given during the six cycles of 
chem otherapy in patients w ith a diagnosis of colorectal (n = 110) and breast (n = 
54) cancer who were receiving oral chem otherapy (capecitabine). Significant 
im provem ents in  symptoms of oral m ucositis, diarrhea, constipation, nausea, 
pain, fatigue, and insom nia were observed in the home care group in comparison 
w ith the control group. However, the im provem ent on fatigue w as only 
significant during the in itia l two cycles, but not thereafter. Thus the intervention  
only had a temporarily effect on fatigue. The effect size of th is study could not be 
calculated, because only m eans were reported.
Berger et al. (2009) evaluated a behavioural therapy consisting of an 
individualized Sleep Promotion Plan, including modified stim ulus control, 
modified sleep restriction, relaxation therapy, and sleep hygiene. This 
intervention w as given to breast cancer patients receiving adjuvant 
chem otherapy treatm ents (n=219). R esults showed that sleep quality improved  
shortly after the intervention10 and after one year follow-up29 compared to 
controls who received healthy eating information and attention. There were no 
differences between the two groups on any of the fatigue assessm ents. Thus, 
there were no short term or long term effects on fatigue.
The RCT of Barsevick et al., (2010)9 evaluated the efficacy of an energy and 
sleep enhancem ent intervention to relieve sleep disturbance and fatigue and
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improve health-related functional status in cancer patients receiving 
chem otherapy (n=153). The intervention had no effect on any of the outcomes 
including fatigue.
To summarize, after September 2008 five new RCTs were published that 
evaluated psychosocial interventions for fatigue during cancer treatm ent. The 
three interventions n o t  specifically aim ed at fatigue did not have an effect on 
fatigue, although one intervention reduced fatigue temporarily. Both  
interventions specifically aim ed at fatigue were effective. These RCTs confirm  
our previous conclusions that the psychosocial interventions specifically aimed at 
reducing fatigue during cancer treatm ent have the h ighest probability of being  
effective. There is no solid evidence for the effectiveness of interventions not 
specific for fatigue.
NOT ALL CANCER PATIENTS N EED A N  INTERVENTION FOR FATIGUE 
DURING ACTIVE CANCER TREATMENT.
As nearly all cancer patients w ill experience fatigue during active cancer 
treatm ent17, we assum ed that most patients could benefit from an intervention  
for fatigue. Therefore in  the design of the RCT it was decided to offer the 
interventions to all recently diagnosed cancer patients who were going to receive 
treatm ent w ith curative intent. Although fatigue w as not assessed  during active 
cancer treatm ent, resu lts of the RCT showed that the number of patients with  
severe fatigue increased in the UC group as expected. The frequency of severe 
fatigue was 19% before the start of cancer treatm ent in  the UC group, and 
increased to 31% at two m onths after cancer treatm ent w as fin ished (see chapter 
four). Furthermore we found that in the UC group 65% were not severely 
fatigued at T1 or T2. Thus these patients managed fatigue them selves w ithout a 
specific intervention. It is reasonable to assum e that about the same percentage 
in our CBT condition also didn’t need th is intervention25. Although we 
dem onstrated the effectiveness of CBT for fatigue during cancer treatm ent, 
offering all cancer patients CBT intervention did probably lead to overtreatment.
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WHICH INDICATIONS CAN BE FO UND FOR CBT FOR FATIGUE DURING  
CURATIVE CANCER TREATMENT?
Because we probably over treated cancer patients w ith CBT for fatigue during 
cancer treatm ent th is raised the question who would benefit the most from CBT, 
or in  other words what are the indicators for CBT for fatigue during cancer 
treatm ent? Therefore we explored which factors moderated the CBT intervention, 
using interaction models. Our results showed that participants who experienced  
more concentration and memory problems benefited more from CBT for fatigue. 
It should be noted that th is exploratory study and that it is  possible that there 
could be other moderators that weren’t found in th is study because of a lack of 
power. In a previous study it w as dem onstrated that fatigued cancer survivors 
also have higher scores on self reported concentration and memory problems30. So 
an interpretation of our findings could be that patients w ith more concentration 
and memory problems benefit more by CBT because they are more severely 
fatigued.
INCREASING PHYSICAL ACTIVITY IS NOT A  MEDIATOR IN  REDUCING  
FATIGUE DURING ACTIVE CANCER TREATMENT.
It is generally assum ed that exercise is  beneficial for cancer patients, but the 
effect on fatigue is  not clear-cut. Some review s found no effect of exercise on 
reducing fatigue31, 32. In addition, some exercise studies did not find an effect on 
fatigue, even though physical fitness increased33-35.
Exercise interventions aim ing to reduce fatigue are based on the  
assum ption that a lack of physical activity and deconditioning during cancer 
treatm ent can worsen fatigue36. W hen patients are diagnosed and treated for 
cancer, their activity pattern changes and they become physically less active, 
possibly leading to deconditioning37. This can result in a downward spiral. 
Patients w ith decreased physical condition become more easily  fatigued, and 
when patients experience fatigue they react by becoming physically even less  
active. Exercise can break th is cycle by increasing physical condition and physical 
activity.
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Physical activity w as an im portant part of both interventions of our RCT. 
The BN I focused only on physical activity and it w as one of the elem ents in  the  
CBT for fatigue during cancer treatm ent. Patients were advised to be as active as 
possible and subsequently to increase their physical activity level stepwise; they  
were encouraged to m aintain it. The assum ption that increasing physical activity 
reduces fatigue is widespread, but the m ediating role of physical activity in 
interventions aim ing to reduce fatigue during cancer treatm ent had never been  
demonstrated. We investigated  if  the reduction in  fatigue induced by the CBT 
w as mediated by increased physical activity.
To test for mediation, physical activity w as assessed  w ith actigraphy 
(actometer) and questionnaires. We found that there w as no effect of the  
interventions on physical activity. This already showed that m ediation w as 
absent. Further analyses showed that the reduction in fatigue realized by CBT 
could not be explained by an increase in physical activity. Contrary to our initial 
expectations increased physical activity did not m ediate the reduction in  fatigue  
realized by CBT, w hether physical activity w as m easured w ith actigraphy or with  
self report m easures.
One could reason that the m ediating role of physical on fatigue could not be 
demonstrated, because the interventions were not successful in increasing  
physical activity. It could be that physical activity increased temporarily during 
the interventions, but th is w as not assessed in  our study. More im portantly our 
study did show that w ithout a lasting increase in physical activity the CBT 
significantly reduced fatigue.
Increasing and regulating physical activity is  also one of the elem ents of 
CBT for postcancer fatigue and chronic fatigue syndrome. The m ediating role of 
physical activity w as also investigated in these types of CBT. These studies also 
dem onstrated that a lasting increase in physical activity w as not necessary to 
reduce fatigue in patients w ith postcancer fatigue and chronic fatigue syndrome38 
(Gielissen et al., submitted).
The results of two recent m eta-analyses on exercise studies can be seen as 
support of our finding that increasing physical activity is  not a necessity to 
reduce fatigue during cancer treatm ent. Speck et al., (2009) investigated  the
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effects of physical activity trials during and post cancer treatm ent on various 
health outcomes. They found that 15 trials assessed  the effect of exercise on 
fatigue, of which six trials found a significant effect. The strength of the effect 
sizes were h ighly heterogeneous probably because the physical activity  
interventions have not targeted participants on a needs-based approach. The 
m eta-analysis dem onstrated no significant effect on fatigue of exercise during 
cancer treatm ent39. Another m eta-analysis identified 18 RCTS, 12 in patients 
w ith breast cancer, four in  prostate cancer patients and two in other cancer 
patients. They found a significant reduction on fatigue of exercise during breast 
cancer treatm ent, compared w ith no exercise, but in  general the effect sizes were 
small. Subgroup analyses even showed that home-based exercise did not lead to a 
significant reduction in  fatigue40. If increasing physical activity would be the 
mediator for reducing fatigue one would expect much more effective exercise 
studies than found.
It could be that physical activity has an indirect effect on fatigue rather 
than a direct effect. This indirect association w as dem onstrated in a recent study 
in breast cancer survivors. They found that physical activity had a direct effect on 
self-efficacy and, in turn, self-efficacy had a direct effect on fatigue41.
It is  probably not the physical activity itse lf leading to a reducing in  fatigue. 
It is  more likely that during exercise certain cognitions are changed that have a 
positive effect on fatigue. Young and W hite (2006) found that self-reported  
activity level bore no relationship to fatigue, but beliefs about activity appeared 
to predict fatigue directly in breast cancer survivors42. R esults of a graded 
exercise RCT for CFS also dem onstrated that not physical condition, but 
symptom focusing m ediated the im provem ent in fatigue43. To conclude, it could 
be that physical activity has an indirect effect on fatigue, but cognitions are 
probably more im portant factors for reducing fatigue during cancer treatm ent.
THE COURSE OF FATIGUE IS ALREADY STABLE FROM TWO MONTHS 
AFTER THE EN D  OF CANCER TREATMENT.
M any patients recover spontaneously from the direct effects of cancer treatm ent, 
but unfortunately part of the cancer survivors rem ain severely fatigued. Between
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20 - 40% of the survivors don’t recover, but continue to be severely fatigued44'48. 
Persistent fatigue can continue for years w ith a major im pact on daily 
functioning and quality of life17, 49, 50.
A review in disease free breast cancer survivors found support for the  
existence of ongoing postcancer fatigue, but found an im provem ent over tim e51. 
In the study of Servaes et al., (2007) fatigue w as investigated  m onthly for two 
years in  breast cancer survivors who were treated at least 6 m onths previously. 
The percentage of severe fatigue w as 39% at baseline and 23% at two years 
follow-up, suggesting that some recovery of fatigue takes place w ithin the first 
3-4 years after breast cancer treatm ent and thereafter stabilizes52. The 
percentages of severe fatigue after treatm ent for m alignant and benign bone and 
soft tissue tum ours w as 43% between the first and second year, 34% betw een the 
second and the third year, and thereafter stabilized betw een 18 to 26%53. Based  
on th is study it w as assum ed that the level of fatigue would be even higher 
shortly after cancer treatm ent w as finished, estim ated betw een 40 - 50%, would 
decrease significantly during the first six to tw elve m onths after cancer 
treatm ent to 30% - 40%, and stabilizing thereafter to about 25%. This w as only a 
presumption, because studies testing th is assum ption were lacking. Studies 
providing insight into the course of fatigue in first year after cancer treatm ent 
were absent. Therefore, as part of our study design, fatigue w as assessed  
m onthly for a year in patients successfully finished treatm ent treated for various 
m alignancies.
Studying the course of fatigue in various diagnosis groups revealed that 
the level of fatigue did not decrease during the year after successful cancer 
treatm ent as in itia lly  expected, but rem ained stable.
One could reason that patients recovered from fatigue in the first two 
m onths after cancer treatm ent finished. For exam ple Given et al., (2001) 
assessed  older cancer patients who were new ly diagnosed w ith breast, colon, 
lung, or prostate cancer and additional assessm ents took place at 6—8, 12—16, 24— 
30, and 52 weeks. They found that after 40 days no extended effects cancer 
treatm ent could be found on fatigue54. So it is possible that levels of fatigue were
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higher im m ediately after cancer treatm ent w as finished and decreased to 21% at 
tim e of T2.
The prevalence of severe persistent fatigue w as lower than presum ed. In 
our study the occurrence of severe persistent fatigue was 21%, and not about 40% 
to 50%. The occurrence of severe persistent fatigue varied significantly between  
the type of cancer in an univariate analysis. P atients successfully treated for 
prostate cancer had significantly less often severe persistent fatigue (3%) 
compared to patients treated for breast cancer (23%), or for other m alignancies 
(34%). The differences in fatigue betw een the diagnosis groups that w as already 
present from two m onths after cancer treatm ent, rem ained stable through the  
year thereafter. This is illustrated in  Figure 1.
To conclude, fatigue rem ains problematic for a part, between 3 and 34 
percent, of the patients after successful cancer treatm ent and the level of fatigue 
is  already stable from two m onths after the oncological treatm ent.
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Figure 1: Course of fatigue in patients w ith various malignancies.
216
G eneral discussion: learning points
WHO ARE AT RISK FOR REMAINING PERSISTENTLY FATIGUED AFTER  
SUCCESSFUL CANCER TREATMENT?
In chapter six we performed a prospective longitudinal study aim ing to identify  
which pre-treatm ent factors, post-treatm ent factors and cancer-related factors 
could predict persistent fatigue in the year after cancer treatm ent.
The occurrence of severe persistent fatigue in  the natural course varied  
significantly betw een the type of cancer patients were treated for. There is 
evidence that patients who receive an intensive oncological treatm ent are more 
likely to rem ain persistently fatigued55- 56. For exam ple, it has been found that 
fatigued breast cancer survivors were more likely to have been treated w ith a 
combination of chemotherapy and radiation therapy or w ith chemotherapy alone 
as adjuvant treatm ent than non-fatigued breast cancer survivors who received  
only radiation therapy55. There w as also found that patients who did not have to 
undergo adjuvant treatm ent at all, and for whom surgery w as without 
complications experienced less often persistent fatigue56. In our study it w as not 
possible to draw separate conclusions about the effect of cancer treatm ent, 
diagnosis, age or sex on persistent fatigue, because the diagnosis groups were 
inherently related to the m alignancy and consequently on types of treatm ent, sex 
and age. For exam ple, prostate cancer is  confined to older men, who don’t receive 
chem otherapy as curative cancer treatm ent.
Although we did found differences in persistent fatigue between the various 
m alignancies the results of the m ulti-variate analysis showed that cancer-related  
characteristics were not predictive of persistent fatigue. Our analysis w ith pre­
treatm ent related factors and cancer and treatm ent related factors showed that 
fatigue before the start of cancer (at T1), and fatigue one year before the 
diagnosis (retrospectively) were the strongest predictors of persistent fatigue. 
Our analysis w ith post-treatm ent related factors showed that post-treatm ent 
fatigue w as the only predictor of persistent fatigue. This strong association  
between fatigue during several phases of cancer treatm ent and thereafter w as 
also found in other studies57-59.
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Thus, cancer patients who are fatigued prior to cancer treatm ent and 
patients who become fatigued shortly after cancer treatm ent is finished are at 
risk for persistent fatigue after successful cancer treatm ent.
THE PERPETUATING FACTORS OF SEVERE FATIGUE IN  LONG TERM  
CANCER SURVIVORS CAN ALREADY BE IDENTIFIED SHORTLY AFTER  
CANCER TREATMENT IS FINISHED.
The finding that severe fatigue is  already present from two m onths after cancer 
treatm ent is finished and that the level of fatigue did not change thereafter, 
raised the question if  CBT for postcancer fatigue, aim ed at the fatigue 
perpetuating factors, that proved to be effective in severely fatigued long term  
cancer survivors, could be offered at an earlier stage, as early as two months 
after successful cancer treatm ent.
First, a short explanation of perpetuating factors of fatigue. To understand  
fatigue in  long term cancer survivors a model of precipitating and perpetuating  
factors w as developed by our group60. According to th is model the cancer itself, 
the consequences of the illness and/or the treatm ent for cancer triggered fatigue 
(precipitating factors). After the direct effects of cancer treatm ent disappear, 
other factors cause severe fatigue to persist (perpetuating factors). Poor coping 
w ith cancer and treatm ent, excessive fear of disease recurrence, dysfunctional 
cognitions regarding fatigue, dysregulation of sleep, dysregulation of activity, low 
social support and negative social interactions were identified as perpetuating  
factors for persistent fatigue in long term cancer survivors61’ 62. CBT for 
postcancer fatigue clinically and significantly reduced fatigue and functional 
im pairm ents in  severely fatigued long term cancer survivors (on average five 
years after successful cancer treatm ent) and the effects were m aintained for at 
least 2 years61, 62. Currently CBT for postcancer fatigue is  offered as a regular 
treatm ent for severely fatigued cancer survivors who finished cancer treatm ent 
at least one year previously.
As it is  unknown if  CBT for postcancer fatigue can be offered shortly after 
cancer treatm ent, we investigated  if  the known perpetuating factors of fatigue in  
long term cancer survivors had a predictive value in the year after cancer
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treatm ent. We tested  if  the six fatigue perpetuating factors assessed  shortly after 
cancer treatm ent (T2) predicted persistent fatigue.
Our resu lts showed that four of the six known fatigue perpetuating factors 
assessed  shortly after cancer treatm ent predicted persistent fatigue in  the year 
after cancer treatm ent. These factors were: stronger somatic attributions 
regarding fatigue, more fatigue catastrophising, a lower level of self-reported  
physical activity and more im paired sleep. The clinical im plication of these  
findings is  that it is  useful and possible to treat severely fatigue cancer survivors 
with CBT for postcancer fatigue as early as two m onths after cancer treatm ent is 
successfully finished.
SUMMARY OF THE NEW  FINDINGS
• CBT for fatigue during curative cancer treatm ent proved to be an effective 
intervention.
• Surprisingly large num bers (24%) of cancer patients are already severely  
fatigued prior to the oncological treatm ent. Although the occurrence of 
severe fatigue varied betw een the types of m alignancies (14% - 28%) 
psychosocial factors contributed more strongly to severe fatigue before 
in itiation of cancer treatm ent.
• Psychosocial interventions specifically aim ed at reducing fatigue during 
cancer treatm ent have the h ighest probability of being effective. There is  no 
solid evidence for the effectiveness of interventions not specific for fatigue.
• Not all cancer patients need CBT for fatigue during curative cancer 
treatm ent. Offering CBT to all cancer treatm ent during cancer treatm ent 
lead to overtreatm ent.
• Concentration and memory problems prior to cancer treatm ent are 
indications for CBT for fatigue during curative cancer treatm ent.
• Increasing physical activity is  not a mediator in  reducing fatigue during 
active cancer treatm ent. CBT for fatigue during curative cancer treatm ent 
w as effective in reducing fatigue. This reduction w as realised w ithout an 
increase in physical activity. The reduction w as most likely realised by 
changing cognitions.
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The course of fatigue is  already stable from two m onths after the end of 
cancer treatm ent and does not decrease thereafter.
P atients experiencing fatigue before cancer treatm ent and becoming 
fatigued shortly after cancer treatm ent are patients at risk for rem aining  
persistently fatigued after cancer treatm ent is  successfully finished.
The known perpetuating factors for persistent fatigue in long term cancer 
survivors already had predictive value from two m onths after successful 
cancer treatm ent. These findings im plicate that it advisable to offer CBT for 
postcancer fatigue to severely fatigued cancer survivors from two months 
after successful cancer treatm ent.
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Summary
Cancer is  potentially a deadly disease, but w ith early detection and modern 
available treatm ents m any cancer patients survive these days. As the number of 
cancer survivors increases concerns were raised about the long term w ell being of 
cancer survivors. One of the long term complications of cancer treatm ent is 
chronic fatigue. Fatigue is  one of the most common symptoms experienced by 
patients during cancer treatm ent. U nfortunately not all cancer survivors recover 
spontaneously from fatigue. About 20 - 40% of the survivors rem ain persistent 
severely fatigued, even for years. Persistent fatigue im pairs their daily activities 
and dim inishes their quality of life substantially. Cognitive behaviour therapy for 
postcancer fatigue proved to be an effective therapy. This w as dem onstrated in  a 
random ised controlled trial (RCT) w ith long term cancer survivors. It would be in 
survivors’ best interest if  postcancer can be treated at an earlier stage and ideally  
if  postcancer fatigue could be prevented. The goal of the studies described in this 
thesis w as to evaluate two intervention strategies for fatigue during curative 
cancer treatm ent. These interventions were aim ed at reducing fatigue shortly 
after cancer treatm ent and preventing patients from becoming chronically 
fatigued. It w as also investigated  if persistent fatigue could be predicted and if 
risk factors or groups could be identified.
The f ir s t  chapter  starts w ith a brief description on the history of cancer, the 
treatm ent and the prevalence. In the last decennia fatigue in  cancer survivors 
has been recognized as a serious problem. The Expert Centre Chronic Fatigue of 
the Radboud U niversity Nijm egen M edical Centre w as one of the first performing 
scientific research on postcancer fatigue and developing a treatm ent. In this  
chapter the performed studies on the prevalence of postcancer fatigue and the  
model of precipitating and perpetuating factors of fatigue are briefly described. 
Furthermore the content of the thesis has been outlined.
Studying the literature we noticed that there w as a lim ited  number of reviews 
evaluating interventions for fatigue, moreover the review s did not distinguish  
interventions provided during active cancer treatm ent from interventions given  
to cancer survivors. B ased on th is finding we system atically studied the 
literature and wrote a review.
In the second chapter  th is Cochrane review is described. We evaluated if 
psychosocial interventions were effective in  reducing fatigue in  cancer patients 
receiving active treatm ent for cancer, and which types of psychosocial 
interventions showed to be the most effective. U ntil September 2008 we 
system atically searched for RCTs that evaluated psychosocial interventions in  
adult cancer patients during active treatm ent, w ith fatigue as an outcome 
measure. The search w as not restricted to type of m alignancy, stage, or cancer 
treatm ent. The psychosocial intervention needed to be a system atic treatm ent 
consisting of a process between the patient and the person giving the 
intervention. The intervention consisted of at least two contacts in which a care 
provider gave the patient some kind of personal feedback concerning the changes 
they were trying to achieve. Providing only inform ation w as not considered a 
psychosocial intervention in th is review. The search yielded 27 studies.
This review dem onstrated that there w as no solid evidence for the  
effectiveness of psychosocial interventions w ith a general approach. Only 3 of the 
22 studies (14%) were effective in reducing fatigue. These interventions were not 
specifically aim ed at fatigue, but at psychological distress, mood and physical 
symptoms in general.
Psychosocial interventions specifically aim ed at fatigue were found to be a 
prom ising type of intervention. Four of the five RCTs (80%) were effective in  
reducing fatigue. The five interventions were brief, consisting of three individual 
sessions, provided by (oncology) nurses. During these interventions participants 
were educated about fatigue, were taught in coping techniques or self-care, and 
learned to balance their periods of activities and rest.
The RCTs were very heterogeneous, on patient and treatm ent 
characteristics, types of interventions, and outcome m easures. This made it 
difficult to establish  which elem ents could be essentia l in  an intervention that
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aim s to reduce fatigue in cancer patients. Long term follow-up assessm ents were 
often lacking.
M ost cancer patients experience fatigue during active treatm ent. It is  generally  
thought, symptoms of fatigue arise as a consequence of the cancer itself, the 
treatm ents patients receive, and associated distress. Although several studies 
that investigated  the quality of life in cancer patients prior to the oncological 
treatm ent indicated that fatigue m ight be problematic at th is stage, fatigue was 
never the primary focus of study.
The study described in the th ird  chapter  investigated  the prevalence of 
severe fatigue and related factors, in  cancer patients before the initiation of 
treatm ent. This cross-sectional study w as based on 179 patients w ith various 
m alignancies who were assessed  before start of the oncological treatm ent with  
curative intention. All participants completed the Checklist Individual Strength  
to assess fatigue.
Contrary to w hat w as expected relatively many cancer patients already 
experienced severe fatigue before initiation of treatm ent. In total 24% patients 
were severely fatigued. The presence of severe fatigue prior to treatm ent w as the 
low est in patients w ith prostate cancer (14%), higher in breast cancer patients 
(20%) and the highest in the rem aining group of patients diagnosed w ith for 
exam ple lymphom as, colon cancer or gynaecological cancer (33%). When patients 
w ith gastrointestinal cancer were considered as a separate group, severe fatigue 
w as 28%. The prevalence of severe fatigue might even be underestim ated as 
fewer patients w ith colorectal cancer (who are more often severely fatigued) were 
present in  th is study, compared w ith the prevalence in the Dutch population.
R esults of th is study showed that four independent factors contributed to 
severe fatigue in  treatm ent naïve cancer patients; self-reported physical activity, 
depressive mood, im paired sleep and rest, and fatigue one year before the 
diagnosis. Psychological and behavioural factors contributed more strongly to 
severe fatigue before initiation of cancer treatm ent than the type of m alignancy  
itself.
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One of the main aim s of th is thesis w as to evaluate two interventions for fatigue 
during curative cancer treatm ent, comparing these w ith usual care. In chapter 
four  th is m ulticentre RCT is  described in  which seven hospitals participated. In 
total 220 patients w ith various m alignancies were assessed  before the start of 
cancer treatm ent (T1) and consequently they were random ized to one of the three 
conditions. P atients assigned to the brief nursing intervention (BNI) received two 
one-hour sessions, three m onths apart. The intervention focused on increasing  
and m aintaining physical activity only, and w hat to do if  complications during 
the oncological treatm ent occurred. Participants also received a booklet w ith the 
same recom m endations, explanations and advises as received during the 
sessions. Patients assigned to the cognitive behaviour therapy (CBT) received of 
up to ten one-hour sessions, w ithin six months, and the same booklet. The CBT 
focused besides physical activity on psychosocial elem ents, such as changing  
dysfunctional cognitions about fatigue and m aintaining a fixed sleep-wake 
rhythm. The third condition w as the control group and received only usual care 
(UC). The post-intervention assessm ent (T2) took place at least two m onths after 
cancer treatm ent, a period in which patients could recover from the direct effects 
of the oncological treatm ent. R esults showed that the CBT group w as 
significantly less fatigued at T2 compared to the UC group, however no 
significant difference w as found betw een the BNI and the UC. To conclude, this  
RCT dem onstrated that CBT given during curative cancer treatm ent proved to be 
an effective intervention, reducing fatigue at a clinical relevant moment; shortly 
after cancer treatm ent. Because the BNI had no effect on fatigue also doubts 
were raised about the role of physical activity on fatigue.
The assum ption that increasing physical activity reduces fatigue is  
w idespread but the m ediating role of physical activity in interventions aim ing to 
reduce fatigue during cancer treatm ent has never been demonstrated. A non- 
param etric bootstrap approach w as used to test if  the effect of CBT on fatigue 
w as m ediated by physical activity, but contrary to w hat w as expected the 
m ediating effect w as not confirmed. Thus, the reduction on fatigue elicited by 
CBT w as realized w ithout an increase in  physical activity.
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This RCT also showed that a large group of the UC condition w as not 
severely fatigued shortly after cancer treatm ent was finished. Apparently this 
group of patients m anaged fatigue during curative cancer treatm ent w ithout a 
specific intervention, such as CBT.
The study described in  chapter five  aim ed to identify the patient characteristics 
predicting an im provem ent in fatigue after CBT. A regression analysis with  
interactions w as performed to determ ine if functional im pairm ents quality of life 
and psychological distress on several domains moderated the effect of CBT on 
fatigue. R esults showed that there w as significant interaction w ith self reported 
cognitive functioning and CBT. This interaction showed that patients who 
reported more concentration and memory problems prior to the oncological 
treatm ent benefited more from CBT for fatigue. These factors are indicators for 
CBT. As th is w as an exploratory study there could be other moderators for CBT 
for fatigue that weren’t found due to a lack of power.
This chapter also describes the long term effect of CBT on fatigue. Two- 
hundred-ten participants in  the RCT were additionally assessed  one year after 
the second assessm ent (T3). M onthly fatigue assessm ents were completed during 
that year. R esults showed that at T3 no significant difference on fatigue could be 
found anymore between CBT and the UC group. Further analysis showed that 
the difference on fatigue betw een the CBT and the UC was observable until 
seven m onths after T2, but thereafter the difference dim inished. Overtreatment, 
treating patients w ith CBT who could manage fatigue them selves, is probably 
one of the main reasons w hy we could not find an effect anymore of CBT at one 
year follow-up. Clinically it is im portant that CBT should not be offered to all 
cancer patients, but to the patients at risk for becoming chronically fatigued after 
cancer treatm ent.
As the course of fatigue w as followed m onthly in  the year after successful cancer 
treatm ent persistent fatigue in cancer survivors could be investigated. In ch a p te r  
s i x  th is prospective study is described. The BNI had no effect on fatigue 
compared to the UC and therefore data of patients in these two groups could be
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combined for studying the natural course on fatigue. First, the prevalence of 
severe persistent fatigue w as investigated. R esults showed that in  total 24% of 
the 169 patients had severe persistent fatigue during the period of the last 6 
m onths of that year. The percentage severe persistent fatigue w as low in  patients 
treated for prostate cancer (3%), but patients treated for breast cancer (23%) and 
other m alignancies (34%) rem ained more often severely fatigued.
Secondly, the risk factors for persistent fatigue after successful cancer 
treatm ent w as investigated. R esults showed that (1) fatigue before the start of 
the oncological treatm ent, (2) fatigue one year before diagnosis, and (3) fatigue 
shortly after the treatm ent were the strongest predictors of persistent fatigue. 
Not former diagnosis and cancer treatm ent seem s to be param eters for 
developing persistent fatigue, but fatigue experienced before or shortly after 
cancer treatm ent proved to be risk factors.
CBT for postcancer fatigue is aim ed at changing the fatigue perpetuating  
factors proved to be a highly effective intervention in  severely fatigued long term  
cancer survivors. Early treatm ent w ith CBT for postcancer fatigue, shortly after 
cancer treatm ent, would be possible w hen the fatigue perpetuating factors have a 
predictive value for persistent fatigue. In th is study it w as tested  if  the six known  
fatigue perpetuating factors assessed  shortly after cancer treatm ent predict 
persistent fatigue in the year after cancer treatm ent. We found that four of the 
six perpetuating factors assessed  shortly after cancer treatm ent (T2) predicted  
persistent fatigue. These factors were strong somatic related attributions 
regarding fatigue, fatigue catastrophising, a low level of self-reported physical 
activity and im paired sleep and rest. The clinical im plication is  that CBT for 
postcancer can already offered to severely fatigued cancer survivors as early as 
two m onths after cancer treatm ent is  successfully finished.
The final discussion is  held in chapter seven. In th is chapter new and 
unexpected findings are discussed and put in  broader perspective in  view  of the 
most recent literature. In the first paragraph we sum m arize our findings of the 
main study aim; evaluating strategies to manage fatigue during active cancer 
treatm ent and to prevent persistent fatigue. In the next paragraphs the following
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new findings and questions are discussed: 1) Surprisingly large num bers of 
cancer patients are already severely fatigued before initiation of cancer 
treatm ent. 2) Not type of m alignancy but psychological and behavioural factors 
contribute to severe fatigue before initiation of cancer treatm ent. 3) There is  no 
solid evidence for the effectiveness of interventions not specific for fatigue during 
cancer treatm ent. 4) Not all cancer patients need an intervention for fatigue 
during active cancer treatm ent. 5) Which indications can be found for CBT for 
fatigue during curative cancer treatm ent? 6) Increasing physical activity is not a 
mediator in reducing fatigue during active cancer treatm ent. 7) The course of 
fatigue is already stable from two m onths after the end of cancer treatm ent. 8) 
Who are at risk for rem aining persistently fatigued after successful cancer 
treatm ent? 9) The perpetuating factors of severe fatigue in long term cancer 
survivors can already be identified shortly after cancer treatm ent is finished.
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Samenvatting
Kanker is potentieel een dodelijke ziekte, maar door vroege detectie en moderne 
beschikbare behandelingen overleven veel patiënten de ziekte. Door het 
toenem ende aantal patiënten die de ziekte overleefden is er meer aandacht 
gekomen voor hun welzijn. Eén van de lange termijn effecten van de behandeling  
van kanker is chronische vermoeidheid. Tijdens de behandeling van kanker is 
verm oeidheid één van de m eest voorkomende symptomen. H elaas herstellen  niet 
alle patiënten van vermoeidheid. Ongeveer 20 tot 40% van de ziektevrije 
oncologie patiënten blijft chronisch vermoeid, soms zelfs jaren lang. Chronische 
verm oeidheid leidt tot beperkingen in  het dagelijkse leven en tast de kw aliteit 
van leven ernstig aan. Cognitieve gedragstherapie voor “verm oeidheid na 
kanker” is  een bewezen effectieve therapie. Dit is aangetoond in een 
gerandom iseerde gecontroleerde studie (RCT) met patiënten die lang ziektevrij 
waren. In het belang van de patiënten is  het w enselijk dat verm oeidheid in  een 
eerder stadium  zou kunnen worden behandeld en chronische verm oeidheid na 
kanker idealiter zou kunnen worden voorkomen. H et doel van de studie in dit 
proefschrift w as om twee interventiestrategieën voor verm oeidheid tijdens 
curatieve behandeling van kanker te evalueren. Deze interventies waren erop 
gericht om verm oeidheid kort na de behandeling van kanker te verm inderen en 
om chronische verm oeidheid na behandeling van kanker te voorkomen. H et is 
ook onderzocht of chronische verm oeidheid te voorspellen w as en of risicofactoren 
of —groepen geïdentificeerd konden worden.
Het eerste hoofdstuk  begint met een korte beschrijving van de geschiedenis over 
kanker, de behandeling, en de prevalentie. In de laatste decennia is  verm oeidheid  
bij ziektevrije oncologie patiënten erkend als een ernstig probleem. Het Nijmeegs 
Kenniscentrum  Chronische Vermoeidheid van het U niversitair Medische 
Centrum St Raboud w as één van de eersten die onderzoek deed naar 
verm oeidheid na kanker en een therapie hier tegen ontwikkelde. In dit hoofdstuk  
worden de uitgevoerde onderzoeken naar de prevalentie van verm oeidheid na 
kanker beschreven en wordt het model van uitlokkende en instandhoudende
factoren van verm oeidheid kort uitgelegd. Verder wordt de inhoud van dit 
proefschrift geschetst.
Bij het bestuderen van de literatuur w as het opvallend dat er een beperkt aantal 
overzichtsartikelen waren die interventies voor verm oeidheid evalueerden, en dat 
deze overzichtsartikelen geen onderscheid m aakten tussen  interventies tijdens 
actieve behandeling van kanker en interventies na behandeling van kanker. 
Naar aanleiding van deze constatering hebben we een system atisch de literatuur 
onderzocht en een overzichtsartikel geschreven.
In het tweede hoo fdstuk  staat dit overzichtsartikel van Cochrane 
beschreven. We hebben geëvalueerd of psychosociale interventies effectief waren  
in het reduceren van verm oeidheid bij patiënten met kanker die actief behandeld  
werden en w elke typen psychosociale interventies het m eest effectief waren. Tot 
september 2008 hebben we system atisch gezocht naar RCTs die psychosociale 
interventies evalueerden in volw assenen met kanker tijdens actieve behandeling, 
w aarin verm oeidheid een uitkom stm aat was. De zoekopdracht w as niet beperkt 
tot een type m aligniteit, stadium  van de ziekte, of behandeling. De psychosociale 
interventie moest een system atische behandeling zijn, die bestond uit een proces 
tussen  de patiënt en de persoon die de interventie gaf. De interventie moest 
tenm inste uit twee contact m om enten bestaan waarin de zorgverlener een vorm  
van persoonlijke feedback gaf over de veranderingen die de patiënt probeerde te 
realiseren. H et geven van inform atie alleen werd niet beschouwd als een 
psychosociale interventie in dit overzichtsartikel. De zoekopdracht leverde 27 
studies op.
Dit overzichtsartikel toonde aan dat er geen sterk bewijs is  voor de 
effectiviteit voor psychosociale interventies met een algem ene benadering. 
Slechts 3 van de 22 studies (14%) waren effectief in  het verm inderen van  
vermoeidheid. Deze interventies waren niet specifiek gericht op vermoeidheid, 
maar op psychologische stress, stem m ing en fysieke symptomen in  het algemeen.
Psychosociale interventies specifiek gericht op verm oeidheid bleek een 
veelbelovend type interventie. Vier van de vijf RCTs (80%)bleken effectief te zijn 
in het reduceren van vermoeidheid. De vijf interventies waren kort, bestonden uit
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3 individuele sessies, die gegeven werden door (oncologie)verpleegkundigen. 
Tijdens deze interventies werden deelnem ers geïnformeerd over vermoeidheid, 
werd hen geleerd over copingstechnieken of zelfzorg en leerden ze een balans te 
vinden tussen  perioden van activiteit en rust.
De RCTs waren zeer heterogeen, w at betreft patiënt- en 
behandelingskarakteristieken, typen interventies en uitkom stm aten. Dit maakte 
het moeilijk om vast te stellen w elke elem enten essentieel zijn in een interventie  
gericht om verm oeidheid in patiënten m et kanker te verminderen. Vaak  
ontbraken follow-up metingen.
De m eeste patiënten ervaren verm oeidheid tijdens actieve behandeling van  
kanker. In het algem een wordt gedacht dat verm oeidheidsklachten ontstaan als 
gevolg van de kanker zelf, de behandeling die patiënten ondergaan en de stress 
die hierm ee gepaard gaat. Ondanks dat verschillende studies naar kw aliteit van  
leven aangeven dat verm oeidheid problem atisch is bij patiënten met kanker 
voorafgaand aan de oncologische behandeling, w as verm oeidheid zelf niet eerder 
onderwerp van studie geweest.
In de studie die in  het derde hoo fdstuk  wordt beschreven is  onderzocht wat 
de prevalentie is van ernstige verm oeidheid en daaraan gerelateerde factoren in 
patiënten met kanker vóór aanvang van de oncologische behandeling. Deze cross- 
sectionele studie is  gebaseerd op 179 patiënten met verschillende m aligniteiten  
die werden gem eten voor de start van de behandeling met curatieve intentie. Alle 
deelnem ers vulden de Checklist Individuele Spankracht in, om verm oeidheid in 
kaart te brengen.
Anders dan we hadden verwacht ervoeren relatief veel patiënten met 
kanker al ernstige verm oeidheid voor aanvang van de behandeling. In totaal 
waren 24% van de patiënten al ernstig vermoeid. Ernstige verm oeidheid w as het 
m inst vaak aanwezig bij patiënten met prostaatkanker (14%), vaker bij patiënten  
met borstkanker (20%) en het vaakst bij de overige groep, bijvoorbeeld patiënten  
met lymfomen, darmkanker en gynaecologische kanker (33%). Als patiënten met 
gastro-intestinale kanker als een aparte groep bekeken werd was het percentage 
ernstige verm oeidheid 28%. De prevalentie van ernstige verm oeidheid kan zelfs
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een onderschatting zijn, omdat minder m ensen met colorectale kanker (die vaker 
ernstig verm oeid zijn) in  de studie aanwezig waren vergeleken met de 
prevalentie in de Nederlandse bevolking.
R esultaten van deze studie lieten  zien dat er vier factoren gerelateerd  
waren aan ernstige verm oeidheid bij patiënten voorafgaand aan de behandeling  
van kanker: zelfgerapporteerde licham elijke activiteit, depressieve stemming, 
gestoorde slaap en rust, en retrospectief verm oeidheid één jaar voor de diagnose. 
Psychologische en gedragsaspecten waren sterker gerelateerd aan verm oeidheid  
voor aanvang van de behandeling van kanker, dan het soort m aligniteit.
Eén van de hoofddoelen van dit onderzoek w as om twee interventies voor 
verm oeidheid tijdens curatieve behandeling van kanker te evalueren, door deze 
te vergelijken met de gebruikelijke zorg. In hoofdstuk vier is  deze m ulticenter 
RCT beschreven waaraan zeven ziekenhuizen deelnam en. In totaal werden 220 
patiënten met verschillende m aligniteiten gem eten voor de start van de 
behandeling van kanker (T1) en vervolgens werden ze random toegew ezen aan 
één van de drie condities. Patiënten die toegewezen waren aan de korte 
verpleegkundige interventie (VPI) kregen tw ee sessies van een uur, drie 
m aanden na elkaar. Tijdens de interventie stond het opbouwen en behouden van  
licham elijke activiteiten centraal. D aarnaast kregen ze adviezen over w at ze 
konden doen als er com plicaties van de oncologische behandeling voor zouden 
doen. Tevens kregen patiënten een boekje met daarin dezelfde aanbevelingen, 
verklaringen en adviezen die ook tijdens de sessies werden gegeven. Patiënten  
die toegewezen waren aan de cognitieve gedragstherapie (CGT) kregen m axim aal 
tien sessies van een uur gedurende zes maanden en hetzelfde patiëntenboekje als 
bij de VPI. De CGT richtte zicht naast licham elijke activiteit op psychosociale 
elem enten, zoals het veranderen van disfunctionele cognities over verm oeidheid  
en het behouden van een vast slaap- waakritm e. De derde conditie w as de 
controle groep, waarin patiënten de zorg kregen die gebruikelijk is  binnen het 
ziekenhuis (ZG). De m eting na de interventie (T2) vond tenm inste twee maanden  
na afronding van de oncologische behandeling plaats, een periode waarin  
patiënten konden herstellen  van de directe gevolgen van de behandeling van
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kanker. R esultaten lieten  zien dat op T2 de CGT groep significant minder 
verm oeid w as vergeleken m et de ZG groep. Er werd geen significant verschil 
gevonden tussen  de VPI en de ZG. Concluderend kan gezegd worden dat deze 
RCT aantoonde dat CGT, gegeven tijdens curatieve behandeling van kanker, een 
bewezen effectieve interventie is  die verm oeidheid reduceert op een klinisch  
relevant moment; kort na de behandeling van kanker. Doordat de VPI geen effect 
had op verm oeidheid ontstond er ook twijfel over de rol van licham elijke activiteit 
op vermoeidheid.
De aannam e dat een toenam e van licham elijke activiteit verm oeidheid  
verm indert is wijdverspreid, maar de medierende rol van licham elijke activiteit 
in interventies gericht op het verm inderen van verm oeidheid gedurende de 
behandeling van kanker is  nooit aangetoond. Een non-param etrische bootstrap 
analyse werd gebruikt om te testen  of het effect van CGT op verm oeidheid  
gem edieerd werd door licham elijke activiteit, maar tegenovergesteld w at werd  
verwacht, kon dit m ediërende effect niet worden bevestigd. Een afnam e van  
vermoeidheid, bew erkstelligd door CGT, w as gerealiseerd zonder een toenam e  
van licham elijke activiteit.
Deze RCT liet ook zien dat een groot deel van de ZG groep niet ernstig  
verm oeid w as kort na dat de behandeling van kanker w as afgerond. 
W aarschijnlijk is  deze groep patiënten in staat om met verm oeidheid om te gaan 
tijdens curatieve behandeling van kanker zonder een specifieke interventie, zoals 
CGT.
De studie beschreven in h o o fd s tu k  v i j f had tot doel om de karakteristieken van  
patiënten te identificeren die de verbetering in verm oeidheid na CGT 
voorspelden. Een regressie analyse met interacties werd uitgevoerd om te 
bepalen of verschillende domeinen van functionele beperkingen, kw aliteit van  
leven en psychologische stress het effect van CGT op verm oeidheid modereerden. 
R esultaten lieten  zien dat er een significante interactie w as tussen  
zelfgerapporteerd cognitief functioneren en CGT. Deze interactie liet zien dat 
patiënten die meer concentratie en geheugen problemen rapporteerden  
voorafgaand aan de oncologische behandeling profiteerden meer van CGT voor
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verm oeidheid Deze factoren zijn dan ook indicaties voor CGT. Omdat dit een 
exploratieve studie was, is  het mogelijk dat we andere moderatoren voor CGT 
voor verm oeidheid hebben gem ist door een gebrek aan power.
Dit hoofdstuk beschrijft ook het lange termijn effect van CGT op 
vermoeidheid. Tweehonderd tien deelnem ers van de RCT werden één jaar na de 
tweede m eting nogm aals gem eten (T3). M aandelijkse verm oeidheidsm etingen  
werden gedurende dat jaar verzam eld. R esultaten lieten  zien dat er tijdens T3 
geen significante verschil op verm oeidheid werd gevonden tussen  de CGT en de 
ZG groep. Verdere analyse liet zien dat het verschil op verm oeidheid tussen  CGT 
en de ZG zichtbaar b leef tot zeven maanden na T2, hierna werd het verschil 
kleiner. Overbehandeling, behandeling van patiënten met CGT die verm oeidheid  
zelf konden hanteren, is  waarschijnlijk de belangrijkste reden waarom er na een 
jaar geen effect van CGT meer gevonden kon worden. Klinisch is  het van belang 
dat CGT niet aan alle patiënten met kanker moet worden aangeboden, maar aan 
de patiënten die het risico lopen om chronisch verm oeid te worden na 
behandeling van kanker.
Omdat het verloop van verm oeidheid m aandelijks gevolgd werd in het jaar na 
succesvolle behandeling van kanker, kon persisterende verm oeidheid worden 
onderzocht in  ziektevrije oncologie patiënten. In hoofdstuk zes  is deze 
prospectieve studie beschreven. De VPI had geen effect op verm oeidheid  
vergeleken met ZG en daarom zijn de data van patiënten in deze twee groepen 
sam engevoegd voor het bestuderen van het natuurlijk beloop van vermoeidheid. 
Eerst werd de prevalentie van ernstige persisterende verm oeidheid onderzocht. 
R esultaten lieten  zien dat in  totaal 24% van de 169 patiënten last had van  
ernstige persisterende verm oeidheid gedurende de laatste 6 m aanden. Het 
percentage ernstige persisterende verm oeidheid w as laag in  patiënten die 
behandeld waren voor prostaatkanker (3%), maar patiënten die behandeld waren  
voor borstkanker (23%) of andere m aligniteiten (34%) ervoeren veel vaker 
ernstige persisterende vermoeidheid.
Ten tweede, werden de risicofactoren voor persisterende verm oeidheid na 
succesvolle behandeling van kanker onderzocht. R esultaten lieten  zien dat
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verm oeidheid (1) voorafgaand aan de oncologische behandeling, (2) één jaar voor 
de diagnose en (3) kort na de behandeling voorspellers waren voor persisterende  
vermoeidheid. N iet de voorm alige diagnose en de behandeling van kanker waren  
param eters voor het ontwikkelen van persisterende vermoeidheid, maar 
verm oeidheid voorafgaand en kort na de behandeling van kanker bleken  
risicofactoren.
CGT voor verm oeidheid na kanker, die gericht is  op het veranderen van de 
instandhoudende factoren van vermoeidheid, is  een zeer effectieve interventie  
voor m ensen met ernstige verm oeidheid lang na succesvolle behandeling van  
kanker. Eerdere behandeling m et CGT voor vermoeidheid, kort na de 
behandeling van kanker, zou mogelijk zijn als de instandhoudende factoren van  
verm oeidheid een voorspellende waarde hebben voor het persisteren van  
vermoeidheid. In dit onderzoek werd getest of de zes bekende instandhoudende 
factoren van verm oeidheid persisterende verm oeidheid voorspelden in het jaar na 
behandeling van kanker. We vonden dat vier van de zes instandhoudende 
factoren gem eten kort na behandeling van kanker (T2) persisterende 
verm oeidheid voorspelden. D eze factoren waren: sterke som atisch gerelateerde 
attributies, catastroferen van vermoeidheid, een laag niveau van  
zelfgerapporteerde licham elijke activiteit, en gestoorde slaap en rust. De 
klinische im plicatie is  dat CGT voor verm oeidheid na kanker tw ee m aanden na 
succesvolle behandeling van kanker al aangeboden kan worden aan ernstig  
verm oeide patiënten.
De afsluitende discussie wordt gevoerd in  hoofdstuk zeven. In dit hoofdstuk  
worden nieuw e en onverwachte bevindingen bediscussieerd en in een breder 
perspectief geplaatst in het licht van de m eest recente literatuur. In de eerste 
paragraaf vatten  we onze bevindingen om trent de belangrijkste doelstelling  
samen: evaluatie van m anagem entstrategieën voor verm oeidheid tijdens 
curatieve behandeling van kanker en ter preventie van persisterende 
vermoeidheid. In de paragrafen daarna worden de volgende nieuw e bevindingen  
en vragen bediscussieerd: 1) Verrassend veel patiënten met kanker zijn al ernstig  
verm oeid voorafgaand aan de behandeling van kanker. 2) N iet het soort
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m aligniteit, maar psychologische en gedragsfactoren dragen bij aan ernstige 
verm oeidheid voorafgaand aan de behandeling van kanker. 3) Er is geen sterk 
bewijs voor de effectiviteit van interventies die niet specifiek gericht zijn op 
verm oeidheid tijdens actieve behandeling van kanker. 4) N iet alle patiënten met 
kanker hebben een interventie voor verm oeidheid tijdens behandeling van  
kanker nodig. 5) Welke indicaties voor CGT voor verm oeidheid tijdens 
behandeling van kanker konden worden aangetoond? 6) Een toenam e in 
licham elijke activiteit is  geen mediator voor een afname in verm oeidheid tijdens 
actieve behandeling van kanker. 7) Het verloop van verm oeidheid is  al stabiel 
vanaf tw ee maanden na afronding van de behandeling van kanker. 8) Wie lopen 
het risico om persisterend verm oeid te blijven na afronding van succesvolle 
behandeling van kanker? 9) De instandhoudende factoren van ernstige 
verm oeidheid bij ziektevrije oncologie patiënten die de behandeling lang geleden  
hebben afgerond zijn al kort na behandeling van kanker aanwezig.
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Terw ijl ik  over m ijn  dankw oord  n adenk , zie ik  een jongen  over de p a rk e e rp laa ts  
lopen. M et z’n  zw are ru g zak  loopt hij een  beetje voorovergebogen, tegen  de zon in  
k ijkend, lan g s de opvallende oude Volvo v an  C arel. Ik  verm oed  d a t h e t een 
s tu d e n t is v an  de p-faculteit. De p a rk e e rp la a ts  is  m ijn  u itz ich t. M ijn b lik  dw aalt 
dagelijks a f n a a r  de gro te  bom en, h e t g rasveld je  en  h e t m et p lan tje s  bed ek t dak. 
T erugk ijkend  zijn de g eb eu rten issen  op de p a rk e e rp la a ts  in  de afgelopen tijd  n ie t 
noem ensw aard ig . F ie tse rs  en  joggers kw am en  voorbij, een  groepje jongens 
“voe tba lden” op h e t g ras, of m ensen  liepen  lan g s m et n e t gekochte lun ch  u it  de 
su p erm ark t. De oude m an  die s tip t om v ie r u u r  zijn hond  kom t u itla ten , heb  ik  al 
een  tijd  n ie t gezien. K auw tjes kw am en  a f en  toe h e t d ak  bezoeken op zoek n a a r  
ie ts  ee tb aa rs . E en  bonte  specht en  een V laam se gaa i spo tten  w aren  enkele  hoogte 
p u n ten . Twee onhand ig  verliefde tien e rs  een  spektakel.
De ee rs te  ja re n  v an  h e t onderzoek w aren  n ie t te  vergelijken  m et de la a ts te  
ja ren . Terw ijl de la a ts te  ja re n  voornam elijk  besto n d  u it  schrijven, lezen, spss-en, 
en  scannen  v an  h e t u itz ich t, w aren  de ee rs te  ja re n  veel hectischer. Bij aanvang  
v an  h e t onderzoek w as h e t b e lan g rijk s te  doel h e t re k ru te re n  v an  deelnem ers. De 
w erving r ic h tte  zich op p a tië n te n  die n e t ged iagnosticeerd  w aren  m et k a n k e r  en 
de b eh andeling  nog m oesten  ondergaan . M ijn d an k  g a a t te n  ee rs te  u it  n a a r  alle 
deelnem ers a a n  h e t onderzoek. Zonder h en  w as h e t onderzoek nooit m ogelijk 
gew eest. Ik  w aa rd ee r h e t enorm  d a t a l deze m ensen  de tijd  hebben  genom en voor 
h e t onderzoek in  deze fase  v an  h u n  leven. V ersch illende m ensen  on tv ingen  mij 
th u is  en  w ond erb aarlijk  w as h e t bezoek som s zelfs gezellig! N ogm aals dank.
Vele m ensen  hebben  m eegew erkt a a n  h e t onderzoek, v a n u it zeven 
versch illende  ziekenhu izen . B ernhoven  te  Oss, C an isius W ilhelm ina Z iekenhuis 
en  h e t UM C St R adboud te  N ijm egen, R ijn s ta te  te  A rnhem  p a rtic ip ee rd en  in  h e t 
onderzoek, en  la te r  ook B ernhoven  te  Veghel, Z iekenhu is G elderse V allei te  Ede 
en  Z iekenhuis Z evenaar. Voor de w erv ing  v an  deelnem ers ben ad erd e  zowel
a rtsen , a ls v erp leegkund igen  p a tië n te n  voor h e t onderzoek, m aa r zeker m et hulp  
v an  o n d e rs teu n en d  personeel. De volgende p ersonen  w il ik  g raag  b ed an k en  (in 
w illekeurige volgorde): H e n rie tte  P e te rs  R it, In g rid  de G raaf, A llert Vos, Luc 
Strobbe, B eppie K lum penaar, H a rm a  de B ru in , A nnet D elisse, A ns W ieland, Eijo 
Balk, L ieneke H om ans, Joke  E n se rin k , H an n ek e  B alk, J e a n  K linkenbijl, Joep 
D oum a, I r is  D ulm us, H ilde de Reus, E llie  V orsteveld, Ilse  Jo rd en , J a n in e  Egging, 
M onica Perebolt, L ise tte  te r  Voert, J a n  v an  W ijk, H a rry  Seinen, Theo Wobbes, 
A nnelies W erner, M arg re th e  Schlooz, M aria  T ielkens, F r its  M ulder, Lucy 
N ab u u rs , K arin  v an  M eerten , K arin  te  P la te , C orrie Holweg, O dette  Sijlbing, 
H an  B onekam p, A nnem arie  A rends, Leon M assuger, Jo a n n e  de H ullu , M aaike 
v an  H am , J a n  W illem  Leer, T itia  v a n  V eenendaal, Tom Rozem a, R aym ond de 
Boer, An Snyers, M arcel S tam , A lja Schoonbeek, S ask ia  R adem akers, E m ile van  
Lin, W illem  H oogenraad, F re d  W itjes, B en K nipscheer, A n ita  S m its-van  de 
Cam p, E ugen ie  M onster, A nja T im m er, N elleke O ttenvanger. Ik  hoop d a t ik  
n iem an d  v erg e ten  ben, m aa r ook p ersonen  die ik  n ie t persoonlijk  genoem d heb, 
b e d an k t voor de in spann ing .
De p ersonen  die de verp leegkund ige  in te rv en tie  hebben  verzorgd  w il ik  
tevens persoonlijk  bedanken . Nicole P rein , H ilde v an  H aaren -d e  H aan , N orm a 
Leeflang, N el v an  de E n t, F ran c ies  v an  der W ijst, Ineke  W eijers, S ask ia  B rouw er, 
E ls R u tten -D ijk stra , H an n ek e  N as, P au lien  K eizer-H eldens, C hriste l v an  R iel en 
M arlies P e te rs . T hea B erends en  H ein  V oskam p w il ik  b ed an k en  voor h e t 
verzorgen  v an  de cognitieve ged rag sth erap ie .
Theo de Boo en  Rogier D onders w il ik  nog b ed an k en  voor de s ta tis tisch e  
o n d ersteu n in g  en  Alice T illem a voor de h u lp  bij sy stem atisch  onderzoek n a a r  de 
ju is te  s tud ies voor h e t cochrane review .
L ianne en  Ju d ith , om sam en  m et ju llie  te  w erk en  w as een  zegen. Ju llie  
w erk te  veel, goed doordacht, m et een  groot veran tw oordelijkheidsgevoel 
nauw keurig , en  ik  w as a ltijd  op de hoogte. Ik  denk  d a t we h e t alle d rie een  
boeiend, som s een m oeilijk, m aa r zeker b ijzonder pro ject vonden  om a a n  te 
w erken , m et boeiende, som s m oeilijke, m aa r zeker b ijzondere personen . We 
w aren  een goed team !
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H et gehele p ro m o tie tra jec t ben ik  begeleid  door Gijs B leijenberg  en  S tan s  
V erhagen . De ja re n  voor h e t p ro m o tie tra jec t heb  ik  g ew erk t en  gestudeerd . D at 
w aren  periodes m et veel v rijheid , w a a rin  veel ze lfstand igheid  w erd  verw ach t. Vol 
zelfvertrouw en  begon ik  a ls onderzoeker bij h e t NKCV, m aa r de ee rste  m aanden  
w erd  d a t snel m inder. De s tra k k e  regie e iste  veel incasseringsverm ogen  v an  mij. 
M aar Gijs, o ndanks onze m oeilijke m om enten, is h e t p roefschrift nu  k laa r. 
Zonder jouw  in p u t w as h e t nooit zo gew orden als h e t n u  is. Ik  w aa rd ee r je 
com m itm ent a ls hoofd v an  h e t NKCV. Door je  ‘v a n  8 to t 8’ m e n ta lite it kon ik  
a ltijd  bij je  te rech t voor een  tu sse n tijd s  overleg en  een vern ieuw de versie. Je  
hech t aa n  goed en gedegen w etenschappelijke  onderzoek, zonder d a t je  daarb ij 
h e t be lang  voor de p a tië n t en  de p ra k tijk  u it  h e t oog verliest. M et deze v isie heb 
je  me opgeleid to t vo lleerd  w etenschappe lijk  onderzoeker. H iervoor m ijn  dank.
S tans, voordat ik  a a n  h e t p ro m o tie tra jec t begon w ist ik  w einig v an  de 
oncologie. O ver d it boeiende v ak  heb  ik  h ee l veel v an  je  geleerd. Je  en thousiasm e 
en je  positieve in s teek  hebben  mij zeer geholpen. Als echte a r ts  h a d  je  tijd  voor je 
p a tiën ten , collega’s en  ook voor mij. Al g af je  de in d ru k  zeeën v a n  tijd  te  hebben, 
de tijden  w aarop  ik  e-m ails on tv ing  gaven toch een an d er beeld  (vb. 6:26, 23:22, 
3:24). B ed an k t voor de begeleider die je  w as.
M arlies, ook jij w as één  v an  de v ijf v an  h e t w ekelijkse overleg. In  de eerste  
ja re n  w as je  a ls  re sea rch  verp leegkund ige  be tro k k en  bij de in te rv e n tie s  en 
d a a rn a a s t heb  je  me veel geholpen m et h e t o pzetten  v a n  de w erving. H e t re ilen  
en  zeilen b in n en  h e t z iek en h u is  w ist (weet) je  goed, w aardoor je  mij kon v e rte llen  
bij w ie en  w a a r ik  m oest zijn. Inm iddels ben  je  zelf ook n ie t s til b lijven z itten  en 
ben  je  n u  ook aan  een  p ro m o tie tra jec t begonnen. Ik  hoop nog lan g  m et je  sam en  
te w erken  (m et m utsje, p ru ik , m aa r h e t lie fst m et je  eigen haar).
M arieke, deze w oorden v an  d an k  zijn voor jou. Vele u re n  hebben  we sam en 
gespendeerd  op de onderzoekerskam er. O m dat je  de enige onderzoeker w as op 
h e t gebied v an  verm oeidheid  n a  k an k e r, w as jij m ijn  v ra a g b a a k  en  d iscussie ­
forum , en  ik  w as jouw  stoorzender en  onbeperk te  w erkverschaffer. N ie t a lleen 
v ak in houdelijk  kon  ik  bij je  te rech t. J e  w ist w a t h e t w as om onderzoeker bij h e t 
NKCV te  zijn. Je  s teunde  mij, h ie lp  mij te  re la tiv e ren  en  w eer v e rd e r te  kunnen .
D ear P a u l Jacobsen  an d  M ichael A ndrykow ski., th a n k  you for giving me
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th e  oppo rtu n ity  to do re sea rch  w ith  you. I t  w as a g rea t le a rn in g  experience to 
w ork w ith  you an d  K ris tin e  D onovan, H e a th e r J im , C h ris tin e  L aronga, K ris tin  
Phillips, an d  B ren t Sm all. E verybody of th e  fa tigue  stu d y  group an d  a ll o ther 
people a t  M offitt an d  K entucky  U nversity  m ade me feel rea lly  welcome. I enjoyed 
being in v ited  to peoples hom es an d  doing v a rio u s activ ities. T h anks again!
Fijne collega’s en  ex-collega’s, A gaat, A nnem arie , Carel, D ennis, H anneke, 
H ans, H ein, H en rie tte , J a n , José  en  José, Ju d ith , K orine, L ianne, L iesbeth , 
M arcia, M arian n e , P au lien , Tiny, T hea de V, T hea B. Ik  vond  h e t hee l fijn om 
ju llie  a ls  collega’s te  hebben. Ik  voelde me h ie r  th u is  (w aarsch ijn lijk  w as ik  h ie r 
ook v a k e r dan  thu is). K ortom , b e te r  fijne collega’s d an  een  vage buu r, gedeelde 
sm a rt b lijft gedeelde sm art, en  vele h a n d e n  doen er een  schepje bovenop. Ik  heb 
m e afgev raagd  w a t h e t NKCV zo bijzonder m aak t?  Zijn h e t de beleven issen  van  
L iesbeth  die een  w ekelijkse colum n w aard ig  zijn? H e t lachsalvo  v an  Tiny, Ju d ith  
en  L ianne en  de daarb ij onm isbare  grap  v an  C arel? Zijn h e t de fru s tra tie -  
oproepende ap p a ra te n ?  H e t gezellige gebabbel v an  M arcia?  H e t boeiende leven 
v an  Thea, w a a ra a n  B ridget Jo n es  nog een  p u n tje  aa n  k a n  zuigen? De groene tru i 
v an  k e rm it de k ik k e r1? Of de borrels, ta a r t  of an d ere  b aksels?  Ik  denk  d a t h e t 
geheel m eer is  d an  de som der delen.
P ap  en  m am . Ju llie  w aren  a ltijd  a l tro ts . N u m ag het. B ed an k t voor alles.
Lieve v rien d en  in  G roningen, N ijm egen en  overal en  nergens, b ed an k t voor 
de gezelligheid, de festivals, feestjes, bbq’s, b ie rtje s  en  ouw ehoeren, ch itch a t en 
serieuse  gesprekken . K an  ik  h ie r  een  con trac t voor tekenen?  E ssie, wij w orden 
sam en  oud!
G roningen: De th u isb a s is  (geen geboortegrond). Nou, ja ...p a r ttim e  dan. 
W at d a t b e tre ft h a d  ik  w el v a a k  h e t e .e .a  u it te  leggen. N a tu u rlijk  g aa t er n ie ts  
boven G roningen, m aa r h e t is n ie t a lleen  de stad . Ronie Lof m ijn  op tim ist, ja  nu  
ga ik  slim ey worden! D at we nog m aa r lan g  sam en  m ogen k lussen , tu in ie ren , 
gekke bekke trekke, lachu , cocoonen, reizen, p ickies m aken , phoop scoopen, en 
...w hat else..f* m y ra 2.
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1. Gielissen MFM. General discussion. Dankwoord. In' Fatigue in  cancer survivors ' from  
assessm ent to cognitive behavior therapy. Wageningen' Ponsen & Looijen B.V.; 2007. p. 131-64.
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Over de auteur
M artin e  M a rg a re th a  G oedendorp is op 13 m ei 1976 geboren te  D rach ten . In  1993 
h eeft ze h a a r  HAVO diplom a behaald , w a a rn a  ze in  B olsw ard  HBO 
levensm iddelen technologie  is  g aan  s tu d eren  a a n  de “Suvelschool”. V ier ja a r  la te r  
n am  ze h a a r  d iplom a in  o n tv an g st aa n  h e t V an H all I n s t i tu u t  te  L eeuw arden . In 
de periode tu sse n  1997 en  2001 heeft ze in  de zu iv e lin d u strie  gew erk t op he t 
gebied v an  k w a lite it en  productontw ikkeling .
N a te ru g k o m st v an  een ja a r  du ren d e  w ere ld re is  in  2002 h eeft ze een 
sw itch g em aak t en  is  fu lltim e psychologie g aan  studeren . D rie ja a r  la te r  
s tu d eerd e  ze a f  a a n  de R ijk su n iv e rs ite it v an  G roningen, m et als 
a fs tu d eerrich tin g  sociale psychologie m et neven rich tin g  gezondheidspsychologie. 
H a a r afstu d eerp ro jec t voerde ze u it bij h e t N ijm eegs K en n iscen tru m  C hronische 
V erm oeidheid  (NKCV) v an  h e t UM C S t Radboud. D aar is  ze gev raagd  om als 
p rom ovendus te  kom en w erken  a a n  een in te rv en tieo n d erzo ek  n a a r  verm oeidheid  
tijd en s cu ra tiev e  behandeling  v an  k an k er. H et w e tenschappelijk  onderzoek is in  
sep tem ber 2005 v an  s ta r t  g egaan  en  h ierop  is  d it p roefschrift gebaseerd.
In  ap ril en  m ei 2010 heeft ze bij h e t H. Lee M offitt C en ter en  de K entucky  
U n iversity  in  de V erenigde S ta te n  onderle id ing  v an  P a u l Jacobsen  en M ichael 
A ndrykow ski onderzoek g ed aan  n a a r  verm oeidheid  bij v rouw en m et b o rs tk an k e r 
en  een gezonde controle groep, w aarvoor ze een  academ ische stag eb eu rs  h a d  
gekregen  v an  de KW F K an k erbestrijd ing . N a te ru g k o m st u it de VS h eeft ze h a a r  
w erk  bij h e t NKCV voorgezet en  gefocused op h e t verk rijg en  v an  subsid ies voor 
n ieuw  onderzoeken. Op basis  v an  v e rk reg en  subsidie v an  h e t d iabetesfonds 
w erk t ze n u  als p a r ttim e  onderzoeker aa n  een project over verm oeidheid  bij 
p a tië n te n  m et d iabe tes type 1.
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